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Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease. Stiffness is a 
major symptom of RA which is commonly reported by patients, affects patients’ daily 
life, and is relevant to patients in relation to fluctuating aspects of RA such as flare 
and low disease activity. Morning stiffness is also frequently used as an outcome 
measure both clinically and in research. Despite the relevance and uses of stiffness, 
it remains poorly understood and was omitted from the RA core set because of poor 
measurement properties. A pragmatic, mixed methods approach was used to better 
understand the patient experience of stiffness in people with RA and to develop and 
test a new RA stiffness patient reported outcome measure (PROM). It involved a 
systematic literature review, semi-structured interviews, focus groups, cognitive 
interviews, the development of appropriate candidate items to characterise stiffness 
and multivariate analysis of a survey using these items. 
 
The systematic literature review found that current stiffness assessment is based on 
items that capture the duration or severity of morning stiffness. However, items were 
often poorly defined, highly variable in wording and format, had limited measurement 
property evidence and had not been developed according to current standards 
including collaboration with patients. Overall, there was no evidence regarding the 
most appropriate way to assess stiffness in RA, indicating the need for a new measure 
developed according to best practice PROM guidelines. Semi-structured interviews 
with RA patients provided an improved understanding of their experience of stiffness, 
demonstrated its relevance to patients and enabled the development of a conceptual 
model. These data also highlighted inconsistencies between current stiffness 
assessment and the patient perspective of this symptom. Focus groups with RA 
patients reinforced the stiffness conceptual model in a new sample, using a different 
method of data collection. They also provided information specifically addressing 
stiffness assessment from the patient perspective, including a number of concepts for 
measurement instrument development. These patient-driven concepts and qualitative 
data were tempered with measurement theory to develop a conceptually sound yet 
practically appropriate preliminary set of items for a new RA stiffness PROM. 
Preliminary items were reviewed and modified by RA patients in cognitive interviews. 
Following refinement, 45 candidate items (39 new items and 6 traditional stiffness 
items) were taken forward to a postal survey to develop and test the structure of a 
new RA stiffness PROM.  
 
Analysis of the survey responses involved rigorous statistical testing including a series 
of iterative principal component analyses (undertaken initially with two different 
approaches), balancing Cronbach’s alpha for internal consistency, bootstrapping for 
stability, and expert judgement for clinical appropriateness. The emergent structure 
was the Rheumatoid Arthritis Stiffness (RAST) questionnaire with 21 items in 3-
components capturing ‘stiffness severity’, ‘physical impact’ and ‘psychosocial impact’. 
The initial qualitative work enhanced its content validity and statistical testing for 
appropriate relationships with other measures of disease demonstrated good 
construct validity. These results provide support for RAST as an appropriate tool for 
use in future stiffness assessment.  
 
The development of the RAST is important in recognising stiffness as a relevant 
patient symptom and is a significant step towards standardised stiffness assessment. 
Further testing in a fresh population will generate additional evidence of reliability and 
sensitivity to change to support its use. The RAST provides a measure for use in new 
investigations of disease mechanisms and response to therapy. 
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Chapter 1: Rheumatoid arthritis and stiffness 
This thesis aims to answer the research question ‘What is the experience of stiffness 
in people with rheumatoid arthritis (RA) and how should it be assessed as a patient-
reported outcome measure (PROM)?’ This chapter will introduce RA, its symptoms, 
aetiology and treatment. It will also explore stiffness specifically within the context of 
RA, and more broadly within other populations. 
 
1.1 Rheumatoid arthritis (RA) 
RA is a chronic, systemic, inflammatory condition causing synovitis and resulting in 
pain, swelling and stiffness (Arthur and Hill, 2006). Typically, RA affects the small 
joints in the hands, feet and wrists but can affect any synovial joint (Hakim, Clunie 
and Haq, 2011). Individuals with RA typically experience fluctuations of disease 
activity between high (flare) and low states, and now with modern treatments, 
remission (Smolen et al, 2010).  
 
The American Rheumatism Association (ARA) defined a set of classification criteria. 
Four of the seven criteria must be met for a classification of RA, the first four of which 
must have been present for at least six weeks: morning stiffness lasting over one 
hour; soft tissue swelling of at least three joints; swelling of hand or wrist joints; 
symmetrical swellings; rheumatoid nodules; positive rheumatoid factor; and 
radiographic changes (Arnett et al, 1988). More recently, the 2010 American College 
of Rheumatology/European League Against Rheumatism (ACR/EULAR) 
classification criteria (Aletaha et al, 2010) were developed, consisting of weighted 
scores from four categories; joint symptoms (number of small or large joints); serology 
(presence and level of rheumatoid factor and/or anti-citrullinated protein antibody); 
acute-phase reactants (normal or abnormal C-reactive protein (CRP)/erythrocyte 
sedimentation rate (ESR)); and symptom duration (<6 weeks or >6 weeks) (Aletaha 
et al, 2010). These criteria focus less on radiographic damage, symmetry and 
rheumatoid nodules, which may not be present in early RA (Kay and Upchurch, 2012). 
 
RA is prevalent worldwide and can affect people of any age and gender, however it 
is three times more common in females (National Institute for Health and Care 
Excellence (NICE), 2009). RA affects around 400,000 people in the UK (NICE, 2009), 
approximately 1% of the population (Symmons et al, 2002). Although its aetiology is 
unknown, smoking (Sugiyama et al, 2010), genetics (Silman and Pearson, 2002), and 
obesity (Symmons et al, 1997) are risk factors. The annual combined indirect and 
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direct cost of RA has been estimated as between £3.8 and £4.8 billion in the UK 
(NICE, 2009). The outcomes for individuals with RA include reduced function, 
reduced life expectancy (Naz and Symmons, 2007), and increased work disability 
(Burton et al, 2006; Sokka et al, 2010). Higher rates of psychological outcomes such 
as depression (Dickens et al, 2002) and anxiety (Isik et al, 2007) are also reported in 
RA populations than in the general population. However, outcomes have improved 
and during the past two decades, RA patients have been shown to be less 
psychologically distressed and physically disabled. This has been suggested to be a 
result of improved treatment and management including earlier diagnosis, increased 
emphasis on physical activity, and more effective medications (Overman et al, 2014), 
in which there have been substantial changes with the introduction of new 
medications and combination regimens (Smolen et al, 2010). These developments in 
medications such as biologics (Section 1.3.2) aim to target the actions of pro-
inflammatory cytokines (White and Bryer, 2006). Cytokines are proteins that transport 
messages to different body systems, and pro-inflammatory cytokines specifically 
increase inflammation as part of the immune response (Oliver, 2006). Cytokines also 
promote joint destruction, and are thought to play a role in aspects such as fatigue 
within the RA process (Choy, 2012). Particularly relevant in RA are pro-inflammatory 
cytokines interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-α) (McInnes and 
Schett, 2003). Improved understanding of these cytokines and their role at a cellular 
level have enabled the development of medications that work by disrupting the 
production of pro-inflammatory cytokines (Oliver, 2006). Cytokines follow circadian 
rhythms, demonstrating a peak in the night and early morning (Cutolo et al, 2003). It 
is suggested that variation in symptoms including stiffness relates to the variation in 
cytokines such as IL-6 (Perry et al, 2009). 
 
1.2 Rheumatoid arthritis symptoms and consequences  
1.2.1 Symptoms 
1.2.1.1 Pain 
Pain is a common and complex symptom with the purpose of protection (Harvey, 
1987). There are different theories explaining the cause of pain, such as gate control 
theory (Melzack and Wall, 1965). Pain has been defined as “[…] whatever the 
experiencing person says it is, existing whenever he says it does” (McCaffrey, 1983, 
cited in Hill, 2006, p.218) to reinforce its subjective nature. It is managed using 
pharmacological interventions such as analgesics or steroids, and therapies such as 
heat and cold application (Hill, 2006). Pain has been linked to other symptoms 
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including disability (Sprangers et al, 2000) and stiffness (e.g. Rhind, Unsworth and 
Haslock, 1987; Hazes, Hayton, and Silman, 1993).  
 
In a study involving the 12 dimensions of health status in the Arthritis Impact 
Measurement Scales (AIMS2) (Meenan et al, 1992), 58 female participants identified 
pain as the most relevant dimension of impairment (Minnock, FitzGerald, and 
Bresnihan, 2003). In another survey of 1,024 male and female RA patients, pain was 
identified by 68.6% (n=702) as the preferred area for health improvement (Heiberg 
and Kvien, 2002). However, both studies were based on the AIMS2, which although 
addresses patient preferences, its dimensions were not patient generated (Meenan 
et al, 1992). Therefore, when the study by Minnock et al. (2003) was repeated with 
the same patients in a follow-up study with the addition of fatigue, an important patient 
generated symptom (Hewlett et al, 2005a), 65% of women prioritised fatigue for 
improvement over pain (Minnock and Bresnihan, 2004; 2008). 
 
1.2.1.2 Fatigue 
Fatigue is another commonly experienced RA symptom (Wolfe, Hawley, and Wilson, 
1996; Overman et al, 2015), that is important to patients, yet has been reported as 
being ignored by healthcare professionals (Hewlett et al, 2005b). However, the 
importance of fatigue has recently been recognised, leading to the recommendation 
that it is assessed in all RA clinical trials (Kirwan et al, 2007) and the development 
and validation of the Bristol RA Fatigue (BRAF) scales (Nicklin et al, 2010a; Nicklin 
et al, 2010b; Dures et al, 2013). There is still limited understanding of the underlying 
cause of fatigue. A recent systematic review identified 25 studies relating to fatigue 
causes. Within these, RA related aspects, physical function, cognitive and emotional 
function, social and environmental aspects, and female sex were identified as 
possible causes of fatigue however, these findings were inconsistent across studies 
(Nikolaus et al, 2013). A conceptual model of RA fatigue has been proposed which 
suggests interactions between three key areas including RA disease processes (e.g. 
inflammation), cognitive and behavioural aspects (e.g. illness beliefs), and personal 
life aspects (e.g. responsibilities) (Hewlett et al, 2011a). Despite the limited 
understanding of fatigue, interventions have demonstrated fatigue reduction indirectly 
by improving aspects identified in the conceptual model (Hewlett et al, 2011b). For 
example, a fatigue self-management intervention has been shown to be effective at 
reducing RA fatigue (Hewlett et al, 2011b; Hewlett et al, 2014), based on cognitive 
behavioural therapy (CBT) which targets the links between thoughts, feelings, and 
behaviours to encourage change (Sage, 2008).  




For individuals with RA, stiffness is a major problem (Hill, 2006). As this symptom is 
the focus of this research, its relevance including its emergence and use in different 
contexts is discussed in detail in Section 1.5.  
 
1.2.2 Consequences 
1.2.2.1 Psychological consequences 
Diagnosis of chronic conditions can result in psychological consequences such as 
depressive symptoms (Polsky et al, 2005). In rheumatic diseases, the prevalence of 
anxiety and depression are twice that found in the general population (Geenan et al, 
2012). A study investigating comorbidities in RA patients (n=7818) on the British 
Society for Rheumatology (BSR) Biologics Register reported that depression was one 
of the most frequent conditions (n=1491, 19%) (Hyrich et al, 2006). As such, 
psychological support provision is an important part of patient care in UK (Luqmani 
et al, 2006; Luqmani et al, 2009) and international guidelines (American College of 
Rheumatology, 2002). Consistent with the above, a recent survey of the 
psychological support preferences of patients with inflammatory arthritis (n=1210) 
indicated that demand for psychological support was high, with only 6% of 
participants reporting that social and emotional aspects were not relevant. Yet despite 
demand, only 23% of participants reported being asked about such issues by 
members of their clinical team, indicating that current provision of psychological 
support does not meet patient need (Dures et al, 2014).  
 
1.2.2.2 Disability 
Disability has been defined by the World Health Organisation as “an umbrella term, 
including impairments (a problem in body function or structure), activity limitation 
(difficulty executing tasks or actions), and participation restriction (difficulty with 
involvement in life situations)” (World Health Organisation, 2015). In an RA 
population, disability is often assessed using the disability component of the Health 
Assessment Questionnaire (HAQ) (Fries et al, 1980). Disability in RA increases with 
disease duration (Scott et al, 2000) and higher amounts of joint damage are related 
to increases in disability over time (Bombardier et al, 2012). It is thought that 
uncontrolled inflammatory activity causes joint damage which subsequently leads to 
disability, although this relationship is not fully understood (Scott et al, 2000). 
However, with the recent improvements in medications, and better control of 
inflammation, disability in RA has declined (Krishnan et al, 2011). This was 
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demonstrated in a prospective cohort study involving 4651 patients from a USA and 
Canadian database which demonstrated annual mean disability reductions from 1993 
to 2006. Use of biologic therapies was introduced in 1998 thus providing a likely 
explanation for this reduction. However, this does not explain the declines in disability 
seen before this time (between 1993 and 1998) which the authors suggest may be 
attributed to the use of medications such as methotrexate, patient selection or decline 
in the severity of RA over time (Krishnan et al, 2011). 
 
A key area of disability in an RA context is work disability. Early research into work 
disability reported that 50% of people with RA stopped work within a decade after 
diagnosis (Yelin, Henke and Epstein, 1987). It was anticipated that the improvement 
in medications especially the introduction of biologics, would result in less work 
disability (Verstappen, Jacobs and Hyrich, 2007). However, work disability still 
appears problematic. One cohort study reported that of the 8082 participants who 
were employed at the onset of RA, 43.8% were not working 12.8 years after onset. 
Of these, 22.7% (n=1837) defined themselves as disabled, 30.5% (n=2496) had 
stopped work for health reasons, and 20.6% were receiving benefits as a result of 
disability (n=1236) (Wolfe, Allaire and Michaud, 2007). Another cohort study across 
32 countries involving 8039 patients reported that of the 5493 participants <65 and 
working at symptom onset, 37% reported work disability as a result of RA (Sokka et 
al, 2010). Work disability appears to remain an important issue in RA however, its 
assessment and evaluation is difficult given different definitions, social policies, and 
cultural attitudes. 
 
1.3 Management of rheumatoid arthritis  
The management of RA involves symptom relief, function maintenance and 
modification of disease activity, specifically the prevention of erosive damage and the 
achievement of remission (Cornell, 2007). Current management for RA is based on 
a combination of non-pharmacological and pharmacological approaches.  
 
1.3.1 Non-pharmacological approaches 
A multidisciplinary team approach to RA management including rheumatologists, 
nurses, physiotherapists, occupational therapists, podiatrists, social services, and 
surgery is recommended by the NICE (2009) and the BSR (Luqmani et al, 2006; 
Luqmani et al, 2009). Randomised controlled trials (RCTs) have demonstrated the 
effectiveness of these in RA for example nurse-led care (Ndosi et al, 2014) and 
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occupational therapy (Hammond, Young and Kidao, 2004). In addition to 
multidisciplinary team management, patients may take complementary therapies 
although further research is required to demonstrate the benefits and/or risks of these 
therapies (Cornell, 2007; Arthritis Research UK, 2012; Arthritis Research UK, 2013a).  
 
1.3.2 Pharmacological approaches 
Pharmacological approaches to RA management rely on combinations of different 
medications. First-line therapies include analgesics (e.g. paracetamol), non-steroidal 
anti-inflammatory drugs (NSAIDs), and glucocorticoids (e.g. prednisolone) which 
focus on the control of symptoms. Second-line therapies include disease modifying 
anti-rheumatic drugs (DMARDs, e.g. methotrexate) which target the underlying 
disease process, and focus on suppression of disease activity. A recent development 
in the pharmacological treatment of RA is biologic therapies which are genetically 
engineered treatments (White and Bryer, 2006). Biologics or targeted therapies, work 
by blocking or altering the actions of pro-inflammatory cytokines and specifically 
target the cell or process that causes inflammation (White and Bryer, 2006). Currently 
there are three targets of biologics; interlukin-1 (IL-1), TNF-α, and CD20 B cells. 
Interlukin-1 receptor antagonist (IL-1ra), in the form of licenced therapy Anakinra, 
works by altering the action of IL-1 (Mertens and Singh, 2009) by binding to IL-1 
receptors and maintaining an appropriate inflammatory response (Oliver, 2006). 
Similarly, the actions of TNF-α can be mediated by anti-TNF-α therapies. There are 
different types of anti-TNF-α including Adalimumab, Etanercept, and Infliximab which 
have slightly different actions e.g. Infliximab binds to TNF-α and stops it functioning 
while Etanercept stops TNF-α binding to its receptor (White and Bryer, 2006). Finally, 
the target of Rituximab is to reduce the number of B cells (Lopez-Olivo et al, 2015), 
thus reducing the production of auto-antibodies e.g. rheumatoid factor (White and 
Bryer, 2006). Cochrane reviews have been performed demonstrating the 
effectiveness of second-line treatments in RA (e.g. Navarro-Sarabia et al, 2005; 
Mertens and Singh, 2009; Lopez-Olivo et al, 2015). 
 
For individuals with newly diagnosed RA, a combination of DMARDs and 
glucocorticoids (oral, intramuscular or intra-articular) are recommended (NICE, 
2009). As biologics are considerably more expensive than other treatments, patients 
must meet specific criteria, such as a minimum disease activity score (Section 1.4) or 
intolerance to or inefficacy of other medications, before being considered for these 
treatments (NICE, 2009). However, despite the recent developments in treatment 
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such as biologic therapies and the effectiveness of the treatments available, there is 
no cure for RA. 
 
1.4 Measurement of disease activity 
In order to monitor each patient and ensure that the management of their disease is 
effective, a standardised measure of disease activity is used. The disease activity 
score (DAS) (van der Heijde et al, 1990)  is a composite score including a tender joint 
count (TJC), a swollen joint count (SJC), ESR, and a patient global (PtG) assessment 
of general health on a visual analogue scale (VAS). The DAS28 is more concise and 
focuses on the assessment of 28 joints (Prevoo et al, 1995). DAS and DAS28 scores 
are calculated using a weighted formula producing final scores ranging between 0-
9.4, from which, disease activity can be classified as low (≤3.2), moderate (3.2-5.1), 
or high (>5.1) (Prevoo et al, 1995; Fransen, Stucki and van Riel, 2003). There are 
also different versions of the DAS28 for example, using CRP rather than ESR 
(Fransen, Stucki and van Riel, 2003). The DAS28 is a well validated tool that is useful 
for monitoring disease activity clinically and in research (van Riel and Schumacher, 
2001; Fransen, Stucki and van Riel, 2003). However, there are a number of criticisms 
of the DAS28. Firstly, it does not include the feet and in early RA patients with mainly 
foot involvement this may underestimate scores (Bakker et al, 2011). Despite this, 
joint counts that do not include the feet have been shown to discriminate between 
patients with different levels of disease activity, and demonstrate as much validity as 
joint counts that do include them (Prevoo et al, 1995). It has also been shown that 
despite foot involvement being common, measurement precision is not improved by 
including this information in joint counts (Siemons et al, 2013). In addition, there are 
practical (de Souza, Williams and Lempp, 2016) and accuracy (van Tuyl et al, 2011) 
related reasons for exclusion of the feet. Therefore, this remains a debated topic in 
the literature (Siemons et al, 2013). Another criticism is that three of the four DAS28 
measures are assessed by a clinician which conflicts with the recent increased focus 
on the patient’s perspective, especially in outcome assessment (Kirwan et al, 2003). 
Furthermore, the weighting given to the PtG VAS is the smallest of all the DAS28 
components (0.014xPtG) and the DAS28 can be scored without the PtG VAS (Prevoo 
et al, 1995). Development of the DAS was based on the clinical judgement of six 
rheumatologists (van der Heije et al, 1993) and did not involve patients including 
during the wording of the PtG VAS. The wording of the PtG VAS is not standardised, 
and a systematic review of the reporting of patient reported outcomes (PROs) found 
that PtG VAS wording differs across studies (Kalyoncu et al, 2009). In a study of five 
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different versions of the PtG VAS, different versions were shown to produce different 
DAS28 scores (French et al, 2013).  
 
1.5 Relevance of stiffness 
Stiffness is a major problem for people with RA (Hill, 2006). To understand the current 
stiffness knowledge base, comprehensive searches of electronic databases (Medline 
(via EBSCO), Allied and complementary medicine (AHMED), Cumulative index to 
nursing and allied heath (CINAHL plus), PsychINFO) were performed to identify 
research published up to December 2015. In addition to database searches, 
evaluation of known articles, theses and reviews, and their reference lists, expert 
suggestions, and other hand searching was performed. Searches for keywords 
included three key topic areas: 1) stiffness (e.g. stiffness, morning stiffness, early 
morning stiffness, joint stiffness); 2) population (e.g. RA, inflammatory arthritis); 3) 
instrument (e.g. patient report, PROM, questionnaire). The not function and title field 
selection were often used for specificity (e.g. not arterial stiffness, vascular stiffness, 
aortic stiffness). 
 
1.5.1 Historical relevance of stiffness  
Traditionally this symptom has been termed early morning stiffness (EMS), but also 
referred to as morning stiffness (MS), or stiffness. As will be discussed later (Section 
1.6), there is little evidence of the appropriate term to use when discussing stiffness. 
Therefore, this thesis will use the term stiffness unless otherwise specified by 
referenced papers. In early RA literature it was stated that “morning stiffness is an 
almost universal manifestation of active rheumatoid arthritis” (Lansbury, 1956, p.11). 
Duration of MS was included in early disease activity composite assessments such 
as the Lansbury index (Lansbury, 1958), the Mallya-Mace index (Mallya and Mace, 
1981), the Stoke index (Jones et al, 1993) and the Paulus Criteria (Paulus et al, 1990). 
Later the presence of “morning stiffness in and around the joints lasting at least 1 
hour before maximal improvement” was included in the 1987 ACR classification of 
RA (Arnett et al, 1988, p.315). Furthermore, absence or short duration (<15 minutes) 
of MS was defined as one of six preliminary remission criteria (Pinals et al, 1981). 
The inclusion of stiffness as part of key RA criteria reflected stiffness being a common 
feature of RA that was frequently reported by patients (Scott, 1960; Vliet Vlieland et 
al, 1997) and considered an indicator of inflammatory activity (Lansbury, 1956). 
However, when the classification criteria were updated (Aletaha et al, 2010), although 
MS duration was considered, it was not included because it did not have enough 
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predictive value for DMARD initiation (Kay and Upchurch, 2012). Stiffness was also 
omitted from the ACR core set for assessing disease activity because it was not 
sensitive to change (Felson et al, 1993). As the revised remission criteria were based 
on the ACR core set, stiffness was not included (Felson et al, 2011). Furthermore, 
during the development of the DAS (van der Heije et al, 1990; van der Heije et al, 
1992), although duration of MS was considered as one of the 19 tested variables, it 
was not included in the final score (van der Heije et al, 1990; van der Heije et al, 
1992). Despite the DAS and the Mallya index (which includes MS duration) 
demonstrating the best validity in the assessment of disease activity, duration of MS 
was among a number of variables that performed poorly as individual variables (van 
der Heije et al, 1992). The usefulness of using MS as a single variable in the 
assessment of disease activity was also questioned (van der Heije et al, 1992). 
Therefore currently, there is no obligation in clinical or in research settings to routinely 
collect information about stiffness, although more recently this has been challenged 
with the inclusion of stiffness in the core set to assess flare (Bykerk et al, 2014a) 
(Section 1.5.2.3). 
 
1.5.2 Relevance of stiffness to RA patients 
Despite not being consistently collected or reported, there is a growing body of 
research highlighting the relevance of stiffness to people with RA. Recent studies 
have demonstrated that stiffness has considerable impact on patients’ daily lives in a 
number of domains.  
 
1.5.2.1 Work and disability 
RA is associated with work disability (Burton and Lloyd, 2006; Sokka et al, 2010) and 
stiffness appears to have a specific role within that. In an observational study of RA 
patients exploring the relationship between MS and early retirement, MS was shown 
to be important (Westhoff et al, 2008). Of the 1023 patients in the cohort at baseline, 
389 (38%) were under the retirement age cut-off of 61 years and not fulfilling other 
roles such as homemaker and therefore were at risk of early retirement. At the three 
year follow up, 65 (17%) of the 389 had taken early retirement specifically due to RA 
and within that population, early retirement was three times more likely in patients 
with severe MS, compared to those with mild MS (Westhoff et al, 2008). There has 
also been work conducted into the effect of MS on individuals who remain in 
employment. A survey across 11 European countries explored RA patients’ 
perceptions of the impact of MS on work life (Mattila, Buttgereit and Tuominen, 2014). 
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Of the 1061 participants, 534 (50%) were currently in work (self-employed or full/part-
time paid work) although the nature of the work was not included. Of these, 50 (15%) 
reported taking sick leave in the past month as a direct result of MS, 176 (33%) 
reported arriving late at work because of MS, and 250 (47%) felt that MS had an 
adverse effect on their work performance every week (Mattila, Buttgereit and 
Tuominen, 2014). Although demonstrating marked impact of MS on work, the authors 
highlighted that study participants were selected on experiencing MS on at least three 
days per week. This may have introduced bias relating to the impact of MS and has 
implications for the relevance of findings to the wider RA population, although given 
that stiffness is a common feature of RA (e.g. Khan et al, 2009), this may not be 
problematic. Given the importance to patients of remaining in employment (Grønning, 
Rødevand and Steinsbekk, 2010), and the broader relevance of reducing work 
disability in people with RA, this is an area requiring further investigation. 
 
1.5.2.2 Quality of life 
A large explorative survey investigated the impact of impaired morning function on 
RA patients’ quality of life (da Silva, Phillips and Buttgereit, 2011; Phillips and Dow, 
2012). Impaired morning function was reported to have a significant impact on 
responders’ quality of life (82%) and work life (73%). Morning activities such as getting 
out of bed and dressing were also affected, with between 50-72% of patients being 
unable to carry out these tasks unimpaired. This affected participant’s emotional state 
with respondents indicating that difficulties completing their morning activities made 
them feel frustrated (58%), angry (32%) and drained (14%) (da Silva, Phillips and 
Buttgereit, 2011). In further analysis, 84% indicated that impaired morning function 
had a significant effect on quality of life, which increased with MS severity (Phillips 
and Dow, 2012). These are important findings that demonstrate the significant impact 
of stiffness on RA patients’ quality of life. However, it is difficult to determine how 
much of that impaired morning function was specifically due to stiffness (rather than 
pain or disability) given the focus on morning function. Yet, this work demonstrates 
the importance of understanding the specific effect of stiffness and highlights the 
relevance of stiffness to RA patients. 
 
Another study investigated what RA patients would be willing to pay for reduction in 
or elimination of MS (Tuominen, Tuominen and Möttönen, 2011; Tuominen, 
Tuominen and Möttönen, 2012). Although three different approaches to estimating 
the monetary value were used producing quite different results, all approaches 
consistently identified that the impact of MS was between five and eight fold higher 
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for patients with severe MS (60-100 on numerical rating scale (NRS)) compared with 
patients with mild MS (0-29 on NRS). When only considering the willingness-to-pay 
estimates, patients with longer duration MS (≥60 minutes) reported that they would 
pay more than patients with shorter duration MS (10-59 minutes or <10 minutes) for 
every percentage reduction (25%, 50%, 75%, 100%). This was mirrored for MS 
severity where patients with more severe MS (60-100 on NRS) reported that they 
would pay more than patients with less severe MS (mild=0-29, moderate=30-59). 
Interestingly, patients with severe MS were willing to pay more than patients 
experiencing ≥60 minutes MS per day for a 100% reduction in the symptom 
(€47.9/£33.71 vs. €21.7/£15.27) (Tuominen, Tuominen and Möttönen, 2011; 
Tuominen, Tuominen and Möttönen, 2012). It is not known whether the same 
participants reported comparable levels for both severity and duration (e.g. whether 
participants reporting high severity are the same as those reporting long duration). If 
reported by different participants, this may explain differences in monetary value, 
although differences in the impact of MS severity and MS duration have also been 
reported in other work (Mattila, Buttgereit and Tuominen, 2014) (Section 2.4.1.4). 
These results could also have been influenced by the phrasing of the questions used 
as MS severity was reported on a NRS between 0 (best possible situation) and 100 
(worst possible situation) which does not fit entirely with the categorisations of mild, 
moderate and severe.  
 
1.5.2.3 RA disease activity  
Stiffness is also important to patients in relation to RA disease activity. RA disease 
activity fluctuates meaning that patients typically experience periods of flare and low 
disease activity. Stiffness has been reported to be experienced by RA patients in 
different disease states. In a recent cohort study involving 5439 RA patients from the 
QUEST-RA database, it was reported that stiffness was experienced by 2884 (79%) 
of those patients with active disease compared to 614 (41%) patients with less active 
disease (Khan et al, 2009). Definitions of disease activity were consistent with 
standard classifications (Prevoo et al, 1995; Fransen, Stucki and van Riel, 2003). In 
contrast, in a smaller interview-based study involving 93 RA patients, stiffness was 
reported by 43 (89%) patients with active disease and 35 (81%) patients with inactive 
disease (Hazes, Hayton, and Silman, 1993). In this case however, the referring 
physician classified each patients’ disease as active or inactive providing a more 
subjective classification than the DAS28. However, both studies demonstrate that 
stiffness appears to be commonly experienced across disease activity states.  
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In relation to remission, a recent study to understand the patient perspective of 
remission was performed (van Tuyl et al, 2015). This study employed qualitative focus 
groups in three centres across Europe and included 47 participants in total, all of 
whom either met the ACR/EULAR remission criteria (Felson et al, 2011), were self-
defined as currently being in remission, or had past experience of being in remission. 
Three main themes were identified: symptoms, impact and normality. Within 
symptoms, patients highlighted stiffness reduction as crucial before they would 
consider themselves to be in remission (van Tuyl et al, 2015). 
 
In terms of flare, qualitative research by the Outcome Measures in Rheumatology 
(OMERACT) flare working group has indicated that MS is an important influence on 
patients’ decisions to seek medication review (Hewlett et al, 2012). An international 
patient and professional Delphi exercise then aimed to identify the relevant domains 
in the assessment of flare. Stiffness was prioritised as a potential item for a core set 
of flare measures (79% consensus) and patients and healthcare professionals were 
equally likely to classify stiffness as an essential characteristic (80% and 76%, 
p>0.05) (Bartlett et al, 2012). Having identified potential items for a flare core set, at 
OMERACT 11 these domains were discussed and assessment of each was 
considered. In the final consensus vote, 91% of delegates agreed that stiffness 
should be included as a core domain to assess RA flare and the identification or 
development of stiffness assessment methods was part of the resultant research 
agenda (Bykerk et al, 2014a). This discussion was continued in breakout groups at 
OMERACT 12 (Bartlett et al, 2015, Orbai et al, 2015). 
 
1.5.3 Relevance of stiffness to healthcare professionals  
Stiffness appears relevant to both patients and healthcare professionals when 
assessing remission and high disease activity (van Tuyl et al, 2015; Bartlett et al, 
2012). A survey (Section 1.5.2.2) involving 518 rheumatologists and 750 RA patients 
investigated the impact of impaired morning function on RA patients (da Silva, Phillips 
and Buttgereit, 2011). In the study, patients and rheumatologists completed group 
specific questionnaires on the same topic. Patients reported a mean duration of MS 
and pain of 83 minutes which was slightly longer than that perceived by 
rheumatologists (70 minutes). Similarly, when considering the duration of morning 
function impairment, rheumatologist perceptions were consistent with patient reports. 
95% of rheumatologists considered that impaired morning function had a significant 
impact of patients’ quality of life (da Silva, Phillips and Buttgereit, 2011). However, 
these results only contain the views of rheumatologists and it may be that other 
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groups of health professionals have differing opinions. Although not reported in the 
paper directly but in a review by one of the principal authors (Buttgereit, 2011), 38% 
of rheumatologists indicated that patients should accept impaired morning function 
as a result of RA. This indicates that despite demonstrating understanding of the 
impact of impaired morning function on patients, some rheumatologists may not 
perceive this as an aspect requiring intervention or treatment. Further research with 
this group of health professionals demonstrated that rheumatologist’s use patients’ 
self-reports of stiffness as a crucial variable in decision-making for changing 
medication (Soubrier et al, 2006). This study aimed to identify the variables that were 
important in predicting change in DMARDs by reviewing demographics, disease 
activity, and outcomes of 204 consecutive patients attending outpatients. 
Rheumatologists were blinded to the intention of the study to avoid bias. MS duration 
was identified as independently associated with decisions to initiate DMARD change. 
It was the second highest influence on judgments (standardised odds ratio (OR) 
3.38), exceeded only by SJC (standardised OR 5.24), and higher than both pain 
(standardised OR 0.98) and CRP (standardised OR 2.8) among other variables, 
which was similar to results reported in a previous study involving rheumatologists 
(Kirwan et al, 1984). The study suggested that MS was so relevant in DMARD change 
initiation because it is an indicator of inflammatory activity, despite not being included 
in the DAS28 or ACR core set (Soubrier et al, 2006).  
 
In relation to other professional groups, a survey explored the management practices 
of Dutch physical therapists (n=233) when managing people with RA. The study 
reported that 168 (72%) of physical therapist responders ‘always’, 59 (25%) 
‘sometimes’, and six (3%) ‘never’ assess MS (Hurkmans et al, 2012), demonstrating 
the use of stiffness in clinical assessment in this population. However, although it 
appears that Dutch physical therapist practices are in accordance with Dutch 
physiotherapy guidance (Hurkmans et al, 2011), there is no evidence of how this 
translates to other professional groups or practice in different countries. There was 
also no indication as to the way in which stiffness was assessed. In contrast, a small 
survey involving 32 experts in RA and/or spondylarthropathy were asked to complete 
a questionnaire about the 1987 RA classification criteria and the 1991 European 
Spondylarthropathy Study Group (ESSG) criteria for spondylarthropathy (Berthelot et 
al, 2002). The removal of MS was suggested in seven (22%) of the returned 
questionnaires. However, within the questionnaire there was a specific question 
about the removal of one or more clinical criteria with a dichotomous yes/no response 
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option and MS was given as an example. This may have biased responses towards 
this outcome.  
 
1.5.4 Relevance of stiffness in research 
Despite being commonly experienced by patients, until recently stiffness has rarely 
been the focus of research studies. As described earlier (Section 1.5.2.2), research 
has explored impaired morning function (e.g. da Silva, Phillips and Buttgereit, 2011; 
Phillips and Dow, 2012), a term defined as “stiffness and pain in the joints (particularly 
the hands) first thing in the morning that causes reduced strength, grip and mobility 
and results in difficulty to function or perform tasks” (da Silva, Phillips and Buttgereit, 
2011, p.7). However, this definition makes it difficult to differentiate stiffness from pain 
and disability. This is made more difficult given the relationship between pain and 
stiffness (Rhind, Unsworth, Haslock, 1987; Lineker et al, 1999). One study explored 
the patient definition of stiffness with and without the use of a list of descriptors in 
three categories (difficulty of movement (n=7), pain (n=4), and sensations (n=2)) 
which was developed with patient input. Patient-generated descriptions were 
classified under the three categories and difficulty of movement followed by pain were 
most frequently used. As it was common for patients to provide combinations of 
descriptors, it was suggested that the patient definition of stiffness was an inter-
relationship between pain and limited movement (Rhind, Unsworth, Haslock, 1987). 
These findings were consistent with a qualitative study in which some RA patients 
related MS to pain, particularly when discussing flare (Lineker et al, 1999). However, 
in a study investigating word meanings in relation to symptoms involving patients with 
rheumatic conditions (RA (n=100), fibromyalgia (FM) (n=50), ankylosing spondylitis 
(AS) (n=50), and osteoarthritis (OA) (n=50)), it was reported that patients were able 
to distinguish pain from stiffness (Helliwell, 1995). External to the patient perspective 
of the relationship between pain and stiffness, early work suggested that pain and 
stiffness are likely the result of different mechanisms (Ingpen, 1968). However, this 
position has seen little development given the limited understanding of the 
pathophysiological causes of stiffness (Section 1.6.1). 
 
There has been a decline in the reporting of stiffness in clinical trials (Labitigan et al, 
2010). In a study comparing the characteristics and outcomes reported of RA patients 
who participated in RCTs in the 1980s and 2000s, it was found that the reporting of 
MS decreased between the time periods. The study identified 114 and 172 RCTs 
from the two time points respectively and within those studies, MS was reported in 
51% of in the studies in the 1980s but in only 27% of studies in 2000s (Labitigan et 
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al, 2010). This figure is consistent with a systematic review that was performed 
between 2005 and 2007 to explore the use of PROs in RA trials. The review identified 
109 papers and found that MS was reported in 27% (n=29) of these (Kalyoncu et al, 
2009). MS, function, pain, and PtG were the only PROs reported in >25% of articles 
(Kalyoncu et al, 2009). 
 
1.5.5 Relevance of stiffness in disease activity 
Stiffness is considered an indicator of inflammatory activity in RA (e.g. Lansbury, 
1956; Hazes et al, 1994; Soubrier et al, 2006) and was included in many early disease 
activity composite assessments (e.g. the Lansbury index, Lansbury, 1956). However, 
it is not included in the DAS or DAS28 (van der Heije et al, 1990; Prevoo et al, 1995) 
which is recommended in the assessment of RA disease activity (Anderson et al, 
2012). Nor is it included in the 2010 ACR/EULAR classification criteria (Aletaha et al, 
2010), revised remission criteria (Felson et al, 2011), or the ACR core set (Felson et 
al, 1993). Therefore stiffness is not addressed in any standardised assessment of RA 
disease activity used in clinical or research settings. A core set is a list of measures 
that must be assessed in trials which standardises assessment and enhances 
comparison of results across studies (Felson et al, 1993; van Riel and van Gestel, 
2000). As RA presents with a diverse range of signs and symptoms and no single 
‘gold standard’ measure could assess all people with RA (Pincus, 2005; van Riel and 
van Gestel, 2000), different sets of measures were used in different trials (van Riel 
and van de Putte, 1994) which led to difficulties when trying to compare trial results. 
Therefore, a standardised core set of measures was developed for use in all clinical 
trials (Felson et al, 1993). The ACR core set was developed following discussion by 
a committee of experts, presentation and consensus gained at the OMERACT 
conference, and further subsequent discussion. It contains seven measures; three 
physician assessed (SJC, TJC, global assessment), three patient assessed (physical 
function, pain, PtG assessment), and one acute phase reactant (ESR or CRP). A 
radiograph is used if the study lasts longer than one year. MS was a candidate 
measure however, it was omitted because it was not sensitive to change (Felson et 
al, 1993). Although the RA core set does not restrict other measures such as stiffness 
being assessed in trials (Felson et al, 1993), it has likely had implications on the use 
of stiffness as an outcome. The lack of requirement for stiffness to be assessed in all 
trials may explain the decline in the reporting of stiffness in trials identified above 
(Labitigan et al, 2010) as the core set was published between the defined time-points 
(Felson et al, 1993). This may have also limited further research into understanding 
and assessing this symptom. Despite not being included in the ACR core set, stiffness 
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is a relevant outcome that is used by clinicians when making treatment decisions 
(Kirwan et al, 1984; Soubrier et al, 2006), and is particularly relevant in certain areas 
of research. For example, MS is a key outcome in research into timed-release 
glucocorticoid treatments (e.g. Buttgereit et al, 2008). 
 
1.6 Current understanding of stiffness in RA 
1.6.1 Stiffness pathophysiology  
It has been well documented that RA symptoms including stiffness demonstrate 
highest activity in the morning. Early RA research using objective stiffness 
assessment (as described in Ingpen and Kendall, 1968) reported higher levels of 
stiffness at 6am compared to 6pm (exact values not reported, Ingpen, 1968). Similar 
findings have been replicated using subjective assessment in the form of MS duration 
(Dekkers et al, 2000) and MS severity (Harkness et al, 1982). However, in the latter 
study, mean MS severity (assessed on a 0 (absent) to 3 (severe) scale) was highest 
at 6am (mean 2.0) and lowest at 12pm (mean 0.9), although mean values at 6pm 
were only slightly higher (mean 1.2) (Harkness et al, 1982). Variation in symptoms is 
thought to be linked to circadian rhythms which drive biological processes such as 
inflammation (Straub and Cutolo, 2007; Perry et al, 2009). Relationships between a 
number of pro-inflammatory cytokines (e.g. IL-6) and RA symptoms, such as MS have 
also been suggested. Arvidson et al. (1994) demonstrated that the mean serum levels 
of IL-6 decreased significantly in RA patients between 7.30am (95.9 
picograms/millilitre (pg/ml)) and 10.30pm (27 pg/ml, p<0.001). Similarly, Perry et al. 
(2009) demonstrated significantly higher mean IL-6 levels at 7.15am (35 pg/ml) than 
at 10pm (64 pg/ml, p<0.001) in an overnight study (thus not truly investigating 
circadian rhythms). Both studies indicated an overnight rise in IL-6 with a peak in the 
early morning (Arvidson et al, 1994; Perry et al, 2009) which is similar to variation in 
stiffness (e.g. Dekkers et al, 2000). Therefore, as the circadian rhythms of IL-6 and 
MS are similar, the circadian variation of MS may be related to increased serum IL-6 
in RA (Arvidson et al, 1994).  
 
1.6.2 The patient perspective of stiffness in RA 
In the early stages of planning this research, little was known about the RA patient 
experience of stiffness. There was one study focusing solely on qualitatively 
understanding the patient experience of stiffness that aimed to develop a patient-
centred definition (Lineker et al, 1999). Twenty-four people with RA took part in 
individual semi-structured interviews. The interview topic guide asked participants to 
Chapter 1: Rheumatoid arthritis and stiffness 
34 
 
describe their MS in relation to how it affected their behaviour; what MS was affected 
by; its duration, severity, location, and variability; and its relationship to other 
symptoms and the previous day’s activities. The topic guide was pretested with RA 
patients prior to use. However, it asked specifically about MS and did not appear to 
provide participants the opportunity to describe stiffness in their own words. Data 
were qualitatively analysed and formulated into statements about the characteristics 
of MS which were subsequently posted to the original interview participants who were 
able to respond to each statement on a 5-point Likert scale (strongly agree to strongly 
disagree). This work resulted in a definition of MS as “slowness or difficulty moving 
the joints when getting out of bed or after staying in one position too long, which 
involves both sides of the body and gets better with movement” (Lineker et al, 1999, 
p.1105). This definition is unclear as it includes stiffness ‘after immobility’ which may 
not necessarily be MS as specified. Furthermore, the term MS was retained despite 
patients describing stiffness as present at other times of day or throughout the day. 
In addition, this paper was performed almost 20 years ago, since when there have 
been substantial changes in RA management and treatment (Smolen et al, 2010) and 
therefore possibly changes in stiffness experience.  
 
1.7 Stiffness treatment and management  
Within the literature a number of pharmacological and non-pharmacological 
interventions are suggested for stiffness. However, there is no standard treatment 
and management approach. 
 
1.7.1 Pharmacological treatment and management 
In terms of pharmacological interventions, recent research has explored 
chronotherapy where treatments are coordinated with circadian rhythms (Buttgereit 
et al, 2013). Here modified-release tablets (MRT) or timed-release tablet (TRT) are 
used, which release the active ingredient four hours after ingestion (Buttgereit et al, 
2013). In RA, MRT or TRT glucocorticoid treatments have been used to target 
symptoms of inflammation such as stiffness, before inflammatory activity starts. 
Observational trials have supported the overnight increase in IL-6 (Section 1.6.1) in 
people with RA. In a study involving nine RA patients, 24-hour blood sampling was 
conducted following two weeks of TRT prednisone. This demonstrated reductions in 
the amount of IL-6 present following TRTs (Clarke et al, 2011). The circadian 
administration of prednisone in RA (CAPRA) 1 and 2 trials, in which MS was a primary 
outcome measure, subsequently demonstrated reductions in MS using TRT 
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prednisone in large RCTs (Buttgereit et al, 2008; Buttgereit et al, 2013). In CAPRA 1, 
a night-time dose of timed-release glucocorticoid targeted at suppressing the early 
morning rise in IL-6, reduced MS duration by a mean 22.7%, compared to 0.4% in 
patients receiving the same dose in the morning (Buttgereit et al, 2008). In CAPRA 
2, significantly less MS severity, duration, and daytime recurrence were reported in 
the TRT group compared to the placebo group (Buttgereit et al, 2013). These studies 
assessed stiffness using a diary where patients recorded the time of waking, whether 
stiffness was present, and the time of resolution of stiffness. The time in minutes was 
then calculated as the difference between the time of resolution of MS and the time 
of waking. Patients were also asked to record the severity of stiffness in the morning 
and whether stiffness recurred during the day (reported in the evening).  
 
Early research suggestions of the effective use of glucocorticoids given in the evening 
(e.g. de Silva, Binder, and Hazleman, 1984) are contrary to early recommendations 
for daily doses being given in the morning (e.g. DiRaimondo and Forsham, 1958; 
Arvidson et al, 1997). Therefore glucocorticoids given in the morning continue to be 
routine as the evidence available for evening treatment is ambiguous (Kirwan, 2011). 
However, following the combination of advances in tablet technology and research 
demonstrating IL-6 and MS can be reduced by TRTs (e.g. Buttgereit et al, 2008; 
Clarke et al, 2011; Buttgereit et al, 2013), this may be changing and this rapidly 
developing area of research will continue using stiffness as an outcome. 
 
1.7.2 Non-pharmacological treatment and management 
There are a number of treatments that have been suggested to relieve stiffness, 
including exercise, hydrotherapy, splinting and heat (Hill, 2006). However, there is 
very little research regarding the effectiveness of these. In a systematic review 
looking at the effects of compression gloves in arthritis, four RCTs were identified 
(Hammond, Jones and Prior, 2015). Two reported significant reductions in self-
reported stiffness, however this was also reported in the placebo glove. Furthermore, 
the studies were identified as being poor quality and the review concluded that there 
is inconclusive evidence for the use of compression gloves in RA (Hammond, Jones 
and Prior, 2015). Another review of therapy gloves identified eight articles, seven of 
which reported on stiffness (Nasir, Troynikov and Massy-Westropp, 2014). Of these, 
six reported an improvement in MS duration or severity following the use of therapy 
gloves. However, the studies were generally of poor quality with little description of 
the therapy glove used (Nasir, Troynikov and Massy-Westropp, 2014). It was 
recognised in the one paper where no improvement was found, that this could be a 
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result of difficulty in stiffness assessment as patients were unable to differentiate 
between ‘mild’ or ‘moderate’ stiffness on the measurement scale used (Swezey et al, 
1979). This suggests that difficulty in the area of stiffness measurement may 
contribute to the limited research in this area.  
 
1.8 Stiffness in other rheumatic diseases 
Stiffness is not only relevant in the context of RA, it is also recognised by patients and 
clinicians in a number of other rheumatic diseases including polymyalgia rheumatica, 
AS, and OA. One of the criticisms of the 1987 classification criteria that includes MS 
(Arnett et al, 1988) was that it was not specific enough and can lead to false positive 
classification of RA in patients with other inflammatory conditions (Levin et al, 1996). 
The symptoms of pain and stiffness in RA, PMR, and AS appear to be highest in the 
early morning (Spies et al, 2010) which may indicate a shared pathology. However, 
there is little work exploring similarities and differences in the patient experience of 
stiffness in these different conditions. 
 
1.8.1 Polymyalgia rheumatica (PMR) 
PMR is a condition characterised by pain and stiffness, particularly of the shoulders 
and hips (Arthritis Research Campaign, 2005). MS >45 minutes is heavily weighted 
in the scoring algorithm in the PMR ACR/EULAR classification criteria (Dasgupta et 
al, 2012) and it features in the outer core of the provisional core domain set for PMR 
(Helliwell et al, 2016). Patients with PMR endorse stiffness as an important treatment 
outcome (Mackie et al, 2014) and a recent qualitative study developed understanding 
of the meaning, experience and impact of stiffness in PMR patients (Hughes et al, 
2012). In this work, MS or EMS were not typically described by patients, who instead 
discussed stiffness affecting them 24 hours a day with worsening at night and in the 
early morning. Patients also described a close relationship between stiffness and pain 
(Hughes et al, 2012). This is an important step towards a clearer understanding of 
stiffness in PMR. 
 
1.8.2 Ankylosing spondylitis (AS)  
AS is the most common of the spondyloarthritides and is an inflammatory condition 
that affects the spine, causing pain and stiffness (Hill, 2006). Stiffness is a feature in 
the modified criteria for AS (van der Linden, Valkenburg, and Cats, 1984) and is 
included in two items within the Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) (Garrett et al, 1994), which is the gold standard AS disease activity 
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assessment. Qualitative work into the patient experience of AS found that along with 
pain and fatigue, stiffness was discussed by participants and featured in all three 
identified themes which captured different life situations across levels of symptom 
management and requiring behaviour adjustment: ordinary life, slowed-down life and 
disrupted life (Mengshoel, 2008). However, the study involved 12 AS patients, eight 
of whom were women, which does not reflect an AS population that has a male to 
female ratio of 3:1 (Hakim, Clunie and Haq, 2011). There appears to be no current 
work specifically exploring stiffness in AS. 
 
1.8.3 Osteoarthritis (OA) 
OA is the most common form of rheumatic disease in the UK causing destruction of 
the hyaline cartilage of bone surfaces and overgrowth of bone, resulting in joint pain 
and stiffness in affected joints (Arthur and Hill, 2006). Stiffness is assessed in a 
number of composite OA assessments such as the Western Ontario McMaster 
Osteoarthritis Index (WOMAC) (Bellamy et al, 1988) and the Australian/Canadian 
Osteoarthritis Hand Index (AUSCAN) (Bellamy et al, 2002). There appears to be no 
current work specifically exploring the patient experience of stiffness in OA, but there 
is qualitative work exploring the patient perspective in relation to symptoms more 
broadly. One study investigated how patients manage symptoms of pain, aching or 
stiffness using focus groups (MacKay et al, 2014a) and interviews (MacKay et al, 
2014b), in total involving 51 people with self-reported OA or knee symptoms. Three 
core themes were identified following the focus groups including control of symptoms, 
seeking solutions, and active management, and two core themes using the combined 
dataset, including disrupted physical, emotional and social life and altered way of 
thinking about the body and self. This work highlights the engagement of patients in 
disease management strategies but also the broad impact, in the form of disruption 
that symptoms had. Another study involving the completion of self-reported 
questionnaires by 80 patients with clinically diagnosed OA, explored patient 
expectations about future symptoms (Dwek et al, 2015). Results indicated that 
generally patients were positive about future symptoms and expected the same or 
less pain and stiffness. Patients who predicted stiffness in one year to be better than 
at present also reported higher levels of behavioural engagement which reinforces 
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1.9 Stiffness in other populations  
Stiffness is also relevant in other populations, unrelated to rheumatology.  
 
1.9.1 Older populations  
Stiffness has been reported as relevant for older individuals within the general 
population. One study compared symptoms in individuals aged >50 years in the 
general population, with symptoms in people with RA (Sokka et al, 2007) to identify 
the proportion in each population that met the ACR remission criteria (Pinals et al, 
1981) or the OMERACT criteria for minimal disease activity (Wells et al, 2005). The 
study was based on a self-reported questionnaire to which 3105 people responded 
(80% response rate), of whom 1705 were RA patients, and 1400 were aged >50 years 
and in the general population. Over 15 minutes of MS was reported by 64.7% of RA 
patients and 36.6% of those aged >50 years in the general population (Sokka et al, 
2007) indicating that MS is relevant in the general population, although not to the 
same extent as in an RA population. 
 
1.9.2 Stiff person syndrome 
Stiff person syndrome is a rare but debilitating condition that causes stiffness and 
spasms, and results in a loss of independence and increased risk of falls (Dalakas, 
2009). Although the underlying process of stiff person syndrome is unclear, it is 
thought to be related to the autoimmune system, in particular the glutamic acid 
decarboxylase autoantibody which is linked to diabetes mellitus, which is often 
present in patients with stiff person syndrome (Hadavi et al, 2011). Although the 
symptom of stiffness is consistent with RA, the underlying mechanisms, although 
poorly understood in both conditions, appear to have different drivers.  
 
1.9.3 Phantom limb syndrome 
Stiffness has also been described by individuals with amputations who experience 
phantom limb. In a small study involving three people with RA and lower limb 
amputation, it was reported that patient-reports of stiffness were similar in their 
amputated and non-amputated limbs. As a result it was suggested that changes in 
the central nervous system may be the driving mechanism behind subjective patient-
reports of stiffness (Haigh et al, 2003). However, it has been argued that this proposal 
does not explain the evidence regarding the objective assessment of stiffness 
(Helliwell, 2004). 
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Chapter 2: Stiffness assessment and PROM development 
The previous chapter provided an introduction to RA and how it is managed and 
assessed. This chapter will address stiffness assessment, the purpose and use of 
PROMs and the literature surrounding their development. It will identify currently 
available stiffness PROMs, and their measurement property evidence. 
 
2.1 Stiffness assessment in RA 
The traditional biomedical model of healthcare focused on physical healing of 
biological dysfunction, therefore traditional measurement concepts focused on 
objective measurement (Elasy and Gaddy, 1998). Early work into stiffness 
assessment used engineering principals to design apparatus called arthrographs to 
measure the elasticity, inertia and plasticity of joints. Scott (1960) used a spring 
applied to the end of a finger and assessed the distance that the finger moved from 
a horizontal position. Ingpen and Kendal (1968) used a lever based mechanism and 
assessed the time taken for the finger to move the required distance. Wright and 
Johns (1960, 1961) used apparatus based on a pulley and lever system and 
assessed the force required to move the finger of individuals with and without 
connective tissue disease. This work concluded that these methods allowed the 
measurement of physical joint stiffness. However, no difference was demonstrated 
between participants with and without connective tissue disease (Wright and Johns, 
1961). The use of such early apparatus was restricted in its practical application 
because it was limited to use in the hands only, and it was bulky and uncomfortable 
for patients (Wright, Dowson, and Longfield, 1969). However, the development of 
lighter and more compact apparatus could be used in applied settings (Howe, 
Thompson, and Wright, 1985). Success with such apparatus was variable, as shown 
in one study which demonstrated that stiffness was no greater in RA patients than 
healthy controls (Helliwell, Howe and Wright, 1988). Despite this, further work 
provided a better understanding about the influence of muscle wasting and the 
positioning of the joint during measurement (Helliwell, Howe and Wright, 1987a), 
which led to a new measurement process that demonstrated increased stiffness in 
RA patients compared to healthy controls (Helliwell, Smeathers, and Wright, 1994). 
Although a positive conclusion was reached about the effectiveness of measures of 
physical stiffness, it has been suggested that this was outweighed by the effort of 
collecting this information in comparison to other tests of inflammation such as CRP 
(Helliwell et al, 2007). Furthermore, much of the literature regarding the assessment 
of physical stiffness is now rather dated which questions the appropriateness of its 
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application to todays population. Although more recently, the issue of physical 
stiffness measurement has been revisited by research focused on the design of a 
‘data glove’ to quantify joint stiffness and range of movement of the hand by 
measuring finger joint kinematics (Connolly et al, 2012). Although this does not solve 
the problem of stiffness affecting more than just the hands, it could provide a solution 
for the practical application of such a device in clinical, community or home based 
settings. Another recent abstract has reported using electromyography, a way of 
measuring electrical activity in muscles, to objectively assess stiffness (Mengi et al, 
2014). 
 
Another method of obtaining symptom assessment information is by asking patients 
directly. MS duration was included in early disease activity assessment (e.g. 
Lansbury index, Lansbury, 1958) and classification criteria (Arnett et al, 1988), and 
MS severity was used in research contexts (e.g. Harkness et al, 1982). Patient-
reported assessment reflects the increased importance of the use of PROs (de Wit 
et al, 2011) and has clear practical advantages over the bulky, apparatus based 
strategies described above. Another important justification for patient-reported 
assessment of stiffness is the lack of relationship between physical stiffness 
measures and patient-reported methods. A study comparing different stiffness 
assessment methods including a physical stiffness arthrograph and patient-reported 
assessment of MS duration and severity showed poor correlations and the authors 
concluded that the objective assessment methods did not relate to the subjective 
patient reports (Rhind, 1988). These finding were replicated in other work suggesting 
that physical stiffness is different to patient-reported stiffness (Helliwell, Howe and 
Wright, 1987b; Helliwell, Howe and Wright, 1988). 
 
2.2 Patient reported outcome measures (PROMs) 
2.2.1 What are PROMs? 
PROMs are an assessment of a patient’s health condition that comes directly from a 
patient, without any interpretation from another individual (US Department of Health 
and Human Services, Food and Drug Administration (USDHHS FDA), 2009). PRO is 
a term used to describe the concept of interest (e.g. disability) while PROM refers to 
a specific questionnaire that represents that PRO concept (e.g. HAQ, Fries et al, 
1980) (Patrick et al, 2011a). PROMs are particularly relevant when measuring 
concepts that are best understood by patients (USDHHS FDA, 2009), such as 
disease symptoms. They are vital in chronic conditions, where the evaluation of 
Chapter 2: Stiffness assessment and PROM development 
41 
 
therapies or interventions is more relevant than survival (Patrick et al, 2007). Here, 
some effects of therapies or interventions may only be known to the patient and this 
information would not be captured if not assessed directly (USDHHS FDA, 2009). 
PROMs also reflect aspects relating to patient priorities for therapies or interventions 
more so than captured in other clinician assessed outcomes (Leidy and Vernon, 
2008). 
 
2.2.2 Use of PROMs 
The recent focus on the use of PROMs highlights the increasing emphasis on 
incorporating patients and the public in all aspects of healthcare (Department of 
Health, 2010a) and is representative of the ideological shift away from patients being 
passive receivers of a service, towards patients as empowered and active 
participants in all aspects of care (Foot et al, 2014). As PROMs capture the patient 
perspective, they are particularly important in facilitating the involvement and 
engagement of patients in healthcare situations such as decision making (Frost et al, 
2007). They are also valuable for highlighting what is relevant to them as a patient, 
including patient-relevant symptoms (Kirwan et al, 2007). A specific example of the 
importance of patient involvement is the involvement of RA patients at OMERACT 
meetings which led to recognition of fatigue as an important patient symptom which 
is now measured alongside the core set in all RA studies as recommended by 
international consensus (Kirwan et al, 2007). As PROMs are only effective if they 
genuinely capture the patient perspective (Kerr, Nixon and Wild, 2010), it is vital that 
patients are involved in their development, specifically in relation to enhancing 
content validity (USDHHS FDA, 2009). Despite this, the development of content 
validity is often neglected (Patrick et al, 2007), and some PROMs are developed with 
little or no input from patients (Section 2.4) and therefore do not include the 
experiences and perspective of the user that is essential for content validity.  
 
2.3 PROM development theory  
2.3.1 Concepts of measurement  
For a measurement tool to be useful it must demonstrate appropriate measurement 
properties including validity, reliability, internal consistency, ability to detect change, 
floor and ceiling effects and interpretability (Terwee et al, 2007). Measurement 
properties and their assessments are described below.  
 
 




Broadly, validity is the degree to which a questionnaire measures what it intends to 
measure (Scientific Advisory Committee of the Medical Outcomes Trust (SACMOT), 
2002; Frost et al, 2007). Face and content validity refer to whether a measure looks 
appropriate (Streiner and Norman, 2008). Face validity refers to whether users 
perceive the instrument to capture the relevant information, while content validity 
looks at whether the instrument captures the appropriate and full range of relevant 
content (Frost et al, 2007; Streiner and Norman, 2008). The development of face and 
content validity requires qualitative methods with the relevant populations to develop 
and select appropriate items (Frost et al, 2007; Terwee et al, 2007; USDHHS FDA, 
2009). Criterion validity refers to how the questionnaire relates to other valid 
measures that assess the same concept (Streiner and Norman, 2008) or to a known 
‘gold standard’ (USDHHS FDA, 2009). This is difficult to assess as there is rarely a 
‘gold standard’ available for comparison (Frost et al, 2007), as the lack of other valid 
measures is often the reason for the development of a new scale. Construct validity 
is the extent to which the measure relates to theoretically relevant constructs (Frost 
et al, 2007; Terwee et al, 2007). Construct validity can target different aspects 
including convergent (demonstration of relationships where expected), divergent 
(demonstration of no relationship where expected), and discriminant (ability to 
distinguish between expected or known groups) validity (Streiner and Norman, 2008). 
A common approach to examine construct validity is to compare responses between 
the instrument to be tested and responses to measures that capture theoretically 
related concepts (SACMOT, 2002). Each aspect of construct validity should be 
performed using correlations to test specific and predefined hypotheses (Terwee et 
al, 2007).  
 
2.3.1.1.1 Definition of correlation cut-offs   
To assess aspects of validity identified in Section 2.3.1.1, Pearsons (parametric data) 
or Spearman’s rank order (non-parametric data) correlations can be used. A 
correlation of 1 or -1 indicates a perfect correlation while 0 indicates no correlation 
(Pallant, 2010). However, there are different recommendations regarding the strength 
of correlations required to define levels of acceptable validity (Table 2.1). For the 
purposes of validity testing in this study, correlations of r=0.5 were defined as weak, 
r=0.5-<0.7 as moderate and r=≥0.7 as strong. Broadly, strong correlations would be 
expected between measures assessing the same construct and weak correlations 
between measures addressing different constructs (Frost et al, 2007). 
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 Table 2.1: Different correlation cut-off definitions 
Authors Correlation cut-off definition 








Very strong: r=≥0.90 
 





Reliability is the degree to which a measure produces the same score each time it is 
administered when the measurement construct has not changed (SACMOT, 2002; 
Frost et al, 2007). Reliability can be assessed using test-retest in a population that 
has not changed (i.e. is the measure reproducible?) (Field, 2009). 
 
2.3.1.3 Internal consistency 
Internal consistency is an aspect of reliability concerned with the homogeneity of the 
items that make up an instrument (Field, 2009; DeVellis, 2012). Internal consistency 
looks at the relationships between items on the basis that items measuring the same 
concept should be consistent with each other. The advantage of internal consistency 
is that unlike test-retest, it can be generated from a single administration of the tool 
(Streiner and Norman, 2008). Internal consistency can be assessed using Cronbach’s 
alpha coefficient (DeVellis, 2012) where values of >0.7 are acceptable but values 
>0.8 are preferred (Pallant, 2010). 
 
2.3.1.4 Ability to detect change 
Ability to detect change or responsiveness is concerned with a tool’s ability to identify 
change (Terwee et al, 2007) for example, when the patient experience changes in 
the attribute being assessed, does the instrument score reflect that change? 
Definition of the minimally important clinical change expected and receiver operator 
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2.3.1.5 Other concepts of measurement  
Other concepts of measurement include floor and ceiling effects and interpretability. 
Floor and ceiling effects enable exploration of whether many participants respond to 
items using the highest or lowest categories and identify if more response options are 
required (Terwee et al, 2007; USDHHS FDA, 2009). Interpretability focuses on 
whether the quantitative scores from the measure relate to appropriate qualitative 
meaning (Terwee et al, 2007).  
 
2.3.2 Meeting the OMERACT filter 
The OMERACT Filter is a method of ensuring quality in PROMs for use in research 
and clinical settings. It is based around three concepts; truth, discrimination and 
feasibility (Boers et al, 1998). Truth relates to validity and whether the measure is 
unbiased and measures what it intends to measure. Discrimination relates to 
reliability and sensitivity and whether the measure can discriminate (e.g. patients with 
active or inactive disease). Feasibility relates to whether the measure is useful in 
applied situations (e.g. understandable and time efficient). The Filter relates to all 
parties involved in assessment including patients and depending on the purpose of 
the tool, researchers and/or clinicians (Boers et al, 1998). The original Filter has 
recently been recently updated. Filter 2.0 maintains the emphasis on the three original 
concepts but puts these in the context of updated philosophical and methodological 
approaches to health assessment (Boers et al, 2014).  
 
2.3.3 PROM development guidelines  
The FDA have produced guidelines on the evaluation, modification and development 
of PROMs, specifically in the context to support labelling claims (USDHHS FDA, 
2009). Although the focus on supporting labelling claims is not specifically relevant in 
this research, the use of a rigorous framework for item development is important. The 
development of content validity is also vital and this has been the focus of the 
International Society for Pharmaceconomics and Outcomes Research (ISPOR) PRO 
Content Validity Good Research Practices Task Force guidelines (Patrick et al, 
2011a, Patrick et al, 2011b). The use of such guidelines enable a rigorous and 
systematic process of PROM development. 
 
2.3.4 Test theory  
There are different approaches to PROM development including classical test theory 
(CTT) and item response theory (IRT). CTT is the traditional approach to outcome 
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measure development (Streiner and Norman, 2008) and is grounded in the idea that 
a participant’s observed score is the result of true score plus error (DeVellis, 2012). 
CTT is a broadly accepted and well used in scale development (Streiner and Norman, 
2008). However, there are limitations with CTT such as its dependency on the sample 
involved in development, which means that to apply items to a different sample 
requires re-testing it in each different sample. IRT includes models such as Rasch 
(Streiner and Norman, 2008), and was developed to overcome the limitations with 
CTT. For example, unlike in CTT, IRT models are not specific to the development 
population therefore the advantage of IRT is its invariance property (Streiner and 
Norman, 2008). However, IRT has its own associated limitations including that its 
invariance properties are not always demonstrated and differences between 
populations have been reported (Cook, Eignor and Taft, 1988; Miller and Linn, 1988).  
 
2.4 Current stiffness PROMs 
A systematic literature review investigating current stiffness assessment was recently 
performed (van Tuyl, Lems and Boers, 2014), aiming to identify currently available 
stiffness assessment measures and summarise their measurement properties. 
However, its focus was narrow, specifically looking at the measures available to 
assess RA patients in low disease activity or remission states. In order to identify 
currently available stiffness PROMs used across all RA disease activity states this 
systematic review was updated and its focus expanded (Section 2.4.1). 
 
2.4.1 Systematic literature review of stiffness PROMs 
2.4.1.1 Objectives 
This systematic literature review aimed to identify currently available stiffness 
assessment measures and summarise the evidence of their measurement properties. 
 
2.4.1.2 Methods  
To retain consistency, methods were based on the systematic review performed by 
van Tuyl, Lems and Boers (2014).  
 
2.4.1.2.1 Search strategy 
The search strategy included three key searches concerning: 1) construct (stiffness); 
2) population (adults with RA); 3) instrument (PROM). These topics were searched 
with a validated sensitivity and exclusion filter, designed to identify studies on 
measurement properties of instruments (Terwee et al, 2009). As the search strategy 
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was provided it was possible to replicate and update the search in accordance with 
the original review (van Tuyl, Lems and Boers, 2014), performed in PubMed on 
20/11/2012. The updated search was also performed in PubMed specifying dates 
from 20/11/2012 to 20/11/2013.   
 
2.4.1.2.2 Selection criteria and data collection 
Four rounds of review were performed to identify articles. Round one involved 
screening titles and abstracts to identify papers that included reports of the 
appropriate construct (stiffness) and PRO measurement, development or validation. 
This was performed by one researcher (Halls). Round two involved screening those 
titles and abstracts to identify papers that included reports of the appropriate 
population (adults with RA) and stiffness measurement properties. This was 
performed independently by Halls and a member of the supervisory team (SH). Any 
disagreements were discussed to guide decision making. Round three involved 
screening those full articles (Halls). Papers were selected for further consideration if 
they reported on stiffness in one of three ways: 1) stiffness as an outcome in relation 
to other core set disease activity measures; 2) the development of a stiffness PROM; 
3) a comparison of two or more different tools to measure aspects of stiffness or 
between a questionnaire that includes a stiffness item against another stiffness item. 
The reference lists of articles included in round three were also reviewed. Round four 
involved identifying the available stiffness PROMs and extracting information 
regarding their measurement properties, performed by Halls and discussed with a 
member of the supervisory team (SH). The data extraction form (Appendix A) was 
developed based on an example used in a study with similar aims (Hewlett, Hehir and 
Kirwan, 2007), and quality criteria for evaluating questionnaires (Terwee et al, 2007).  
 
2.4.1.3 Results  
2.4.1.3.1 Articles  
Nineteen full articles were included in the final selection round of the review. Three 
articles were found in the updated search and the other 16 were taken from the 
original review (van Tuyl, Lems and Boers, 2014) (Figure 2.1). During round two, the 
reviewers had different opinions about six papers (Shirinsky et al, 2013; Zakeri et al, 
2013; Jastrząbek et al, 2013; Cutolo et al, 2013; Wiesinger et al, 2013; Buttgereit et 
al, 2013). Given the uncertainty, these were retained for full review in round three. 
Although the reference lists were reviewed and two papers of interest were identified 
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(Lineker et al, 1999; Buttgereit et al, 2008), they did not contain relevant information 
but have been discussed elsewhere (Sections 1.5.4 and 1.7.1).  
 
 
Figure 2.1: Flow diagram showing article selection process 
 
2.4.1.3.2 Stiffness PROMs 
The stiffness assessment measures identified in the 19 articles (Table 2.2) all 
assessed stiffness from the concepts of duration or severity. Two studies did not 
define the concept that was assessed (Borstlap et al, 1995; Wiesinger et al, 2013). 
Stiffness assessment measures predominantly assessed MS or EMS. There were 
two exceptions; one investigated the severity of stiffness after sitting, lying down or 
resting during the day with clearly defined wording (Wolfe, 1999). Another assessed 
‘starting stiffness after a time of rest’ which appeared to be a severity item given by 
the anchors but the item wording was not defined (Leeb et al, 2003). Despite the few 
concepts assessed, there was considerable variation not only in respect to the 
Search dates: 20/11/2012 - 20/11/2013 
58 articles identified 
48 articles taken 
forward to 
Round 2  
8 articles taken 
forward to 
Round 3  
 3 articles taken 
forward to 
Round 4  
16 articles taken 
forward from 
original article 
(van Tuyl, Lems 
and Boers, 2014)  




19 full articles included in the updated review    





Round 3: 5 articles 
excluded (stiffness 
report not adequate) 
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wording of the question and response options, but also in relation to format (e.g. VAS 
or NRS) and timeframe (e.g. today, last 48 hours, last week). Many articles did not 
define the wording or other aspects of the items used. As a result it is not clear how 
stiffness questions were asked or reported. This means that not only are there many 
different versions of questions but where different questions are used, the exact 
format in which they are used is unknown, which further limits comparison across 




Table 2.2: Description of current stiffness assessment measures 





Severity of MS Exact wording unclear 10cm VAS: No stiffness to Very 
severe stiffness 
At the time 
of interview 




Severity of MS Exact wording unclear 11-point NRS: 0 (No stiffness) to 10 
(Very severe stiffness) 
Severity of MS Exact wording unclear 5-point verbal scale: No stiffness, 
mild, moderate, severe, very severe 
stiffness  
Duration of MS How long did it take for your 
stiffness to begin to ease after 







Severity of MS Exact wording unclear 10cm VAS: No stiffness to Very 
severe stiffness 















Severity of MS Exact wording unclear 11-point NRS: 0 (No stiffness) to 10 
(Very severe stiffness) 
Today 
Duration of MS How long does you MS last 
until it begins to improve? 
Minutes Today 
Duration of MS How long does your MS last 
until maximum improvement 
occurs? 
Minutes Today 
Duration of MS How long does it take you to 







Authors  Item concept Stem question  Response options/anchors Timeframe Patient sample 
Hazes et al, 
1994 
Duration of MS Waking to first improvement of 
MS 
Reported in minutes and categorised 
into: >1 hour; 1-3 hours; ≥3 hours 
Today 49 RA 
Duration of MS Waking to maximum 
improvement of MS 
Today 
Duration of MS Waking to complete 
disappearance of MS  
Today 
Duration of MS Getting up to maximum 
improvement of MS 
Today 
Duration of MS Getting up to first improvement 
of MS  
Today 
Duration of MS Getting up to complete 
disappearance of MS 
 
Today 
Ward, 1994 Duration of MS Patients were asked to report if 
they experienced morning 
stiffness and if so to estimate 
how long it typically lasted. 
Exact wording unclear 
 
Minutes. Exact options unclear Unclear 24 RA  
Buchbinder et 
al, 1995 
Duration of MS Patients asked to record time 
of awakening, time of arising, 
and time of cessation of MS. 
Exact wording unclear  
 







Borstlap et al, 
1995 
No mention of 
duration or 
severity 





10cm VAS: the lower the score, the 
more favourable the patients’ 
condition. Anchor wording unclear 
Unclear 62 OA+35 RA 
 51 
 
Authors  Item concept Stem question  Response options/anchors Timeframe Patient sample 
Vliet Vlieland 
et al, 1997 
Duration of MS How long does your morning 
stiffness last from waking until 
maximum improvement 
occurs?  
Minutes (cut-off at 240 minutes) Today 63+39 trial RA 
Severity of MS Exact wording unclear 
 
10cm VAS: None to Very severe Today 
Houssien, 
McKenna and 
Scott, 1997  
 
Duration of EMS Exact wording unclear Minutes Unclear 200 RA 
Wolfe, 1999  Severity of MS How severe has your stiffness 
been after you first woke up in 
the morning? 
Both validated in 5-point Likert scale 
(0=none, 1=mild, 2=moderate, 
3=severe, 4=extreme), 100mm VAS 
(0 (none)-10 (extreme)) and 11-point 
NRS (0 (none)-10 (extreme)). Item 
wording begins with: Think about 
stiffness (not pain) you felt during the 
last 48 hours caused by the arthritis in 
your knee to be injected. Stiffness is 
the sensation of decreased ease in 




1013 RA, 625 
OA, 531 FM 
Severity after 
sitting, lying 
down or resting 
during the day 
How severe has your stiffness 
been after sitting or lying down 
or while resting later in the 
day? 
Fransen et al, 
2000  
Duration of MS Were your joints stiff when you 
woke up today? No/Yes  
If yes, how long did this extra 
stiffness last? 
 
7-point Likert scale (0=none, 1=<30 
minutes, 2=30 minutes to an hour, 
3=1-2 hours, 4=2-4 hours, 5=more 
than 4 hours but less than all day, 
6=all day) 
 
Today 584 RA 
Sarzi-Puttini 
et al, 2002 
Duration of MS Exact wording unclear 
 
 
Minutes reported on a 100 mm VAS? 
Anchor wording unclear 
Unclear  105 RA 
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Authors  Item concept Stem question  Response options/anchors Timeframe Patient sample 
Leeb et al, 
2003  
Daily MS severity Exact wording unclear  
 
100mm anchored VAS: no stiffness to 
unbearable stiffness 
Unclear 103 RA+69 OA 
Starting stiffness 
after a time of 
rest 
Exact wording unclear  
 
100mm anchored VAS: no stiffness to 
unbearable stiffness 
Unclear 
Duration of MS Exact wording unclear  
 
Minutes Unclear 
Yazici et al, 
2004 




Reported in minutes and 
subsequently categorised into four 
groups: 0, 1-15, 16-59, and 60+ 
Unclear 337 RA 
Westhoff et 
al, 2008 
Severity of MS Exact wording unclear 
 
 
11-point NRS: No morning stiffness at 
all to Extremely severe morning 
stiffness 
Unclear 916 RA  
Duration of MS Exact wording unclear Minutes 
 
Unclear 
Khan et al, 
2009 






Reported in minutes and 
subsequently categorised into: None 
(0 minutes), mild (1-30 minutes), 
moderate (31-60 minutes), severe 
(>60 min) 
Last week 5439 RA 
El Miedany et 
al, 2010 
Duration of MS ‘Over the last week when you 
awakened in the morning, did 
you feel stiff? Please indicate 
the number of minutes, or 
hours until you are as limber 
as you will be for the day.’ 
 
Minutes/hours Not defined 
for question 




Authors  Item concept Stem question  Response options/anchors Timeframe Patient sample 
Wiesinger et 
al, 2013 




Exact wording unclear Unclear Unclear 451 RA 
Jastrzabek et 
al, 2013 
Duration of MS 
 
 
Exact wording unclear  
 
Minutes Unclear 40 RA 
Lie et al, 2014 Severity of MS How would you describe the 
overall level of morning 
stiffness you have had from 
the time you wake up? (Q5 
from BASDAI; Garrett et al, 
1994)  








for 39% of 
patients) 
Duration of MS How long does your morning 
stiffness last from the time you 
wake up? (Q6 from BASDAI; 
Garrett et al, 1994) 
 
10cm VAS: 0 (0 hours) to 10 (2 or 
more hours) with marked intervals at  
½ hour, 1 hour, and 1½ hours 
NIC=non-inflammatory complaint; PsA=psoriatic arthritis; IBD=inflammatory bowel disease 
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2.4.1.3.3 Measurement properties of stiffness PROMs 
2.4.1.3.3.1 Validity 
Most measurement property evidence related to validity including face, content, 
criterion and construct validity (Section 2.3.1.1). 
 
2.4.1.3.3.1.1 Face and content validity 
No studies reported directly on the face validity of the stiffness items. However, two 
studies reported on content validity (Leeb et al, 2003; Lie et al, 2014). One described 
the process of item generation which involved the study authors proposing relevant 
items which were ranked and reduced using a Delphi approach and discussions with 
other health professionals (Leeb et al, 2003). This provides content validity evidence 
given item development involved clinical experts. However, no patient involvement 
was reported. The study by Lie et al. (2014) was interested in the content validity of 
the proposed flare domains rather than stiffness specifically. Therefore studies 
provided limited evidence regarding the content validity of the identified stiffness 
items.  
 
2.4.1.3.3.1.2 Criterion validity 
Seven studies reported the relationship between different stiffness items (Rhind, 
Unsworth and Haslock, 1987; Hazes, Hayton, and Silman, 1993; Hazes et al, 1994; 
Vliet Vlieland et al, 1997; Leeb et al, 2003; Westhoff et al, 2008; Lie et al, 2014). 
These included comparisons between items assessing different concepts (duration 
and severity) and between items assessing the same concept (e.g. duration using 
different wording or timeframes). When looking at comparisons between items 
assessing different concepts, weak to strong correlations were reported (Table 2.3). 
This suggests that despite severity and duration being used interchangeably, these 
concepts may capture different information. However, this is difficult to tell given the 
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Table 2.3: Correlations between items assessing different concepts 
Authors Items compared Results 
Westhoff et 
al, 2008 
Severity of MS vs duration of MS (baseline) rs=0.75, p<0.001 




Lie et al, 
2014 
 
Severity of MS vs duration of MS 
 
rs=0.63* 
Leeb et al, 
2003 
 




et al, 1997 
Severity of MS vs duration of MS (Study 1) rs=0.63, p<0.001 








Severity of MS vs duration of MS (VS) rp=0.42* 
Severity of MS vs duration of MS (NRS) rp=0.41* 






Severity of MS vs duration of MS Reported as 
‘poor’+ 
VS=verbal scale; *=p not reported; +=no values provided 
 
The evidence also varied when reviewing comparisons between items assessing the 
same concept using different wording or timeframes. Although items assessing the 
same concept using different formats were highly correlated, items assessing the 
same concept using different timeframes correlated weakly (Table 2.4). This 
questions the value of using different stiffness time cut-offs and which is the most 
appropriate. The differences in results when excluding patients who reported stiffness 
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Table 2.4: Correlations between items assessing the same concept 




MS severity NRS vs MS severity VAS rp=0.84* 
MS severity verbal scale vs MS severity NRS rp=0.81* 
MS severity verbal scale vs MS severity VAS rp=0.84* 
Present stiffness VS vs present stiffness NRS rp=0.90* 
Present stiffness VS vs present stiffness VAS rp=0.87* 
Present stiffness NRS vs present stiffness VAS  rp=0.91* 
MS severity VS vs present stiffness VS rp=0.47* 
MS severity NRS vs present stiffness NRS rp=0.42* 







MS duration time to initial improvement vs MS 
duration time to maximum improvement 
 
r=0.41* 
Hazes et al, 
1994 
MS duration (time until first improvement) diary vs 




MS duration (time until maximum improvement) 




MS duration (time until MS disappears) diary vs 
MS duration (time until MS disappears) interview 
rp=-0.06* 
(rp=0.88)*^ 
VS=verbal scale; *=p not reported; ^=excluding patients reporting stiffness all day 
 
2.4.1.3.3.1.3 Construct validity 
As construct validity explores relationships between items and theoretically related 
concepts (SACMOT, 2002), stiffness items would be expected to demonstrate 
relationships with other measures of RA including disease activity and other 
symptoms. It would also be expected that items could discriminate between known 
groups. Firstly, given that stiffness is considered an indicator of inflammatory activity 
in RA (e.g. Lansbury, 1956; Scott, 1986; Hazes et al, 1994; Soubrier et al, 2006) it 
would be expected that stiffness items would demonstrate moderate relationships 
with other variables reflecting inflammatory activity such as disease activity. Only two 
studies investigated the relationship between stiffness items and composite RA 
disease activity assessment (DAS28) (Westhoff et al, 2008; Khan et al, 2009). These 
reported weak or moderate correlations, with MS severity demonstrating marginally 
stronger correlations. Studies have also reported on relationships between stiffness 
and other disease activity measures including core set variables (e.g. SJC), again 
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DAS28 rs=0.47, p<0.001 
TJC  rs=0.31, p<0.001 
SJC rs=0.28, p<0.001 
CRP  rs=0.20, p<0.001 





DAS28 rs=0.58, p<0.001 
TJC  rs=0.48, p<0.001 
SJC  rs=0.35, p<0.001 
CRP  rs=0.22, p<0.001 
ESR  rs=0.21, p<0.001 
 




DAS28 rs=0.46, p<0.001 
TJC  rs=0.39, p<0.001 
SJC  rs=0.33, p<0.001 
ESR  rs=0.23, p<0.001 
PGA  rs=0.39, p<0.001 
 




TJC  rp=0.54, p<0.0001 
SJC  rp=0.38, p<0.05 
ESR  rp=0.21, p<0.05 






TJC  rs=0.36, p<0.0001 
SJC  rs=0.25, p<0.0001 
ESR rs=0.17, p<0.0001 
PGA  rs=0.36, p<0.0001 
 




TJC  OR 1.23, 95% CI 1.14-1.30 
SJC  OR 1.05, 95% CI 1.01-1.10 










et al, 1997 
Duration of 
MS 
SJC rs=0.12 (Study 1), rs=0.07 (Study 2)** 
CRP rs=0.10 (Study 1), rs=0.08 (Study 2)** 
PGA  rs=0.20 (Study 1), rs=0.06 (Study 2)** 
Severity of 
MS 
SJC  rs=0.00 (Study 1), rs=0.11 (Study 2)** 
CRP  rs=0.01 (Study 1), rs=0.14 (Study 2)** 
PGA  rs=0.06 (Study 1), rs=0.17 (Study 2)** 
PGA=physician global assessment; **=p not significant 
 
Secondly, articles demonstrated relationships between stiffness and theoretically 
relevant constructs including disability, pain (Tables 2.6-2.7), and fatigue. A number 
of studies reported weak correlations between MS duration and disability while weak 
to strong correlations were reported between MS severity and disability (Table 2.6). 
However, some reported correlations included the whole study sample and not 
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exclusively RA patients (Wolfe, 1999; El Miedany et al, 2010; Jastrzabek et al, 2013) 
and disability assessment varied across studies. Overall, the evidence regarding the 
relationship between stiffness using current measures and disability is inconclusive. 
Although MS severity items appear to demonstrate stronger relationships with 
disability than MS duration, evidence is limited and comparisons are difficult given 
inconsistency and poor reporting of items.  
 











HAQ (Fries et al, 
1980) 
rs=0.42, p=0.0068 





HAQ (Fries et al, 
1980) 
rp=0.25, p<0.01 





HAQ (Fries et al, 
1980) 
rs=0.43, p<0.001 









et al, 1997 
Duration 
of MS 
HAQ (Fries et al, 
1980) 
rs=0.04** (Study 1), 
rs=0.24, p<0.05 (Study 2) 
Severity of 
MS 
HAQ (Fries et al, 
1980) 
rs=0.42, p<0.05 (Study 1), 








HAQ (Fries et al, 
1980) 
rs=0.33, p<0.05 






et al, 1990, in 




p<0.001 (three year 
follow-up) 




indices (Bellamy et al, 
1988) 
 
rs=0.76, p<0.0001  




MHAQ (Pincus et al, 
1983) 
OR 6.89, 95% CI 3.82-
12.4 
**=p not significant 
 
The relationship between stiffness and pain was reported in a number of studies. As 
seen with disability, pain has been reported to correlate weakly with MS duration but 
weak to strong correlations have been reported with MS severity (Table 2.7). As with 
disability, the evidence regarding the relationship between pain and stiffness using 
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current measures is varied depending on the items used. Again, stronger correlations 
are observed for MS severity than MS duration however, evidence is limited.  
 
Table 2.7: Correlations between stiffness items and pain 
Authors Stiffness item Results 
Sarzi-Puttini, 2002 
 
Duration of MS rs=0.43, p<0.001  
Khan et al, 2009 
 
Duration of MS rs=0.48, p<0.001 
Fransen et al, 2000 
 
Duration of MS rs=0.49, p<0.0001  
Vliet Vlieland et al, 
1997 
 
Duration of MS rs=0.19** (Study 1), rs=0.36, p<0.05 
(Study 2)  
Severity of MS rs=0.48, p<0.001 (Study 1), rs=0.47, 
p<0.001 (Study 2) 
 
Houssien, McKenna 
and Scott, 1997 
 
Duration of MS rs=0.41, p<0.05  
Westhoff et al, 2008 Severity of MS rs=0.66, p<0.001 (baseline), rs=0.76, 
p<0.001 (three year follow-up) 
 
Wolfe, 1999 WOMAC 
stiffness index  
 
rs=0.73, p<0.0001 
Yazici et al, 2004 Duration of MS OR 1.44, 95% CI 1.32-1.58  
**=p not significant 
 
The relationship between stiffness and fatigue was infrequently reported. In studies 
with RA patients only, MS duration was significantly associated with fatigue in 
regression analyses (OR 1.28, 95% CI 1.19-1.39) (Yazici et al, 2004) and correlated 
weakly with fatigue (rs=0.39, p<0.001) (Khan et al, 2009). In a study including RA, OA 
and FM patients, a moderate correlation was demonstrated between the WOMAC 
stiffness index and fatigue (rs=0.52, p<0.0001) (Wolfe, 1999).  
 
Finally, some studies provided evidence that stiffness items could discriminate 
between expected groups. Three studies reported stiffness items discriminating 
patients in relation to disease activity. One study compared three and six month 
changes in flare domains between patients in flare and not in flare. MS severity 
demonstrated one of the largest standardised mean differences (SMD) (SMD=1.17, 
95% CI 0.78-1.55) of all assessed variables along with physician global assessment 
(SMD=1.31, 95% CI 1.07-1.55), pain VAS (SMD=1.30, 95% CI 1.06-1.54), and body 
pain (SMD=1.24, 95% CI 1.00-1.48). These were similar to DAS28 (SMD=1.26, 95% 
CI 1.00-1.52) which was collected for reference. However, the CI’s for MS severity 
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were wide, suggested to be the result of less stiffness data than other variables (Lie 
et al, 2014). Another study reported that MS duration was significantly different 
among patients defined by different disease activity states (F(35226)=273.8, 
p<0.001). A ROC demonstrated that MS duration could moderately differentiate 
active from inactive disease (area under the curve=0.74, 95% CI 0.72-0.75) (Khan et 
al, 2009). In another study, MS severity demonstrated marginally better ability to 
discriminate between RA patients with active and inactive disease (sensitivity=85%, 
specificity=44%) than MS duration (sensitivity=78%, specificity=30%). However, 
disease activity definitions were based on physician judgement rather than 
standardised assessment. The study also reported that MS severity (sensitivity=72%, 
specificity=31%) and MS duration (sensitivity=74%, specificity=30%) were unable to 
discriminate patients with RA from those with non-inflammatory conditions (Hazes, 
Hayton, and Silman, 1993). A further study reported ROCs of the stiffness change 
scores for patients that had demonstrated improvement consistent with ACR criteria. 
Here MS severity appeared more sensitive to change than MS duration (area under 
the curve 0.77 and 0.70 respectively) (Vliet Vlieland et al, 1997). Although severity 
items appear to perform better than duration items, overall the evidence regarding 
discriminant validity is inconclusive and the use of different item formats limits 
comparison. 
 
2.4.1.3.3.2 Other measurement properties 
There was limited evidence in relation to other measurement properties including test-
retest reliability, internal consistency, ability to detect change, floor and ceiling effects 
and interpretability. Two studies provided evidence regarding internal consistency 
(Leeb et al, 2003; Fransen et al, 2000). The SACRAH demonstrated good internal 
consistency overall (α=0.98) and for each domain (function α=0.98, stiffness α=0.79, 
pain α=0.90), although these results were generated from the whole sample which 
included patients with OA and RA. However, strong correlations (rs=0.80-0.86) were 
reported between domain items and the total SACRAH specifically for RA patients 
(Leeb et al, 2003). Good internal consistency was also reported for the RADAI 
(α=0.87), which could have been increased slightly with the removal of the MS item 
(α=0.89). The stiffness item demonstrated moderate correlations with all combined 
RADAI items (rs=0.51), although correlations between MS duration and each item 
individually were weak (disease activity last 6 months rs=0.37, disease activity today 
rs=0.46, pain rs=0.47, tender joints rs=0.48, all p<0.0001). 
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Four studies reported on ability to detect change (Vliet Vlieland et al, 1997; 
Buchbinder et al, 1995; Borstlap et al, 1995; Ward et al, 1994). One study 
demonstrated that stiffness scores significantly improved across time points (pre-
operative, 3, 6, 12 months) in the RA group (Borstlap et al, 1995). However, this study 
provided no description of the stiffness question used other than that it was measured 
on a VAS. Another study reported that MS duration was not sensitive to changes in 
clinical status (Ward et al, 1994). However, sensitivity to change was not based on 
outcomes assessed before and after a treatment but over time, with estimates of 
clinical change based on minimum and maximum scores of other variables (physician 
global assessment, PtG, disability index, ESR). The time interval between the 
maximum and next minimum value represented the rate of change and this time 
interval was used to explore scores of other variables (such as stiffness). Thus the 
relationship between the variables used to generate the rate of change and the 
comparison variable could influence the results. Although a range of assessments 
(laboratory, clinician and patient) were used and MS duration performed consistently 
poorly across all measures. Another study investigated the ability of commonly used 
outcome measures to detect treatment effects. Here the relative efficiency (RE) of 
variables was compared to that of TJC. Although the RE of MS duration was only 
0.23, it was not significantly different to TJC, as were pain (measured on a 5-point 
scale, RE=0.18) and ESR (RE=0.01). However, it was lower than other patient-
reported variables including PtG (RE=1.17) and pain (measured on a 10cm VAS, 
RE=0.45) (Buchbinder et al, 1995). Finally, one article involving two studies 
investigated the ability to detect change using different stiffness items (Vliet Vlieland 
et al, 1997). The first study was observational and involved 63 RA patients who were 
hospitalised because of disease activity or functional decline. As expected, 
improvements in outcomes were reported between hospitalisation and discharge. 
When comparing different stiffness items, MS severity (effect size (ES)=0.74, 
standardised response mean (SRM)=0.64) demonstrated greater change than MS 
duration (ES=.41, SRM=.46). The second study was an RCT involving 80 RA patients 
starting or changing treatment. Differences between treatment and control group 
were greater for MS severity (two weeks ES=0.68, 12 weeks ES=0.49, 52 weeks 
ES=0.43) than MS duration (two weeks ES=0.30, 12 weeks ES=-0.07, 52 weeks 
ES=-0.16) at all time points, and were significantly different at the two later time points 
(12 weeks z=2.49, p=0.013 and 52 weeks z=2.60, p=0.009). Overall the article 
concluded that MS severity was a responsive outcome in comparison to other 
outcomes and MS duration (Vliet Vlieland et al, 1997).  
 




This review aimed to identify currently available stiffness PROMs and provide a 
summary of the evidence of their measurement properties. The 19 identified studies 
contained 37 individual stiffness assessment measures. All studies that defined the 
concept of stiffness assessment were based on either duration or severity and most 
assessed MS or EMS. However, despite the narrow focus of items, the variation in 
assessment of these concepts was considerable and item definition was poor, even 
in studies where stiffness assessment was the primary purpose. There was limited 
evidence of the measurement properties of stiffness items with evidence principally 
related to construct and criterion validity. However, given the variation and poor 
reporting of items, it was difficult to compare across studies, highlighting the 
difficulties posed when using stiffness PROMs in research.  
 
Acknowledging the limited evidence and difficulties with item comparison, severity 
items appeared to perform better than duration items. Severity items displayed 
stronger construct and criterion validity and better discriminatory ability than MS 
duration. Of the six studies that contained assessment of both severity and duration 
items, four articles specifically recommended severity items over duration items 
based on their performance (Hazes, Hayton, and Silman, 1993; Vliet Vlieland et al, 
1997; Westhoff et al, 2008; Lie et al, 2014). For example, Westhoff et al. (2008) stated 
that despite assessing both MS severity and MS duration, they only reported results 
for MS severity because it was more responsive. Conversely, in stiffness assessment 
in low-disease states, the two identified studies (Hazes, Hayton, and Silman, 1993; 
Khan et al, 2009) made conflicting recommendations regarding whether severity or 
duration was best (van Tuyl, Lems and Boers, 2014). Overall, there appears to be no 
clear evidence regarding the most appropriate measure to use to assess stiffness in 
RA. 
 
From a content validity perspective, little evidence suggested that current stiffness 
measures have been developed using recommended methodology including 
qualitative exploration (USDHHS FDA, 2009; Patrick et al, 2011a; Patrick et al, 
2011b). This may in part explain some difficulties identified with duration items. One 
study suggested that patients find completing duration items difficult and are often 
forced to report a cut-off time (Hazes et al, 1994). In another study, 19 participants 
reported that they had no stiffness when responding to an MS duration item yet 
reported a measurable amount of stiffness on an MS severity item (Vliet Vlieland et 
al, 1997). This may indicate difficulties for patients completing duration items or that 
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the items capture different information. Uncertainty regarding the content of duration 
items has also been reported by experts in RA and/or spondylarthropathy (Berthelot 
et al, 2002). Participants were asked “when you ask patients how long their morning 
stiffness lasts, do you indicate: until there is no more stiffness or until maximal 
improvement of stiffness is reached?” (p.149). There was inconsistency in responses, 
with six and 26 of the 32 responders indicating the respective options (Berthelot et al, 
2002). In terms of severity, other studies have suggested that there are no difficulties 
for patients (Rhind, Unsworth and Haslock, 1987; Vliet Vlieland et al, 1997). These 
suggestions may relate to work indicating that MS severity has more impact on RA 
patients than MS duration (Mattila, Buttgereit and Tuominen, 2014), and that patients 
would pay more for a reduction in MS severity than MS duration (Tuominen, 
Tuominen and Möttönen, 2011; Tuominen, Tuominen and Möttönen, 2012). These 
results are particularly interesting when considering that duration items are most 
frequently implemented in research trials (Kalyoncu et al, 2009). It has been 
suggested that further research into different wording of stiffness items and better 
understanding of the value of assessing duration versus severity would be a useful 
addition to the literature (Lie et al, 2014). Further work therefore, to explore the patient 
perspective regarding stiffness assessment would be appropriate to enhance content 
validity and would also be consistent with PROM development recommendations 
(USDHHS FDA, 2009). 
 
Having stated that the evidence regarding measurement properties provided by this 
review was limited, it is acknowledged that this review is not exhaustive. The search 
strategy used specifically identified articles containing measurement property 
information thus identifying a manageable number of articles containing relevant 
information. However, given that stiffness is a commonly used outcome measure 
(Kalyoncu et al, 2009), there will be many studies that were not identified by this 
review which may provide additional evidence for some or all of the stiffness 
assessment measures identified. This review was also limited in its focus on 
measures developed for an RA population. However, the search strategy was initially 
broad and included a wide range of rheumatic conditions so as to include any 
measures that may have been validated or tested in an RA population. Studies tested 
in an RA population were specifically included in Round 2 of the review and the 
broader literature including other conditions is addressed later (Section 2.4.2). 
Another limitation of the review is that there was no assessment of the quality of the 
identified studies. The strengths of the review include performing an update on a high 
quality, published systematic literature review (van Tuyl, Lems and Boers, 2014).  
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Overall, this review indicates that there is currently no clear evidence regarding the 
most appropriate measure to use to assess stiffness in RA. Current stiffness 
assessment relies on non-standardised and unvalidated EMS/MS duration or severity 
questions, which do not appear to have been developed according to current 
standards including collaboration with patients (USDHHS FDA, 2009; Patrick et al, 
2011a; Patrick et al, 2011b), or methods recommended by OMERACT (Boers et al, 
1998). Further work into the development of a stiffness measure with appropriate 
content validity would be a beneficial addition to the literature, as would further work 
to test defined stiffness measures to provide recommendations regarding the most 
appropriate stiffness tool to use in future research.  
 
2.4.2 Identification of other stiffness measurement literature 
Stiffness is not exclusively experienced by people with RA but also by those with other 
rheumatic diseases. Discussion at the OMERACT 12 conference (Orbai et al, 2015) 
highlighted that a number of PROMs used in other rheumatic conditions include 
stiffness items and that investigation into stiffness assessment in a broader 
rheumatology context would be relevant. As such, a scoping review was performed 
to identify common tools used in a rheumatology context that included stiffness items. 
The scoping review was performed based on expert suggestions during discussion 
at OMERACT and was furthered by evaluation of known articles, and other hand 
searching to identify relevant measures. In addition, some RA specific scales that 
were known to the researcher, and included stiffness items but had not been identified 
in the earlier review were also included here. The development and validation papers 






Table 2.8: Papers that describe scale development and/or validation where stiffness item/s are included within the scale 












How would you describe the 
overall level of morning 
stiffness you have had from 
the time you wake up? 
 





How long does your morning 
stiffness last from the time you 
wake up? 
 
10cm VAS: 0 (0 hours) to 10 (2 or 
more hours) with marked intervals 
at  ½ hour, 1 hour, and 1½ hours 
Past week 








How long does your morning 




10cm VAS: 0 (0 hours) to 10 (2 or 
more hours) with marked intervals 















100mm anchored VAS: no stiffness 
to very stiff with marked increments 
Past 7 
days 




Severity Please rate your level of 
stiffness 
100mm anchored VAS: no stiffness 
































































Exact wording unclear  
 
100mm anchored VAS: no stiffness 








Exact wording unclear  
 
100mm anchored VAS: no stiffness 








Exact wording unclear  100mm anchored VAS: no stiffness 









Exact wording unclear  
 
100mm anchored VAS: no stiffness 








How severe was your joint 
stiffness immediately after 
waking up first thing in the 
morning? 
 
Anchored Likert scale: 0 (no 














How severe has your stiffness 
been after you first woke up in 
the morning? 
 
Both validated in 5-point Likert 
scale (0=none, 1=mild, 
2=moderate, 3=severe, 
4=extreme), 100mm VAS (0 
(none)-10 (extreme)), and 11-point 
NRS (0 (none)-10 (extreme)). Two 
items transformed to one score. 





How severe has your stiffness 
been after sitting or lying down 




Population Authors  Scale Concept Stem question  Response options/anchors Timeframe 
OA cont. about stiffness (not pain) you felt 
during the last 48 hours caused by 
the arthritis in your knee to be 
injected. Stiffness is the sensation 












Targets stiffness after first 
wakening in the morning (exact 
wording unclear) 
Validated in 5-point Likert scale 
(0=none, 1=slight, 2=moderate, 3= 
severe, 4=extreme), 100mm VAS 
(0 (none)-10 (extreme)), 11-point 






























Were your joints stiff when you 
woke up today? No/Yes  
If yes, how long did this extra 
stiffness last? 
7-point Likert scale (0=none, 1=<30 
minutes, 2=30 minutes to an hour, 
3=1-2 hours, 4=2-4 hours, 5=more 












Were your joints stiff when you 
woke up today? No/Yes  
If yes, how long did this extra 
stiffness last? 
7-point Likert scale (0=none, 1=<30 
minutes, 2=30 minutes to an hour, 
3=1-2 hours, 4=2-4 hours, 5=more 








Did you experience joint (hand) 
stiffness on awakening 
yesterday morning? If yes, how 
long was this stiffness? 
 
11-point Likert scale: 0 (no 






Population Authors  Scale Concept Stem question  Response options/anchors Timeframe 








Were your joints stiff when you 
woke up today? No/Yes  
If yes, how long did this extra 
stiffness last? 
7-point Likert scale (0=none, 1=<30 
minutes, 2=30 minutes to an hour, 
3=1-2 hours, 4=2-4 hours, 5=more 











I have morning stiffness of one 
hour or more? 
 
7-point Likert scale: 0 (always)- 
10 (never) 
Last week 
   Stiffness 
after rest 
I feel stiffness in my joints after 
rest? 




*disease activity composite assessment 




The scoping review identified 15 scales containing 20 individual items (Table 2.8). As 
in the systematic literature review (Section 2.4.1), the identified stiffness items 
generally assessed the concepts of duration or severity. Most items assessed MS, 
although some assessed stiffness after rest (Bellamy et al, 1988; Anderson, 2001; 
Leeb et al, 2003; Sautner et al, 2004), and others assessed stiffness more broadly 
(Burckhardt, Clark, Bennett, 1991; Bennett et al, 2009). There was variation in 
stiffness item wording, response options, format, and timeframe. Although there was 
slightly better definition of items, this was still not consistent across all scales and 
identification of the precise question often entailed exploring a number of validation 
papers or scale documents.  
 
There was replication of some items, as a number of the scales identified were 
updates of previous scales. For example, the original RADAR (Mason et al, 1992) 
was developed into the RADAI (Stucki et al, 1995), from which the PDAS2 (Choy et 
al, 2008) was developed, and all include the same MS duration item. However, no 
evidence was provided regarding the development of the content of the scale 
including involvement of patients. The RADAI-5 (Leeb et al, 2008) was developed to 
increase the ease of scoring of the original RADAI (Stucki et al, 1995) thus the 
anchors for all items were standardised on an 11-point Likert scale. However, the 
wording of the stiffness item was also changed to emphasise the hands and the 
timeframe was changed, yet no justification was provided (Leeb et al, 2008). The 
SACRAH (Leeb et al, 2003) was developed into the M-SACRAH (Sautner et al, 2004) 
and the SF-SACRAH (Rintelen et al, 2009). The SACRAH (Leeb et al, 2003) and M-
SACRAH (Sautner et al, 2004) only define the question concept and the anchors used 
while the SF-SACRAH (Rintelen et al, 2009) defines the full item wording. However, 
the original SACRAH (Leeb et al, 2003) was developed in German and is not 
validated in English (Rintelen et al, 2009). 
 
The WOMAC (Bellamy et al, 1988) and the AUSCAN (Bellamy et al, 2002) share 
similar items and development process. There is considerable evidence regarding 
the measurement properties of the WOMAC (McConnell, Kolopack and Davis, 2001) 
which was developed with substantial OA patient involvement (Bellamy and 
Buchanan, 1986). However, there is limited measurement property evidence for the 
stiffness subscale which demonstrates good internal consistency but has been 
reported to have inadequate test-retest evidence, and is omitted from some trials 
(McConnell, Kolopack and Davis, 2001). The AUSCAN was developed to assess 
hand pain, stiffness and disability in OA (Bellamy et al, 2002) and was based on the 




rigorous item generation process used in the WOMAC (Bellamy et al, 1988). This 
involved item generation from a systematic literature review and clinician involvement 
in closed-question development for use in patient interviews that focused on the 
importance of the developed items (Bellamy et al, 2002). Therefore, although patients 
were involved in item review, they were not directly involved in item development 
(Poole, 2011). 
 
The BASDAI contains two stiffness items, on MS severity and duration (Garrett et al, 
1994). The BASDAI was developed with input from clinical and patient AS experts. 
However, no detail about the specific patient involvement was provided. The ASDAS 
was developed as a new method of disease activity assessment in AS (Lukas et al, 
2009) and includes the MS duration question from the BASDAI (Garrett et al, 1994). 
The development of the ASDAS was based on the process used in the development 
of the DAS (van der Heije, 1993). A Delphi exercise involving clinical and patient AS 
experts was performed and after three Delphi rounds (where items were retained if 
endorsed by >80% responders), the MS duration item was one of 12 retained items. 
The advantage of this process was the involvement of patients in the Delphi. 
However, it was unclear whether both stiffness items from the original BASDAI were 
included in the Delphi exercise, and the voting process during each round was not 
reported, so there is no evidence as to why the duration item was selected and the 
severity item was not. 
 
Finally the FIQ (Burckhardt, Clark, Bennett, 1991) and the updated FIQR (Bennett et 
al, 2009) were developed for FM assessment. The updated FIQR items were 
developed to overcome scoring difficulties with the original FIQ that restricted its use. 
Items were modified based on the original FIQ and relevant literature and were 
discussed with a focus group of 10 FM patients (Bennett et al, 2009).  
 
The two remaining items were not based on development of other scales. The PMR 
activity score was developed as a composite assessment of disease activity (Leeb 
and Bird, 2004). The RAPS (Anderson, 2001) was developed specifically to assess 
pain in people with RA. Items were developed based on the content from pain theories 
within the literature and interviews with RA patients. However, as in many of the 
above scales, the involvement of patients in the development of items was not 
described. 
 




This scoping review has identified that within the broader rheumatology literature, 
there are a number of validated questionnaires that include stiffness items. Although 
the validated nature of these tools provides evidence for their use, they were 
developed in populations other than RA. It is not known whether stiffness assessment 
could be general across conditions or whether disease specific stiffness assessment 
is required. The advantage of consistent assessment across diseases would be the 
ability for comparison. However, not enough is known about the consistency of the 
patient experience of stiffness across conditions to understand this fully. As such, an 
OMERACT stiffness special interest group has been endorsed to enable investigation 
across conditions (Orbai et al, 2015). In addition, although validated, the identified 
tools still demonstrate considerable variation in stiffness item wording, response 
options, format, and timeframe, and poor definition in some articles. Furthermore the 
measurement property evidence of stiffness items specifically is limited (e.g. WOMAC 
stiffness subscale), and as highlighted above, some of the concepts these items 
capture have been challenged in the RA specific literature (Section 2.4.1.4).  
 
This review also highlights that there is very little documented evidence of the 
development process of these items, particularly in relation to patient involvement 
and the enhancement of content validity, which is an essential part of current PROM 
development guidelines (USDHHS FDA, 2009; Patrick et al, 2011a; Patrick et al, 
2011b). Patient involvement in some scale development was poorly described (e.g. 
BASDAI, Garrett et al, 1994), limited to clinicians (e.g. SACRAH, Leeb et al, 2003), 
or to patients responding to closed-questions created by clinicians (AUSCAN, 
Bellamy et al, 2002). Furthermore, although the WOMAC (Bellamy et al, 1988) 
described a rigorous item development process involving patients, this was 
performed in an OA population and given the uncertainty regarding the general or 
specific nature of stiffness assessment, further work in an RA population is necessary 
to develop understanding. 
 
It is acknowledged that given the review approach, there are likely to be other scales 
that include stiffness items within the literature that have not been identified, although 
the most common scales will have been recognised. Overall, consistent with the 
systematic literature review (Section 2.4.1), this scoping review suggests that despite 
the development and validation of a number of measures that include stiffness items, 
there is still considerable variation in the content of stiffness PROMs, poor definition 
of items, and little reported or implemented patient involvement. This highlights the 
need for further work into the development of a stiffness measure with appropriate 




content validity, and identification of the most appropriate stiffness tool to use in 
stiffness assessment.  
 
2.5 Importance of appropriate stiffness assessment 
As stated earlier, there is currently no standardised method of assessing patient-
reported stiffness in RA and no clear evidence regarding the most appropriate 
measure to use. Standardised assessment is vital in both research and clinical 
contexts to enable comparison across studies and consistent measurement of 
disease progress incorporating the patient perspective. The use of PROMs is vital 
when assessing concepts that are best understood by patients (USDHHS FDA, 
2009). However, as identified earlier (Section 2.4.1), current stiffness assessment 
does not appear to have been developed according to current standards including 
collaboration with patients (USDHHS FDA, 2009; Patrick et al, 2011a; Patrick et al, 
2011b), or methods recommended by OMERACT (Boers et al, 1998). Furthermore, 
there may be difficulties with some concepts currently used in stiffness assessment 
from the patient perspective. Therefore further work to explore the patient perspective 
of stiffness would fit with recommendations in the literature (e.g. Lie et al, 2014) and 
be relevant in the development of a RA stiffness PROM with appropriate content 
validity. This requires understanding how patients experience, conceptualise and 
evaluate stiffness so that questions to capture its essence can be developed, using 
language that patients understand (USDHHS FDA, 2009). The development of any 
new RA stiffness PROM should consider measurement properties, the OMERACT 
Filter (Boers et al, 1998), PROM development guidelines (e.g. Patrick et al, 2011a), 
and appropriate test theory (Section 2.3). Further work into testing any new RA 
stiffness PROM against current defined stiffness measures would also be important 
to provide recommendations regarding the most appropriate stiffness tool to use in 
future work, thus providing standardised stiffness assessment. 
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Chapter 3: Purpose and structure of research 
The previous two chapters have discussed the relevance and assessment of stiffness 
within RA and other conditions, and considered PROM development. This chapter 
will describe the purpose and aims of this research, how they will be achieved and 
structured, the researcher perspective and aspects of research design.  
 
3.1 Purpose of research 
The purpose of this research is to better understand stiffness in people with RA, and 
then use this to develop and test a new RA stiffness PROM. The purpose of the 
development of a new RA stiffness PROM is to capture and assess the patient 
experience of stiffness in a standardised way. This is important because stiffness is 
a relevant patient symptom used in clinical and research settings (Chapter 1), but 
current stiffness PROMs are poorly defined and have limited measurement property 
evidence (Chapter 2). As PROM provide an assessment of a patient’s health 
condition that comes directly from a patient, they are particularly useful when 
measuring concepts that are best understood by patients, such as disease symptoms 
(USDHHS FDA, 2009). Therefore, the development of a new stiffness PROM will 
provide standardised assessment that captures this patient relevant symptom. It is 
proposed that this will be developed for use in clinical and research environments.  
 
The development of a new RA stiffness PROM will create the potential for stiffness 
to be included in the ACR disease activity core set, from which it is currently omitted 
because it was not sensitive to change (Felson et al, 1993). It would also address the 
OMERACT research agenda for development of a stiffness PROM in relation to flare 
(Bingham et al, 2011, Bykerk et al, 2014a). Most importantly, it aims to provide a 
standardised method of assessing a symptom that is important and relevant to 
patients, in research and clinical situations. This work may also lead onto further 
research into the assessment of stiffness across conditions.   
 
3.1.1 Research aims 
The overall purpose of this research is to explore the experience of stiffness in people 
with RA and use this to develop and test an RA stiffness PROM. The aims and 
objectives for each study can be found in subsequent chapters. The specific thesis 
objectives are detailed below: 
 To understand the experience of stiffness in people with RA 
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 To explore which aspects from the RA patient experience of stiffness might 
be relevant in the patient-reported assessment of stiffness 
 To develop a set of items that capture those patient-relevant aspects using 
appropriate wording and formatting 
 To explore the acceptability of the draft items with people with RA 
 To explore the performance of these items to develop the smallest and 
internally consistent set of items to form an RA stiffness PROM 
 To test how these items perform compared to current stiffness assessment 
 To make recommendations about the most appropriate way to assess 
stiffness in clinical and research environments  
 
3.2 Researcher perspective 
3.2.1 Prior knowledge 
The researcher came to this project with a background in sport, health and physical 
activity. She had a particular interest in exercise and physical activity in long-term 
conditions and some experience of conducting small research projects. In the early 
stages of this PhD, focus was put into developing a better understanding of RA. This 
was achieved by reading within the rheumatology literature, attending rheumatologist 
and specialist nurse clinics within the department, and listening to the personal 
experiences of the patient research partners in the supervisory team. Engagement in 
research training courses provided by the University and the local hospital trust 
helped develop research skills and ensured compliance with good practice 
guidelines.  
 
3.2.2 Epistemological position 
The researcher’s position for this research was based on pragmatism. Pragmatism 
encourages a focus on the research question and outcome (Creswell and Clark, 
2011; Tashakkori and Teddlie, 1998). This emphasis enables freedom to choose 
methods or procedures most appropriate and compatible with the purposes of the 
research (Creswell, 2003, p.12) rather than being driven by an epistemological or 
ontological standpoint (Johnson and Onwegbuzie, 2004). As this research was driven 
by specific research questions and outcomes, freedom in relation to the choice of 
methods was vital in the planning and execution of each study. Specifically, a mixed 
methods approach was essential for this research and a philosophical underpinning 
of pragmatism fits well with such an approach (Denscombe, 2008). 
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3.3 Methodological approach 
3.3.1 Mixed methods 
As a result of considering the research objectives and outcome, it was clear that the 
use of both qualitative and quantitative methods would be necessary to answer the 
research objectives effectively. Mixed methods research is referred to as the third 
paradigm in addition to qualitative and quantitative research (Johnson, Onwuegbuzie 
and Turner, 2007). Although there are different opinions among researchers as to 
what constitutes mixed methods research (Sandelowski, 2000; Bryman, 2007; 
Tashakkori and Creswell, 2007), an overview of the literature by Denscome (2008) 
suggested that the characteristics of a mixed methods approach include: the use of 
both qualitative and quantitative methods within the same research project; clear 
description of the sequencing and priority given to each of these aspects, and 
pragmatism as the philosophical underpinning (Denscombe, 2008). Mixed methods 
research is used for a number of purposes including instrument development 
(Bryman, 2006), making it an appropriate choice for this research. This is also 
consistent with best practice guidelines for PROM development which recommend 
the use of both qualitative and quantitative methods (Fitzpatrick et al, 1998; USDHHS 
FDA, 2009). 
 
3.3.1.1 Mixed methods sequencing 
Within the literature there has been a drive for the development of classification 
systems of mixed methods research designs (e.g. Leech and Onwegbuzie, 2009; 
Creswell and Clark, 2011). Creswell and Clark (2011) propose a sequential 
exploratory strategy with an instrument development variant. This fits with the aims 
of this research as it involves initial exploratory qualitative phases, which inform the 
development of the draft items for quantitative testing. 
 
3.3.2 Research design 
This research used three phases to meet its objectives (Figure 3.1). The exploratory 
phase aimed to better understand the RA patient experience of stiffness and used 
qualitative interviews (Study 1, Chapter 4). The development phase then focused on 
the development of the content (items) for an RA stiffness PROM. Firstly, focus 
groups were used to validate the findings from Study 1 in a new sample of patients, 
and to explore stiffness specifically from a measurement perspective (Study 2, 
Chapter 5). Following this, draft items were developed in iterative rounds of 
discussion with the supervisory team and patient research partners (Chapter 6). Items 
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were then tested and refined using cognitive interviews (Study 3, Chapter 7). The final 
testing phase aimed to develop and subsequently test the item structure using a 
quantitative survey (Study 4, Chapters 8 and 9).  
 
3.3.3 Thesis structure 
This thesis is structured around nine chapters. It aims to capture the process of 
development and progress from one study to the next. The first three chapters contain 
background information and reviews of the literature. Chapters 4, 5, 7, 8 and 9 
describe each of the four studies within the research (Figure 3.1) and each contain 
background, methods, results, discussion, and conclusion sections. Chapter 6 
ensures a transparent process of item development. The final chapter is a discussion, 






Figure 3.1: PhD outline 
 




3.4 Research process and influences 
In addition to the researcher’s perspective and the methodological approach, there 
have been a number of other influences on the design and conduct of the research. 
 
3.4.1 Patient research partner involvement 
The public involvement national advisory group INVOLVE defines public involvement 
as “research being carried out ‘with’ or ‘by’ members of the public rather than ‘to’, 
‘about’ or ‘for’ them” (INVOLVE, 2012). Within the literature, there is evidence for the 
involvement of the public and patients in research (Brett, 2010). In a recent literature 
review, the benefits of public involvement in a number of key areas of the research 
process were reported such as participant recruitment and project design (Stanley, 
2009). A specific example of the benefits of public involvement is OMERACT which 
has been involving patients in research for 10 years and allocates 10% of its 
conference places to patients. A recent review aimed to explore the effect of patient 
involvement on OMERACT by reviewing conference documents and interviewing 
conference participants (de Witt et al, 2014). The review identified a number of 
facilitators and barriers to patient involvement which led to recommendations to 
enhance development of future patient involvement. A particular benefit of patient 
involvement was the identification of important areas for the research agenda, such 
as fatigue (de Witt et al, 2014). It also highlighted challenges to patient involvement 
in research, for which there are guidelines describing appropriate considerations 
when involving patients in research (e.g. Hewlett et al, 2006; de Witt et al, 2011; 
INVOLVE, 2012). 
 
Public involvement has been suggested to be particularly important in qualitative 
research involving sharing views or experiences (Stanley, 2009), and the involvement 
of patients in PRO development has been reported to enhance relevance, 
acceptability and quality (Stanley, 2009; Staniszewska et al, 2012). Therefore, for this 
thesis it was vital not only to involve patients as participants but also to involve 
patients within the research process. Therefore from the outset of this project and 
throughout, two patient partners (GB and AE) were part of the supervisory team. 
 
3.4.2 Supervisory team 
Supervisory teams are made up of experienced individuals with knowledge and 
expertise in the topic of the research project. Table 3.1 provides a brief description of 
each team member, and the abbreviation that is used to identify them. The team has 




a wide range of experience from academic, clinical, and experiential perspectives 
which have been vital throughout the planning and execution of this project.  
 
Table 3.1 Supervisory team characteristics  
Team Gender Position Years of rheumatology 
experience 
ED F Rheumatology psychology 
researcher (Senior Research 
Fellow) 
7 years 
JK M Academic rheumatologist 
(Emeritus Professor) 
30 years 
JP M Epidemiologist (Associate 
Professor) 
10 years 
GB F Patient research partner RA diagnosed ≥10 years 
AE F Patient research partner RA diagnosed ≤10 years 





Reflexivity has been defined as “thoughtful, self-conscious awareness” (Finlay, 2002, 
p.532). It is an acknowledgement of personal (e.g. gender) and intellectual (e.g. 
professional background) biases that may have influenced the research (Mays and 
Pope, 2000), and is used to enhance rigor in qualitative research (Koch and 
Harrington, 1998). However, there are criticisms of the practicalities of reflexivity, 
such as the suggestion that researchers need to have “superhuman self-
consciousness” and have no problem accessing their feelings or motivations (Seale, 
1999, p.168). Finlay (1998; 2002) argues that reflexivity is more of a resource than a 
problem and should be used as a research tool. In this context, the aim is not to 
achieve impartiality, but to use reflexivity tools to better understand the influence of 
bias (Frank, 1997). It is suggested that researchers state any biases (e.g. intellectual 
or personal) at the start of their research to enhance credibility of their findings 
(Goodwin, 2006). This includes disclosing professional background to readers and 
participants (Richards and Emslie, 2000). Initial statements of the biases such as 
background and perspective of the researcher and supervisory team have been 
presented (Sections 3.2.1 and 3.4.2). In relevant studies, professional background 
disclosure to participants has been described and a personal reflection of the 
research is given in Chapter 10. 
 
The next chapter will describe the first study within this thesis aiming to understand 
the RA patient experience of stiffness. 
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Chapter 4: Understanding stiffness from the patient 
perspective (Study 1) 
The previous chapters discussed the background literature surrounding RA, stiffness, 
and outcome measures, and outlined the aims and structure of this thesis. This 




Stiffness is commonly reported by RA patients (Scott, 1960; Vliet Vlieland et al, 1997; 
Khan et al, 2009) and it is known to affect patients’ daily life, work life, and quality of 
life (Westhoff et al, 2008; da Silva et al, 2011; Phillips and Dow, 2012). It has also 
been demonstrated to be relevant to patients in relation to fluctuating aspects of the 
disease such as flare (Bartlett et al, 2012) and low disease activity (van Tuyl et al, 
2015). Stiffness initially featured in early RA disease activity indices (e.g. the 
Lansbury index, Lansbury, 1958) and was included in the original RA classification 
(Arnett et al, 1988) and remission criteria (Pinals et al, 1981). Stiffness is commonly 
used as an outcome in research (Kalyoncu et al, 2009) and has been suggested to 
influence clinical decision making (Kirwan et al, 1984; Soubrier et al, 2006). 
 
Despite the broad relevance and uses of stiffness, it remains poorly understood and 
inconsistently assessed. Current stiffness assessment is based on EMS/MS duration 
or severity items which are often poorly defined. There is no clear evidence regarding 
the most appropriate measure to use to assess stiffness in RA, and no standardised 
approach (van Tuyl, Lems and Boers, 2014). There are reported difficulties with 
current assessment methods (e.g. Vliet Vlieland et al, 1997; Westhoff et al, 2008), 
and items do not appear to have been developed according to current standards 
(USDHHS FDA, 2009; Patrick et al, 2011a; Patrick et al, 2011b). The one previous 
study that focused on understanding the patient experience of stiffness (Lineker et al, 
1999) was performed over a decade ago, since when there have been substantial 
changes in RA treatment (Smolen et al, 2010) and therefore possibly changes in 
stiffness experiences. In order to work towards better assessment of stiffness, 
understanding the patient experience is essential. This will enable development of a 
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4.2 Aims and objectives 
The overall aim of this study was to develop a better understanding of the experience 
of stiffness in people with RA. The specific study objectives were: 
 To investigate the experience of stiffness and how it is described by people 
with RA 
 To understand how people with RA evaluate stiffness and how they describe 
changes in it  
 To understand how people with RA describe stiffness in relation to other 
symptoms such as pain 
 
4.3 Methods 
4.3.1 Semi-structured interviews 
Qualitative methods involve the use of words as data (Braun and Clarke, 2012) and 
are a way of exploring and understanding the views and experiences of participants 
(Mays and Pope, 1995). Qualitative methods can encompass a variety of data 
collection approaches including interviews and focus groups (Braun and Clarke, 
2012). Semi-structured interviews are a method of investigating a particular topic 
using a flexible structure of open-ended questions. From these open-ended questions 
the interviewer can follow-up responses in more detail with further questions (Britten, 
2006). Semi-structured interviews are useful because they provide structure but also 
flexibility; as such, topics can be discussed in the order most appropriate to the 
participant, enable further detail to be given around topics of discussion, and provide 
an opportunity for unexpected ideas to be generated and discussed (Arthur and 
Nazroo, 2003; Britten, 2006). The study aims and objectives could have been 
achieved with other qualitative methods such as focus groups. Focus groups naturally 
facilitate interaction between group participants and are useful to explore and clarify 
the views of the group on particular topics (Kitzinger, 1994). However, it has been 
suggested that focus groups can be negatively influenced by dominant participants 
and provide a less detailed understanding of a topic than other methods such as semi-
structured interviews (Krueger and Casey, 2009). Therefore, to enable a detailed 
exploration of individual patients’ experiences of stiffness it was considered that semi-
structured interviews would be the most appropriate method for this study.   
 
4.3.2 Participant identification and sampling 
Ethics approval was obtained from the University of the West of England research 
ethics committee (REC) (HLS/13/01/26) and from the Leeds East REC following 
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proportionate review (13YH0050). The recruitment criteria defined that participants 
had a confirmed diagnosis of RA (Arnett et al, 1988; Aletaha et al, 2010), were aged 
18 years or over, could speak English to a sufficient degree to participate in the study 
unaided, and had self-defined experience of RA related stiffness. Qualitative research 
commonly utilises purposive sampling where individuals with the relevant experience 
or insight are recruited to provide information on the topic (Patton, 2002). Within the 
purposive sampling approach, a mix of age, gender and disease duration were 
targeted to ensure that a range of participants were recruited (Sandelowski, 1995; 
2000). Data saturation is commonly used as a guideline regarding sample size 
however, sample size recommendations in the literature vary and are often not 
supported by rationale (Guest, Bunce and Johnson, 2006). Data saturation, defined 
as the point at which no new information is generated (Guest, Bunce and Johnson, 
2006) has been criticised for having multiple interpretations (O'Reilly and Parker, 
2013). In an attempt to identify a target sample for this study, it has been suggested 
that researchers consider other studies using similar designs where saturation was 
achieved when deciding on adequate sample size (Onwuegbuzie and Leech, 2007). 
As such, following a review of the literature it was decided that 15-20 participants 
should be initially recruited. Recruitment could then be continued if required.  
 
Recruitment took place at hospital out-patient rheumatology clinics at the Bristol 
Royal Infirmary (BRI) in University Hospitals Bristol Trust and at Cossham Hospital in 
North Bristol Trust (NBT). At both sites, interested potential participants were given a 
patient information sheet (PIS, Appendix B) to take away and consider. A reply slip, 
prepaid envelope and contact information were provided so that interested 
participants could contact the researcher by post, telephone or email to discuss the 
study further and arrange a convenient date and time for an interview.  
 
4.3.2.1 Site specific differences in participant identification and approach 
There were slight differences in the identification and approach of potential 
participants at the two recruitment sites. At the BRI, eligible participants were 
approached directly by the researcher while in the waiting room. At NBT, eligible 
participants were identified and initially approached by a member of their direct clinical 
team. If the eligible potential participant agreed to hear more about the study, they 
were introduced to the researcher to discuss the study further in a private clinic room. 
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4.3.3 Interview guide development 
An interview guide (Table 4.1 and Appendix C) was developed to explore the aims of 
the study and was based on a literature review and discussion with the research team, 
particularly the patient research partners (GB and AE). The interview guide was 
flexibly observed during each interview, as such, the first question “Can you tell me 
about your experience of stiffness in relation to RA?” was asked and subsequent 
questions and prompts followed depending on each individual participant’s response. 
Interviews followed an iterative process, which allowed ideas and concepts identified 
in early analysis to be explored in subsequent interviews (Legard, Keegan and Ward, 
2003). In addition, participants were asked to describe stiffness using the metaphor 
of an animal. Metaphors are commonly used in discourse and have been utilised in 
healthcare research to describe personal experiences of diseases (Youngson et al, 
2015) and symptoms (e.g. Wylde et al, 2014). They are also specifically used within 
a rheumatology context, for example in Sjögren's syndrome where ‘gritty eyes’ is 
often used in patient literature (Arthritis Research UK, 2014), and the use of a 
metaphor of an animal has been used in previous work with RA patients (Flurey, 
2012). Metaphors are particularly useful with concepts that are difficult to describe 
literally (Ortony, 1975) thus this question attempted to capture the potentially abstract 
concept of stiffness.  
 
Table 4.1: Interview guide 
 
A. Can you tell me about your experience of stiffness in relation to RA? 
B. How does this vary in a 24 hour period? 
C. Has stiffness changed over the course of your disease?  
D. How does stiffness differ from other RA symptoms? 
E. What are the consequences of stiffness? 
F. How do you deal with stiffness? 
G. How to you assess stiffness? 
H. Is there anything that you feel is important to stiffness that we have not 
talked about? 
I. If your stiffness was an animal what would it be and why?  
 
 
A pilot interview was performed with one patient research partner (GB) and was 
observed by a member of the research team (ED) with qualitative research expertise. 
This provided an opportunity to test and refine the interview guide and allowed the 
researcher to gain experience and confidence prior to commencing interviews with 
participants. 
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4.3.4 Interview procedure 
Eighteen participants agreed to participate. However, one individual did not wish to 
be audio recorded and following consideration it was decided that this would produce 
inconsistent data. This was explained to the individual who was thanked for her 
interest. Another individual cancelled our first interview appointment and despite 
original enthusiasm to participate was unable to rearrange the appointment around 
her busy full-time work schedule. Other reasons given for declining participation 
included recent participation in other research studies and time commitments such 
as work, children or hospital appointments.  
 
Interviews took place in non-clinical rooms in the Academic Rheumatology Unit at the 
BRI and at Cossham Hospital. All interviews were performed by one researcher who 
was unknown to participants prior to the study and introduced herself as a doctoral 
student with a non-clinical background. Most participants (n=13) chose to attend an 
interview at the location in which they normally attended clinic. Three participants 
chose to be interviewed at the other site for convenience and were provided with 
maps and directions if required. Each participant was greeted by the researcher and 
was provided with refreshments. Prior to commencing each interview, participants 
gave informed consent, completed a questionnaire pack (Section 4.3.4.1) and were 
asked if they had any questions. All interviews lasted between 30-80 minutes and 
were conducted with only the researcher and participant present, apart from one 
interview where the participant was accompanied by her young son. Interviews were 
audio-recorded and transcribed verbatim. Two interview recordings were transcribed 
by the researcher. All other recordings were transcribed by a transcription service but 
were checked for accuracy and anonymised by the researcher. 
 
4.3.4.1 Questionnaire pack 
A short questionnaire pack was developed to describe the recruited sample and their 
perceived level of disease severity and disability. The pack (Appendix D) contained 
demographic, clinical disease measures and medication questions. A brief 
description of each of the validated items is given below. 
 
4.3.4.1.1 Health assessment questionnaire (HAQ) 
The HAQ is a 20 item patient report of functional disability that focuses on eight 
categories (dressing and grooming, rising, eating, walking, hygiene, reach, grip, 
activities) (Fries et al, 1980). Patients rate questions within each section with a score 
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between 0 (without any difficulty) and 3 (unable to do). The highest score from each 
section is then added together to produce an overall score. This overall score is then 
averaged to give a total score between 0 and 3 where higher total scores indicate 
worse perceived function and disability.  
 
4.3.4.1.2 PtG 
The PtG assessment of general health is a 10cm VAS which asks patients to indicate 
how well they are doing with their arthritis (0=very well, 10=very badly). The PtG is 
one of two patient reports in the validated DAS28 (van der Heijde et al, 1993). 
 
4.3.4.1.3 Pain 
This assessment of pain is a 10cm VAS which asks patients how much pain they 
have experienced as a result of their arthritis within the last week (0=no pain, 
10=severe pain) (Farrah et al, 2001; Hawker et al, 2011). 
 
4.4 Analysis 
Thematic analysis is a method of identifying, analysing and reporting patterns in 
collected data (Braun and Clarke, 2006). A justification for thematic analysis being 
appropriate for this study is provided below. 
 
4.4.1 Analysis approach 
Thematic analysis (Braun and Clarke, 2006; 2012) was considered most appropriate 
for use in this research, although three approaches to analysis were considered; 
interpretive phenomenological analysis (IPA); grounded theory (GT); and thematic 
analysis. IPA allows exploration into the lived experiences of particular phenomena 
of individuals or small groups of people (Smith, Flowers and Larkin, 2009) which 
made it a sensible consideration for use in this study. IPA has been praised for its 
accessibility for those unfamiliar with the approach given its detailed guidance (Smith, 
Flowers and Larkin, 2009), and for its suitability in research projects with time and 
resource limitations (Braun and Clarke, 2012). However, there are criticisms of IPA 
including that it is labelled by some as a ‘descriptive’ approach (Larkin, Watts and 
Clifton, 2006, p.102), and its precise guidelines allow little flexibility (Braun and 
Clarke, 2012). It has also been suggested that because IPA focuses on individual 
participants as well as patterns across participants that this dual focus may not enable 
the same detail as provided by approaches such as thematic analysis or GT (Braun 
and Clarke, 2012). GT aims to generate plausible and useful theory that is grounded 
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in the data (Glaser and Strauss, 1967; McLeod, 2001). This ‘bottom up’ or ‘data 
driven’ approach (McLeod, 2001) made it a sensible consideration for this study, 
especially considering its focus on the development of theory (Holloway and Todres, 
2003). However, GT has been criticised for being time consuming, and suggested as 
most effective in large research projects (Braun and Clarke, 2012) which from a 
practical perspective, was not compatible with a small scale PhD project. GT also has 
multiple versions (e.g. Charmaz, 1990), which can create uncertainty about the most 
appropriate version to utilise (Birks and Mills, 2011). One of these versions, termed 
GT ‘lite’, encourages a GT approach without the strong emphasis on the theoretical 
position. However, it has been argued that most GT approaches actually are GT ‘lite’ 
and that this approach is very similar to thematic analysis (Braun and Clarke, 2006). 
Within the literature, thematic analysis can include a number of approaches, such as 
Boyatzis’ (1998) ‘process’ that can be used with qualitative information, and Attride-
Stirling’s (2001) visual thematic networks, which vary in the approach taken and 
outcome attained. However, Braun and Clarke’s thematic analysis (2006; 2012) 
provided a standardised name and approach to performing thematic analysis. Thus 
subsequent discussion of thematic analysis refers to thematic analysis as described 
by Braun and Clarke (2006; 2012). Thematic analysis presents clear guidelines for 
performing the method and provides an opportunity to learn basic data handling 
strategies (Braun and Clarke 2006; 2012) which was considered beneficial for a 
developing qualitative researcher. Additionally, thematic analysis provided a flexible 
approach to analysis as it is a method only approach and does not enforce other 
aspects such as data collection methods or theoretical positions (Braun and Clarke, 
2012) as seen in other approaches such as GT. It is also flexible in that it is applicable 
in a ‘bottom up’ (inductive) and ‘top down’ (deductive) manner (Braun and Clarke, 
2012). Inductive thematic analysis involves coding in a data driven manner while 
deductive thematic analysis is coded in an approach driven by pre-existing theory 
(Braun and Clarke, 2006). The ‘data driven’, inductive thematic analysis was most 
appropriate for Study 1 to develop understanding of a patient symptom. Overall, the 
clear guidance and flexible nature of thematic analysis were key factors in its 
consideration as appropriate for use in this research.  
 
4.4.1.1 Thematic analysis process 
Thematic analysis involved transcripts being read, re-read, and systematically coded, 
codes were then explored for patterns, which led to theme development. The six 
stages of this process have been described below and include description of specific 
actions and reflexive notes from each stage for transparency. 
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4.4.1.1.1 Stage 1: Familiarisation  
The first stage of the thematic analysis process involves becoming immersed in the 
data, allowing the researcher to detect features that are relevant to the research 
question. To familiarise herself with the data the researcher transcribed two audio 
recordings, and checked the accuracy of all other transcripts by listening to the audio-
recording while also reading each transcript. Early thoughts and ideas were noted by 
hand on the transcripts to begin understanding the data. 
 
4.4.1.1.2 Stage 2: Coding 
Coding is a process of identifying and labelling features of data that are relevant to 
the research question. Although this process was conducted systematically, as the 
researcher used software with which she was unfamiliar, the approach was initially 
experimental and led to checking data across different software packages. This was 
likely to have been time inefficient however, all data were treated equally and this 
approach did mean that data were rigorously checked. First, each transcript was 
coded by hand by highlighting relevant text and labelling it. The researcher then used 
NVivo 10 (QSR International Pty Ltd, 2012) to broadly ‘bucket code’ features relating 
to similar topics within each transcript. Following this, NVivo 10 (QSR International 
Pty Ltd, 2012) and Microsoft Office Word 2013 were used to code data again by 
highlighting and labelling relevant text. This was double checked against the ‘bucket 
codes’. As the coding structure developed it was reviewed and previously coded 
transcripts were also revisited and re-coded. Two transcripts were also independently 
coded by two members of the supervisory team (SH, ED) with experience of 
qualitative analysis. Following a brief introduction, patient research partners (GB, AE) 
also read two transcripts and highlighted relevant points from their perspective. 
Following the completion of five interviews, a team meeting was held to discuss early 
analysis and possible directions for future interviews.  
 
4.4.1.1.3 Stage 3: Searching for themes 
The process of identifying patterns or themes involves reviewing the codes and trying 
to identify connections. Originally, the researcher worked around the ideas generated 
for the original ‘bucket codes’ as themes. She revised and reworked topics that 
related to group of codes. However, Braun and Clarke (2012) also suggest that a 
theme has a central organising concept that should say something meaningful about 
the data. The researcher found it difficult to derive a clear central organising concept 
around these themes that also encompassed the patient voice. So at this point the 
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researcher went back to working by hand using diagrams and the ‘long table 
approach’ (Krueger and Casey, 2009) to group codes to try and explain these data 
more clearly. This was refined into a thematic diagram to visualise relationships 
between themes. 
 
4.4.1.1.4 Stage 4: Reviewing themes 
The next step of analysis has been described as a ‘quality control’ measure involving 
checking that the candidate themes in the analysis fit with the overall dataset. Here 
the researcher reviewed the thematic diagram and coding structure to ensure that 
nothing major had been omitted. A suggested thematic diagram was taken to a team 
meeting where the proposed themes were presented and the diagram was refined 
with the research team and the patient research partners. Once the thematic diagram 
was finalised, each of the transcripts was re-read to ensure that the key ideas were 
correctly captured. 
 
4.4.1.1.5 Stage 5: Defining and naming themes 
Writing theme definitions is an essential part of being able to define each theme. 
Theme names were derived iteratively during team meetings and in particular during 
discussion with ED. This really aided capturing the data from the patient perspective 
and highlighted the patient voice in the analysis. 
 
4.4.1.1.6 Stage 6: Writing – finalising the analysis 
Braun and Clarke (2012) argue that analysis is not complete until it is written, as 
writing helps clearly define the themes. A draft chapter was written which was refined 




Sixteen of the 38 individuals approached agreed to participate (42% recruitment rate): 
11 were female (69%), age range between 33 and 78 years and disease duration 
between 1 and 27 years (Table 4.2). 
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Table 4.2: Participant demographic information  










Work status Education 
101 M 62 22 BRI 1.375 1.3 9 NSAIDs, DMARDs, GCs, Biologics RIB University 
102 F 48 25 BRI 1.75 3.9 5.4 NSAIDs, DMARDs, Biologics RIB/Homemaker University 
103 M 71 11 BRI 1.5 3.7 2.2 NSAIDs, GCs Retired University 
104 M 78 1 BRI 0.5 4.7 0 DMARDs, GCs Retired College/apprenticeship 
105 F 62 15 BRI 1.375 Inc. Inc. DMARDs, GCs, Biologics Retired University 
106 F 62 2 BRI 0.75 Inc. Inc. DMARDs, GCs Retired School 
107 F 37 9 NBT 1.375 3.5 3.6 NSAIDs, GCs, Biologics Unemployed College/apprenticeship 
108 F 60 2 BRI 2.125 10 10 DMARDs Paid work School 
109 F 33 3 BRI 2 1.6 5.8 NSAIDs, DMARDs, Biologics Paid work University 
110 F 63 7 NBT 2.5 4.9 4.9 NSAIDs, DMARDs Retired School 
111 M 74 7 NBT 0.125 1.8 5.2 DMARDs Retired School 
112 F 48 23 NBT 2.625 4.6 7.6 NSAIDs, DMARDs RIB School 
113 F 48 14 NBT 1 3.2 3.7 NSAIDs RIB College/apprenticeship 
114 F 71 14 NBT 1.625 Inc. Inc. NSAIDs, DMARDs Retired School 
115 M 45 2 NBT 1.25 2.8 6.7 DMARDs, Biologics Paid work School 
116 F 55 27 NBT 1.25 6.5 7.7 DMARDs Paid work College/apprenticeship 
Median and interquartile range (IQR) †=61 (48-67), ‡=10 (3-19), §=1.375 (1.125-1.875), ¥=3.7 (2.3-4.8) ¤=5.4 (3.7-7.7) 
Pt ID=Patient identification number; dis dur=disease duration; HAQ=Health assessment questionnaire 0-3 (3=most disabled); PtG=Disease activity score 0-10 
(0=very well, 10=very badly); Pt pain=Pain assessment 0-100 (no pain-severe pain); NSAIDs=Non-steroidal anti-inflammatory drugs; DMARDs=Disease 
modifying anti-rheumatic drugs; GCs=Glucocorticoids; RIB=Receiving incapacity benefit; Inc.=Incomplete data  
 




4.5.2 Thematic analysis 
Analysis identified 219 codes which were grouped into six themes and smaller 
subthemes (Appendix E) that captured patients’ experiences of RA stiffness. The four 
themes on the left are all interlinked, relating stiffness to RA, to behaviour and 
environment, as experienced both locally and widespread, and as highly variable. 
These themes influence and are influenced by the two themes on the right which 
capture a process of impact and management (Figure 4.1). Each theme and its 
subthemes are described below with patient quotes for illustration.  
 
 
Figure 4.1: Conceptual diagram of the patient experience of stiffness 
 
4.5.2.1 Theme 1: Part of having RA 
Stiffness was discussed by patients within the context of RA. As such, discussions 
included a wide range of RA related topics that patients perceived as relating to 
stiffness.  
 
4.5.2.1.1 Stiffness is a normal consequence of RA 
Patients considered stiffness as part of their disease and a normal consequence of 
RA.  
 
“All rheumatoid arthritis sufferers get used to a level of pain and a level of stiffness 
which they consider to be normal” [101]  
 
“[…] it’s really one of the most obvious symptoms of the condition” [103] 




Some patients articulated stiffness being part of the broader context of RA using quite 
negative dialogue, indicating the negative influence of the disease. 
 
“[…] it’s all part of a picture that for me at the moment is just looking a bit black” 
[108] 
 
“And then I sit in bed telling myself that I do feel like death although I shouldn’t use 
such a phrase […] Now I think that stiffness is part of that story” [103] 
 
There was discussion about the specificity of stiffness to RA. RA stiffness was 
considered different from stiffness as a result of exercise, due to differences in 
location and experience. 
 
“[…] you swim a couple of miles and the next day […] I’d say I felt a bit stiff. That 
doesn’t describe how I feel with arthritis in any way shape or form. It is a lot more 
uncomfortable” [108] 
 
“It’s different to, you know if you did like a long run and you had sore muscles when 
you get up in the morning and you think ‘oh God’, and you’ve got that sort of 
stiffness of movement […] It’s like you move like that but it’s not in your muscles” 
[109] 
 
RA stiffness was also perceived as negative, unlike stiffness as a result of exercise. 
 
“For me, muscle stiffness used to be, because obviously it’s associated with 
working out […] it was like a nice ‘ooh God yeah, I’m really stiff today’ […] but with 
arthritis you know it’s an on-going […] so it’s a negative stiffness” [112]  
 
Although only considered by a small group of patients, the specificity of RA stiffness 
was also discussed in relation to other diseases. One patient described how she had 
a ‘different’ stiffness as a result of OA, differentiated by location.  
 
“With me I am sure it is a different kind from my arms and my hands […] I think 
that is more the rheumatoid, but the stiffness I get from here [knees] and just sitting 
in any confined area, I think that is probably just general, because I have got 
osteoarthritis in my knees […] so that is a different stiffness” [106] 
 
Another patient however, stated that she was unable to differentiate between RA and 
OA. 
 
“The thing is I’ve got rheumatoid and osteo, so I’ve got them both, so, I don’t know 
which is which” [114] 
 
 




4.5.2.1.2 Stiffness varies with disease fluctuation  
Patients identified that stiffness varied with fluctuations in disease activity and 
described this using a variety of terms. Many (n=10) used the term “flare”, and other 
terms such as “not being controlled very well” [102], “bad period” [103], “bad patch” 
[113], or “bad time” [109] were also used. During high disease activity or flare, patients 
described how all symptoms including stiffness were generally worse (“it's much 
worse on a flare-up” [113]). Stiffness worsening was discussed from a number of 
perspectives. Patients described how general physical functioning during periods of 
higher disease activity or flare was more restricted. 
 
“Just everything I think when you get a flare and it’s really bad. Again it’s just your 
hands just don’t work basically. They can’t bend them, grip things, and obviously 
it’s really painful and it makes everything awkward. When they are not so bad you 
can do basic stuff, you can pick up a kettle, you can do bits and bobs. There is a 
big difference between the two” [115] 
 
Patients highlighted that stiffness had an increased effect on activities of daily living 
during periods of higher disease activity or flare.  
 
“[…] a frequent test, namely opening the car door […] is quite easy, not a problem. 
It causes a certain amount of discomfort but it’s not difficult. But when I've been 
having a bad period […] then it’s actually impossible, I’d get somebody else to do 
it” [103] 
 
“If I’ve got morning stiffness normally, it’s just when I take a joint right to its end of 
range of movement […] in mid-range when you’re kind of relaxed you don’t feel 
any stiffness. It’s just when you try to do something. When I’m severe it is as if I’m 
coated in a tight corset, even when I’m doing nothing at all. So it’s like wearing, 
you know those Spandex underwear that Gok Wan always uses […] that’s what it 
feels like without any of the benefits […] it is that sensation that you’re, it’s as if 
someone is just holding on to it and you’ve got to kind of fight against the 
movement to it” [109] 
 
Patients also perceived stiffness during higher disease activity or flare to be 
associated with other symptoms such as pain and inflammation.  
 
“Oh I couldn’t describe it to anybody how bad it was and that was stiff and painful 
as well” [106] 
 
“Yeah, I think it’s because in flare there’s always a lot more swelling with it as well, 
and for me swelling causes a lot more pain than just stiffness, especially in the 
bigger joints” [107] 
 




There was also an element of persistence with stiffness in periods of higher disease 
activity or flare. Here patients described how stiffness lasted longer, occurred at any 
time of day and for some patients there was no respite overnight which affected sleep.  
 
“[…] in a bad time, I can’t sleep because it’s so bad overnight and then I’m woken 
every time I try to turn in bed […] So I struggle to sleep when I’m in a bad stage 
because the stiffness doesn’t ease off overnight” [109] 
 
Some patients specifically highlighted that stiffness in periods of higher disease 
activity or flare could not be reduced with usual self-management techniques.  
 
“So if I have a hot shower on a standard day I’m up and going and you know, that’s 
pretty okay, whereas on a bad day I can’t get it to reduce as well so it’s just, it just 
lasts and I can’t shift it” [109] 
 
In addition to amplified persistence, patients identified increased severity of stiffness 
in periods of higher disease activity or flare. 
 
“I can tell if its, if I am going through a period when [I’m] not being controlled very 
well cause’ the activity will increase […] I am stiffer either first thing in the morning 
or getting towards tea time in the evening” [102] 
 
The speed of onset of stiffness in times of higher disease activity or flare also featured 
in discussions. 
 
“The other one, which is what happens when you are having a flare up which in 
my case happens, takes about an hour to 45 minutes and I know I am having a 
flare up and that is how quick it happens, I go from being mobile to being seized 
up very very quickly” [101] 
 
“Well I seem to be alright and then all of a sudden bang and I was that blooming 
stiff, to move or anything else” [105] 
 
The location of stiffness was another area of discussion with some patients feeling 
that stiffness was more widespread in the body during higher disease activity or flare. 
 
 “[…] it affects more joints than it does when I’m not so bad […]” [109]  
 
Other patients felt that stiffness was more specific in location during higher disease 
activity or flare. 
 




“[…] for me the word that springs to mind is like acute, when it’s like pain and stiff 
together […] it is so localised and you can’t, you can’t take your mind off of it 
because it’s just so painful and stiff” [112] 
 
Patients who also had stiffness from joint damage indicated that stiffness from 
mechanical and inflammatory processes felt different in terms of severity and 
persistence.  
 
“I suppose a joint that’s gone over, it’s knackered, is a restrictive stiffness and pain 
but a joint that’s flared is a completely different feeling [...] once you’ve got damage, 
you’re always stiff” [112]  
 
Within this, patients suggested that damage is a direct cause of stiffness. 
 
“In that [damaged] joint you will always have stiffness and pain because you do. It 
doesn’t completely go away” [112] 
 
As a result of damage, patients were physically unable to move affected joints. 
 
“[…] there's nothing I can do to move my hands. Nothing” [110]  
 
Damage was identified by one patient as being the result of long disease duration 
and not having access to aggressive treatment from the start of the disease. 
 
“The next generation coming through your system with rheumatoid arthritis are 
already being treated with these new drugs so they are not having the same issues 
with the mechanics of the body” [101] 
 
Finally, it was suggested that damaged joints varied in severity in periods of higher 
disease activity or flare. 
 
“[…] sometimes you can feel the start of it because it feels like somebody’s 
dropped an Alka-Seltzer in your joint […] it is like a pins and needles, but it also 
throbs. There’s like a pulse to it […] like a heartbeat in your joint, […] I say to him 
[consultant] I’ve got a fizzy joint” [112] 
 
“I’ve had ops on my feet, I’ve had all the toes done, all the toes straightened. But 
my big toes on each foot, […] they are very stiff, very stiff. Um, I can’t really wiggle 
that about […] And that’s worse when I’m in a flare and when it’s cold, because I 









4.5.2.1.3 Relationship between stiffness and other RA symptoms 
Relationships with other RA symptoms were apparent, significantly between pain and 
stiffness. Some patients found it difficult to differentiate stiffness while others used 
both pain and stiffness descriptors (Section 4.5.3).  
 
“[…] stiffness is the same as pain” [105] 
  
“[…] for me, stiffness is pain. I don’t always have pain but I relate stiffness to pain” 
[112] 
 
Most patients however could discuss pain and stiffness independently and felt they 
were different yet related concepts. 
 
“I mean the other thing is to sort of like pick out stiffness from all the other things 
that are part of the disease of fatigue and pain […] cause’ they are intertwined” 
[102] 
 
“They’re connected and related but they’re not inter-dependent […] if I've got 
stiffness it’s not guaranteed I've got pain” [107] 
 
“Stiffness can become pain [...] Initially, definitely they are separate” [108] 
 
The relationship between pain and stiffness was perceived to be stronger during 
higher disease activity or flare. 
 
“I think they are separate but when, you know, when everything’s sore, 
everything’s swollen and everything’s stiff, it’s all kind of you know, in a bag 
together and then you’re just in a pickle really” [109]  
 
There were less common discussions about the relationship between stiffness and 
fatigue and inflammation. One participant suggested that the relationship between 
fatigue and stiffness was stronger than between stiffness and pain as the physical 
sensation was similar.  
 
“Um, I would say it was more [related] with fatigue rather than pain [...] its feeling 
just no energy and everything is just shutting down basically, seizing up, and just 
thinking I need to go to bed” [102] 
 
Other patients indicated that stiffness and fatigue were independent and 
distinguishable by timing and experience.  
 
“[…] no I don’t think stiffness and fatigue are linked at all, they’re different. They 
come on at different times of day and they’re really different in nature” [103] 




“It’s different to if I’m fatigued and therefore my joints are achy and it’s different to 
if I’ve had a busy day with the kids and I’m a bit sore” [109]  
 
Some patients reported that inflammation related to and caused stiffness.  
 
“[…] I just seem to have a permanent bit of swelling just under my knuckle, and 
that always creates a lot of stiffness” [107] 
 
“Well that’s stiff because it’s swollen” [114] 
 
However, inflammation was also described as independent and distinguishable from 
stiffness. 
 
“[…] you can have the stiffness, i.e. the joint just feeling tight and heavy, whereas 
you can have inflammation which is obviously then causing it to be more difficult 
to move, because obviously there’s more stuff in there” [107] 
 
“In the same way, I had knee surgery before I had the rheumatoid arthritis, and 
that created a lot of swelling and your joint was stiff but it was visibly really big and 
swollen. It’s the same sensation but without any visible swelling. Well I might have 
a bit but it’s completely unrelated almost” [109] 
 
A number of patients suggested that they may not recognise inflammation.   
 
“I suspect it [stiffness] probably is [related to inflammation], but I haven’t got any 
particular way of gauging that relationship” [103]  
 
“I mean when you see somebody who knows something about it they say, ‘oh yes, 
I can see the swelling there’. Oh, I didn’t know there was swelling there. Oh I don’t 
notice. It’s only when they’re quite fat that I would notice it you know, they might 
be painful, but I wouldn’t really notice the swelling” [116] 
 
4.5.2.1.4 Varying prominence of stiffness during the course of the disease  
There were differences between patients regarding the prominence of stiffness during 
their disease. Stiffness was identified as being particularly significant in early disease 
and for some patients, it was one of the first noticeable symptoms. 
 
“My rheumatoid arthritis started just after [son] was born [...] and it started with 
morning stiffness” [109]  
 
“Yeah, I’ve had RA now for roughly about 18 months, came on rather quick, started 
on my feet, stiff, painful to walk. It was like that for a few months, seemed to go 
away, get a bit better. It just came back with, like a vengeance, started off getting 
stiff thumbs and first finger” [115] 
 




Some patients reported that at disease onset, stiffness was particularly severe. It 
caused difficulty functioning and was perceived as relating to pain and inflammation. 
 
“Well not so bad now, but […] when I had it first of all I could hardly move” [105]  
 
“Well when it first started […] one morning I woke up and I just couldn’t move. I 
just couldn’t literally move” [106]  
 
Other patients felt that during the early stages of their disease, stiffness was not as 
prominent as other symptoms.  
 
“[…] when my disease was not very well controlled […] at the beginning, and very 
active, I didn’t find stiffness was so much of a problem because it, the pain was 
sort of prevalent really and it went all the way through the day it was just continuous 
and all the way through the night so I didn’t particularly notice stiffness as being 
particularly an issue” [102] 
 
“In the very beginning, I didn’t have a lot of stiffness at all” [111] 
 
4.5.2.2 Theme 2: Local and widespread 
Theme 2 captured the patient perception of stiffness being a physical bodily 
experience.  
 
4.5.2.2.1 Affected body structures 
Patients considered stiffness to relate to joints and many used the word joints to 
elaborate descriptions of the experience of stiffness. 
 
“Yeah in, actually in, in the joint […] and right deep in the joint” [110] 
 
“[…] it feels like it’s right inside […] well stiffness is right, it feels like it’s right in your 
core like of whatever joint that is” [112] 
 
“I would say it was a joint and spreading out from the joint. So say that one there 
is quite stiff and I can feel it tense in there I suppose, tense in either side of the 
joint” [113] 
 
There was some ambiguity regarding the bodily structures (i.e. joints, muscles) 
related to stiffness. Some patients expressed uncertainty regarding stiffness being 
related to joints. One patient’s description of stiffness in flare, which he likened to 
cramp, described muscles and tendons as being the relevant structures.  
 




“You see it’s the muscles and the tendons that are like contracting […] almost as 
if you are paralysed, you cannot move. So that’s extreme stiffness, and I am not 
exaggerating that” [101] 
 
However, interestingly other patients differentiated stiffness and pain by the body 
structure that was involved. This could be a result of the complex relationship between 
pain and stiffness.  
 
“[…] stiffness I tend to relate more to the joints […] And pain tends to be […] it sort 
of radiates more out and it goes all up the tendons and ligaments and muscles” 
[102]  
 
“I think it’s more sort of muscly I think. I think well, the actual, the real bad pain is 
[…] because it’s swelled up, it’s like all your tendons and stuff are kind of all pushed 
out and I think that’s what causing the actual pain” [115] “And what bit is stiff?” 
[Halls] “Just, like, the joint” [115] 
 
4.5.2.2.2 Location within body 
Many patients described their experience of stiffness with reference to its location. 
 
“Well I don’t have a lot, but I have stiffness in my left hip and knee” [104] 
 
“[…] it’s nearly always in my hands and my shoulders” [107] 
 
“It's mostly my hands and my feet […] I don’t get the stiffness all over, I just get it 
very badly in my hands and my feet” [114] 
 
It was suggested that over the course of the disease, the location of stiffness varied. 
 
“[…] sometimes it is in my feet and sometimes it isn’t, it’s not in my feet at the 
moment so. It is a bit random, it does tend to move around […] I might be sort of 
six months with it really bad in my feet and my knees and then I might find that it 
is worse in my back and hips and then it might move up […] to my shoulders and 
my elbows” [102] 
 
“Originally my knees were a bit stiff, but apart from that my knees have been fine 
[…] Ankles are not much stiff, just [my] feet and it’s like the front bit […] so the tops 
of your toes” [115] 
 
For some patients, stiffness was described as being more of a whole body experience 
or more widespread, particularly during the morning or flare.  
 
“[…] it’s more general in the morning and more specified during the day. So it’s 
more of an all-round stiffness because obviously you haven’t moved around” [112]  
 
“[…] stiffness when you’re getting up, it feels like all up your arms and your legs 
and your whole body more” [116] 




4.5.2.3 Theme 3: Linked to behaviour and environment 
While patients related stiffness to their disease, they also associated it with their 
behaviour and environment.  
 
4.5.2.3.1 Movement and stiffness 
The topic of movement featured regularly throughout patient dialogue. Within this, 
stiffness was considered a result of both immobility and over-activity. 
 
“[…] if I have had like a busy day, and I haven’t been able to rest […] then I might 
find that it is creeping back in the evening as well” [102] 
 
“Oh it’s always much more difficult to get up after sitting still” [103] 
 
In relation to over-activity, one patient suggested that stiffness was a signal to stop or 
change current behaviour. 
 
“[…] it rings warning bells […] it tells you there's something wrong […] I mean your 
joints wouldn’t be stiff if everything was fine. So it's, if the, alarm bells start ringing 
[…] It's telling you like, you know, you know, you've done something wrong or you 
should be doing something differently” [110] 
 
Another patient suggested that after a restless night, her stiffness was worse in the 
morning which was not compatible with stiffness as a result of being immobile. 
 
“Well, I am quite tired at the moment cause I am not sleeping very well […] And 
that, I tend to find that stiffness is worse in the morning but then I have probably 
been more active during the night, you know, so, you know really it should be better 
shouldn’t it cause I haven’t actually just sat and lay in one position for a long while” 
[102] 
 
Stiffness was also felt to be a result of a joint being in a fixed or restricted position.  
 
“So I use the mouse, that’s what makes my hand go stiff by holding the mouse” 
[113] 
 
4.5.2.3.2 Relationship between medications and stiffness 
Many participants were keen to discuss their medications, within this there were 
discussions specifically regarding the relationship between medications and stiffness. 
 
“[…] but since I’ve on the Humira injections I have found a difference […] I’m not 
as stiff as I was” [105] 
 




“[…] this morning it was about half an hour [...] and that’s with taking the steroids, 
which does make it easier” [113]  
 
Some participants reported dramatic effects of medications on their stiffness, in 
relation to enabling completion of activities of daily living and regaining normality. 
 
“I was on originally which was Enbrel. Which was like a miracle drug for me […] I 
woke up in the morning […] and I was like ‘oh my God’, I could like move my hands, 
I got out of bed, like usually for me I have got to kind of like rock me-self up and 
then go like ‘oh ah ah ah’ like some old man. And I got up and it was just amazing. 
It was like every joint had been injected with some lubricant. I was like unbelievable 
and I just walked down the stairs one step after another like a normal person. It 
was like absolutely fantastic” [115]  
 
Other patients indicated that medications had reduced stiffness to such an extent that 
it was no longer a problem. 
 
“And now that I am on this infusion […] that seems to sort of alleviated that 
problem” [101] 
 
“I have been on the Humira now for just coming up to 3 months [...] I feel better but 
I still suffer with the stiffness, especially in the mornings. Whereas on the Enbrel I 
never suffered any of that” [115]  
 
One participant stressed that she felt the dramatic effect of medication on stiffness 
was ignored by the clinical team due to the lack of appropriate assessment. 
 
“I kind of feel that it’s sort of a lost entity because actually the drugs working, one 
of the things that they’ve really transformed has been my stiffness, but it’s never 
been a measure that’s kind of been considered [...] the one thing they’ve never 
asked me about is joint stiffness and the one thing I’m absolutely delighted about 
is that I can now get up and get him [son] up whereas I haven’t for two and a half 
years because I can’t do that in the morning [...] and like the nurses all know and 
that’s great but if they measured it they’d be brilliant because I could then say 
‘Yeah, look’, you know?” [109] 
 
4.5.2.3.3 Lifestyle and environment and stiffness 
A number of lifestyle and environmental factors were discussed as influencing the 
experience of stiffness. It was suggested that cold and wet conditions accentuated 
stiffness duration, severity and impact. 
 
“Air conditioning is a killer by the way […] You get on a plane and they blow cold 
air at you, your joints will go stiff and painful within minutes” [101] 
 




“[…] I do like the sunshine […] I just feel not so stiff everywhere, normally you know 
what I mean I’m quite good, whereas when it’s tipping in rain I’m so blooming stiff 
I’ve got a job to move” [105] 
 
A small group of patients suggested that certain foods and alcohol affected stiffness. 
 
“I wouldn’t eat cheese every day of the week because I found cheese erm makes 
me stiff as well” [105] 
 
“[…] once I was at a party and I drank a bit too much and I noticed it in the morning, 
it was stiff but not like, not hangover wise, but […] I seemed to be stiffer” [115] 
 
4.5.2.4 Theme 4: Highly variable 
Theme 4 reflected the highly variable nature of the experience of stiffness. Patients 
emphasised this in relation to individual experience, time, duration and intensity; both 
within and between patients. Although there is inherent overlap in content with Theme 
1 (Section 4.5.2.1.2), here these aspects capture the variability of stiffness from a 
broad perspective whereas Theme 1 captured specific aspects of change in stiffness 
relating to disease activity. 
 
4.5.2.4.1 Stiffness is individual 
The first feature of this theme was the very individual nature of stiffness. Participants 
felt that stiffness was a personal and subjective experience that meant they could 
only describe their own experience. 
 
“[…] I've only obviously got my own personal experience” [107] 
 
4.5.2.4.2 Temporal pattern of stiffness 
There was considerable discussion regarding the timing of stiffness. Many patients 
suggested that stiffness was experienced in the morning. 
 
“[…] stiffness, it’s always there in the mornings, sometimes it’s very bad” [103] 
 
“Well first thing in the morning, I’m stiff as monkeys” [105] 
 
“[…] it starts off when I get up […] That is the worse time of the day for me” [111] 
 
However, for some patients stiffness was not related to the morning period. 
 
“There is no particular time of the day and people will say well what about 
mornings? No” [101] 
 




“[…] there used to be a question called morning stiffness […] it is a little bit more 
at the moment, but I never really associated it with mornings” [102] 
 
The majority of patients highlighted a broader, variable temporal pattern with stiffness 
as lasting all day or recurring in the evenings. 
 
“[…] I’d say I have the usual, stiffer in the morning and stiffer at the end of the day” 
[107] 
 
“[…] stiffness is there give or take 24/7. It comes and goes in waves as it were, but 
at the same time, it never really goes away” [110]  
 
“On a good day it is really just morning and evening” [109]  
 
A small group of patients suggested that the temporal pattern of stiffness had 
changed over the course of their disease. 
 
“[…] I used to have the morning stiffness only really. It’s only really in the last few 
years that I've started getting evening stiffness as well, although the drug I’m on at 
the moment, that’s now fading again so exciting!!” [107] 
 
4.5.2.4.3 Duration of stiffness 
There appeared to be wide variability in the duration of stiffness both between and 
within individuals. 
 
“[…] sometimes is only 10 minutes and I can get rid of it really quite quickly and 
then other times it is just hanging on […] and I just gradually just shed it through 
the first hour or so of the day” [102] 
 
During higher disease activity or flare, stiffness was perceived to increase in duration 
and persistence and was suggested to be more frequent in occurrence.  
 
“[stiffness] will vary anything from about half an hour to, I have had up to about 
two/three hours, unless I've obviously had a bit of a flare up then obviously it can 
be all day thereabouts” [107] 
 
“[…] if it’s well-controlled then I probably get about maybe an hour, hour and a half 
of stiffness in the mornings […] if I’m not as well controlled, not necessarily in a 
flare, just not having a brilliant day, it’s just 24/7. It just never quite shrugs off” [109] 
 
Some patients were able to give a rough estimate of the duration of stiffness in the 
morning. These patients did however state that it was difficult to put a figure on 
duration.  
 




“Erm oh it’s difficult. A good hour. Yeah, a good hour. After a steroid it’ll be shorter 
[…] but in general it’s about an hour” [112] 
 
“Well there again it varies, um normally about two hours” [114] 
 
Despite variation in stiffness duration for some patients, for another group of patients, 
stiffness duration appeared to be constant throughout the day.  
 
“[…] there would probably always be some” [102] 
 
“Yeah that doesn’t alter for me […] From the minute I wake up to the minute I go 
to sleep” [108] 
 
This led to suggestions that duration is not relevant when discussing stiffness. For 
some this was because of the unchanging duration, for others this was because of 
the impracticality of defining its duration. 
 
“Ah yes, I think really the morning stiffness, which actually sort of comes on kind 
of during breakfast and lasts until mid-morning […] it’s fairly fixed. So I don’t think 
that how long it lasts is a very interesting variable […] But generally speaking it’s 
always the same amount of time” [103]  
 
“[…] and when you’re asking specifically about stiffness in the morning, when does 
it start or when do you notice it from […] [Halls”] “[…] Time’s not a factor because 
[…] I might only sleep half an hour like, you know, or an hour at a time […] so the 
time of day isn’t a factor” [110] 
 
4.5.2.4.4 Severity of stiffness 
Severity of stiffness was another area where the variability was apparent. The general 
experience of stiffness did not appear to be severe and one patient termed this “mild 
stiffness” [101]. Patients described how general stiffness could be managed and was 
not specifically related to pain or other symptoms, although it did still effect function.  
 
“Yeah yeah, the mild stiffness is something you can overcome quite easily and you 
expect it to happen […] So if I sit in my car and drive too far without taking a break 
I know when I go to get out the car it’s going to be a struggle for a couple of 
minutes. I am aware of it, I know it’s happening, so I am prepared, alright” [101] 
 
“[…] morning stiffness, once you get up and start moving it all tends to loosen up” 
[107]  
 
Similarly to duration, during periods of flare or having less well controlled disease, the 
experience of stiffness was more severe, related to other symptoms and had a greater 
impact. 
 




“Now, when you get what I call cramp stiffness, let’s call it that then, that is pain 
like you have never experienced, it’s like having an abscess toothache alright, it’s 
severe alright” [101] 
 
4.5.2.5 Theme 5: Impacts on daily life 
Importantly, patients described and evaluated their stiffness in terms of its impact on 
a number of domains.  
 
4.5.2.5.1 Daily life impact 
Patients stressed the impact of stiffness on daily life. Activities of daily living such as 
eating and dressing were highlighted as being affected. 
 
“[…] I’d end up eating a lot of soup because I just can’t get my mouth open as wide 
to take even just a simple fork of food, and chewing just becomes a total non-
starter. Yeah so I get joint pain in my jaw but also it’s really stiff” [109] 
 
“And it’s like doing up your shoe laces and things like that you know […] And 
buttons, sometimes trying to do a button up, it’s awful because you can’t move 
properly you know. Well yeah I mean especially with this as well, you try and do a 
button up and this is stiff and swollen and it’s difficult to do” [114] 
 
For some patients, stiffness limited participation in leisure activities and hobbies. 
 
“I’m making my step-daughter her prom jewellery at the moment […] whereas 
before I would’ve just made it in a night no problem at all but when I’m stiff [...] I 
can’t do it because I can’t pick up the bead or pick up the needle” [109]  
 
Other patients described stiffness as disrupting normality. 
 
“It’s also true that the stiffness in the mornings means that I don’t get around to 
doing things which other people do in the mornings, like going to the pool and 
swimming” [103] 
 
“[…] my best time usually is late evening […] any time sort of past 7/8 o’clock-ish 
and sometimes before I go to bed I feel quite good. It seems to take that long to 
get back to some normality” [115]  
 
Patients also explained that stiffness affected their work. 
 
“I am not safe enough to be on a building site I don’t think, I couldn’t get up steps 
and stuff, things that I used to do” [102]  
 
“[…] at work I struggle a lot more because I’m more desk-based on a bad day so 
I’m not getting up and talking to patients so much and then my hands will be okay 




because I’ll be typing and therefore they’re just doing a little amount of movement 
whereas my lower half where I’ve been sat, just stationary” [109] 
 
Interestingly, some patients perceived stiffness to have less of an impact following 
stopping work. 
 
“[…] getting up to go to work was getting worse because it was taking longer to be 
able to get to move to be able to put the car in gear and, you know, things like that 
[…] but, I think now because I'm not working […] it’s easier, I can cope with it 
better” [113] 
 
4.5.2.5.2 Physical impact 
Physical function was considerably influenced by stiffness, including reduced 
mobility, balance, dexterity, grip and range and speed of movement. Patients 
described general inability or difficulty moving as a result of stiffness.   
 
“Just, I mean a job to move really, your limbs and your joints, your fingers, erm you 
can move them but they just, I just find it sometimes initially quite hard to do” [106] 
 
“[…] when I wake up in the morning if you could imagine, say you’ve got two bucket 
fulls of quick drying cement and you stick your hands in, and it’s drying and you’re 
trying to move your hands, you’re kind of like forcing against it […] you can’t sort 
of move very much” [115] 
 
As well as patients highlighting general movement difficulty, they also reported 
restriction of quite specific movements. The first of these related to stiffness limiting 
range of movement. 
 
“[…] but I would say stiffness is just about, just it’s painful to move it and it is difficult 
to actually get any joint to full extension” [102] 
 
“[…] this stiffness I think has only occurred in the last few months but it’s not 
painful, and it’s just that I can’t exercise the full movement of my leg” [104] 
 
Some participants explained how their dexterity was affected by stiffness.  
 
“I mean it’s like the other day I lost a screw out of my glasses and I could see this 
screw and it was down there, and do you think I could get my fingers to pick it up, 
I could not, I could not get my fingers to pick up this blooming stupid screw” [105] 
 
Grip was another physical function that was limited by stiffness. 
 
“You haven’t quite got the right grip, you can’t quite make a full fist like you would 
expect to make” [109] 




“I suppose it makes things more difficult to do, like I wouldn’t be able to open […] 
a bottle of milk say on a morning […] Because I can't grip” [113]   
 
Patients explained how they were not able to complete tasks quickly.  
 
“[…] sometimes I move and I’m not in pain, I’m just sort of slow getting going” [109] 
 
“I think it's not being able to rush, I think or not being able to do something quick if 
you wanted to do it” [113] 
 
Finally mobility and balance were also stressed as being affected by stiffness.  
 
“[…] walking on stiff feet is just, it feels awkward, your balance is a bit skew, quite 
likely to fall over […] all of the bones in the feet aren’t operating properly […]” [102]  
 
“[…] in a chair, you can't stand straight up […] you tend to walk around with your 
hands on walls and […] you're looking for support all the time” [110] 
 
4.5.2.5.3 Cognitive impact 
A small group of patients described a cognitive element that appeared to be impacted 
by stiffness. Here patients described how thought processes were influenced by 
stiffness.  
 
“[…] say for example, walking with a stick, you've got to remember to walk the right 
way […] if you go just on a kerb, because not every where’s got dropped kerbs 
unfortunately […] you've got to remember to do it the right way” [110] 
 
“[…] it sounds silly but I’d almost forgotten how to walk properly, because I was 
kind of always hobbling around […] because I’d gotten into the habit of doing it, 
[…] I was thinking, I don’t have to do that, I don’t have to limp or hobble” [115] 
 
4.5.2.5.4 Psychosocial impact 
Stiffness was also felt to have psychosocial impact. One participant suggested that 
stiffness impacted on her personal image in terms of how she perceived herself and 
how she portrayed herself to others. 
  
“[…] even my good leg I’m quite stiff and uncomfortable and look awkward, […] 
because also a lot of it is vanity that you don’t want people to see you looking quite 
like that, do you know what I mean I’d quite like to kid myself and kid everybody 
else that I’m fit and I’m healthy” [108] 
 
In relation to emotional wellbeing, many patients spoke about how the restrictions 
imposed by stiffness resulted in feelings of frustration.  




“Disruptive, I can find it quite frustrating at times, especially when I’m up against I 
really want to get something done by a certain time or by a certain day of the week, 
or because I've got something else happening I need to get that done” [107] 
 
“They [hands] wouldn’t do anything. I mean, you could do a basic, you know you 
could pick up that pen, but you got no kind of dexterity or anything. It’s just kind of 
just useless, which as I say I was really frustrated” [115] 
 
For a small group of patients, stiffness appeared to cause low emotional states. 
Although this appeared to relate specifically to stiffness, it was also relevant within 
the broader context of RA, reinforcing the link between stiffness within the context of 
RA. 
 
“So stiffness then to some extent is not so much a limiting, limited clinical term of 
experience, it could also relate to a wider feeling. Now looked at from another point 
of view, you could describe that as malaise, or you could describe it as 
hopelessness, or I've used the word aporia” [103] 
 
“[…] this morning I put a couple of pancakes in and wanted some jam and couldn’t 
undo the lid and didn’t have any jam, now some days that’ll make me cry, some 
days I think Jesus Christ I can’t even have any jam on my toast, and that will finish 
me off, and other days like today I just think I can’t have any jam […] that is borne 
more from frustration than pain and stiffness of not being able to do simple tasks 
feeling a bit useless” [108] 
 
“[…] I got one thing wrong with me I don’t want another thing wrong with me by 
getting depressed but it grinds you down so much that you end up becoming 
depressed as well. And it’s like a real tough thing to deal with. You know, you’ve 
probably spoken to lots of people and they can, a lot just of get on with it but you 
can get on with it, but you know you can’t, it just it makes your life stop […] you’re 
virtually disabled, you can’t do anything. And people don’t understand it, just don’t 
understand. They think ‘Oh what, you’ve got stiff hands or something’ they don’t 
understand the pain and how it kind of affects you” [115] 
 
Interestingly it was also suggested that emotional states impacted on the disease and 
subsequently stiffness.  
 
“I think people’s emotional state […] I mean I just ached everywhere and the 
stiffness I am sure it was worse then […] so I think that might have an impact” [106] 
 
“[…] sometimes you think I can’t do that so you just don’t try. See what I mean? 
And then therefore makes the pain, stiffness, and it does because I, and a lot of it 
is up here [in your head]. You’ve got to try and be as positive as you possibly can 
because if you’re not, well you might as well just give up […] I would say stress 








4.5.2.5.5 Pain impact 
Patients also discussed how pain would result from performing movements restricted 
by stiffness. 
 
“[…] I think for me it’s a case of I can have the stiffness, I can be sat here and like 
my shoulder’s feeling a little bit stiff, but I’m not having a lot of pain, whereas if I 
start moving it, if I tried to lift it now I’d be having pain” [107] 
 
“[…] the […] stiffness thing for me, my legs well you just end up hobbling, I hobble 
because the flexibility in your joints just, just isn’t there and if you push it a bit too 
much to bend or use that knee as you would normally […] it just hurts” [108] 
 
Pain following stiffness restricted movement appeared to be exaggerated in periods 
of high disease activity or flare.  
 
“[…] you must keep your range of movement, it’s difficult when you are in pain to 
continuously move a joint into that position where it hurts. But then if you don’t it 
gets stiffer” [102] 
 
4.5.2.6 Theme 6: Requires self-management 
Patients articulated numerous strategies to self-manage stiffness. Strategies targeted 
a range of domains and were both direct (targeting stiffness) and indirect (targeting 
the consequences of stiffness). 
 
4.5.2.6.1 Direct strategies 
4.5.2.6.1.1 Movement 
General movement, including walking and stretching, was highlighted by many 
patients as being an effective way to reduce stiffness. 
 
“After you walk round for a few minutes and your joints start moving again, the 
stiffness goes” [101] 
 
“But as soon as you wake up […] it all starts up again and, and it is purely moving 
that’s going to put it right” [110] 
 
Specifically, moving while still in bed was a strategy used to target morning stiffness. 
 
“[…] before I get up out of bed I try to move all my joints […] to actually just try and 
get everything moving a bit” [102] 
 
“[…] I sort of sit on the edge of the bed and just move just gently before I get up 
[…]” [106] 
 




General and specific exercises were also suggested as being beneficial to loosen up 
and relieve stiffness. 
 
“[…] that would ease up if I actually exercised it, it’s kind of loosening up all the 
fluids and everything, or that’s what it feels like […]” [107] 
 
“I do a variety of different exercises […] So I’ve got a gyro ball, a very lightweight 
gyro ball […] I use it to just loosen out my joints […] so it kind of eases out the 
stiffness” [109] 
 
Supporting and physically manipulating joints was discussed.  
 
“[…] you realise that you have worked into that sort of stiffness place […] and you 
need to actually lower it back into place and then just get it in a more comfortable 
position” [102] 
 
“Sometimes like this morning I had to physically bend my hands to get them to 
work because they just won’t, they’re kind of just locked” [115] 
 
4.5.2.6.1.2 Treatment or devices 
Heat and cold techniques such as hot water bottles and ice packs were regularly 
employed by patients to directly relieve stiffness. 
 
“Ice is really good […] It is good for comfort but then it’s like a cold, hard stiffness 
then and pain. Whereas warm is, if I put a wheat bag on my ankle, it feels like ooh 
cwtch […] But then it doesn’t get rid of the swelling, so you’ve still got the stiffness 
but it’s duller, but the cold is like going back to that pointy and round as the cold 
reduces it but God that is really stiff then, as in the pain is more er, spikey” [112] 
 
For many patients, a hot shower first thing in the morning was a simple measure that 
enabled them to get going.  
 
“First thing in the morning, to get me mobile […] hot water is wonderful [...] I can 
move then” [105]  
 
“So if I have a hot shower on a standard day I’m up and going […]” [109] 
 
Some patients stated how they used medications and painkillers as part of their 
morning routine to relieve stiffness. 
 
“Well by the time I’ve done my hot water and had a shower and got me pills into 
me […] they start to work so, and you know it’s nowhere near as stiff at 12 o’clock” 
[105] 
 




“Normally what happens is I get up, I go downstairs, have a cup of coffee, 
painkillers every morning, I’ve been taking those now for about two years.” [114] 
“For your stiffness particularly?” [SH] “Yeah, yes […] and then it’s about two hours 
after, then I start to loosen up” [114] 
 
It was suggested by one patient that in a period of flare the only effective management 
was a steroid injection. 
 
“So that’s extreme stiffness, and I am not exaggerating that […] it seems the only 
way to resolve that one is to have a massive injection of steroid” [101] 
 
A number of alternative therapies were also used to directly relieve stiffness. Again 
although these strategies were discussed in the context of stiffness, it was felt that 
these also related more broadly to RA. 
 
 “[…] she had some of these oils and that and she just went up and down my arms, 
10 minutes and I could blooming move them […]” [105] 
 
“[…] relaxation techniques, I have relaxation hypnotherapy CDs” [110] 
 
The use of gadgets and aids also appeared to be an effective way to manage 
stiffness. 
 
“And I’ve got a few aides to use, like a button thing and the zipper thing, oh and a 
brilliant thing to open a jar of milk, a carton” [112] 
 
Some patients used splints to support joints, during a flare or as a reminder, although 
this strategy was not universally considered effective.  
 
“I sometimes put splints on at night time because it makes it more comfortable, but 
then the stiffness is just brutal when I take them off” [109] 
 
“[…] sometimes if it’s just a bit bad in the morning, not too bad but a bit bad, I get 
up and I put my splints on and I’ll keep it on for about an hour and a half, […] It’s 
always like a reminder for yourself to be careful with your hands […]” [116] 
 
4.5.2.6.2 Indirect strategies 
4.5.2.6.2.1 Behaviour adjustment 
Indirect strategies to manage the impact of stiffness included behaviour adjustment 
especially in relation to daily tasks and dressing. When the idea of working through 
stiffness was proposed to one patient she replied, “I can work round it, really” [105]. 
 




“People say oh that’s a nice dress and I think yeah it’s because I couldn’t get my 
jeans on but you know, thanks […] And [son], I dress him differently […] like these 
are the trousers that my husband put him in this morning and I bought them as a 
spare pair because you can see they’re fitted, so you have to kind of work them 
and you work the button and all that, whereas those are loose and you just pull 
them straight off […] and you just do it, you don’t really think it I suppose. You just 
adapt in the morning” [109] 
 
“Well yeah I mean especially with this as well, you try and do a button up and this 
is stiff and swollen and it’s difficult to do. So I’ve got lots of things with no buttons 
on” [114]  
 
Changes in behaviour also related to performing certain activities later in the day. 
 
“Sometimes I don’t have it [a shower] in the morning, because I can’t do it. So I 
might have it in the evening and if I can’t do it that day, I’ll do it the next” [114] 
 
There was discussion in the broader context of RA where patients aimed to ensure 
that RA did not take over their lives for example “I can’t let it beat me” [112]. One 
patient however, was changing career specifically as a result of stiffness yet this was 
not perceived negatively, rather as an opportunity.  
 
“So I was thinking in some ways how it limits me and in other ways what it gives 
me opportunities to do […] I’m about to start a new career and in part that’s 
because I struggle so much starting at 8.30 with my early morning stiffness […]” 
[109] 
 
4.5.2.6.2.2 Prepare and plan 
Patients also described having to prepare and plan tasks, including getting going 
earlier to compensate for slower movements. 
 
“I had to go for an MRI scan […] and that was about 10 o’clock in the morning but 
it was the only one that they had and I thought well, I’ve just got to do it haven’t I? 
I’ve just got to move myself a lot earlier” [105] 
 
“But otherwise it doesn’t interrupt my life too much, because I do try and pace as 
much as possible to try and make sure I can do as much as possible when I want 
to, or take prolonged rest periods before prolonged activity. And then rest 
afterwards again” [107] 
 
4.5.2.6.2.3 External support 
Patients discussed help from family and friends including support with particular tasks 
and encouragement or facilitation with the use of gadgets. 
 




“[…] my daughter is brilliant […] she got me an electric jar opener that takes the 
lids off, because I couldn’t undo them” [106] 
 
“[…] and when I’m really stiff I have to wake my husband and he then turns me 
sort of by shifting me […] and I whinge away at him like nobody’s business and 
then he puts the pillows back into the right place” [109] 
 
For other patients, family and friends were flexible in the way that they planned or 
conducted their day-to-day life. 
 
“[my children] who are 11 and 13 […] they just step into it and just, you know, do 
whatever, and one morning I’ll offer them scrambled eggs or porridge and the next 
morning it’s just cereal and help yourselves. And they just kind of roll with it” [109] 
 
4.5.3 Stiffness descriptors and metaphors 
4.5.3.1 Stiffness descriptors 
Many of the stiffness descriptors used by patients were based around impact (such 
as movement difficulties and frustration) and these were discussed in Theme 5. 
Descriptors have been grouped under related headings (Table 4.3).  
 
Table 4.3: Stiffness descriptors (number of transcripts identified in) 










Not fluid (3) 
Pulling (3) 
Not loose and limber (1) 






















Descriptions of the physical sensation of stiffness were aided by the use of 
metaphors.  
 
4.5.3.2.1 The physical sensation of stiffness in metaphors 
Many metaphors were based around the difficulty of movement including unbalanced, 
heavy and lack of fluid movement, perhaps to articulate rigidity. 
 
“I’m rather walking like somebody on stilts” [104] 
 
“[…] it’s like the treacle that was affecting the movement” [109]  
 
“I’m walking like a robot first thing in the morning” [114] 
 
Some patients likened the physical sensation of stiffness to feeling elderly. 
 
“[…] you act as if you are like 80 and 90” [101] 
 
“[…] hobbling about and well, being a bit like a little old lady really” [108] 
 
“[…] it’s like an old person feeling stiff in the morning” [112] 
 
Other patients suggested that their joints required lubrication.  
 
“And that’s how my joints are. WD40 obvious!” [101] 
 
“Like oiling a hinge […] Replace all the synovial fluid with WD40, lovely” [107] 
 
4.5.3.2.2 Descriptions of stiffness using metaphors 
The interview guide included a question asking patients to describe stiffness using 
the metaphor of an animal. This was not asked in every interview and not all patients 
responded to this question as some found it too unusual a concept to answer. 
However, it did appear to resonate for some patients and a number of interesting 
metaphors were described capturing a range of stiffness characteristics.  
 
“I feel a bit like a tortoise sometimes [laughs] […] Slow and a bit precarious. I just 
feel sort of slow and a bit sort of um, I suppose a bit sort of to do with the feeling 
of being a bit encased within, sort of like being a bit, constricted, I suppose” [102] 
 
“Any fossilised animal would probably be a good one […] fossils are very stiff, they 
don’t move at all you see” [103] 
 




“[…] obviously something like a lion […] because sometimes, you know, it roars at 
you […] to give you warnings, messages […] Stop, don’t or do” [110] 
 
“A hyena. […] Because they’re a bloody nuisance […] They’re nasty […] And a 
pain (Laughs)” [111] 
 
“Well I would say stiffness is like a dog […] Because a dog is your companion so 
is constantly with you and […] he’s constantly with you but you can control it […] 
So it’s like, well it’s a companion because it’s always with you but then you do have 
some control because for me that’s a dog isn’t it? […] Always there, always with 
me, my companion but you’ve got some degree of control whether that be i.e. for 
me, drugs, attitude, do you know what I mean? So for me it’s a dog” [112] 
 
Other patients’ answers appeared to describe the broader experience of RA. 
 
“[…] it would probably be something quite nasty and aggressive in my opinion, 
because […] that’s the way it affects me and makes me, personally the way I feel, 
it can make me feel angry and frustrated. So maybe kind of like a bear with a sore 
head sort of thing, maybe or a vicious cat or something […] Something you couldn’t 
100% trust sort of thing yeah, you don’t want to stick your hand in the cage, 
because you know what’s going to happen” [115] 
 
Some patients used the opportunity to describe their experience using a metaphor to 
illustrate differences between stiffness as a result of different processes. Here some 
patients differentiated general daily stiffness from stiffness in higher disease activity 
or flare. One patient indicated that she would choose a different animal to describe 
stiffness in the two situations. 
 
“Probably say something along the lines of a sloth […] but it doesn’t quite cover it, 
if that makes sense […] they’re quite slow and sluggish and that’s kind of how 
stiffness makes me feel, especially when I've got it in lots of joints, it’s just the slow 
and sluggish and heavy and, which is my impression. I mean sloths are slow and 
sluggish but I don’t know about the heavy but it’s just the impression of, or the 
mental relationship […] so the sloth doesn’t quite cover it […] I’m not completely 
happy with my answer […] because I’d say during flare it should be worse, that 
sounds really disparaging of sloths doesn’t it? [107] 
 
Another patient described her stiffness in flare as an exaggeration of her usual 
experience based on the metaphor of a teenager. 
 
“I think it’s just an exaggeration of itself. I don’t think it is a different beast […] But 
exactly like a teenage daughter who’s lovely and then she’s hormonal and she’s 
still the same beast, just kind of a little bit more unpredictable, a bit worse, a bit 
more door-slammy and stompy, and then the next day everything’s great” [109] 
 




One patient elaborated on her description of daily stiffness as a dog and described 
different experiences of stiffness using metaphors and separated flare stiffness from 
morning stiffness and stiffness throughout the day. 
 
“[…] acute flare up would be a right snappy little git. Yeah. He’s be a real snappy 
one […] In the morning he would be like a cuddly er, like a cuddly, furry thing […] 
no he’d be a Pitbull if it was acute flare-up, like a proper you really don’t know what 
to expect, a real aggression, could hurt you […] in the morning it would be a, not 
a Bichon because that’s a bit specific but more of a furry overall and then 
throughout the day he’d be a Westie. He’s lovely to stroke, you never know when 
he’s going to have you” [112] 
 
Another participant described the difference between stiffness as a result of a 
mechanical rather than inflammatory process using metaphor.  
 
“The inflammation around the joints has been taken away quite successfully […] 
Leaving joints which have been hammered for 20 odd years, which are absolutely 
wrecked, exposed. Now that’s, the analogy I draw from that is like pulling up an 
old wreck [laughs] from the sea bed and as soon as it gets the air on it, umm it 
starts to decay” [101] 
 
“If you take a rusty old engine and try to move it, right, you will eventually move it 
if you apply enough pressure, that’s stiff” [101]  
 
4.6 Discussion 
Stiffness was reported to be a normal part of having RA, be experienced in joints and 
more widespread, be related to behavioural and environmental factors and have 
marked variability (including not being limited to early morning). It resulted in wide-
ranging consequences, which had wide ranging impact on patients’ daily lives and 
necessitated self-management. 
 
The key finding was the emphasis that patients placed on the impact of stiffness. This 
finding is consistent with much of the literature relating stiffness to aspects of quality 
of life and work life (e.g. Phillips and Dow, 2012) (Section 1.5.2) and with other 
qualitative work that has focused on stiffness in an RA population. As detailed earlier 
(Section 1.6.2), Lineker et al. (1999) conducted a qualitative study that aimed to 
develop a patient centred definition of stiffness. The results from that study 
highlighted the importance of the impact of stiffness however, it resulted in no change 
to the way stiffness was conceptualised or assessed. In addition, other very recent 
work exploring the RA patient experience of stiffness identified the impact of stiffness 
on daily life as an overarching theme and broadly covered very similar domains to 




this study (Orbai et al, 2014). This study was performed in the US and involved 20 
RA patients across four focus groups. Importantly, one of the key messages of this 
article was the identification that patients shared a common language in their 
descriptions of stiffness impact (Orbai et al, 2014). This is relevant especially given 
that in all three qualitative studies (Lineker et al, 1999; Orbai et al, 2014; Halls et al, 
2015) the patient experience of stiffness was identified as being individual and varied. 
Therefore, areas of unity and shared relevance are particularly significant when 
considering stiffness assessment and the importance that patients placed on stiffness 
impact has implications for PROM development. Taking this into account, the 
potential effectiveness of measuring stiffness based on concepts beyond severity and 
duration should be considered. Given that impact was how patients in this study 
defined and evaluated stiffness, and the identification of impact as a topic of shared 
relevance across patients (Orbai et al, 2014) there would be an argument for basing 
stiffness assessment on the concept of impact. This suggestion would also fit with the 
impact triad (Sanderson et al, 2011) which is a concept developed by patients and 
health professionals and recommends considering not only the severity of an 
outcome, but also its importance to patients and their ability to self-manage it. It is 
important to note that self-management is a term that has been defined in a number 
of ways and has no gold standard definition (Barlow et al, 2002). The theme relating 
to self-management in relation to the experience of stiffness captured a broad range 
of components including a variety of physical and psychosocial aspects. This fits well 
with Barlow’s (2001) definition where self-management is defined as “[…] the 
individual’s ability to manage the symptoms, treatment and psychosocial 
consequences and life style changes inherent in living with a chronic condition. 
Efficacious self-management encompasses ability to monitor one’s condition and to 
effect the cognitive, behavioural and emotional responses necessary to maintain a 
satisfactory quality of life” (p.547). This definition will be used when referring to self-
management throughout this research. 
 
These data may also help explain reasons for the poor performance of current 
stiffness questions. As highlighted in Chapter 2, current stiffness assessment is 
generally based on items capturing the severity or duration of EMS/MS. However 
there is considerable variation in item wording, response options, format and time 
frame. For example MS duration items include various baselines (‘from awakening’ 
or ‘from getting up’) and endpoints (‘initial improvement’ or ‘complete resolution’) (e.g. 
Hazes, Hayton and Silman, 1993). The inconsistency of stiffness assessment is 
compounded by patient suggestion that stiffness does not solely relate to the 




morning. This may also explain difficulties in trying to determine a start or end point 
and why it has been suggested that patients are often forced to report a cut-off time 
(Hazes et al, 1994). Furthermore, traditional simple questions appear to assume that 
patients are evaluating stiffness related to inflammatory processes. However, some 
patients in this study appeared to be able to identify differences between inflammatory 
and mechanical stiffness. Finally, in existing assessment there is no consideration of 
stiffness location, yet patients in this study reported stiffness in single and multiple 
joints, and also discussed a more widespread experience of overall stiffness. 
Therefore, in order to enhance stiffness assessment, individual items that capture 
patient relevant concepts such as impact, location, process and timing should be 
developed and tested for inclusion in an RA stiffness PROM. This is supported by 
results from other work (Orbai et al, 2014) and reinforced by discussion at OMERACT 
(Orbai et al, 2015). 
 
Another interesting result from this study was the significance of stiffness at different 
times during the course of the disease, particularly in early disease, where for some 
patients, stiffness was particularly prominent. The relevance of symptoms in early 
disease has been an area of recent research partly due to better outcomes as a result 
of earlier treatment initiation (van der Linden et al, 2010). Recent work that produced 
a synthesis of qualitative literature focusing on symptoms in early RA, reported that 
stiffness was not regularly described in detail in the literature and also highlighted that 
there was no description of the meaning of stiffness or exploration of the concept of 
stiffness particularly at RA onset (Stack et al, 2013). However, stiffness was identified 
as a relevant symptom in early RA by some patients in Study 1. This finding reinforces 
the potential importance of stiffness in further work into the development of a 
‘symptom questionnaire’ to identify individuals at risk of RA as early as possible, as 
suggested by Stack et al. (2013). It also identifies another area where effective 
stiffness assessment would be relevant.  
 
Similarly to some of the research conducted in PMR (Hughes et al, 2012), and other 
work into the patient experience of stiffness (Rhind, Unsworth and Haslock, 1987; 
Lineker et al, 1999; Orbai et al, 2014), this work identified a relationship between 
stiffness and pain. Orbai et al. (2014) went as far as to suggest stiffness-pain 
interdependence based on their results, including that the experience of stiffness was 
overshadowed by pain, separation of the two symptoms is meaningless as they are 
so related, and as stiffness is less well understood, pain is a more useful outcome. 
This is an interesting argument especially from a measurement perspective, as there 




is little value in assessing a concept that is already captured in other assessments. 
However, this argument fails to address the importance of stiffness as a relevant 
patient outcome that regardless of its potential placement in any hierarchy of 
symptoms is still commonly experienced by patients and regularly used clinically and 
in research. Although this study did indicate a clear relationship between the two 
symptoms, distinctions were identified including management strategies and 
medications that targeted pain and stiffness differently e.g. “the heat will affect my 
stiffness for longer than it affects the pain” [109]. It is also important to consider that 
certain patient-reported symptoms may be more relevant to some patients than 
others. Therefore, only by developing effective stiffness measures (that assesses the 
relevant concept/s) will we be able to adequately make decisions on the usefulness 
of stiffness as an outcome in RA. Further exploration into the usefulness of stiffness 
assessment in RA is supported in a recent paper that investigated which aspects of 
RA disease activity correlate best with PtG assessment (Ward, Guthrie and Alba, 
2014). In the study, a full range of patient reported (pain, disability, MS duration, MS 
severity, fatigue, depression) and clinical (CRP, SJC, TJC) outcomes were evaluated. 
It was reported that MS severity was associated with changes in PtG assessment 
independent of changes in pain, indicating that pain cannot be used as a substitute 
assessment of stiffness. As a result the paper promoted further investigation into the 
use of stiffness severity as a useful RA outcome (Ward, Guthrie and Alba, 2015). 
 
Finally, the investigation into metaphor provided a novel way of further investigating 
the patient experience of stiffness. The metaphors used elaborated these data, for 
example, some reinforced the stiffness descriptors relating to lack of movement and 
restriction (e.g. “[…] walking like a robot […]” [114]) while others highlighted the 
unpredictability of stiffness reflecting Theme 4 (e.g. “[…] like a teenage daughter […] 
[109]”). Although many metaphors were spontaneously generated in participant 
dialogue, some participants found describing stiffness using the metaphor of an 
animal difficult. This may have been due to the use of a specifically defined metaphor, 
although during a recent study that used colour to describe osteoarthritis pain it was 
reported that the task appeared easier for some participants than others (Wylde et al, 
2013) indicating that it may be the concept of the metaphor that is difficult for some 
participants. Despite this, the use of metaphor provided useful data and a valuable 
insight into the patient experience of stiffness. 
 
Although the study sample was small (n=16) with participants from two NHS trusts in 
the same city, it comprised a range of age, gender, treatment regimens and disease 




duration. All participants were White British despite participants from other ethnicities 
being approached during recruitment. Although research suggests that stiffness is a 
relevant symptom in ethnically diverse populations (Kett et al, 2010), there may be 
cultural differences in the perception of stiffness, thus this is an area for further 
research. However, given the similarities between results in this study and that 
conducted by Orbai et al. (2014) where participants were ethnically heterogeneous, 
this may not be necessary. Slight differences in recruitment strategies across sites 
(Section 4.3.2.1) may have influenced the sample. Patients are more likely to 
participate in research if initially approached by their usual doctor (Newington and 
Metcalfe, 2014). However, as participants were recruited at two sites, any influence 
this may have had would have been small. Furthermore, this study was conducted in 
a transparent and systematic manner (Meyrick, 2006) with careful record keeping 
(Mays and Pope, 1995) to enhance rigor and reduce bias. Data saturation was 
achieved (Guest, Bunce and Johnson, 2006) and a key strength was the independent 
analysis by team members to enhance the validity of the findings (Mays and Pope, 
1995; Cohen and Crabtree, 2008). Finally, following recommendations during the 
review process, the paper (Halls et al, 2015) was also reported in compliance with 
the consolidated criteria for reporting qualitative studies (COREQ) in an attempt to 
improve rigor and transparency (Tong, Sainsbury and Craig, 2007). The 32-item 
COREQ checklist was reported for this study and is available in Appendix F. 
 
4.7 Conclusion 
This study has demonstrated the relevance of stiffness to patients. Specifically, it 
included one patient who reported that the significant impact of her medications went 
unrecognised due to lack of an appropriate stiffness measure (Section 4.5.2.3.2). This 
important point now needs to be addressed in further research as currently, there is 
no clear evidence regarding the most appropriate measure to use to assess stiffness 
in RA and assessment relies on non-standardised items which do not appear to have 
been developed in accordance with recommended methods including collaboration 
with patients (Kirwan et al, 2007; Patrick et al, 2011a; Patrick et al, 2011b). 
Development and validation of a stiffness PROM would provide a standardised 
assessment method which could be implemented in clinical and research 
environments. It would open up the potential for stiffness to be included in the ACR 
disease activity core set (currently omitted omitted because it is not sensitive to 
change (Felson et al, 1993)) and would also address the OMERACT 2010 research 
agenda item to investigate stiffness assessment in relation to flare (Bingham et al, 




2011). Most importantly, it will recognise and provide a systematic method of 
assessing a symptom that is important to patients and has a significant impact on 
patients’ daily lives. As such, the next chapter will focus on the development of the 
content for a new RA stiffness PROM. 
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Chapter 5: Checking the conceptual model and investigating 
stiffness assessment (Study 2) 
The previous chapter developed understanding of the patient experience of RA 
stiffness. This chapter focuses on the development of content for an RA stiffness 
PROM using focus groups to validate the findings from Study 1, and explore the 
patient perspective of RA stiffness assessment.  
 
5.1 Background 
Literature identified previously (Chapters 1 and 2; Study 1) demonstrated the 
relevance of stiffness to people with RA. However, current stiffness assessment tools 
are not standardised, poorly defined, have little measurement property evidence and 
do not appear to have been developed according to current standards (e.g. Patrick et 
al, 2011a) (Chapter 2). In order to recognise this relevant patient symptom and 
address the concerns associated with its assessment, the development and validation 
of a stiffness PROM is required.  
 
Recommendations regarding the development of PROM highlight that collaboration 
with patients is essential for item generation (USDHHS FDA, 2009; Patrick et al, 
2011a; Patrick et al, 2011b). Study 1 developed a conceptual model of the patient 
experience of stiffness in RA which will inform item generation. It is important to 
demonstrate rigor in qualitative results which can be achieved in different ways (Mays 
and Pope, 1995). Therefore, Study 2 provides the opportunity to test the conceptual 
model in a different sample of patients, using a different method of data collection. 
This will enhance the robustness of findings and may identify different views and 
opinions. Study 2 will also develop current understanding further by providing the 
opportunity to explore stiffness assessment with patients, which was not specifically 
investigated in Study 1. For example, impact was a concept identified in Study 1 as 
relevant to patients, and was suggested (Section 4.6) to fit with concepts in the 
literature that relate to measurement such as the impact triad (Sanderson et al, 2011). 
This study will enable investigation into the patient perspective into whether and how 
to incorporate this in stiffness assessment.  
 
5.2 Aims and objectives 
The overall aim of this study was to start working towards the development of the 
content for an RA stiffness PROM. The specific study objectives were: 
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 To test the results from Study 1 in different populations of patients using a 
different method of data collection to confirm and elaborate understanding 
 To investigate the patient perspective of stiffness assessment  
o To investigate how patients would like stiffness captured in a 
questionnaire 
o To explore patient thoughts about how to improve current stiffness 
assessment 
o To explore patient thoughts about the impact triad as a possible 
conceptual basis for stiffness assessment 
 
5.3 Methods 
5.3.1 Focus group methodology  
Focus groups are a method of collecting data on a particular topic from multiple 
individuals at the same time (Braun and Clarke, 2012). Researchers have suggested 
that focus groups have five characteristics: they involve people; specifically those with 
certain characteristics; they provide qualitative data; they involve focused discussion 
and they result in further understanding of the topic of interest (Krueger and Casey, 
2009). Within the literature, a key use of focus groups has been to confirm not only 
the completeness of data gathered using other methods, but also to check that 
researchers have understood and interpreted data correctly (Finch and Lewis, 2003). 
Both of these uses were relevant outcomes for this study. In particular, it was 
important to test the interpretation of data collected in Study 1, and to generate 
discussion regarding stiffness assessment. For example, explore the link between the 
conceptual model of stiffness and the concept of the impact triad, and whether this 
was an acceptable and understandable basis for stiffness measurement. Additionally, 
in relation to investigating the patient perspective regarding stiffness assessment, 
focus groups have been suggested to be useful to elicit creative thinking (Lewis, 2003) 
through discussion, therefore providing an opportunity to capture ideas regarding 
patient relevant stiffness measurement.  
 
5.3.1.1 Comparing interview and focus group methodology 
Unlike interviews, which allow in-depth exploration of individual experiences, focus 
groups instead concentrate on the interaction between participants to explore the 
topic of interest (Finch and Lewis, 2003). The importance of interaction between 
participants, facilitated by the use of focus groups is a way of exploring participants’ 
attitudes and the context in which they are set (Kitzinger, 1994). This allows 
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participants to influence, and be influenced by each other and reflects real life 
discussion (Krueger and Casey, 2009). This means that focus groups may provide a 
setting that is more natural than other qualitative methods such as interviews (Krueger 
and Casey, 2009) and it has been suggested that due to this, participants may 
communicate more naturally and use everyday language (Finch and Lewis, 2003). 
This would also provide the opportunity to further explore the language that patients’ 
use when discussing stiffness, which would be relevant to capture in item 
development. 
 
5.3.2 Participant identification and sampling 
Participant identification and sampling was conducted as described in Chapter 4 
(Section 4.3.2). The study specific PIS used during recruitment can be viewed in 
Appendix G. It is recommended that the number of focus groups should be based on 
consideration of the aims of the study and practical issues such as time, rather than 
quantitative estimates (Bloor et al, 2001). This is reinforced by Morgan (1997) who 
adds that the more heterogeneous the groups are, the more focus groups will be 
required. It has been suggested that the number of participants per group depends 
on the purpose of the focus group (Bloor et al, 2001; Barbour, 2008). Although in 
market research contexts, it is common to have as many as 12 participants per focus 
group, Barbour (2008) suggests that for social science purposes, eight participants’ 
enables efficient moderation and analysis. At the lower end, a minimum of three or 
four participants is felt to be acceptable (Bloor et al, 2001). Barbour (2008) also 
acknowledges that practical considerations such as room size affect decisions 
regarding sample size. Given these recommendations, it was decided that the target 
for recruitment would be between two and four focus groups, each containing 
between four and eight participants. This target sample size was consistent with 
recommendations, suited the aims of the study and acknowledged practical 
considerations of time and the number of participants that could be comfortably 
accommodated in the rooms available. Additional focus groups could be conducted if 
required or data saturation was not achieved.  
 
5.3.2.1 Site specific differences in participant identification and approach 
As described in Chapter 4 (Section 4.3.2.1) there were slight differences in the 
identification and approach of potential participants at the two recruitment sites. 
Recruitment at NBT was consistent with earlier description but recruitment at the BRI 
differed slightly. As a result of the department being research active, multiple research 
studies often occur simultaneously. At the time of recruitment for this study there were 
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two other studies recruiting RA patients within the rheumatology department at the 
BRI. To minimise researcher presence in precious clinical space and to reduce 
burden on patients by being approached multiple times for different research studies, 
recruitment was conducted in conjunction with other researchers. Here, only one 
researcher was present at each clinic and recruited for all studies in an order 
dependent on the timeframe and inclusion criteria of each study. Study specific 
information was shared between researchers to ensure consistency. 
 
5.3.3 Focus group topic guide development 
A focus group topic guide was developed based on the Study 1 results, discussion 
with the supervisory team, and relevant literature. Topic guides were flexibly adhered 
to during each focus group. The original focus group topic guide (Appendix H) focused 
on the development of the content of the RA stiffness PROM and concentrated on 
two key areas 1) the experience of stiffness; and 2) measurement instrument 
development based on a critique of current questions used to assess stiffness. The 
original focus group topic guide was used in focus group 1 only and was then revised 
following feedback from the progression exam and discussion with the supervisory 
team. The progression exam is a University procedure to ensure adequate progress 
and enable discussion of the research with examiners external to the supervisory 
team. Feedback from the progression exam prompted further interrogation of the 
Study 1 analysis (Chapter 4 reports the updated analysis). It also resulted in changes 
to the focus group topic guide in an attempt to strengthen the study by ensuring that 
the topic guide matched the study aims. The revised focus group topic guide 
(Appendix I) also focused on the development of the content of the RA stiffness 
PROM and again concentrated on the same two key areas, but from a slightly different 
perspective. Initially it concentrated on confirmation and further elaboration of the 
Study 1 data and following this, it explored patient preferences for stiffness 
measurement instrument development. The approach to addressing the latter point 
was revised as it was felt that the original approach was too specific (discussed in 
Section 5.3.3.2). Given the changes to the focus group topic guide and to enhance 
transparency, the content of, and changes to, each section of the focus group topic 
guide and which focus groups these were relevant to, has been described below. 
 
5.3.3.1 Focus group Part A: The experience of stiffness  
In every focus group, participants were asked to start by discussing their experience 
of stiffness and the words they use to describe it. Generated words were written up 
on a flip-chart. Participants were then shown cards, each with a single stiffness 
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descriptor that had been used by participants in Study 1 (Table 4.3 and Section 
4.5.3.2.1), or in the literature (Table 5.1). Words generated that were not already on 
cards were written on cards for discussion. Participants were asked to separate the 
cards into two piles; one including words that they liked and would use and another 
including words that they disliked and would not use.  
 
Table 5.1: Stiffness descriptors from Study 1 and the literature  












Gelling (Wright and Johns, 1960; 
Goddard et al, 1970) 
Wooden (Helliwell, 1995) 
Grating (Helliwell, 1995) 
Stiff (Helliwell, 1995) 




During discussion with the supervisory team, following the review of the Study 1 
analysis (following the progression exam), a number of aspects were identified that 
would benefit from further clarification: 1) the specificity of stiffness; 2) the location of 
stiffness; and 3) changes in prominence of stiffness over disease duration (Table 5.2). 
As the focus groups presented an opportunity for further discussion of these questions 
from the patient perspective, participants were asked for their help in elaborating on 
these areas in addition to extending understanding of the patient experience. The 
discussion points in Table 5.2 were used as prompts in the focus group topic guide in 
focus groups 2 and 3. 
 
5.3.3.2 Focus group Part B: Proposed ideas for PROM development 
Participants were then asked about their thoughts, ideas and preferences in relation 
to the development of a stiffness measurement instrument. This was performed 
differently in focus group 1 and focus groups 2 and 3. In focus group 1, participants 
were asked to critique current stiffness questions (Box 5.1) and suggest how they 
could be improved. Questions were chosen from those identified in the literature 
review (Section 2.4.1) and represented both severity and duration. Questions were 
written up on a flip-chart and presented to participants for discussion. 
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Table 5.2: Areas of further discussion in focus groups 2 and 3 
Area of discussion Key discussion points 
1) The specificity of 
stiffness 
 Further exploration of the relationship 
to/independence from pain 
 Does this relationship change depending on 
disease activity? 
 Is stiffness a patient word? 
2) The location of 
stiffness 
 Does the idea of a wider/whole body experience 
of stiffness resonate? 
 Would this be an appropriate concept for 
assessment? 
3) Changes in 
prominence of stiffness 
over disease duration 
 The idea that stiffness was more prominent at 
certain points during the disease duration was 
proposed. Is this about changes in the 
severity/impact of stiffness or about changes in 
ability to manage? 
 
In focus groups 2 and 3, participants were not presented with stiffness questions from 
the literature (Box 5.1), as during reflection and early analysis of focus group 1, this 
did not appear to provide the opportunity for creative thinking to capture ideas 
regarding the development of patient-centred items as had been hoped for. Instead, 
this appeared to limit and shape participants’ thinking in relation to item development. 
Therefore rather than generating new ideas to improve the presented questions, 
much of the discussion focused on their inadequacy. Although this information was 
useful, it did not achieve the aims of the study. Therefore, in focus groups 2 and 3, 
participants were given an overview of the results from Study 1 and the link to the 
impact triad was proposed. This approach provided an explicit link between Studies 
1 and 2, and was felt to be a broader way of generating discussion about developing 
a patient relevant stiffness measurement instrument. Each aspect of the triad was 
then discussed in relation to question development, focusing on the development of 
potential stem questions, response options, timeframe and layout. This enabled 
discussion of aspects relevant to patients but in a broader yet more targeted manner. 
Additionally, the aspect of severity within the impact triad is also a commonly used 
concept in traditional stiffness assessment, which linked the approach used in focus 
group 1, and focus groups 2 and 3.  
 
5.3.4 Focus group procedure 
All focus groups took place in non-clinical rooms in the Academic Rheumatology Unit 
at the BRI and were conducted by two researchers (Halls and ED). Each participant 
was greeted, introduced to other participants and provided with refreshments. All 
participants gave informed consent and completed a questionnaire pack as previously 
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described (Section 4.3.4.1). Once all participants were present, the researchers 
introduced themselves and explained the purpose and process of the session (Finch 
and Lewis, 2003). Some participants were known to the researchers through other 
research projects or departmental activities. Each group was asked if they had any 
questions before beginning. Each focus group was audio-recorded and transcribed 
verbatim. All recordings were transcribed by a transcription service and were checked 
for accuracy and anonymised by the researcher. 
 




Data were analysed using a deductive approach. Thematic analysis can be performed 
using an inductive or data driven approach (as in Study 1), or in a deductive or 
theoretical approach (Braun and Clarke, 2006). Deductive analysis is driven by 
theoretical influences such as existing theory, previous research, or coding frames 
(Braun and Clarke, 2006). To address the first objective of the study, to test the Study 
1 findings, the coding frame identified in Study 1 (Appendix E) was used as a 
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theoretical framework for analysis. This approach enabled exploration of the extent to 
which these data were consistent with the original coding frame and where aspects 
could be elaborated to incorporate further understanding. The approach also 
attempted to enhance consistency across Study 1 and Study 2 analyses (Part A). To 
address the second objective, to investigate the patient perspective of stiffness 
assessment, existing literature was used to develop a framework based on 
considerations from the questionnaire design literature (e.g. Tourangeau, 1984; 
Fowler, 1995; Streiner and Norman, 2008). The framework included the broad 
categories of: stem questions and anchors, response options, timeframe, layout and 
format (Part B). Analysis was performed using the Nvivo 10 (QSR International Pty 
Ltd, 2012) software package and Microsoft Office Word 2013. Notes made during the 
focus groups were reviewed during analysis. Coding was performed by the researcher 




5.5.1 Participants  
Of the 143 individuals approached, 21 agreed to participate (15% recruitment rate). 
As is common with focus groups, five individuals did not attend on the day (Happell, 
2007) therefore, 16 RA patients participated: 11 were female (69%), age range 
between 43 and 85 years and disease duration between one and 38 years (Table 
5.3). Reasons given for declining participation were as described in Chapter 4 
(Section 4.3.4) however, additionally multiple study recruitment will likely have 
affected participation.  
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Table 5.3: Participant demographic information 








Work status Education 
2101 F 71 1 1 0.75 0.2 0.2 DMARDs, GCs Retired University 
2102 F 64 16 1 1.625 6.7 2.9 Analgesics, DMARDs, GCs Retired School 
2103 F 43 2 1 0 0.3 0.1 DMARDs, GCs Paid work University 
2104 F 67 4 1 1.875 8.7 9.3 NSAIDs, DMARDs, GCs, Bios Retired School 
2105 M 85 6 1 1.375 4.7 9.1 DMARDs, GCs Retired University 
2206 M 72 10 2 1.75 5.0 7.3 Analgesics, DMARDs Retired School 
2207 F 59 3 2 1.875 3.4 6.2 Analgesics, DMARDs RIB University 
2208 F 73 10 2 2.125 1.8 7.4 Changing Retired University 
2209 F 78 8 2 0.75 7.2 3.8 DMARDs Retired College 
2210 M 60 25 2 1.75 6.1 5.0 DMARDs, Bios Retired/RIB College 
2311 M 72 2 3 1.875 5.2 5.3 DMARDs Retired School 
2312 F 64 4 3 0 1.4 1.2 NSAIDs, DMARDs, GCs Retired University 
2313 F 65 7 3 2.375 5.0 9.0 DMARDs, GCs Retired University 
2314 F 55 5 3 1.625 2.4 1.2 DMARDs, GCs Retired/student College 
2315 M 43 38 3 Inc. 5.3 4.8 No medication Unemployed School 
2316 F 54 27 3 2.125 3.5 2.6 Analgesics, NSAIDs, Bios RIB College 
Median and interquartile range (IQR) †=65 (57-72), ‡=7 (4-13), §=1.75 (0.75-1.875), ¥=4.9 (2.1-5.7) ¤=4.9 (1.9-7.4) 
Pt ID=Patient identification number; dis dur=disease duration; HAQ=Health assessment questionnaire 0-3 (3=most disabled); PtG=Disease activity score 0-
10 (0=very well, 10=very badly); Pt pain=Pain assessment 0-100 (no pain-severe pain); NSAIDs=Non-steroidal anti-inflammatory drugs; DMARDs=Disease 
modifying anti-rheumatic drugs; GCs=Glucocorticoids; Bios=Biologics; RIB=Receiving incapacity benefit; Inc.=Incomplete data  
 




5.5.2 Focus groups 
Three focus groups, each containing participants with a range of age, gender and 
disease duration were performed (Table 5.4). Focus groups lasted approximately 120 
minutes each and were conducted with only the researchers and participants present. 
 
Table 5.4: Comparison of participants across groups 
 Focus group 1 Focus group 2 Focus group 3 
Gender 
Male 1 2 2 
Female 4 3 4 
Age range (yrs) 44-85 59-78 43-72 
Disease duration (yrs) 1-16 3-25 2-38 
 
5.5.2.1 Focus group dynamics reflection 
The interaction and engagement of participants differed between focus groups. The 
participants in focus group 1 were relaxed and easy to engage. They listened to each 
other and related what they had to say to others’ experiences, which made it easy for 
the researchers to encourage relevant discussion. The participants in focus group 2 
engaged really well together. All participants appeared to feel comfortable within the 
group very quickly and therefore were forthcoming with sharing information and 
experiences. This did mean that discussion strayed off topic on occasions but 
generally this was monitored by group members who brought discussion back on 
point. The researcher did not feel that the participants in focus group 3 engaged as 
well with each other in comparison to the previous two groups. Discussions were 
overly polite and participants tended to wait their turn to speak to the researchers 
rather than engage with each other. Due to this, discussions took longer and this was 
accentuated by the group being slightly larger than the previous two groups. In 
addition, the researchers found some members of the group difficult to keep on topic 
and unlike in other groups, this was not monitored by other group members.  
 
5.5.2.2 Focus group Part A: The experience of stiffness 
The six themes within the conceptual model identified in Study 1 were supported and 
reinforced by the focus group data. The conceptual model appeared consistent with 
the experiences of a new population of patients, using a different method of data 
collection which enhances the robustness of the findings. Themes and subthemes 
were reinforced by these data and an additional 23 codes were identified and added 
to the coding tree (Appendix J). To avoid repetition, only new codes are detailed 
below under each theme heading, with patient quotes for illustration. Key discussion 
points in the revised topic guide (Table 5.2) are also illustrated where relevant.  




5.5.2.2.1 Theme 1: Part of having RA 
Discussion relevant to Theme 1 related to the specificity of stiffness (Section 5.3.3.1). 
Here it was highlighted that stiffness was an acceptable word that was used by 
patients.  
 
“Well, stiffness would be used, wouldn’t it?” […] Everybody says it, don’t they?” 
[2210] “Yes” [multiple responders] “Okay, so it’s not the medical word?” [ED] “No” 
[multiple responders]  
 
It was also identified that stiffness was a usual part of aging which may detract from 
the specificity of stiffness in RA. 
 
“[…] you get a bit stiff and kind of forget, we are all getting older and sometimes 
overdo it […]” [2103] 
 
“[…] I suspect a lot of older people get stiff anyway, you know what I mean?” [2312] 
 
As in Study 1, much discussion concentrated on the relationship between pain and 
stiffness and the differences and similarities between the two symptoms. 
 
“And stiffness to me […] I define as, I can’t bend something. You know? Like a stiff 
piece of paper, you can’t bend it. But it is trying to separate out pain from stiffness, 
it’s very difficult” [2102] “It is, it is difficult” [2104] 
 
It was suggested that difficulty describing stiffness influenced the difference between 
pain and stiffness. 
 
“And you know when you said about the stiffness I thought well actually, we know 
what stiffness is but [laughs] is it this or is it that? […] It is difficult to define” [2104] 
 
It was suggested that the sensation of stiffness may linguistically fall under the 
heading of pain. This was also reflected in Study 1 where there was crossover 
between descriptive words for pain and stiffness.  
 
“[…] if you’re stiff, you know you’re stiff because you’ve got a pain. It may not be 
the same as a sharp pain, but you feel it […] you’re sitting down for a while and 
then you get up. It’s stiff, it’s awkward. But how do you know it’s stiff? There’s 
nothing saying, I’m stiff. You feel something. It’s a form of pain, I think” [2105] 
 
“It’s not a stabbing pain […] it’s just there” [2208] “It’s just there, and it feels tight” 
[2207] 
 




Consistent with Study 1, the relationship between stiffness and pain was more 
relevant in periods of high disease activity or flare. This was described by one group 
as “painful stiffness” [2210].  
 
“Because at the moment I’m in a really bad flare up […] I’ve got a lot of pain and a 
lot of stiffness […] But trying to define which is which, I don’t know” [2104] 
 
Furthermore the specificity of stiffness in RA was challenged by one participant who 
suggested that pain may differ across conditions, but stiffness was similar. 
 
“The stiffness, yes, yes, yes, yes, very similar, but the pain is different […] my pain 
for rheumatoid is in the joints, whereas […] with the polymyalgia it’s in the muscles 
and so it feels different, if that makes sense” [2208] 
 
Despite the close relationship between pain and stiffness, participants in focus group 
1 suggested that it was difficult to respond to questions where stiffness and pain were 
asked within the same question.  
 
“I find it very difficult when you are asked ‘are you experiencing pain and stiffness?’ 
Because I don’t know what it is they are asking […] we’ve all got a different 
response and we do know there’s a difference” [2101] “Are you often asked it 
together, then? In one sentence? [ED] “Oh yeah. Invariably. Related to osteo and 
RA things […] Always, pain and stiffness” [2101] 
 
Furthermore, it was highlighted that impact based tasks were more affected by 
stiffness than pain.  
 
“If we’re going to separate, it’s the stiffness that’s preventing you being as, you 
know doing that” [2104] […] “That was a fastening the bra movement for the tape” 
[2103] [laughter] “I’m not going to not put my bra on because it’s going to hurt me. 
I’m going to find it difficult, because I’m too stiff” [2101] [agreement] 
 
“I think the stiffness is more of a factor than the pain, in getting dressed or 
undressed […] I find it impossible to do up my top button on a shirt if I’ve got to go 
somewhere formally. I can put the tie on, I can do all that. But I cannot do that 
button. Just can’t. That’s it” [2105] 
 
“Sometimes stiffness is prevention of doing things, like I used to enjoy sewing and 
threading a needle. I can’t do that any longer, and that’s the stiffness, it’s not the 
pain. There’s no pain in threading a needle, but I just can’t do it because my 
fingers, parts of me just don’t work in the way that they should do […]” [2208] 
 
The varying prominence of stiffness was also briefly addressed (Section 5.3.3.1). 
Consistent with Study 1, some participants felt that stiffness was more prominent at 
different times throughout their disease duration. In focus group 1, one participant 




suggested that her stiffness had been more prominent in early disease but this had 
changed over the disease duration.  
 
“[…] I don’t have that sort of stiffness. I mean I used to, but when I was put on 
medication, the stiffness totally went for years and years and years […] it only 
happened in the morning for over an hour […] and after that, I was totally normal” 
[2102] 
 
Another participant suggested that in early disease other symptoms were more 
prominent than stiffness. 
 
“[…] when it first came on I think I had stiffness but the pain was the overriding 
factor so I don’t think I really recognised that I had stiffness and also it was all new 
to me […] now I can get stiffness and it could be just stiffness or it might be stiffness 
and pain” [2316] 
 
This participant went on to suggest that the ability to manage stiffness may be more 
effective in individuals with longer disease durations. 
 
“[…] I think those of us who have had RA for a long time, we manage the stiffness” 
[2316] “That’s right” [2311] 
 
Overall, the identification of stiffness as a usual part of aging, the association of 
stiffness as a symptom in other diseases, and the complicated relationship between 
stiffness and pain all reinforced that the focus on stiffness should be emphasised 
throughout any newly developed tool. Although it was highlighted that impact based 
tasks may be a patient-relevant way of separating stiffness and pain. The cause of 
change in the prominence of stiffness was also briefly discussed.  
 
5.5.2.2.2 Theme 2: Local and widespread 
Discussion relevant to Theme 2 related to the location of stiffness (Section 5.3.3.1). 
The idea of stiffness affecting the “whole body” was discussed.  
 
“I used to get so embarrassed because my whole body was stiff” [2207] 
 
This was suggested to occur during periods of high disease activity or flare. 
 
“It was a flare up […] I never had no swelling” [2210] “Okay, but you did have 
stiffness?” [ED] “Oh yeah! It stiffens your whole body up” [2210]  
 




This expanded the idea from Study 1 that stiffness in many joints may indicate 
severity, highlighting that stiffness in the “whole body” may also be relevant, 
particularly during high disease activity. This also identified patient-centred wording 
for inclusion in item development. 
 
5.5.2.2.3 Theme 3: Linked to behaviour and environment 
Within Theme 3, participants reinforced that environmental factors influenced the 
experience of stiffness. 
 
“I think the dampness does something though isn’t it” [2311] “[…] there is definitely 
evidence that it’s something to do with the pressure” [2314] 
 
Although, the influence of environmental factors was not relevant for everyone. 
 
“[…] mine also I don’t think it’s affected by the weather” [2312] 
 
5.5.2.2.4 Theme 4: Highly variable 
The key additional discussion point highlighted within Theme 4 was the relevance of 
stiffness during the night.  
 
“Sorry, but I find stiffness during the night. Never mind when I wake up” [2105] 
 
It was suggested that stiffness during the night could affect sleep especially in relation 
to movement during that time. 
 
“I noticed at the very beginning I think you said stiffness wakes you at night […] Is 
that something that would be important?” [ED] [agreement] “I think you can twist 
and turn all night because of it” [2206] […] “I think I wake up about every 2 hours 
because I’m stiff, and […] if the stiffness wakes me up I can’t turn over in my sleep” 
[2208] 
 
5.5.2.2.5 Theme 5: Impacts on daily life 
As in Study 1, there was lots of discussion about the impact of stiffness. One focus 
group highlighted that it was not only dressing but undressing that was affected. This 
may be relevant to include as patient-centred wording during item development. 
 
“You don’t include there getting undressed […] I can get a tight sleeved thing on 
[...] but it’s going to be more difficult to take it off” [2101] 
 




Another focus group suggested that stiffness makes daily life activities more of an 
effort. This related to discussion with one patient partner (AE) during a team meeting 
while reviewing the first two interview transcripts from Study 1 where it was discussed 
that stiffness required effort while pain did not. 
 
“[…] but stiffness is an important part of it because you may not feel like putting on 
your glad rags […] you know, you’re so stiff it’s difficult […] I just don’t want to 
change and put something fresh on” [2208] “you just can’t be bothered like, you 
know” [2206] [agreement] 
 
“[…] as the pain is wearing down, then you find that its more and more difficult to 
move, it’s more difficult to get up [and] my joints are more slow when I’m walking, 
so then walking becomes more ‘Oh I just want to get somewhere’ but I’m having 
to do just very small steps because I can’t go very fast” [AE] “So is there an issue 
there with effort?” [SH] “Yeah” [AE] “The pain doesn’t require extra effort” [SH] “But 
the stiffness does I think definitely” [AE] 
 
Loss of strength was also discussed in all focus groups in relation to physical impact. 
 
“Some of it is just total loss of strength, isn’t it?” [2104] [agreement] 
 
“So is stiffness sometimes related to strength then as well?” [ED] “Yes” [Multi] […] 
“Once you’re stiff you lose all your strength” [2210] “It seems to sap you” [2208] 
 
Although there was some debate about whether loss of strength was directly a result 
of stiffness. 
 
“One word that you mentioned 2312 that I don’t know if it’s to do with stiffness, was 
you said strength […] Is feeling a lack of strength part of stiffness?” [ED] “It can be 
but also […] we lose strength anyway” [2316] “I don’t know about that” [2312] “You 
lose the muscle don’t you […] [2315] “But there is also, so we lose strength quite 
quickly as you say and the strength is also affected if you’re in a lot of pain with 
your hands for example, you haven’t got the same strength but when they’re stiff, 
you know, you can’t move them as easily so then you’ve lost a bit more strength” 
[2316] “Like a chicken and an egg situation” [2314] 
 
There was also elaboration regarding the impact of stiffness on cognitive processes. 
Participants suggested that when you are stiff, your body does not move as expected.  
 
“Bits of my body won’t move when my brain is expecting them to move” [2101] 
“That’s fair enough” [2105] “So you try and nothing happens or? [2102] “It’s the 
stage before I try, it’s an awareness that it’s not working” [2101] [laughter] […] “And 
it’s not fear that it’s going to hurt. You just suddenly think, oh […] for me, like the 
first time I couldn’t get out of the bath which was a few years ago. Almost as if I’d 
forgotten how to do something very regular” [2101]  
 




This was furthered by suggestion that the automatic instinct of movement was 
impaired by stiffness and movements required extra thought to complete.  
 
“[…] it has been that I couldn’t get up from the chair without thinking about it” [2101] 
 
“You’ve suddenly got to think, literally think, differently […] Because the stiffness 
isn’t giving me that extra couple of inches […]” [2101] “I find stairs particularly 
difficult, whereas automatically you’d raise your foot enough to clear the step […] 
I’ve got to think about placing my foot […] I’ve got to consciously think, I’ve got to 
lift my foot. I shouldn’t have to do that. I mean that’s, it’s instinctive” [2105] 
 
“It’s almost like the messages aren’t getting from the brain through to where they 
should be going, if that makes sense” [2208] 
 
Finally there was discussion about the psychological impact of stiffness. This was 
particularly discussed by one group where one quite newly diagnosed participant 
highlighted that stiffness caused worry.  
 
“I’d say sort of looking at these frozen and seized, that’s certain. But there’s no, 
you know, I’d say emotional, anxiety, I’ve always been very scared. You know 
you’d be panicking, what’s this leading to? [2103] 
 
This discussion continued with the suggestion that having guidelines about expected 
amounts of stiffness would be useful to reduce worry.  
 
“So it’s something I’m very aware of, so the slight stiffness when I wake up and I 
have mentioned it a couple of times when I come for review and they [clinical team] 
just say ‘look if it’s only five, ten minutes, you’re alright’ […] So it’s nice to have 
some, if you get sort of look, 30 minutes, then start worrying. I find that really helpful 
[…] because otherwise, you just do worry” [2103] 
 
However, worry was not something that was relevant for all participants, although this 
was discussed in the broader context of RA rather than being stiffness specific. 
 
“One of the other things I think that makes a difference is, I am, um, unlike you, 
I’ve never been anxious about the RA and how it goes” [2102] “What’s your 
secret?” [2103] [laughter] 
 
One participant also suggested that stiffness caused embarrassment which although 
only mentioned by one participant was a powerful statement. 
 
“But when I got up, [laughs] I used to get so embarrassed because my whole body 
was stiff, and okay, people get stiff when they’ve been sat down, but I had to sort 
of, a stop or so before, I had to kind of start getting myself, you know, ready 
[laughs], and then, oh right, here we go, yes, next stop, and then push up, but 




nothing was working. Push up and stand up, and then press the bell, and [laughs] 
the walk down the bus to get off was so embarrassing, because I was so stiff, and 
I thought well, there’s something wrong here, I shouldn’t be like this” [2208] 
 
5.5.2.2.6 Theme 6: Requires self-management 
Similar points were discussed in Studies 1 and 2. However, during the focus groups 
there was further discussion about whether movement always reduced stiffness. This 
may reinforce the suggestion from Theme 1 that stiffness in periods of higher disease 
activity or flare cannot be reduced with usual self-management strategies.  
 
“So if your knees are stiff, even just moving them a little does it help to ease the 
stiffness gradually” [2316] “Erm sometimes I can have stiffness that literally just 
lasts a few minutes or it might last a while […] but whether movement helps I don’t 
really know because with my hands, they were particularly bad over Christmas and 
there was inflammation as well and it was painful […] but I mean I use my hands, 
you have to use your hands so it wasn’t as if I wasn’t using them and using them 
wasn’t helping at all” [2314] 
 
5.5.2.2.7 Stiffness descriptors 
Participants used a variety of words and phrases to describe the experience of 
stiffness which varied across groups (Table 5.5). 
 
Table 5.5: Stiffness descriptors generated by each focus group 
Focus group 1 Focus group 2 Focus group 3 
Fizzing 
Anxiety 
Set in stone 

















In addition to the independently generated stiffness descriptors, participants were 
asked to discuss descriptors used in Study 1 and from the literature. Table 5.6 
indicates patient preferences for the descriptors. Here restricted, need oiling, and 
weakness were liked across all focus groups however, none of these words were 
used independently by participants. There was general dislike across the focus 
groups for gelling. Apart from the word stiff or stiffness, there was no single word or 
phrase that was used consistently across focus groups. As highlighted above 
(Section 5.5.2.2.1), stiffness was regarded as a patient relevant word rather than a 
medical term. 
 




Table 5.6: Patient preferences for stiffness descriptors  
Descriptors Focus group 1 Focus group 2 Focus group 3 
Rigid    
Seized   ? 
Locked    
Frozen    
Restricted    
Not loose and limber ?  ? 
Need oiling    
Pain    
Ache    
Tight    
Weakness    
Heavy  ?  
Gelling    
Wooden    
Grating    
Stiff    
Liked descriptors=; Disliked descriptors=; Mixed opinions=? 
 
5.5.2.3 Focus group Part B: Proposed ideas for PROM development 
Each heading of the deductive analysis framework was populated by participant 
responses and a coding tree was developed (Appendix K). Each heading is described 
below with patient quotes for illustration. 
 
5.5.2.3.1 Stem questions and anchors 
5.5.2.3.1.1 Relevant to the individual 
The individuality of stiffness, initially highlighted in Study 1, was emphasised by focus 
group participants who felt that measurement should reflect this.  
 
“It’s how you feel, not the average or somebody else” [2105] 
 
“It’s all down to the individual. I shouldn’t think there’s two people the same” [2104] 
[agreement] 
 
It was suggested that wording questions to reflect the individual would be relevant, 
particularly in the context of whether people’s current experience was typical for them. 
 
“I did [a] questionnaire for one of your colleagues the other day […] I was like, last 
week I’d had a brilliant week. The two and half months before that had been an 
absolute nightmare and I wanted a box to say, is this usual?” [2103] 
 
However, it was suggested by one group that wording questions on a personal level 
may be difficult given the variability of the experience.  
 




“I don’t think you could say usual, but if you are on direct access and you want to 
come in and see somebody and then by the time you turn up it’s all [fine] you know 
[…] You say, I came in because […] everything was on fire last week” [2103] 
 
In one focus group it was suggested that measurement may need to consider 
changing perspectives over time or response shift. One patient discussed how 
perceptions may be different for newly diagnosed patients and those who have had 
RA for longer duration.  
 
“I think with you though, you’re long established rheumatoid […] With us we’re new 
diagnosed […] I think it changes doesn’t it” [2311] 
 
Another patient mentioned discussing response shift during a clinical appointment in 
relation to fatigue. She suggested that she based her assessment on how she felt 
before she had RA, while others may assess their symptoms based on a readjusted 
perception of what is usual for them now they have RA. 
 
“[…] they ask you all these questions and because I’m still relatively newly 
diagnosed I couldn’t understand […] am I supposed to be comparing it with how I 
feel on a good day or am I supposed to be comparing it to how I used to feel? And 
he [consultant] talked about something called a response shift whereby you get 
used to something and that becomes your norm […] I still know how I used to feel 
so for me I still always measure it compared to how I used to be because that is 
my measure […] But for some other people they’ve got used to being that this is 
my normal” [2314] 
 
5.5.2.3.1.2 Impact 
Impact was specifically discussed in relation to stiffness assessment. It was 
suggested that to capture stiffness, questions could be worded around its impact on 
daily tasks or movements.  
 
“I know it’s straight forward questions but it’s serious questions for people that can’t 
do it […] Comb your hair, brush your teeth, general daily, you think of what you do 
every day when you get up” [2210] 
 
This was furthered by consideration of the increased time required to complete certain 
tasks or activities. 
 
“I think the time element as well, how long it takes you to do these things” [2207] 
[agreement] “That’s another thing, even though you may be able to do these jobs, 
does it take you, how much longer does it take you to carry these out?” [2210] 
“Okay. So say something like, my daily tasks take me longer than usual?” [ED] 
“Definitely” [2210] [agreement] 




Another participant suggested that quality of life impact was a useful assessment for 
any symptom. 
 
“[…] no matter whether you’re discussing stiffness, pain, at the end of the day for 
me personally it boils down to my quality of life within the last week […] so what is 
your quality of life or how has it affected you within the last week?” [2313] 
 
Despite the importance of impact being captured in measurement being stressed by 
participants, a number of considerations were also identified. It was noted that some 
impact based questions were gender specific.  
 
“And for ladies, fastening your bra” [2101] “We would have to have gender 
questions then, wouldn’t we?” [ED] [laughter] 
 
It was also suggested that some impact based questions were time and location 
specific.  
 
“But I think that […] getting dressed is probably in the morning. So if you’re stiff in 
the morning, that’s going to be really difficult for you. So I think that’s perhaps not 
representative of later on in the day. That is morning specific question, isn’t it, 
really?” [2103] 
 
“It depends, doesn’t it? I mean, if you’re not going to use those joints in the things 
you want to do, you’re not going to have the problem, perhaps. The converse could 
apply” [2105] 
 
Another participant noted that impact questions should capture the degree of difficulty 
rather than whether or not tasks and activities can be completed. 
 
“And I was still at work then and I never missed a day. So despite being stiff for an 
hour, I was still able to shower, get myself dressed and get to work in time. So, 
although I was obviously aware of it, it did not actually impinge on my life” [2102] 
“But it wasn’t easy I bet” [2103] “The difficulty was still there” [2105] “Yes, but you 
just, you do it” [2102] 
 
The concept of the impact triad was proposed to participants in focus groups 2 and 
3. In general this was well received by participants and it was felt that it would be an 
acceptable concept on which to base measurement. 
 
“[…] if you don’t want lots of questions […] is there a way of condensing it all down? 
[Halls] […] “Yes, I think you’ve got the answer there in front of you now […] Four 
questions there, there’s four answers there, so how does it affect your self-
management, how does it affect you severely, how important is it and what is the 
impact on your life?” [2210] 




“Yeah I would agree […] because it can vary, it really does, the importance is the 
impact that it’s having not necessarily the severity, it’s the impact that is the all-
important” [2314] 
 
It was felt that the impact triad could relate to any symptom and could reflect the 
individual experience. 
 
“Any symptom, any activity” [2316] 
 
“I think each person is different to everyone else aren’t they” [2311] […] “I think 
that’s possibly why that might work isn’t it” [2316] […] “I was just going to say that, 
it wouldn’t really matter that our experiences are all different because the important 
thing is the impact it’s having on us as an individual” [2314] 
 
Specifically, it was suggested that importance could be graded. 
 
“Sorry, the importance, I think you could grade that as well […] Not very important, 
and then maybe you could put something else in, it hardly bothers me because I 
live with it, of medium importance maybe okay, it’s there, but I get on with it. And 
then maybe ending up with another two – actually, it is really important because I 
can’t do my daily functions, you know, your activities of daily, I can’t do it, because 
I am so stiff” [2207]   
 
5.5.2.3.1.3 Stiffness after a period of immobility 
Focus group 1 participants suggested that it would be relevant to ask about stiffness 
following a period of immobility.  
 
“[…] 2104 said earlier on that you know if you’re sitting watching a film on the telly 
for a couple of hours, [when getting up] oh you’re a bit stiff [laughs]” [2102] “That’s 
right, it’s like getting up again” [2105] “So it’s not only during the night or first thing 
in the morning, it’s also” [2102] [agreement] “It could be anytime” [2104] “Yes, 
you’re right. Sitting here, for example” [2105] [laughter] “Exactly!! After a period of 
immobility, whether it’s asleep or you’re awake” [2101] “That’s a good word, I like 
that […] Immobility. If you’ve been immobile for, I don’t know, an hour. Whatever. 
Certainly longer. Then, how are your joints then? Nobody has asked that” [2105]  
 
This was reflected in participant experiences in focus group 3 where stiffness would 
result from sitting for a period of time.  
 
“[…] standing up after you’ve been sitting for a little time I have to stand up for a, 
you know, I say to friends “I’m just kind of just having my moment standing up” 
when I have to gather, my legs have to kind of gather themselves ready to move. 
I couldn’t just always stand up and […] move straightaway” [2316] [agreement] 
 
 




5.5.2.3.1.4 Timing and temporal pattern 
The timing and temporal pattern of stiffness was reinforced as relevant for patients. 
However, current questions regarding the duration of morning stiffness were identified 
as being difficult to answer, inaccurate and hard to remember or quantify. 
 
“I don’t know how long […] you can’t put a time on it” [2105] 
 
“[…] I have been asked how long does the stiffness last” [2209] “Yes. Is that an 
easy question to answer?” [ED] “No, it’s not, because quite often by then I’ve 
forgotten how long it lasts” [2209] 
 
“Well, I don’t know, this is when you come to the doctors and they say how long 
does it last, well, it’s about that long but it’s a guess really” [2209] “Yes and you 
suddenly realise you haven’t got it then” [2208] [agreement] 
 
Patients suggested that they were unsure what the start or endpoint for these 
questions were. 
 
“Do you take notice though of how long it takes you to get rid of your stiffness? 
Because I don’t” [2311] “No that’s it […] we’re not working in the same way that 
the doctors are working, you know. In our minds we’re not sort of sitting there 
timing it” [2316] [agreement and laughter] “Oh I am thoroughly unstiffened, no […] 
that’s not the real world” [2316] 
 
These questions were not felt to capture the whole experience of stiffness. 
 
“But we’ve also been talking about people who are stiff all day as well. So that 
would be a different question […] ‘Cause my experience was you know, the sort 
of the fixed hands. And then it would go during the rest of the day. But other people 
are talking about that they’ve got it during the day. So that would be another 
question that you’d need to ask as well […] If you’re asking people if they are stiff 
during the day and then asking if they are stiff when they wake up, is there extra 
stiffness when you wake up? They are two different questions” [2103]   
 
“I kind of find the whole ‘how long does your stiffness last?’ quite a difficult one […] 
if they’re just looking at morning stiffness, then that doesn’t capture the general 
on-going seizing up through the day stiffness, sometimes it does but quite often, 
well it doesn’t at all and morning stiffness for me is mostly where my RA is in a 
flare or it’s not well managed […] at the moment it’s sort of fairly okay-ly managed 
so I’m not getting a lot of morning stiffness but I do seize up through the day” [2316] 
 
It was also highlighted that the duration of other symptoms was not questioned, 
therefore why was it relevant for stiffness. 
 
“Because we don’t ask ‘how long does you pain last?’ Do we? […] So why do we 
always need to say ‘how long does your stiffness last?’ You know if you take 
painkillers it doesn’t always make it go away. It might ease it so moving certainly 




on the whole eases off the stiffness but we don’t expect to say ‘oh my pain went 
within ten minutes’ or ‘my pain went away within an hour” [2316] 
 
Specifically in relation to MS it was again highlighted that stiffness was relevant at 
times of day other than just the morning. 
 
“I think, now we’re talking about it, we only talk about the morning because you 
ask us” [2101] [laughter] “That’s right, that’s right” [2105] “But it is, it’s after anytime” 
[2101] “Any time of day really” [2104]  
 
It was also suggested that questions about the morning make an assumption that 
people only get up in the morning and that they get up when they wake up. Therefore 
there was uncertainty about what information to include in answers to these 
questions. 
 
“I mean, dependent on age and other things I mean we don’t have an unbroken 
eight hour period [of sleep], which I think is what […] these young doctors think we 
do [laughs]” [2101]   
 
Instead of asking about the duration of MS, patients suggested that asking ‘when are 
you stiff’ may be more relevant and would be easier to answer. Suggestions for 
formats for this were described and drawn up on the flip chart.  
 
“[…] is there any aspect that particularly springs out when you think about 
assessing stiffness?” [Halls] “When is it worse throughout the day? And is it on 
waking, is it mid-morning, is it lunchtime, is it afternoon, is it when you feel you’re 
tired? […] I think it’s important that you know which parts of the day that individuals 
have the worst problems? [2208] 
 
“I think you’ve got to differentiate, haven’t you, between whether it’s all day, 
morning, evening or whenever, really” [2209] [agreement] “You could do AM, PM, 
noon, sorry AM, PM, night” [2208] “Well, couldn’t you have hourly […] how often 
does your stiffness affect you on a 24 hour basis” [2210] […] “I was wondering, 
could you have a clock” [2209] “with the hours and then some people might be 
able to shade it in [2208] “Yes, you could have an AM/PM clock” [2210] 
 
It was also suggested that asking ‘when are you stiff’ would capture stiffness during 
the night which was relevant for some participants. 
 
5.5.2.3.1.5 Location 
The idea of the number of affected joints was originally identified in Study 1. It was 
proposed to groups for discussion as a topic that required further elaboration.  
  




“So could we ask a question here maybe about if stiffness affects more joints or is 
more widespread, would that indicate it being worse?” [Halls] “It would definitely 
be worse” [2206] [agreement] 
 
“[…] but when you’re talking about levels, there could be just a question as to 
whether it’s just one joint or you know, a number of joints. Say, is it one to three 
joints?” [2314] “OK so number of joints” [Halls] “Is it all over stiffness or is it […]?” 
[2316] 
 
It was suggested that location was a natural way to think about the individual 
experience of stiffness. It was highlighted that this could be captured visually and 
potential formats were described and drawn up on the flip chart. 
 
“You know the picture they have of a person […] with the massive hands […] I 
always go to my consultant, that’s how it feels [laughs] […] it would be quite nice 
if you know, you could say, these bits are stiff” [2103] 
 
It was also suggested that stiffness may affect different joints in different ways.  
 
“I’ve just put up a sort of example, of a question […] What do you think of that 
one?” [Halls] “Again, it depends on the joint, doesn’t it?” [2105] 
 
“[…] can we ask what your level of stiffness is? [Halls] “But wouldn’t that be like on 
a level of each different joint then no? […] Because I find the different joint like I 
mean obviously my wrists are stiff, they don’t move so like up to my knees, which 
will bend and like my elbow. They don’t bend straight out so they are like totally 
different so then obviously there’s a level between each joint then isn’t there” 
[2315] “That’s another point yeah” [2314] “That’s really interesting okay so in terms 
of severity we’d have to consider different joints? [Halls] “Yeah” [2315] “Yeah” 
[2313] 
 
It was identified that asking about location also related the usual experience of 
stiffness for each individual.  
 
“You’d want to say […] it’s my fingers or my knees” [2103] “Yes, you’ve got to 
define the part of the body” [2105] “[whether] It’s a new thing. You know?” [2103]  
 
“[…] so have a way of saying okay my stiffness level that day is on this line but you 
know we’re both saying I can mark or we can mark either the whole body as stiff 
or these joints are particularly stiff that day. Like you do with the inflammation. 
They tick off which joints are stiff yeah” [2316] 
 
5.5.2.3.1.6 Pain, stiffness and other symptoms 
As in Study 1, the relationship between stiffness and other symptoms was discussed. 
In relation to measurement, it was suggested earlier (Section 5.5.2.2.1) that questions 
about different symptoms needed to be asked separately for clarity. However, another 




group suggested that the combination of stiffness and pain had more impact than just 
stiffness, thus it may be relevant to ask about both together. 
 
“[…] do people need to ask about painful stiffness?” [ED] [agreement] “Yes. You’ve 
got to link the two together” [2210] “Because one goes with the other. So if you’re 
stiff and you want to do something then you know you’re going to get pain” [2206] 
“[…] so the question is, if that joint is stiff […] does it stop you doing something 
because it’s painful, or because it’s stiff” [2210] […] “As we said earlier, the 
stiffness is a warning that if you carry on […] It’s going to hurt” [2206] […] “I don’t 
think the stiffness has that major impact, but put pain with it, it becomes a major 
impact” [2210] 
 
Furthermore, stiffness as a result of different processes also complicated this issue 
as it was suggested that stiffness as a result of mechanical processes was not related 
to pain and therefore has less impact. 
 
“[…] both my wrists are fused, so they’re stiff. No pain, but they’re stiff all the time, 
but I still get on with things and I haven’t got pain, I can’t bend them, right, I can’t 
bend them or nothing like that, but they’re stiff […] they’re stiff, but I do everything, 
and I don’t even give them a thought that they’re stiff, because there’s no pain with 
it. So take away the pain from stiffness […] it wouldn’t affect me, would it” [2210] 
 
A method of capturing pain, swelling and stiffness was suggested by two groups 
relating back to the visual format proposed earlier (Section 5.5.2.3.1.5). 
 
“If you are interested in measuring stiffness, well isn’t the next question, is this 
accompanied by any pain? […] Quite happy to separate them out” [2101] “You 
could have two little men or women […] One for stiffness and one for pain” [2105] 
[…] “you can say well […] I’ve got the stiffness but no pain” [2101]  
 
“[…] there’s three questions there, isn’t there, that you could ask and have tick 
boxes, and then underneath, how does each one affect […] your daily life? […] 
The stiffness, yes or no, with pain, yes or no, with swelling, yes or no” [2210] 
 
5.5.2.3.2 Response options 
Response options were discussed mainly in focus groups 1 and 2. There were 
differences in opinion about response options. Some patients highlighted that VAS 
were easy to respond to but others felt they were imprecise. 
 
“I don’t like lines. Because they are so imprecise. And in my brain, boxes are more 
precise” [2101] 
 
“And those variation lines are good” [2210] “Yes” [2208] “What do you mean?” 
[Halls] “Like on there [VAS]” [2208] […] “Because all you’ve got to do is put a little 
line down, it’s so easy” [2210] “That’s right” [2206] 
 




However, other patients preferred NRS to VAS as the numbers made it clearer. 
 
“I would prefer numbers, personally” [2208] “Yes, it is easier, 1 to 10” [2206] “1-10 
rather than putting a line in […] I think a number is much easier, rather than a little 
line” [2208] 
 
Other patients suggested that NRS provide too many options.  
 
“I have a problem over what’s the difference between five and seven?” [2105] 
[agreement] “No tell me. What is the difference? Subtle difference, between five 
and seven. It’s over complicated and it tells you nothing” [2105] “Oh, so what would 
you rather have?” [2103] “I would rather simply have low, medium and high. A, B, 
C. Whatever” [2105]   
 
When asked about a Likert scale response, some patients suggested a shorter 
option.  
 
“If you said agree on that, they may ask you then, why do agree, and that goes on 
and on and on then, doesn’t it?” [2206] “Yes or no then” [2210] “Yes or no would 
be better, yes” [2206]   
 
Fewer options were felt to reduce burden on the participant. 
 
“If you had to do the degree [of stiffness], how would you like that?” [Halls] “1-10” 
[2105] “Yeah” [2103] […] “Or if you want to make it simpler, A, B, C […] None or 
moderate or severe. Three options, you know?” [2105] “Yeah yeah. Low, moderate 
and high or something” [2101] “Low, moderate and severe” [2105] 
 
“Yes, less options” [2206] “Yes, less options” [2210] “More straightforward 
questions, less options” [2206] 
 
5.5.2.3.3 Timeframe 
There was considerable debate about the timeframe over which it would be relevant 
to ask about stiffness. It was felt that questions must ask about a recent timeframe. 
 
“It’s no good going over last year” [2208] “No” [2206/2210] “It’s, it’s it’s recent, has 
to be pretty recent” [2208] 
 
Initial discussion suggested that stiffness over the last week would be acceptable and 
accurate. 
 
“I think most people could remember how it’s been over the last week” [2208] […] 
“I think you’d be able to remember the last week” [2209] […] “Because if you go 




too far it’s just guess work” [2210] “That’s right. And then it’s not true […] It’s not 
credible, is it” [2208] 
 
However, it was also suggested that over the last week would not capture the 
variability of stiffness within recent months or within that week.  
 
“You can remember and recall [a week] properly, accurately” [2208] “Do you think 
people could say over the last week, or do you think there’d be so much possible 
up and down over that week that…? [ED] “It varies every day, really” [2206] “That’s 
true, isn’t it, yes” [2209] 
 
Another suggestion was current stiffness which was considered to be relevant and 
would provide a record if it was documented. 
 
“And that’s what you are now. Today. When they ask you. Over the phone or with 
a consultant” [2105] [agreement] “I think 2105 has used that expression, snap 
shot” [2101] [agreement] 
 
However, it was also acknowledged that this approach may not capture stiffness 
variability either. 
 
“If you think when you’re stiff, the fact that you’ve got here quite often means you’ve 
walked off that stiffness or you’ve moved off that stiffness because you’ve got up, 
you’ve got yourself together, you’ve got on the bus or you’ve driven down. A lot of 
the stiffness that you’d have had in the morning, has gone because you’re already 
here and you’re moving so it’s kind of, we need to have something that kind of 
captures what was it like overnight or that day” [2316] 
 
5.5.2.3.4 Layout and format 
The first aspect that was discussed in relation to layout and format was that images 
may be an appropriate way of capturing stiffness information. One suggestion was 
using a visual clock face to record when participants are stiff.  
 
“I was wondering, could you have a clock” [2209] “Yeah yeah” [2210] “with the 
hours and then sort of, some people might be able to shade it in” [2208] “Yes, you 
could have an AM/PM clock” [2210] 
 
Another suggestion, discussed in two focus groups was using a diagram of a person 
to indicate the location of stiffness. It was felt that this approach would be particularly 
effective at capturing the individuality of the experience of stiffness.  
 




“A person, yes, a little pin figure” [2209] “The only trouble with that is you’d be 
ticking it all over” [2206] “But not all of us, we wouldn’t all be ticking it all over” 
[2209] 
 
Another point was the importance of simplicity of the questionnaire.  
 
“Which is why it needs to be fairly simple doesn’t it” [2316] [agreement] “It can’t be 
too complicated” [2316] 
 
This specifically related to preferences for fewer questions and response options to 
enhance simplicity.  
 
“Yes, less options” [2210] “More straightforward questions, less options” [2206] 
 
It also related to the use of current language to aid clarity and understandability.  
 
“And try and update these very old fashioned questions” [2101] [laughter] “It really 
does makes me feel, I am stereotyping, a little old lady. Well, I am a little old lady. 
But, you know, doddering around you know with the bath and no shower” [2101] 
[laughter] 
 
There was also discussion regarding the format of the response options. One group 
suggested that free text options would allow appreciation of the individuality of the 
experience of stiffness.  
 
“[…] maybe room for the person to write in their own remarks as well, depending 
on what they’ve [put], can you explain this […]” [2207] 
 
However, it was also recognised that free text may not be appropriate for generalising 
responses.  
 
“[…] you need to generalise about how it affects you […] because otherwise, you 
start listing things you could go on forever about [how] it affects you” [2210] 
 
Practical considerations regarding marking responses were also highlighted. This 
included that a simple mark is preferable to considerable writing and that circles are 
more difficult than crossing a box. 
 
“I think things to circle or tick is better because if you’ve got to write it, sometimes 
it’s very difficult” [2206] “Sometimes you can’t write” [2208] 
 
“[…] I don’t like circling […] cross out is best” [2210] 
 




A final interesting point was made in two focus groups that indicated that participants 
would like to know the purpose of the questionnaire and what the answers you give 
is going to affect.  
 
“Yes, but as you said if we know why you want to measure in a particular way […] 
it’s fine […] But it’s not knowing how that’s going to affect how you are going to be 
treated. Whether it’s for you, or for the practitioner” [2101] 
 
This related to a point made by one participant in focus group 3 who questioned the 
purpose of completing a pre-clinic questionnaire, again stressing the importance of 
ensuring patient awareness of purpose to ensure accurate results.  
 
“But then I don’t know, does anybody actually look at those things?” [2315] 
[laughter] “She rubs them out doesn’t she!” [2313] “Yeah but that’s what they do. I 
say that because I fill them out all the time, yeah and I just go, yeah, yeah 
[demonstrates ticking each box not looking] […]” [2315] 
 
Finally there was brief discussion about how to word items. This included whether to 
include ‘stiffness’ in every stem question (focus group 2) and how to ask about 
severity (focus group 3). 
 
“[…] would it be helpful to have the word stiffness in the questions […]” [ED] “Yes, 
but not in every one […] although, I suppose because it’s about stiffness then it 
needs to be kind of […] affirmed” [2207] 
 
“I don’t know, yeah I would say level, I would say level yeah” [2315], “I would say 
level” [2313] […] “So stiffness level, like pain level” [2316] “So if we asked you a 
question about your level of stiffness?” [SH] “Yeah” [2313] 
 
5.6 Discussion 
Focus group data supported the Study 1 results, and appeared consistent with the 
experiences of this new population of patients, using a different method of data 
collection. This enhances the robustness of the stiffness conceptual model. In 
addition, a significant new finding was the information gathered regarding the patient 
perspective of stiffness assessment. This provided insight into patient relevant stem 
question categories and preferences regarding response options, timeframe, and 
format.  
 
The consistency between the results from Study 1 and Study 2 is reassuring and 
demonstrates the strength of the findings (Mays and Pope, 1995). Although additional 
codes were added to the coding framework during analysis of Study 2, these 




elaborated areas that had been identified in Study 1 rather than generating new and 
unexpected areas of discussion, confirmed by no new themes being identified. 
Therefore the conceptual model appears to provide a robust foundation of qualitative 
data on which to base and develop items for a stiffness PROM.   
 
In relation to the patient perspective of stiffness assessment, a number of key areas 
were identified. The first related to the identification of difficulties with, and dislike of, 
the concept of duration. Given the variations in the topic guide between focus groups, 
this was discussed in more detail in focus group 1, but interestingly was also identified 
in focus groups 2 and 3. Particular issues with duration questions included difficulties 
regarding quantification, uncertainties regarding the start or endpoints of such 
questions, and concerns that the concept does not capture the full stiffness 
experience. Difficulties with the wording of duration questions in other literature have 
been highlighted previously (Section 2.4.1.4) and is concerning given that MS 
duration is the most commonly employed stiffness assessment method in trials 
(Kalyoncu et al, 2009). However, Study 2 did provide information that may allow 
development of the concept of duration to be more relevant to patients with the 
suggestion that assessing the temporality of stiffness was still important and may 
capture more of the patient experience of stiffness. Study 2 data also reinforced the 
relevance of the concept of impact. The participant emphasis on impact was a finding 
that emerged strongly from Study 1 and has been identified in other research as a 
topic of shared relevance across participants (Orbai et al, 2014). The relevance of the 
impact triad to patients is unsurprising as it was developed in collaboration with 
patients to capture patient relevant outcomes (Sanderson et al, 2011). However, as 
it is recommended for consideration in the development of PROM (Sanderson et al, 
2011), it was relevant to explore in this study and take forward to later stages of item 
development. Another key finding related to the wording used to describe the 
experience of stiffness. Within the literature, many different words are used to 
describe the experience or sensation of stiffness (e.g. Helliwell, 1995) and when 
proposed to participants in this study, many of these words were relevant, although 
their use was not often initiated by participants. The term stiffness had been used 
consistently throughout Study 1 and Study 2 by participants and the focus groups 
provided clarification that it was a patient relevant word rather than a medical term 
used by clinicians. The many words discussed in this study and other literature may 
be useful in certain contexts, for example in clinical consultations where the nature of 
the stiffness experience is being discussed. However, in relation to the development 
of a stiffness PROM it appears that the word stiffness would be an appropriate and 




acceptable term to use. The term stiffness is also consistent with the patient 
descriptions from Study 1 and 2 that the symptom is not only experienced in the 
morning period. This challenges the traditionally accepted concept of MS or EMS and 
was also supported in the work by Orbai et al. (2014). 
 
Consistent with discussions in Study 1, the close relationship between stiffness and 
pain was discussed across all focus groups, particularly in relation to the specificity 
of stiffness. Interestingly, the researcher felt that this relationship was much more 
strongly conveyed by participants during Study 2 compared to Study 1. This may be 
a result of differences in the methods of data collection. It is suggested that interaction 
between participants generated in focus groups can lead to reinforcement of 
similarities and differences (Lambert and Loiselle, 2007). As pain has been suggested 
to be a priority for people with RA (Minnock et al, 2003), it is not surprising that it was 
relevant within discussions. Given the opportunity to identify similarities in shared 
experiences from the focus group method, and the prominence of pain in the 
experience of RA, this relationship may have been accentuated during Study 2. As 
discussed earlier, other research has suggested stiffness-pain interdependence 
based on the results of a qualitative focus group study (Orbai et al, 2014). In contrast, 
although Studies 1 and 2 provide evidence of a close relationship between these 
symptoms, they also indicated that stiffness can be separated from pain by impact, 
and differences in management strategies and medications. Furthermore, some 
participants identified difficulties when responding to questions asking about pain and 
stiffness together in one question. Overall, differences in the emphasis placed on the 
relationship between pain and stiffness, in otherwise very similar pieces of work 
(Orbai et al, 2014; Halls et al, 2015) may in part be explained by the data collection 
method. Yet, both studies conclude that stiffness is an important aspect in the patient 
experience of RA and that the development of an appropriate assessment tool for 
stiffness specifically is significant (Orbai et al, 2014; Halls et al, 2015). The identified 
relationship between pain and stiffness does have implications for item development 
where it will be important to reinforce the emphasis on stiffness specifically (e.g. state 
in stem questions), and also base measurement on concepts that enable 
differentiation (e.g. impact). 
 
A final discussion point relates to the participant identification of stiffness in diseases 
external to RA. This is not surprising as stiffness is a common symptom in other 
rheumatic conditions. However, what was interesting was the suggestion that there 
may be similarities between those experiences. While some participants in the focus 




groups felt that the experience of stiffness was different across conditions, others 
identified that it was similar. This was consistent with findings from Study 1 and is 
particularly relevant in relation to stiffness assessment in both an RA context and 
more broadly in the wider rheumatology community. If there are tangible similarities 
in stiffness experiences across conditions, this may have implications for the wider 
use of any new measurement instrument developed in an RA context. The value in 
exploring stiffness assessment across conditions has been recognised with the 
development of an OMERACT special interest group to coordinate further research 
in this area (Orbai et al, 2015).  
 
The total sample in Study 2 was small (n=16) but each focus group included 
participants with a range of age, gender and disease duration, and was similar to the 
Study 1 sample. The main difference between the samples was that all but one 
participant was recruited from a single site (BRI) as recruitment at NBT was stopped 
due to other research commitments and considerations regarding the provision of 
focus groups in convenient locations for all participants. Therefore, the sample may 
represent a slightly less diverse population. Another consideration related to the 
purposive sampling approach, which was employed to enable recruitment of a range 
of participants. However, in practice it proved difficult to systematically reflect a range 
of characteristics within each focus group session while ensuring recruitment of 
enough participants per group. This practical consideration meant that although each 
group included a range of participants, this is only partly due to the sampling 
approach, which was more of a convenience sample than the intended purposive 
sample. Another limitation relating to recruitment was the poor response rate (15%). 
It was likely that recruitment was affected by being performed during the Christmas 
and New Year period. It also may have been influenced by different researchers 
recruiting for this study and other studies simultaneously which may have diluted the 
emphasis on all studies. Despite these considerations, the use of triangulation to 
validate qualitative results (Ritchie, 2003) demonstrated the consistency of results 
across Study 1 and Study 2, which is a key strength of this study. The reliability of 
findings was enhanced by discussion during analysis with other members of the 
supervisory team (Mays and Pope, 1995; Cohen and Crabtree, 2008). Furthermore, 
Study 2 was reported in accordance with the COREQ framework to enhance 
transparency of the qualitative work (Tong, Sainsbury and Craig, 2007) (Appendix L). 
The final consideration in this study was the influence of the progression exam, which 
resulted in changes to the focus group topic guide between focus group 1 and focus 
groups 2 and 3, which fits with recommendations that topic guides are refined and 




revised throughout the process of qualitative data collection (Arthur and Nazroo, 
2003). Furthermore, as the aims and objectives of the study remained consistent and 
the approach to analysis was not affected (as it may have been in an analysis such 
as content analysis), it could be argued that changes made in order to collect data 
more effectively is a strength of this study. Overall, although the feedback from the 
progression exam had time and content implications, it enabled the researcher to 




This study has supported and reinforced the conceptual model identified in Study 1 
in a new population of patients, using a different method of data collection. It has also 
provided information that specifically addresses stiffness assessment from the patient 
perspective. A number of concepts for measurement instrument development were 
proposed for further exploration including individuality, impact, temporality, 
immobility, and location. Patient preferences to capture and format these concepts 
were discussed.  These patient-driven concepts now require consideration alongside 
measurement theory to develop a conceptually sound yet practically appropriate draft 
set of items. Chapter 6 will describe the process of combining the qualitative data 
generated in both Study 1 and Study 2, along with measurement theory evidence, to 
inform item development. 
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Chapter 6: Item development 
Preceding chapters have developed understanding of the patient experience of RA 
stiffness and stiffness assessment from the patient perspective. This chapter will now 
describe the development of preliminary items for an RA stiffness PROM using these 
data. The chapter will discuss how relevant aspects for measurement were identified 
from the codes and themes in the conceptual model, and were combined with the 
stiffness assessment data. It will illustrate the process of drafting and re-drafting of 
items, and the involvement of the supervisory team. 
 
6.1 Background 
As highlighted previously, current stiffness assessment relies on non-standardised 
EMS/MS duration or severity questions which are poorly defined, have limited 
measurement property evidence, and do not appear to have been developed 
according to current standards including collaboration with patients (USDHHS FDA, 
2009; Patrick et al, 2011a; Patrick et al, 2011b) (Chapter 2). Difficulties when 
responding to currently used duration questions have been identified (Section 2.4.1.4 
and Study 2), and consideration of more appropriate and patient relevant concepts, 
such as impact, has been suggested to assess stiffness (Studies 1 and 2; Orbai et al, 
2014; Halls et al, 2015; Orbai et al, 2015). Given this, the development of items for a 
new RA stiffness PROM that capture the patient perspective and demonstrate face 
and content validity is necessary.  
 
Face and content validity refer to whether a measure looks appropriate (Streiner and 
Norman, 2008), and are both essential in PROM development (Frost et al, 2007). 
Studies 1 and 2 provided qualitative data to inform the development of items for new 
RA stiffness PROM. Therefore, item development was based on the stiffness 
conceptual model, and coding trees generated in earlier qualitative studies (Chapters 
4 and 5). It was important that the patient-driven concepts generated in the qualitative 
data were considered alongside measurement theory to develop conceptually sound 
yet practically appropriate preliminary items for use in clinical and research 
environments. Consideration of PROM development theory (Section 2.3), such as the 
OMERACT Filter which was developed to determine the applicability of measurement 
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6.1.1 PROM development guidelines 
The USDHHS FDA guidelines (2009) concentrate on the development of PROMs 
specifically for the purpose of supporting pharmaceutical labelling claims. The ISPOR 
guidelines (Patrick et al, 2011a; Patrick et al, 2011b) focus specifically on the 
development of content validity in PROM development. Although the primary reason 
for the development of this stiffness outcome measure is not to support labelling 
claims, it is an area that pharmaceutical companies might wish to explore in future 
work and as such guidelines provide a rigorous and systematic process to guide 
PROM development, they were used to inform the development of preliminary items. 
The generation of items should include involvement from the relevant population, as 
should the development of appropriate item wording and also assessment (USDHHS 
FDA, 2009). This chapter addresses preliminary item wording, stem question and 
anchors, response options, timeframe, and format by developing them from the 
stiffness conceptual model and coding trees generated in Chapters 4 and 5, in 
consideration with measurement theory. 
 
6.2 Aims and objectives 
The aim of this study was to use the qualitative data to develop preliminary content 
for an RA stiffness PROM. The study objectives were: 
 Demonstrate the process of combining the qualitative data from Study 1 and 
2 and the drafting and re-drafting of items 
 Develop a list of preliminary items using the concepts and language identified 
by patients in Study 1 and 2 including appropriate instructions, wording, 
response options or anchors, timescale, and format 
 Prepare the agreed preliminary items for cognitive interviewing with RA 
patients (Study 3) 
 
6.3 Item development  
Item development was performed between February and June 2014. It was 
implemented from the dual perspectives of being informed by the qualitative data 
generated in Studies 1 and 2, measurement theory (Section 2.3), and consideration 
of the purpose that the developed tool would serve. Item development involved an 
iterative process of development and discussion with different members of the 
supervisory team.  
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It is suggested that the source of items and their subsequent editing, selection, and 
reduction should be documented (Patrick et al, 2011b), which can be performed using 
tracking tables (Patrick et al, 2007; USDHHS FDA, 2009). The development of items 
is described below and illustrated in a series of tables (Appendices E, J, K, M, N, O, 
P) starting from the coding tree identified in Study 1 (Appendix E), and ending with 
the final set of items to be taken to cognitive interviews in Study 3 (Appendix P). 
 
6.3.1 Moving from the qualitative experience of stiffness to stiffness 
measurement  
Studies 1 and 2 provided insight into the patient experience of stiffness and stiffness 
assessment. This broad information, particularly from Study 1 was vital in gaining 
understanding into the patient experience of a seemingly complex symptom. 
However, some of this information was more relevant for experiential understanding 
than for measurement purposes. Specifically for this project, the aim was the 
development of a stiffness PROM for use in clinical or research situations. Use of 
PROMs in these areas include testing the outcome of a treatment or intervention 
(research), or monitoring patient progress (clinical) (Nelson et al, 2015), as captured 
in the OMERACT Filter heading of discrimination (Boers et al, 1998). Thus, it was 
important to identify aspects that address these purposes. Additionally, although the 
data gathered regarding the experience and assessment of stiffness were analysed 
separately in Study 2, participants discussed the two issues in the context of one 
another. Therefore, to retain that context, information from both areas of analysis 
were mapped on to each other to proceed with item development.  
 
Firstly, the coding tree of patient experiences of stiffness generated from Study 1 
(Appendix E), expanded with data generated in Study 2 (Appendix J) was reviewed 
and discussed with the supervisory team to identify aspects only relevant to 
measurement (Appendix M). Appendix M demonstrates that three groups of codes 
were removed as they were only relevant to the development of experiential 
understanding of stiffness: varying prominence of stiffness across the course of the 
disease (level 2 group); medications have other considerations (level 1 group); and 
internal – part of general RA management (level 1 group). All other information was 
retained and renamed to clarify the target for measurement. Figure 6.1 provides a 
concise account of the key areas and associated level 2 groups (renamed for clarity) 
that were identified for potential measurement. 
 




Figure 6.1: Key areas for measurement from the conceptual framework 
 
Secondly, review of the data relevant to stiffness assessment generated in Study 2 
was performed following the same process. Again, this was examined to identify key 
aspects for measurement which were grouped together and renamed (Appendix K, 
column 5).  
 
Finally the data regarding the experience of stiffness (Appendix M) and stiffness 
assessment (Appendix K) were mapped onto each other to combine all key data from 
all sources (Appendix N). The first column in the Table in Appendix N lists the key 
areas identified from the experience of stiffness (Appendix M, column 6). The second 
column includes the key areas regarding stiffness assessment (Appendix K, column 
5) which were mapped onto relevant areas from column 1. Columns 3 and 4 provide 
a summary of the ideas for measurement and points from discussion with supervisory 
team members. 
Normal and specific nature 
Fluctuation with disease 
Process 

















Part of having RA 
Local and widespread 
Linked to behaviour and 
environment 
Highly variable 
Impacts on daily life 
Requires self-management 
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6.3.2 Process of item development 
The retained and reorganised data were then used in the development of a set of 
preliminary items. Initially this focused on development of stem questions and 
anchors with all potential item ideas within each key area for measurement being 
documented and developed though discussion with the supervisory team. Appendix 
O details the earliest phase of item development and includes the key areas for 
measurement (column 1), the potential items to capture within these (column 2), draft 
wording (column 3), and considerations from discussion with the supervisory team 
(columns 4 and 5). 
 
Following this, a first draft of all preliminary items was developed. Appendix P is an 
item tracking table including each preliminary item, revision and development points 
from discussion with supervisory team members, and the final items to be taken 
forward for testing in cognitive interviewing (Study 3). This process involved 
consideration of each of the components of item development; stem questions and 
anchors; response options; timeframe; and layout and format. 
 
6.3.2.1 Stem questions and anchors 
The stem questions and anchors were formed from the qualitative data generated in 
Studies 1 and 2 together with consideration of ideas or concepts within the pre-
existing literature. Preliminary item stem question and anchor development is 
described under five sections; 1) severity items; 2) impact items; 3) attribution items; 
4) traditional stiffness items; 5) response shift items but were not defined a priori. 
Each section is described individually below along with any relevant literature. The 
sections also map onto the item tracking matrix (Appendix P) where the ‘item section’ 
collumn highlights the relevant section for each preliminary item. 
 
6.3.2.1.1 Severity items (Items 1-7, Appendix P) 
Patient relevant concepts to address severity were identified from earlier qualitative 




During qualitative studies (Chapters 4 and 5), location was identified as a way of 
discussing stiffness that was relevant to the individual experience. Patients in Study 
2 felt that location was an intuitive way of being asked about stiffness and suggested 
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it could be captured using a diagram. This was explored during early item 
development (Appendix O). 
 
Within the literature there are other assessments that employ the use of diagrams, 
including those used in the assessment of pain. The Brief Pain Inventory (developed 
for use in patients with cancer) asks responders to mark the location of their pain on 
front/back body diagrams (Cleeland and Ryan, 1994). The Body Chart (developed for 
use in AS) goes one step further by asking responders to mark the location of their 
pain and its severity on a 4-point scale (1=mild, 4=very severe) (Dziedzic, 1997). 
Within the RA literature, the use of diagrams in assessment are employed as part of 
questionnaires assessing patient reported disease activity, including the RADAI 
(Stucki et al, 1995) and the PDAS2 (Choy et al, 2008). These assessments include 
diagrams for patient reported tender (RADAI, Stucki et al, 1995) or swollen (PDAS2, 
Choy et al, 2008) joint counts but there are no examples of stiffness assessment 
using diagrams. When the idea of the use of a diagram was discussed with one 
patient partner (GB) it was suggested that this would be possible for patients to 
complete, but that it might be optimal to provide a diagram and a written question so 
that patients could complete whichever version they found easiest. Additionally, when 
attempting to design an item using a diagram, a number of practical issues were 
identified, including how to instruct responders to mark it, and how it would be scored. 
Although there are options regarding the scoring of diagrams including the use of 
percentage estimates (e.g. Margolis, Tait and Krause, 1986; Margolis, Chibnall and 
Tait, 1988), and more recently using computer software (e.g. Jaatun et al, 2015), 
feasibility in clinical or research settings was questioned. Concerns relating to the 
OMERACT Filter component of feasibility (Boers et al, 1998), and the suggestions 
from one of the teams patient partners (GB) led to the decision to develop this as a 
written question rather than as a diagram.  
 
6.3.2.1.1.2 Timing  
The temporal pattern of stiffness was an important area for patients. Study 1 identified 
that the experience of stiffness was not limited to the early morning, on which much 
of traditional assessment is based and although in Study 2 patients discussed that 
the traditional duration items were hard to answer, the timing of stiffness was still felt 
to be important. To assess timing, a question was generated to capture when stiffness 
occurs. This removed the traditional emphasis on EMS/MS that patients disliked and 
felt didn’t fully capture their experience. However, that the stiffness might have 
occurred in the morning was available as a response option, thus capturing 
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information relating to current understanding of stiffness pathophysiology. As above, 
this item could have been captured in diagram format (e.g. clock face) but for 
practicality reasons it was developed as a written item.  
 
An item to capture increased stiffness variability was also generated. This aimed to 
capture the patient suggestion from Study 1 that during higher disease activity, 
stiffness was more variable (e.g. more frequent in occurrence).  
 
6.3.2.1.1.3 Stiffness after immobility  
Stiffness after a period of immobility was another idea generated from Studies 1 and 
2. Interestingly the definition resulting from previous qualitative work on stiffness in 
RA included stiffness ‘after immobility’ but confusingly this was included in the 
definition of MS (Lineker et al, 1999). Furthermore, two of the 36 individual stiffness 
assessment measures identified in the systematic literature review update 
investigated this concept. One article assessed ‘starting stiffness after a time of rest’ 
but did not define the wording used (Leeb et al, 2003), likely because it was developed 
in German and had not been validated in English (Rintelen et al, 2009). The other 
assessed stiffness using the question ‘How severe has your stiffness been after 
sitting or lying down or while resting later in the day?’ (Wolfe, 1999). As this item had 
been developed as part of the WOMAC in an OA population (Bellamy et al, 1988) it 
was felt that the development of a new item using data collected from an RA 
population would be appropriate.  
 
6.3.2.1.1.4 Medication effectiveness 
Discussion regarding medications was identified as relevant to patients during 
Studies 1 and 2. A preliminary item was based on an item used in the AS literature 
that is sometimes included above the BASDAI (Garrett et al, 1994) which asks 
responders to indicate the effectiveness of their medication in relieving symptoms on 
a VAS (0=No effect, 10=Very effective).  
 
6.3.2.1.2 Impact items (Items 8-59, Appendix P) 
The importance of the impact of stiffness to RA patients was highlighted throughout 
Studies 1 and 2. For a symptom with such variability and individual nature, impact 
has been described as a “common language” across RA patients (Orbai et al, 2014, 
p.10). For this reason, items to capture the impact of stiffness were developed in two 
ways: 1) impact items developed directly from the qualitative data generated in earlier 
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studies (Section 6.3.2.1.2.1); 2) impact items developed based on the concept of the 
impact triad (Section 6.3.2.1.2.2). These are described below.  
 
6.3.2.1.2.1 Impact items generated directly from qualitative data 
A number of items to capture impact were developed based on the combined coding 
framework from Studies 1 and 2 (Appendix J) and the patient language used in those 
studies. It has been suggested that outcome measure development can be informed 
by the conceptual framework of the international classification of functioning, disability 
and health (ICF) and its disease specific core sets (World Health Organisation, 2002). 
The ICF is a framework providing a standard approach to describing health and health 
related conditions (World Health Organisation, 2002). ICF core sets have also been 
developed for specific conditions including RA. The ICF core set for RA is an RA 
specific framework that includes 96 ICF categories in four sections: 1) body functions 
(e.g. mobility of joint functions); 2) body structures (e.g. elbow joint); 3) activities and 
participation (e.g. doing housework); 4) environmental factors (e.g. immediate family) 
(Stucki et al, 2004). However, the ICF core set for RA was not used as framework to 
inform the development of the stiffness items because it captures all aspects of the 
experience of RA for patients (Stucki et al, 2004) making it very broad and likely 
including aspects that are not relevant to stiffness specifically. Furthermore, although 
integration would have been possible, not using the ICF core set for RA framework 
meant that item development could be based on the patient-generated stiffness 
conceptual model identified in Studies 1 and 2, which reinforced the content validity 
of item development.  
 
6.3.2.1.2.2 The impact triad 
One concept that related specifically to aspects already captured in the literature was 
the impact triad. The impact triad was developed by patients and researchers and 
recommends considering not only the severity of an outcome, but also its importance 
to patients, and their ability to self-manage it (Sanderson et al, 2011). These three 
aspects combine to form impact. The concept of the impact triad has been 
recommended for inclusion in the development of PROMs, particularly given its 
relevance from the patient perspective (Sanderson et al, 2011). As the best approach 
to its assessment is currently undetermined (Sanderson et al, 2011), the approach 
used in the development of impact triad items was based on a previously used 
method, employed in the development of the Bristol Rheumatoid Arthritis Fatigue 
NRS (BRAF-NRS, Nicklin et al, 2010a; Nicklin et al, 2010b). This involved developing 
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one question for each component of the impact triad. In discussion with the 
supervisory team, some of whom had been involved in the development of the impact 
triad, it was also recommended that a question be developed to capture the overall 
concept of impact.  
 
In relation to the development of items to capture the impact triad, the RA literature 
includes a considerable amount of research into self-management or self-care. Self-
care is defined by the Department of Health as “[…] the actions people take […] to 
stay fit and maintain good physical and mental health; meet social and psychological 
needs; prevent illness or accidents; care for minor ailments and long-term conditions; 
and maintain health and wellbeing after an acute illness or discharge from hospital” 
(Department of Health, 2005, p.1). Some suggest a distinction between self-
management and self-care with self-care being a ‘normal activity’ relating to daily 
lifestyle decisions, and self-management being an extension of that, relating 
specifically to “ailments” (Chambers, 2006, p.129; Ahmad et al, 2014). As defined 
earlier (Section 4.6), the term self-management is used according to Barlow’s (2001) 
definition which captures the broad descriptions of self-management used by patients 
in Studies 1 and 2. Specifically in an arthritis context, self-management has been 
identified as important for patients in recent qualitative work (Ryan et al, 2013), and 
also as a component of the impact triad (Sanderson et al, 2011). Different words to 
capture the patient perception of their ability to self-manage have been used in the 
literature. During the development of the BRAF-NRS, questions using both ‘cope’ and 
‘manage’ were tested and patients suggested a distinction between them where 
‘manage’ was more practical and ‘cope’ was more relevant to emotions. Although 
patients did also use the terms interchangeably. The final BRAF-NRS included the 
‘cope’ wording (Nicklin et al, 2010b). In the qualitative data gathered in Studies 1 and 
2, words including ‘cope’, ‘manage’, ‘adapt’, ‘deal with’ were used by patients. When 
discussed with the team, a patient partner (PR) identified that the term ‘self-
management’ was not patient-driven and instead suggested ‘cope’, ‘deal with’, and 
‘make do’ as more patient relevant. Given the lack of consistency in the wording to 
capture ‘self-management’, several items using different words were taken for testing 
in Study 3 to further explore the patient perspective regarding the most appropriate 
wording.  
 
In addition to discussion regarding stem question wording, in the BRAF development 
there was also discussion regarding the anchors in the ‘cope’ question (Nicklin, 2009). 
Often in the development of scales, positive anchors (doing well, score 0) are placed 
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on the left and negative anchors (doing badly, score 10) on the right (Meyer, 2007). 
In the development of the BRAF-NRS, the patients in the focus groups felt it intuitively 
better to put the coping anchors the other way round with not coping (0) on the left, 
and coping well (10) on the right hand side of the scale. Although there were 
differences in patient opinion, overall patients felt that this was the best layout (Nicklin, 
2009). Given the considerable patient involvement in the development of the BRAF 
(Nicklin et al, 2010a; Nicklin et al, 2010b), the same anchor placement was used for 
this item in this study for the coping items. 
 
6.3.2.1.3 Attribution items (Items 60-68, Appendix P) 
Some items were developed in an attempt to capture the different ways in which 
patients described the experience of stiffness. These included perceptions that 
stiffness was influenced by other symptoms, disease activity, joint damage, the 
weather, doing too much or too little, and the effect of medications. There was 
discussion with the supervisory team about the relevance of these items from the 
perspective of their use in a measurement context as they seemed related to stiffness 
characterisation rather than quantification. But it was felt that if this was the way that 
some patients made sense of stiffness they should be tested as questions. These 
items were therefore included and taken for further investigation (Study 3).  
 
6.3.2.1.4 Traditional stiffness items (Items 69-74, Appendix P)  
It was also important to decide which traditional stiffness items from the literature to 
include in further testing. Traditional stiffness items assess a narrow range of 
concepts (MS or EMS, severity or duration) and are poorly defined or use variable 
wording or formats. There is limited evidence regarding the measurement properties 
of these items, and difficulties have been identified with some of the concepts 
assessed. The aim was to include a range of traditional stiffness items including those 
with defined wording, most commonly used, and with a range of different formats 
(Table 6.1). 
 
Three traditional stiffness duration items were included (items D, E and F, Table 6.1). 
A recent review of stiffness assessment in low-disease states (van Tuyl, Lems and 
Boers, 2014) identified two stiffness PROM validation studies (Hazes, Hayton, and 
Silman, 1993; Khan et al, 2009) and those made conflicting recommendations 
regarding whether severity or duration was most effective. However, others have 
suggested that severity items are more effective than duration items (e.g. Westhoff et 
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al, 2008). Despite this uncertainty, duration items are the most commonly used 
stiffness assessment question in clinical trials (Cutolo, 2011), therefore it was 
important to include some duration items. Traditional stiffness duration item D is a 
component of a number of validated composite scales to assess disease activity, 
including the RADAI (Stucki et al, 1995; Fransen et al, 2000; modified from the 
RADAR (Mason et al, 1992)), and the PDAS2 (Choy et al, 2008; Choy et al, 2015). 
These scales have been validated in an RA population, and face validity was 
assessed as part of the development and validation of the PDAS2 (Choy et al, 2008). 
Traditional stiffness duration items E and F were both based on the same item 
wording. In a study that tested different wording of duration items, it was concluded 
that this wording was the best indicator of MS duration (Hazes et al, 1994). The 
wording of “morning stiffness […] to maximal improvement” is also in accordance with 
the ARA criteria (Arnett et al, 1988, p.315) and has been used in a number of other 
studies (e.g. Khan et al, 2009).  
 
Table 6.1: Traditional stiffness items  
Item concept Item 
Traditional stiffness 
severity item A 
How would you describe the overall level of morning 
stiffness you have had from the time you wake up? 
11-point NRS (0=No stiffness, 10=Very severe stiffness) 
 
Traditional stiffness 
severity item B 
How would you describe the overall level of morning 
stiffness you have had from the time you wake up? 
100mm VAS (0=No stiffness, 10=Extreme stiffness) 
 
Traditional stiffness 
severity item C 
How would you describe the overall level of morning 
stiffness you have had from the time you wake up? 
5 option adjectival scale (No stiffness, Mild stiffness, 




duration item D 
Were your joints stiff when you woke up today? If yes, how 
long did this extra stiffness last? 
Less than 30 minutes, 30 minutes to an hour, 1-2 hours, 2-
4 hours, More than 4 hours but less than all day, All day) 
 
Traditional stiffness 
duration item E 
How long does your morning stiffness last from waking 
until maximum improvement occurs?  
3 option adjectival scale (Up to 1 hour, 1-3 hours, More 
than 3 hours) 
 
Traditional stiffness 
duration item F 
How long does your morning stiffness last from waking 
until maximum improvement occurs? 
Minutes/Hours 
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The timeframe over which stiffness is assessed is often not specifically stated in the 
wording of traditional items (e.g. Vliet Vlieland et al, 1997). Where a timeframe is 
specified, it is not standardised, for example, in the work by Hazes et al. (1994), 
responses to the stiffness item were collected in a daily diary, while in the study by 
Khan et al. (2009) the same wording was used but with a timeframe of a week. As 
stated in their paper, this may have been for consistency across all collected self-
reported information (Khan et al, 2009). However, this lack of standardisation makes 
comparison across studies difficult. To test items in accordance with the literature 
where currently articles either do not define a timeframe or pick the most appropriate 
timeframe to suit their study, the wording of this traditional item in our draft PROM 
was included as explicitly stated, i.e. without a timeframe.  
 
The response options provided for traditional stiffness duration items also vary, hence 
our duration items E and F differ. Item E provides responses on a 3 option adjectival 
scale. This was decided upon because fewer options and simplicity of items had been 
suggested by patients in Study 2, these categories had also been used in 
categorisation of responses in the literature (Hazes et al, 1994), and they provided 
fewer response options than provided in item D. Finally, item F reflected the 
commonly used response option provided for this item of minutes and hours (Rhind, 
Unsworth and Haslock, 1987; Arnett et al, 1988; Hazes, Hayton, and Silman, 1993; 
Hazes et al, 1994; Vliet Vlieland et al, 1997). 
 
Three traditional unvalidated stiffness severity items were included (items A, B and 
C, Table 6.1). Despite stiffness severity items not being as common as duration items, 
some literature has suggested that stiffness severity items have better measurement 
properties than duration items (Section 2.4.1.4). Traditional stiffness severity items A 
and C were based on the items used in previous literature (Rhind, Unsworth and 
Haslock, 1987; Hazes, Hayton, and Silman, 1993). These studies explicitly defined 
the response options of the items used, but not the wording of the question. When 
looking across the literature to identify appropriate wording used for severity items, 
explicit wording could not be found within the RA literature. The only explicit wording 
identified was the wording of the severity item used in the BASDAI (Garrett et al, 
1994), which although not ideal given its development and use in an AS population, 
provided defined wording, and used a VAS (item B). This question has also been 
used in studies involving RA patients (e.g. Lie et al, 2014).  
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6.3.2.1.5 Response shift items (Items 75-77, Appendix P) 
Response shift has been defined as “a change in the meaning of one's self-evaluation 
of quality of life as a result of changes in internal standards, values and the 
conceptualisation of quality of life” (Sprangers and Schwartz, 1999, p.1509). The 
response shift theoretical model proposes how the response shift occurs and includes 
five key factors; a catalyst (e.g. change in health status), antecedents (e.g. gender), 
mechanisms (e.g. social support), response shift, and perceived quality of life 
(Sprangers and Schwartz, 1999; Schwartz and Sprangers, 1999). From a 
measurement perspective, it has been suggested that measurement may be 
influenced by the response shift and that assessment of response shift may be 
necessary to capture these changes (Sprangers, 2010). Interestingly, the patient data 
gathered in Studies 1 and 2 highlighted the individuality of the patient experience of 
stiffness yet how stiffness was a normal symptom of RA. This led to the suggestion 
to capture stiffness that was different (e.g. more severe) than RA stiffness that 
occurred most days and was now considered ‘normal’ by patients following a 
response shift in internal standards. Following discussion of this suggestion with the 
supervisory team, one item was developed in an attempt to assess response shift. 
This item would be used with the aim of standardising responses and would be placed 
within the demographics section so as not to influence response to other items. 
 
6.3.2.2 Response options 
It is recommended that the purpose and intended use of any PROM are considered 
in relation to decision making regarding response options (USDHHS FDA, 2009). As 
such, response options were a key component of draft item development. The current 
literature regarding response options relates to a number of areas including the 
optimal number and format of response options. It was also relevant to consider 
currently used response options in relevant literature and data capturing the patient 
perspective.  
 
Firstly, the optimal number of response options was considered. The traditional work 
of Miller (1956, reprinted 1994) suggested that seven (plus or minus two) is the limit 
of the working memory thus that guideline has been implemented in a range of areas 
including response options in questionnaire development. Streiner and Norman 
(2008) suggest two further considerations related to this rule. Firstly, more response 
options may help to deal with ‘end-aversion bias’ where responders avoid scoring in 
the most extreme response categories. Secondly, when the aim is to gain a total score 
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from a number of individual items, reducing the response options to three or five will 
likely not result in loss of information. The latter is also consistent with earlier work 
that suggested four or five response options are the preference of survey scientists 
and reviewers because with fewer response options, there is less burden on the 
responder but still enough response options to be precise (Fries et al, 2006). These 
suggestions also fit with the patient preference for fewer responses and simplicity of 
items (Study 2). Following discussion with the supervisory team and in accordance 
with recommendations (USDHHS FDA, 2009; DeVellis, 2012), it was felt that primarily 
response options must fit the stem question. However, it was not vital or possible for 
all items to have the same uniform response options. This is also true of other PROMs 
including the BRAF (Nicklin et al, 2010a; Nicklin et al, 2010b) and the HAQ (Fries et 
al, 1980).  
 
Secondly, format of the response options was considered. There are many different 
available response option formats including Likert scales, VAS, NRS, and adjectival 
scales (Streiner and Norman, 2008; DeVellis, 2012). Each of these options has been 
described below along with relevant literature regarding the strengths and limitations 
of each approach.  
 
6.3.2.2.1 VAS 
VAS are commonly employed in medical contexts, especially in the assessment of 
pain (Huskinsson, 1974), but also in the RA specific context of disease activity 
assessment using the DAS28, which includes a PtG VAS (van der Heijde et al, 1992). 
VAS benefit from being simple, requiring only a mark on a 100mm line (Streiner and 
Norman, 2008). However, it has been suggested that while VAS may appear simple 
to researchers, this is not always the case for responders. In qualitative interviews 
with patients with a range of chronic conditions, VAS were the least preferred 
response option format compared to NRS and adjectival scales (Quadri et al, 2012). 
Similar findings resulted during the development of the RADAI questionnaire, where 
the VAS format used in the original RADAR questionnaire, from which the RADAI 
was developed (Mason et al, 1992), was changed to NRS because patients had 
difficulty with the VAS (Stucki et al, 1995). Difficulty with VAS has also been observed 
in older populations, where it has been demonstrated that NRS are preferred to VAS 
(e.g. Gagliese et al, 2005). Another important consideration with VAS is the anchor 
wording which can influence results (Streiner and Norman, 2008). This was 
demonstrated in a recent study of the DAS28 where the PtG VAS is not standardised. 
Five different PtG VAS wordings and anchors were completed by patients and DAS28 
Chapter 6: Item development 
168 
 
were calculated resulting in different DAS28 results that could be clinically significant 
in terms of access to anti-TNF therapy (French et al, 2013). In addition, practical 
limitations of VAS include difficulty in use over the telephone and distortion of line 
length when photocopied (McCormack 1988, Snow and Kirwan, 1988; Hawker et al, 
2011), which may limit applicability in research and clinical contexts. Overall, despite 
the simplicity of VAS, it has been suggested that other approaches produce more 
accurate assessment and are preferred (Streiner and Norman, 2008). 
 
6.3.2.2.2 NRS 
NRS are similar to VAS but include numbers at regular intervals and can be 11, 21, 
or 101-point scales (Williamson and Hoggart, 2005). NRS have been suggested to 
have good completion rates by responders. In a recent systematic review looking at 
the assessment of pain intensity using NRS, VAS, and adjectival scales, 54 studies 
were identified (Hjermstad et al, 2011). Of the 19 studies that reported on compliance 
(including ability to complete, correct responses and error rate), most (n=15, 78.9%) 
reported better compliance using NRS. Overall, 11 studies recommended the use of 
NRS due to higher compliance rates, responsiveness, and ease of use (Hjermstad et 
al, 2011). However, this review did include articles reporting on broad populations 
including elderly and cognitively-impaired patients. It also reported that the articles 
reported compliance inconsistently across studies (Hjermstad et al, 2011). In another 
study comparing assessment using VAS and NRS in AS, the NRS was suggested as 
more effective as it took patients less time to complete (Akad et al, 2013). This is 
reinforced in an AS population where the assessment of spondyloarthritis 
international society recommend the use of NRS over VAS for BASFI and BASDAI 
(Sieper et al, 2009). Finally, from a practical perspective, NRSs benefit from the ability 
to be completed over the telephone.  
 
6.3.2.2.3 Ordinal scales and Likert scales 
Ordinal scales (also referred to as verbal rating scales or adjectival scales) provide 
descriptors along a continuum and are often used in self-reported health assessment 
(Streiner and Norman, 2008). In a cognitive interviewing study regarding difficulties 
completing questionnaires it was reported that patients prefer verbal statements to 
numbers (Meyer, 2007). A narrative review into different scales (VAS, NRS, and 
verbal rating scales), again in the context of pain intensity concluded that verbal rating 
scales were easy to use but not as sensitive as VAS or NRS, although it did highlight 
that the verbal rating scales format is under-researched (Williamson and Hoggart, 
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2005). Likert scales are comparable to adjectival scales however, rather than 
assessment being unipolar, Likert scales are bipolar and assess the full range of an 
attribute (e.g. strongly disagree to strongly agree) (Streiner and Norman, 2008). It has 
been suggested that Likert scales are common in nursing research (Rattray and 
Jones, 2007).  
 
Other scales with which patients may be familiar were also considered. The response 
options of other PROMs employed within the rheumatology literature or that had been 
identified earlier within this study were explored. A number of PROMs including HAQ 
(Fries et al, 1980), Routine Assessment of Patient Index Data 3 (RAPID3, Pincus et 
al, 2008), and the Patient Activity Scale (PAS, Wolfe, Michaud and Pincus, 2005) use 
four response options based on difficulty (without any difficulty, with some difficulty, 
with much difficulty, unable to do). The BRAF also uses four response options, again 
based on difficulty but with slightly different wording (not at all, little, quite a bit, very 
much). Other scales such as the NHP (Hunt and McEwen, 1980) and the Rheumatoid 
Arthritis Quality of Life questionnaire (RAQoL) (Tijhuis et al, 2001) use binary (yes, 
no) response options. Finally, the recently developed Rheumatoid Arthritis Impact of 
Disease score (RAID) (Gossec et al, 2009; Gossec et al, 2011) uses individually 
worded 11-point NRS. Although not gathered in a comprehensive scoping review, 
this provided an idea of the response options currently in use in a number of regularly 
used scales within the rheumatology literature.  
 
Finally, the patient perspective regarding response options was considered. During 
Study 2 there was some discussion regarding the patient perspective of response 
option formats. This included identification of advantages and disadvantages with 
VAS, and the importance of simplicity and low patient burden. However, no 
conclusive preference regarding response option format was generated. Despite this, 
data generated from discussion with patients did inform decision-making regarding 
appropriate response options.  
 
As a result of consideration of the literature and qualitative work, items with different 
response options were developed. As recommended, formulation of response options 
should occur alongside item development to ensure compatibility (DeVellis, 2012). As 
a number of different ideas regarding item stem questions were being considered 
(Section 6.3.2.1) it was felt that different approaches may be required for different 
items and should be developed on an item-by-item basis. Given earlier discussion 
regarding the number of response options, it was decided that fewer response options 
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would fit with the literature and the patient perspective, and would be used where 
possible but the specific wording of response options would be developed alongside 
each item. During the development of the impact items which were generated directly 
from qualitative data it was felt that a standard response option could be used for all 
items in this section. During development, items were tested with different response 
options, particularly those identified from other PROMs used in rheumatology to 
identify response options that matched the question wording. The wording used in 
the BRAF-MDQ (Nicklin et al, 2010a; Nicklin et al, 2010b) appeared to be the best fit 
for the developing items in this section. Furthermore, given the considerable work 
conducted in the development of the BRAF to ensure the patient perspective (Nicklin, 
2009; Nicklin et al, 2010a; Nicklin et al, 2010b) this was felt to be a rigorous and 
appropriate option. The impact triad items have been assessed previously for fatigue 
using NRS (Nicklin et al, 2010a; Nicklin et al, 2010b) but given the above discussion, 
both these and the response shift item were taken to Study 3 in different formats for 
further investigation into the most appropriate response option from the patient 




It was also important to consider the timeframe over which items would be assessed. 
In PROMs or other questionnaires, respondents are required to answer questions 
within a specified time period which can be immediate (e.g. now) or more long-term 
(e.g. over a year). Bias can result from inappropriate recall periods (Stull et al, 2009) 
and the most appropriate recall period in the development of PROMs is an area of 
debate (Stull et al, 2009). In a review of the literature around recall periods it was 
identified that there are two broad categories of factors that influence responder 
recall; the characteristics of the concept of interest, and the context of the concept of 
interest to the responder (Stull et al, 2009). When defining the recall period for a 
PROM it is important to consider both the ability of the responder to provide accurate 
information within the specified timeframe and what is most appropriate for the 
purpose of the instrument (USDHHS FDA, 2009). Norquist et al. (2012) defined 
criteria for consideration in the selection of the length of the recall period for PROMs. 
These included consideration of the nature of the concept of interest (e.g. natural 
temporal fluctuation), the purpose for which the outcome measure is being used (e.g. 
intervention evaluation), the ability of the responder to recall the required information 
and the burden that poses (e.g. participant recall capacity), and finally the context in 
which the PROM will be used (e.g. study type). These criteria were used to address 
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the most appropriate recall period in the development of these preliminary stiffness 
items (Norquist et al, 2012).  
 
In relation to the nature of the concept of interest, from the qualitative data generated 
in Studies 1 and 2 it was clear that the patient experience of stiffness was highly 
variable. Stiffness appeared to fluctuate with disease activity, and also vary within a 
24-hour period. Variability was thus important to take into account when deciding on 
the recall of any stiffness item. In addition to variability, although stiffness was 
reported to occur in the morning period, the traditional concept of EMS/MS was 
challenged by patients. However, the current understanding of stiffness 
pathophysiology indicates a natural temporal fluctuation of stiffness in the early hours 
of the morning. These considerations were important to consider in decisions 
regarding timeframe. 
 
In relation to the purpose of the outcome, it is the aim that the new stiffness tool could 
be used in clinical or research contexts. In terms of research, although there is no 
specific study for which this tool is being developed it is likely that any tool used in a 
research trial would be included as part of a questionnaire pack for example, for 
completion at baseline and at other time points during interventions. From this 
perspective, relative consistency of the timeframe with other PROMs may be useful, 
if it is clinically or biologically appropriate to the concept being measured. In terms of 
clinical use, the only consideration would be that the recall period provides useful 
enough information to inform decision making. In relation to the recall requirements 
and burden, the nature of the disease in this population will not the influence 
participant’s ability to respond as might be the case in other chronic conditions such 
as dementia. However, this population is likely to be familiar with completion of 
PROMs given that many of its primary symptoms are patient reported (e.g. function, 
pain, and fatigue). The most frequently employed PROM used in trials involving RA 
patients is the HAQ (Kalyoncu et al, 2008) which asks responders to rate their 
functional ability over the past week (Pincus et al, 1983). In addition to these 
considerations, participants in Study 2 debated the advantages and limitations of 
different timeframes for items. However, no definitive timeframe was identified as 
optimal from the patient perspective. When discussed with the supervisory team, 
discussions centred on the purpose of use for the newly developed tool and 
highlighted that it was likely that in relation to interventions, the tool would need to be 
able to identify changes over days, weeks and months, but not hours (for example, it 
would be more likely to explore whether a course of timed release glucocorticoids 
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reduced stiffness in the subsequent days rather than whether analgesics relieve your 
stiffness within 30 minutes). From a clinical perspective it was felt that clinicians would 
expect some variation in a condition such as RA thus identifying sustained change 
would be more useful than short-term variation. Overall, it was felt that a short recall 
period (the past week or less) would be appropriate given the nature of stiffness. A 
very short recall period such as ‘now’ would only suit very frequent or variable 
concepts, and such approaches may also not capture relevant aspects of the patient 
experience (the purpose of the PROM) (Patrick et al, 20011b), therefore the past 
week was felt to be more appropriate. It was felt that the past week was an 
appropriate timeframe that would be acceptable to the population, consistent with 
other PROMs, and useful in terms of the information that it would provide. The past 
week could be used for any newly developed items and additionally, the traditional 
stiffness questions would capture different timeframes for comparison and 
exploration.  
 
6.3.2.4 Layout and format 
As formatting can improve response rates (Fanning, 2005) it was the final area to 
address during item development. There are a number of considerations within layout 
and format including reading level and style. It is generally recommended that 
completion of scales should only require a reading level of a 12-year old (Streiner and 
Norman, 2008). Similarly in health settings it has been suggested that reading levels 
required for health literature should be between 10 and 14-years old (Chapman and 
Langridge, 1997). There are a number of ways to assess reading levels including the 
Flesch Reading Ease Formula (Kincaid et al, 1975), Flesch-Kinkade grade level 
(Kincaid et al, 1975), the Gunning Fog Index (Gunning, 1968), and the Simple 
Measure of Gobbledygook (SMOG) (McLaughlin, 1969). These assessments 
generate scores based on the number of words per sentence and syllables per word. 
Assessment of the reading age of the newly developed items could be explored 
during development (prior to cognitive interviews) and involved testing of all 
preliminary items. Both the Flesch Reading Ease Formula and Flesch-Kinkade grade 
level (Kincaid et al, 1975) can be generated using Word, while the Gunning Fog Index 
and SMOG scores can be generated on the internet. Following their review of the 
literature, Chapman and Langridge (1997) identified a number of practical ways to 
improve the readability of health literature. Specifically in the development of PROMs, 
the use of short sentences (10-12 words) and avoidance of complicated words is 
recommended (Adams et al, 2013). The above recommendations were consistent 
with discussions with the supervisory team. Consideration of all recommendations 
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were used in the development of items during this study. The reading age of the 
preliminary items was assessed at the end of the development process (Table 6.2). 
Reading age requirements for the preliminary items met the recommended guidelines 
above (Streiner and Norman, 2008; Chapman and Langridge, 1997). They were also 
consistent with the reading age required (assessed by the Gunning Fog Index and 
SMOG) for other commonly used PROMs in a rheumatology context (Adams et al, 
2013). The readability of the preliminary items was comparable to that of the HAQ 
(Fries et al, 1980) and the RAQoL (Tijhuis et al, 2001), reported in the study by Adams 
et al. (2013). However, as acknowledged by Adams et al. (2013) despite meeting 
readability recommendations, 22% of the UK population would still be unable to 
complete these PROMs, highlighting broader issues regarding their application.  
 
Table 6.2: Reading age required for the preliminary stiffness items  
The Gunning Fog 
Index 
SMOG Flesch Reading 
Ease 
Flesch-Kinkade 
grade level  
13 years 11 years 12 years 11 years 
NB All 77 items were tested together to generate a score for each assessment method 
  
A number of suggestions were also made by patients in Study 2 regarding the layout 
and format of the questionnaire. Suggestions included preferences for simple marks 
rather than lots of writing, and that circles may be more difficult than a cross or a 
mark. The preference for simplicity was also reaffirmed, as was clear instruction 
describing the purpose of the questionnaire. These aspects, and those highlighted 
above (Chapman and Langridge, 1997) were taken into account prior to cognitive 
interviewing (Study 3) and were further discussed with the supervisory team following 
the outcome of item reduction and testing of the results of the final PROM (Study 4).  
 
6.3.3 The final set of items for further testing 
Following the process of item development involving iterative rounds of discussion 
with members of the supervisory team and consideration of the above elements, a 
set of 77 preliminary stiffness items was finalised to be taken forward for further 
testing in cognitive interviews (Study 3). The item tracking matrix (Appendix P) 
includes the final version of the 77 individual items (question numbers) within the 5 
sections identified above, which were taken forward for further testing: 1) severity 
items (1-7); 2) impact items (8-59); 3) attribution items (60-68); 4) traditional stiffness 
items (69-74); and 5) response shift items (75-77). Chapter 7 will next describe the 
use of cognitive interviews to evaluate and further refine these preliminary items.




Chapter 7: Testing the draft content of the RA stiffness PROM 
with patients (Study 3) 
Chapter 6 discussed the process of the development of draft items for an RA stiffness 
PROM. This chapter will discuss the process of testing and subsequently refining 
items with a relevant patient population.  
 
7.1 Background 
Previous Studies (1 and 2) used qualitative investigation to understand the patient 
experience of stiffness. These data enabled development of preliminary items for an 
RA stiffness PROM (Chapter 6). The next step was to address whether the items were 
acceptable to and understood by the target population. Potential problems with items 
include whether the wording is appropriate and whether the response options 
provided are suitable (Conrad and Blair, 1996; Drennan, 2003). Cognitive interviews 
are a method of critically evaluating products that provide information such as 
questionnaires, forms or brochures (Willis, 2005). They can also be used for item 
development for poorly understood concepts, questionnaire translation, and 
questionnaire development for populations where there may be difficulties with 
questionnaire completion (Drennan, 2003). Specifically, the use of cognitive 
interviews are recommended in PROM development guidelines (Patrick et al, 2011a; 
Patrick et al, 2011b) to ensure that that items are understood by patients in the 
intended way and difficulties with wording, response options, timeframe or format can 
be addressed. Cognitive interviews have been identified as a vital part of scale 
development as they are the last opportunity to adjust a measure prior to quantitative 
testing (Patrick et al, 2011b). 
 
7.2 Aims and objectives 
The aim of this study was to develop the draft content for a new RA stiffness PROM. 
It specifically aimed to test items with patients using cognitive interviews to ensure 
each item was clear, acceptable, and understood in the intended way, and to enable 
refinement prior to quantitative testing. The specific study objectives were: 
 To test whether the instructions, items, and response options were clear and 
understandable to patients 
 To investigate patient preference in relation to different item formats  
 To investigate patient perspective in relation to different item wording  
 





7.3.1 Cognitive theory 
The cognitive aspects of survey methodology (CASM) approach has been influential 
in questionnaire design. The CASM approach identifies that “reporting errors in 
surveys arise from problems in the underlying cognitive processes through which 
respondents generate their answers to survey items” (Tourangeau, 2003, p.5). The 
cognitive processes required to respond to survey items have been captured in a four-
stage cognitive model where the participant has to understand the item 
(Understanding); retrieve the relevant information from memory (Retrieval); make a 
decision about what information is relevant (Judgement); and match their response 
with the response categories provided (Response) (Tourangeau, 1984). To test the 
survey response process in relation to the cognitive model, cognitive interviewing is 
used (Willis, 2005). 
 
7.3.2 Cognitive interviewing methodology 
Cognitive interviewing is a method of testing survey instruments (Collins 2003; Beatty 
and Willis, 2007). ‘Think aloud’ and ‘probing’ are the two main cognitive interview 
techniques. During the ‘think aloud’ method, participants are instructed to ‘think aloud’ 
(i.e. articulate their interpretation and reasoning) as they read and respond to items. 
The interviewer has little input other than to encourage the participant to continue to 
speak (Willis, 1999). The alternative method of ‘probing’ allows the interviewer to ask 
questions regarding specific information following the participants’ response to the 
item (Willis, 1999). This approach was developed for pragmatic reasons such as 
providing useful information for researchers (Beatty and Willis, 2007). There are 
benefits and limitations of each approach. In a summary of these approaches it was 
reported that ‘think aloud’ requires little interviewer training, may generate unexpected 
information and minimises interviewer bias, but is more burdensome for the 
participant partly because ‘thinking aloud’ can be difficult to do. ‘Probing’ on the other 
hand is easy for participants and enables the interviewer to maintain control of the 
session, but it allows the potential for interviewer bias (Willis, 2005). However, despite 
the apparently separate approaches, it has been suggested that researchers do not 
necessarily have to decide on the most appropriate method as for best results, 
aspects of both approaches should be integrated. Collins (2003) recommends that 
‘think aloud’ and ‘probing’ methods can be combined and Willis (2005) suggests that 
in the practical application of cognitive interviewing “‘think aloud’ and ‘probing’ actually 




fit together very naturally” (p.57), and as such researchers should adopt a flexible 
approach that incorporates aspects of both approaches for optimal results. 
 
7.3.3 Participant identification and sampling 
Participant identification and sampling were performed as described for Studies 1 and 
2 (Section 4.3.2) but at the BRI only. A study specific PIS (Appendix Q) was used 
during recruitment. 
 
7.3.3.1 Sample size and sampling 
Often in qualitative research, little attention is given to sample size recommendations 
(Guest, Bunce and Johnson, 2006). This is also true for cognitive interviews where 
sample size recommendations have been highlighted as an area requiring further 
research (Beatty and Willis, 2007). Within the guidance available, 5-15 cognitive 
interviews have been recommended. Rounds of interviews of such numbers can be 
performed followed by review and interpretation (Willis, 2005). Given these 
recommendations, it was decided that the target for recruitment would be 10-15 
participants. If further cognitive interviews were required because new problems were 
still being identified, recruitment could be continued. 
 
7.3.4 Cognitive interview topic guide development  
A topic guide (Appendix R) was developed to achieve the aims of the study (Section 
7.2). The topic guide began with a set of instructions to introduce each participant to 
the cognitive interview procedure. This included emphasising the purpose of the 
interview and to reassure participants that they were in a safe environment in which 
they could speak freely. The set of instructions (Box 7.1) was adapted from the 
literature (Willis, 2005) and was discussed with each participant prior to commencing 
the interview. The preliminary PROM items that were developed in Chapter 6 
(Appendix P) were formatted into a questionnaire pack for completion by participants 
during cognitive interviews (Appendix S), with input from the supervisory team and a 
patient partner (GB). A number of probes were also drafted for use by the interviewer 
throughout cognitive interviews (Appendix T). These probes were developed based 
on consideration of the questionnaire appraisal system (QAS) (Willis and Lessler, 
1999). The QAS was originally developed for identifying sources of error when 
performing surveys over the telephone but can also be used for cognitive interviews 
(Willis, 2005). It is a checklist of items across eight categories of common error 
sources: 1) reading; 2) instructions; 3) clarity; 4) assumptions; 5) knowledge/memory; 




6) sensitivity/bias; 7) response categories; 8) other (Willis and Lessler, 1999; Willis, 
2005). The use of such a checklist provided an opportunity to consider and investigate 
suspected problems in items and enabled a systematic approach to probing (Willis, 
2005). Therefore, the preliminary items were considered in relation to the categories 
included in the QAS which were used to develop a list of probes (Appendix T).  
 
Box 7.1: Cognitive interview instructions for participants 
 
Thank you for coming in. Let me tell you a little more about what we will be doing 
today: 
 
 We are not collecting information about you but are trying our items out on 
people like you so we can make the items better  
 Our goal here is to get a better idea of how the items are working. So I’d 
like you to ‘think aloud’ as you answer the items – just tell me everything 
that comes to mind as you go about answering them 
 At times I might ask you about what you think an item is asking about, how 
you come up with your answers and how you interpret the items  
 Some of the items might look very similar. This is because we are trying to 
find the best way to word the item, so if there are things you particularly 
like or don’t like please do say! 
 If any item is unclear, hard to answer or doesn’t make sense please tell 
me that – don’t be shy! There are no right or wrong answers.  
 Finally, we will do this for about an hour unless I run out of things to ask 
you before then 
 Do you have any questions before we start? 
 
(Adapted from Willis, 2005) 
 
 
7.3.5 Cognitive interviewing procedure 
All cognitive interviews took place in non-clinical rooms in the Academic 
Rheumatology Unit at the BRI. They were performed by one researcher (Halls) who 
was unknown to participants prior to the study and who introduced herself as a 
doctoral student with a non-clinical background. Each participant was greeted by the 
researcher and was provided with refreshments. Prior to starting each interview, each 
participant gave informed consent and completed a questionnaire pack (Section 
4.3.4.1). The instructions for participants (Box 7.1) were explained and each 
participant was asked if they had any questions prior to turning the audio recorder on. 
Each participant was asked to complete the draft items as they would any 
questionnaire but were asked to ‘think aloud’ as they did so. The researcher spoke if 
the participant stopped talking, and followed up silences, hesitations and questions 
from the participant with prompts or encouragement. Each cognitive interview was 




audio-recorded and transcribed verbatim by a transcription service. All transcripts 
were checked for accuracy and anonymised by the researcher. 
 
7.4 Analysis 
As the process of analysis of cognitive interviews has been described as the major 
drawback in questionnaire pretesting due to the lack of standardisation (Drennan, 
2003), the questionnaire testing literature has attempted to address this issue using 
taxonomies of possible problems (e.g. Conrad and Blair, 1996). These taxonomies 
are usually based on the four headings of the four-stage cognitive model: 
Understanding, Retrieval, Judgement and Response (Tourangeau, 1984; Collins, 
2003; Drennan, 2003). As such, analysis in this study was deductive and coded under 
the four headings of the cognitive model. Coding was performed by the researcher 
and discussed with the supervisory team. The Nvivo 10 (QSR International Pty Ltd, 





Of the 84 potential participants approached, 12 agreed to participate (12% recruitment 
rate). One participant who originally agreed to participate cancelled our interview at 
short notice and was unable to rearrange therefore, 11 RA patients participated. 
Seven were female (64%), age range between 51 and 83 years and disease duration 
between one and 25 years (Table 7.1). Reasons given for declining participation were 
as described in Chapter 4 (Section 4.3.4) however, the influence of multiple study 




Table 7.1: Participant demographic information  
Pt 
ID 










Work status Education 
2401 F 83 20 1.5 4.8 3.1 Analgesics, NSAIDs Retired College/apprenticeship 
2402 F 61 2 1.375 5.9 4.7 Analgesics, DMARDs RIB School 
2403 M 61 20 1.5 5.8 2.9 Analgesics, NSAIDs, Bios RIB/Carer School 
2404 M 73 25 Inc. 6.1 7.1 DMARDs, Bios Retired School 
2405 M 78 16 0.5 2.4 1.6 DMARDs Retired College/apprenticeship 
2406 F 67 8 2 6.8 6.9 DMARDs, GCs Retired School 
2407 F 51 1 1 7.3 9.5 Analgesics, NSAIDs, DMARDs, GCs Paid work University 
2408 F 61 1 0 0.8 0.9 DMARDs, GCs Paid work School 
2409 F 52 5 0.5 3.3 7.0 Analgesics, NSAIDs Paid work College/apprenticeship 
2410 F 77 3 1.625 7.2 5.9 DMARDs Retired School 
2411 M 56 3 0.625 4.3 5.0 DMARDs Paid work School 
Median and interquartile range (IQR) †=61 (56-77), ‡=5 (2-20), §=1.1875 (0.5-1.5), ¥=5.8 (3.3-6.8) ¤=5.0 (2.9-7.0) 
Pt ID=Patient identification number; dis dur=disease duration; HAQ=Health assessment questionnaire 0-3 (3=most disabled); PtG=Disease activity 
score 0-10 (0=very well, 10=very badly); Pt pain=Pain assessment 0-100 (no pain-severe pain); NSAIDs=Non-steroidal anti-inflammatory drugs; 
DMARDs=Disease modifying anti-rheumatic drugs; GCs=Glucocorticoids; Bios=biologics; RIB=Receiving incapacity benefit; Inc.=Incomplete data  
 
 




7.5.2 Cognitive interviews 
All participants completed the draft items in the order specified in Appendix S, 
although the order of the three different formats (NRS, VAS and ordinal scale) of the 
impact triad items varied between interviews. In the first five interviews, all versions 
of the items were included in the questionnaire pack, with the NRS first, VAS second 
and ordinal scale last (as seen in Appendix S). Following comments by participants 
regarding the large number of items, in an attempt to reduce participant burden, the 
questionnaire pack was edited to contain only the one version of these items and the 
other formats were shown to participants for discussion only. Therefore, in the 
following three interviews the VAS format was included in the questionnaire pack and 
in the final three the ordinal scale format was included in the questionnaire pack. 
 
Responses to each item are discussed below in relation to the headings of the four-
stage cognitive model (Tourangeau, 1984). Items are presented in the five sections 
described in Chapter 6: severity items; impact items; attribution items; traditional 
stiffness items; response shift items. Each section provides an overview of the 
performance of items and participant quotes for illustration. Following analysis of the 
cognitive interviews, potential changes to items were identified and discussed with 
the supervisory team to generate the final wording. Changes made to items are 
reported below in boxes identifying the original and the refined item. If items were 
added, these were referred to as additional items. Changes to introductions and 
instructions are also discussed along with changes made for formatting and 
consistency reasons.  
 
7.5.2.1 Severity items (1-7) 
Generally items in this section were well responded to. Minor difficulties were 
identified under the headings of Understanding (n=4), Response (n=5) and 
Judgement (n=1). All items were refined for clarity, two items were added to enhance 
understanding and two were removed.  
 
7.5.2.1.1 Have you experienced RA stiffness in your joints during the past 7 
days? (item 1): Understanding and Response 
This item was generally well understood by participants. However, two participants 
questioned the specificity of the word ‘joint’. 
 
“Well, all joints that it’s affected by” [2404] 
 




“[…] when I get up it’s a bit stiff to move my back […] now is that a joint?” [2405] 
 
Two other participants questioned how many responses they could tick. 
 
“So […] I can answer two boxes in one?” [2403]  
 
“So I can just tick those can I?” [2409] 
 
Minor changes to the wording, grammar and emphasis of the instructions were made 
for clarity (Box 7.2). 
 
Box 7.2: Changes to item 1 
Original 
item 
Have you experienced RA stiffness in your joints during the past 7 
days? 
Not in any of my joints 
 
Yes, in some of my joints 
 
Yes, in many of my joints 
 




Have you experienced RA stiffness in your joints during the past 7 
days? 
No, not in any of my joints 
 
Yes, in a few of my joints 
 
Yes, in many of my joints 
 
Yes, in all of my joints 
 
 
7.5.2.1.2 Have you experienced RA stiffness in your body (outside of your 
joints) during the past 7 days? (item 2): Understanding and Response 
Item 2 was clearly understood by four participants who highlighted the relevance of 
this to their experience. 
 
“Well yeah last week I just had it in […] all over stiffness. This one I’d say all over 
[item 2]. I just felt like I’d been in a boxing ring with a, you know, serious boxer, 
and just all over. So it wasn’t just my joints I suppose is what I’d say there” [2407] 
 
Six participants indicated uncertainty about this item.  
 
“In your body, outside of your joints, oh heavens! Erm, when I’ve got a stiff neck, 
is that body rather than joints?” [2401]  




“In your body, outside of your joints, that’ll be a no I haven’t had any in my body, 
what do you mean in your body?” [2402] 
 
To understand these responses further the researcher explained what the item was 
trying to capture. Four participants felt that the concept was not relevant to their 
experience of stiffness. For some this was more relevant to aspects external to RA 
stiffness including ageing (n=1), overdoing physical activities (n=1), and pain (n=3). 
 
“Oh yeah I think you do [get stiff everywhere] but I mean […] I am 60 odd, what do 
you expect?” [2402] 
 
“Yes. I see what you mean, […] when I’ve had good days and I’ve gone in the 
garden and I’ve overdone it […] and I just feel I want to get in the bath […] because 
it does feel all over, tense muscles and things, so outside of your joints, I suppose 
you could say yes if you’re talking about your muscles […] I don’t know if RA affects 
the muscle” [2403] 
 
“Yes, that could be pain as well” [2409] 
 
This item was identified as not relevant to some participants’ experience and two 
participants were unable to provide an appropriate response. However, other 
participants were able to respond as appropriate response options were available.  
 
“Have you experienced RA stiffness in your body outside of your joints? I can’t 
answer that, to be honest” [2403]  
 
“Well I don’t think I am bad enough to feel it except in bones. So not in any part of 
my body” [2401] 
 
As a result of the difficulties highlighted by some participants, this item required 
changes to enhance clarity. As identified earlier (Chapter 4 and 5), stiffness ‘all over’ 
was not a concept that was relevant to everyone. However, removing the item might 
result in loss of information for participants to whom it was relevant. In later cognitive 
interviews, the researcher asked participants to whom the concept was relevant to 
suggest improvements to the wording.  
 
“All over your body […] Yeah just ask them say have you ever experienced waking 
up and your whole body has gone stiff” [2408] 
 
Following discussion, this item was divided into two items (Box 7.3). The first was 
similar to the original item with minor changes to grammar and emphasis, and wording 
that better reflected the patient experience and use of language (e.g. ‘all over’ rather 
than ‘whole body’). The second item reflected the suggestion from the qualitative work 




that all over stiffness was either present or absent. This was mirrored in the response 
options and wording, and was based on participant suggestions to better reflect the 
patient experience (Box 7.3). 
 
Box 7.3: Changes to item 2 
Original 
item 
Have you experienced RA stiffness in your body (outside of your 
joints) during the past 7 days? 
Not in any parts of my body 
 
Yes, in some parts of my body 
 
Yes, in many parts of my body 
 













Have you experienced RA stiffness in your body (outside of your 
joints) over the past 7 days? 
No, not in any part of my body 
 
Yes, in a few parts of my body 
 
Yes, in many parts of my body 
 











7.5.2.1.3 During the past 7 days have you experienced RA stiffness coming 
and going as frequently as usual for you? (item 3): Understanding and 
Response 
Generally this item was understood by participants, however there was some 
uncertainty regarding the complexity of the item.  
 
“[…] coming and going as frequently as usual, is that even English?” [2402] 
 
“Are they saying is coming and going within seven days, is that what it? […] so are 
they asking me do I normally have what I’ve had in the last week […]?” [2411] 
 
One participant suggested that the wording of the item assumes that stiffness is usual 
for everyone. 
 




“Ah, you’re making an assumption there [laughs] as usual for you. For me, it’s 
unusual anyway because I’ve not really experienced any stiffness from RA since 
my elbows were replaced” [2405] 
 
One participant also highlighted that the concept of usual as difficult due to variability.  
 
“Well, I would say same as usual, which is random. [...] There is no usual.” [2411] 
 
During discussion, this item seemed to be asking a lot in one question, which might 
be contributing to the difficulties with Understanding and Response. When looking 
back at the qualitative data and early item development (Appendix O) the importance 
of both normality and frequency had been identified. Therefore this item was split into 
two items; one asking about normality (e.g. the usual experience of stiffness); and 
one asking about frequency (e.g. the occurrence of stiffness) (Box 7.4). Although the 
concept of stiffness being ‘different to usual’ had been important in earlier qualitative 
work and was reinforced by the patient partners, during cognitive interviews it was 
identified that this was not clear as a question. Therefore for clarity, the concept of 
‘usual’ was retained in one item and the wording ‘usual’ was removed from 
























Box 7.4: Changes to item 3 
Original 
item 
During the past 7 days have you experienced RA stiffness coming and 
going as frequently as usual for you? 
It has been much less frequent than usual 
 
It has been less frequent than usual 
 
It has been the same as usual 
 
It has been more frequent than usual 
 













Over the past 7 days has your RA stiffness been different to usual for 
you? 
It has been much better than usual 
 
It has been better than usual 
 
It has been the same as usual 
 
It has been worse than usual 
 





Over the past 7 days has your RA stiffness been as variable (coming 
and going) as usual for you? 
It has been much less variable than usual 
 
It has been less variable than usual 
 
It has been the same as usual 
 
It has been more variable than usual 
 
It has been much more variable than usual 
 
 
7.5.2.1.4 During the past 7 days have you experienced stiffness after a period 
of immobility (for example, in a chair or in bed)? (item 4): Understanding 
This item was generally acceptable to participants. However, one participant 
suggested that the two tasks included in the example were not comparable.  
 
“Bed, you assume, […] you’ve been in bed at night, which is a decent length, but 
[…] if we watch a programme on television I can get up without using my arms or 
anything to get up from a chair, straight away afterwards, it doesn’t [compare to 
getting up from bed]” [2405] 
 
As above (Section 7.5.2.1.3), the concept of stiffness being ‘usual’ was identified in 
the response options of this item.  




“Again, you’ve got ‘than usual’” [2405]  
 
One participant highlighted that this item was not consistent with other items that 
specified RA stiffness.  
 
“I think you need to separate those two really, the osteo and the rheumatoid” [2404] 
“Do we need RA stiffness there?” [SH] “Yeah I think so yeah” [2404]  
 
In response to participant comments, RA stiffness was added for consistency and the 
wording was changed to include only one action. To remove the emphasis on ‘usual’ 
and for consistency, the response options were changed to reflect increasing severity 
(Box 7.5). 
 
Box 7.5: Changes to item 4 
Original 
item 
During the past 7 days have you experienced stiffness after a period 
of immobility (for example, in a chair or in bed)? 
I have had much less than usual 
 
I have had less than usual 
 
I have had the same as usual 
 
I have had more than usual 
 




Over the past 7 days have you experienced RA stiffness after a 
period of immobility (for example, after sitting for a while)? 
No, not at all 
 
Yes, a little 
 
Yes, quite a lot 
 
Yes, very much 
 
 
7.5.2.1.5 During the past 7 days have your RA medications been controlling 
RA stiffness as usual for you? (item 5): Judgement 
This item was identified by four participants as being difficult to answer as it required 
factual information.  
 
“I don’t know whether it’s that that’s stopping me from getting so much stiffness 
and pain” [2402] 
  




“Oh, that’s a difficult item […] it has been better controlled than usual the last 7 
days because I’ve had the steroid injection, but the blood [still] shows that it’s high” 
[2403] 
 
This item had been included because it addressed an area that was discussed in 
detail during previous work (Chapter 4 and 5). However, given these participant 
comments it was removed as it appeared difficult for participants to answer and 
captured information that was contextual rather than useful for measurement. 
 
7.5.2.1.6 During the past 7 days when have you experienced RA stiffness (in 
your joints or your body)? (items 6 and 7): Response 
Items 6 and 7 both had the same wording but different response options (Box 7.6). 
Both items were generally well comprehended by participants. A number of 
suggestions were made in relation to the available response options. One participant 
suggested adding another response option in item 6. 
 
“[…] you might want to put one in about, on getting out of bed first thing” [2405] 
 
Two participants suggested additional response options for item 7 to provide 
comprehensive options. 
 
“[…] first thing when I wake up, when I get out of bed, […] during the night when I 
get up it’s bad, sometimes going to the bathroom, but does not when you are in 
bed” [2401] 
 
Another participant highlighted a common difficulty with questionnaire completion 
based on how recently stiffness had been experienced. 
 
“Can I just say that these items, I could answer them straightforward, when I’ve 
been going through it, but when you haven’t got it, you forget you’ve had it” [2403] 
 
The constant nature of stiffness was discussed by three participants. Some 
uncertainty was expressed about how to answer the item in relation to this however, 
generally it was felt that there were appropriate response options available. 
 
“But my stiffness is like a continual stiffness […] so I don’t know how to answer 
that one, morning, noon, or night, during the night […] I don’t know what to put, to 
be honest, because it’s there all the time” [2403] 
 
“[…] it seems as though I am going to tick them all [laughs]” [2409] 
 




Furthermore, one participant was unsure how many response options they could 
mark which indicated that clarification of the instructions was necessary. In discussion 
it was thought that it may be confusing and unnecessary to include both items. The 
response options provided in item 6 had greater simplicity and would limit different 
interpretations across participants. To improve item 6, a response option was added 
to capture if stiffness had not been present during the indicated times, and further 
minor changes were made to the instructions, emphasis and wording (Box 7.6). 
 
Box 7.6: Changes to items 6 and 7 
Original 
item 
During the past 7 days when have you experienced RA stiffness (in 
your joints or your body)? 
During the morning 
 
During the afternoon  
 
During the evening  
 













During the past 7 days when have you experienced RA stiffness (in 
your joints or your body)? 
First thing when I wake up  
 
When I get out of bed 
 
During the first few hours after I get up 
 
During the late morning 
 
During the early afternoon 
 
During the late afternoon 
 
During the evening 
 





Over the past 7 days when have you experienced RA stiffness? 
Please tick all that apply to you 
In the night 
 
In the morning 
 
In the afternoon 
 
In the evening 
 
None of these 
 
 




7.5.2.2 Impact items (8-59) 
Items in this section were generally well responded to by participants. Each impact 
item (8-38) is discussed below, apart from items 8, 9, 12, 15, 21, 25, 29, 32, 34, 36 
for which no difficulties were identified or no changes were made. Minor difficulties 
were identified under the headings of Understanding (n=18), Judgement (n=3) and 
Response (n=3). Five items were removed from this section (18, 26, 27, 33, 37, 38). 
All items in this section had consistent response options (not at all, a little, a lot, very 
much) which were not changed. The items developed to address the impact triad (39-
59) are discussed separately (Section 7.5.2.2.21).  
 
7.5.2.2.1 Has stiffness made it difficult to bath or shower? (item 10): 
Judgement  
Four participants identified difficulties with the double-barrelled example provided in 
item 10. Some participants suggested that bathing was very difficult, others 
suggested that using a bath was not comparable to using a shower.  
 
“[…] I am alright in the shower if I am stiff but not the bath” [2408] 
 
As a result the double-barrelled item was exchanged for wash, with an example 
provided. This broader wording was designed to ensure the item was relevant to a 
wider range of patients and the wording ‘wash’ had been suggested by participants 
in focus group 2 (Box 7.7).  
 
Box 7.7: Changes to item 10 
 
7.5.2.2.2 Has stiffness made it difficult to work? (item 11): Understanding 
Five participants suggested that this item may be interpreted differently depending on 
participants’ personal circumstance. 
 
“Work, well of course I am not at work […] so work to me means keeping the house 
clean, cooking the meal, things like that” [2401] 
 





Has stiffness made it difficult to bath or shower? 
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“Well, I’m retired [laughs] so […] what people regard as work is where they go out 
and earn some money […] but it’s more than that, because we’ve done a load of 
voluntary work and raising money” [2405] 
 
Following the first few interviews where participants indicated that work was broader 
than just paid work, the researcher asked participants in subsequent interviews 
whether combining item 11 (work) and item 12 (daily activities) would be acceptable. 
However, an important area of difference between the two items was noted by one 
participant. 
 
“No, I think it should be different […] if you’re a younger person and you’ve got to 
go to work, its different to being at home, retired and doing your chores. You can 
pick and choose when you do your chores […] you don’t have to stick to the time 
factor or the routine of having to do it” [2406] 
 
The researcher reviewed the earlier qualitative work to check patient quotes 
regarding the origin of this item. It was found that participant discussions in earlier 
qualitative work (Chapter 4) had related to daily activities, responsibilities and 
commitments including work, family life, making plans and childcare roles. However, 
as work was relevant to more participants, the researcher had taken that forward for 
item development without consideration of the other aspects. Therefore the item was 
edited with input from members of the supervisory team and checked with a patient 
research partner (GB) to attempt to capture all of these aspects (Box 7.8).  
 
Box 7.8: Changes to item 11 
 
7.5.2.2.3 Has stiffness made it difficult to eat? For example, chew or cut your 
food? (item 13): Judgement 
Three participants reported difficulties with the double-barrelled example provided in 
this item. 
 
“[…] I think if you take that bit out there, chew. Cut food yes, it does, because I 
can’t hold a knife and fork properly” [2404] 
 
Again, the researcher referred back to earlier qualitative work to check the origin of 
this item. In Study 1, two participants had identified difficulties with eating and chewing 
as a result of jaw stiffness. During item development the researcher had then added 
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chew or cut as examples to make the item more broadly applicable. However, on 
consideration of this following participant comments it was identified that this was not 
appropriate. Therefore, the item was reworded to target the original aspect 
highlighted by participants (Box 7.9). It was also felt that cutting would be captured in 
other questionnaire items (e.g. item 21). 
 
Box 7.9: Changes to item 13 
 
7.5.2.2.4 Has stiffness made it difficult to do hobbies or activities you enjoy? 
(item 14): Understanding and Judgement 
This item was generally well understood but some participants expressed concerns 
regarding its broad nature. 
 
“You can certainly read however stiff you are […] but gardening is a hobby of 
course and that is not easy sometimes” [2401] 
 
In discussion it was felt that the broad nature of the item was important for relevance 
to as many people as possible, therefore only changes for consistency were made. 
 
7.5.2.2.5 Has stiffness made it difficult to rise from a chair? (item 16): 
Understanding 
This item was well responded to although three participants suggested their response 
would be dependent on the type of chair. 
 
“[…] oh definitely to rise from a sofa, when you’ve got nothing to push on […] if it’s 
got arms [its] much easier yes” [2401] 
 
“[…] sometimes can be, depending how low the chair is” [2409] 
 
The wording of this item was changed to focus on the action of getting up after being 











Has RA stiffness made it difficult chew? 




Box 7.10: Changes to item 16 
 
7.5.2.2.6 Have your daily activities required more effort than usual because of 
stiffness? (item 17): Understanding and Response 
Generally participant comments regarding this item reinforced its relevance. 
However, one participant’s interpretation of ‘activities’ indicated that the wording could 
be interpreted as only recreational activities. 
 
"No I don’t really do that much activities […] I used to do a little bit of dancing […]” 
[2409] 
 
This item wording was changed to include both tasks and activities and for 
consistency with earlier comments regarding the use of the term ‘usual’ (Section 
7.5.2.1.4) (Box 7.11).   
 
Box 7.11: Changes to item 17 
 
7.5.2.2.7 Has stiffness had an impact on your daily life? (item 18) 
This item was removed because the concept of impact was captured by other items, 
including another specific impact items (45, 52, 59), and to reduce participant burden.  
 
7.5.2.2.8 Has stiffness made you slower? For example unable to rush (item 
19): Understanding 
Two participants identified different interpretations of the word ‘rush’ used in the 
example.  
 
“No, that’s not a good example for me. Has stiffness made you slower, yes, for 
example unable to rush. I do rush. Like I was saying earlier, this rush and this 
irritableness with the rush. I’ve got to get it done, things like that […] I know some 
people will say I am unable to rush, but whether the rush word is the right word. 
The item’s okay ‘til it gets to the rush” [2403] 
 
“Yeah. That is my problem, I rush around too much [laughs]” [2411] 
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The word ‘rush’ was originally included as it was the wording used in earlier qualitative 
work (Chapter 4). However, on re-examination of the earlier data, being unable to 
perform things ‘quickly’ was also discussed. Therefore for clarity this item was 
reworded (Box 7.12). 
 
Box 7.12: Changes to item 19 
 
7.5.2.2.9 Has stiffness made it difficult to do fine movements? For example, 
do up buttons on a shirt or cardigan? (item 20): Understanding 
Some uncertainty was expressed regarding the examples provided in this item. One 
participant suggested that the example was seasonal and may not be relevant all 
year round while another suggested possible differences between genders. 
 
“Well, it’s this time of year, you don’t do up buttons, do you?” [2403]  
 
“[…] quite a bit of female dressing involves hands behind the back [laughs]. 
Whereas us blokes we don’t have that problem” [2405] 
 
It was felt that the example should be changed to something broadly relevant and 
gender neutral. On re-assessment of the earlier qualitative data the example of writing 
with a pen had been identified as difficult and was substituted as a more appropriate 
example (Box 7.13).   
 
Box 7.13: Changes to item 20 
 
7.5.2.2.10 Has stiffness made it difficult to make a fist? (item 22): 
Understanding 
Three participants identified different interpretations of this item. One participant 
suggested that her experience would relate to both opening and closing her fist. 
 
“Difficult to make a fist. No. Not now. But it was a few, you know a week or two 
ago, I couldn’t get it, it went down like that [closed fist], well that’s a fist alright but 
it would not straighten up [open fist]” [2401] 
Original 
item 
Has stiffness made you slower? For example unable to rush 
Refined 
item 




Has stiffness made it difficult to do fine movements? For example, do 
up buttons on a shirt or cardigan? 
Refined 
item 
Has RA stiffness made it difficult to do fine movements (for example, 
write with a pen)? 




Another participant suggested that the current wording sounded rather aggressive. 
While another suggested that this was not an essential everyday action. 
 
“[…] you don’t always make a fist, do you, you don’t always need that to make a 
fist […] it’s not like life and death, is it?” [2406] 
 
This item was originally developed because although many participants in previous 
qualitative work (Chapter 4) described difficulties with grip, some described difficulties 
specifically making a fist. Therefore both were included to identify which item 
performed better or whether they captured different information and were both 
important. To retain the original idea of this item, participant comments were taken 
into account and the wording was edited to include both opening and closing a fist. 
This aimed to make the item more broadly applicable and less aggressive sounding 
(Box 7.14). 
 
Box 7.14: Changes to item 22 
 
7.5.2.2.11 Have you lacked physical strength to do your daily activities 
because of stiffness? (item 23): Understanding 
Some participants identified the wording ‘physical strength’ as difficult to understand 
how this related to stiffness was also questioned. The earlier qualitative data were re-
examined and ‘strength’ was identified as important during Study 2 (Chapter 5). 
However, the word ‘physical’ had not been used by participants, therefore this word 
was removed (Box 7.15).  
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7.5.2.2.12 Have you found that your movement is restricted because of 
stiffness? For example, reaching to get an item (item 24): Understanding 
Although this item was generally acceptable to participants, difficulties were identified 
with the example provided. Two participants acknowledged that the example was 
quite specific and not relevant to their personal experience.  
 
“[…] it depends where the stiffness is, doesn’t it?” [2405] 
 
“Your movement is restricted, yes, not reaching out I don’t think […]. Well you can 
reach because this part [upper arm] is usually okay on me but this part is worse 
[shoulder]. Do you see what I mean?” [2408] 
 
Following discussion and review of earlier qualitative data, the example was removed 
to ensure the item was as broadly relevant as possible (Box 7.16).  
 
Box 7.16: Changes to item 24 
 
7.5.2.2.13 Has stiffness made it difficult to move parts of our body or your 
whole body? (item 26): Understanding 
This item generated some uncertainty regarding its wording and whether it was 
capturing similar information to item 24.  
 
"No I don’t think that’s right, it’s only my body, it does move, but it just doesn’t move 
as smoothly as it should" [2407] 
 
During the original development of items 24 and 26, both came from discussions 
regarding movement difficulties. Both items were developed in an attempt to capture 
this idea and explore different approaches to asking about it. Given the similarity of 
these items, it was decided that item 26 would be removed to reduce the number of 
items and participant burden. 
 
7.5.2.2.14 Has your body not moved like your brain tells it to because of 
stiffness? (item 27): Understanding 
This item generated considerable discussion. The item resonated with some 




Have you found that your movement is restricted because of stiffness? 
For example, reaching to get an item 
Refined 
item 
Has your movement been restricted because of RA stiffness? 




“[…] I wonder if you could word that slightly different […] you want to do something, 
like pick up that thing, and your brain’s telling you, you want to pick that up […] 
and you can’t, because your hands or your shoulder, or whatever bit […] You want 
to do it and you want to reach it, but because of the restricted movement, your 
brain’s telling you, yes you’ve got to move that mug, but it won’t [go]” [2406] 
 
For these participants it was identified that this item captured similar information to 
item 28.  
 
“This one is quite a good item. Well I don’t know if you get the same from the two 
[27 and 28]” [2407] 
 
For other participants however, the item did not relate to their experience.  
 
“Does your body not move like your brain tells it? No” [2402] 
 
Participant discussions in Studies 1 and 2 identified the cognitive impact of stiffness. 
Two items (27 and 28) were developed to capture this idea however, the item concept 
was quite abstract. Given the participant suggestion that these items captured similar 
information and following discussion, item 27 was removed to reduce participant 
burden. 
 
7.5.2.2.15 Have you had to concentrate more than usual to move your body 
because of stiffness? (item 28): Understanding 
Two participants discussed this item in detail. One participant suggested that the word 
‘concentrate’ was only applicable to cognitive tasks while another indicated that this 
may be task dependent. 
 
“I don’t concentrate for that, it’s just for reading” [2403] 
 
“[…] if you’re doing fiddly little things you know, then yes, you’ll have to concentrate 
more, but normal day to day things, no I don’t think so […] If you’re doing more 
intricate things I would say yes” [2404]  
 
Despite these comments, when this item was discussed, it was retained in favour of 
item 27. The item wording was edited slightly for consistency with other items (Section 








Box 7.17: Changes to item 28 
 
7.5.2.2.16 Have you felt worried because of stiffness? (item 30): 
Understanding 
This item was generally considered acceptable although one participant identified 
uncertainty regarding the wording.  
 
“Have you felt worried because of stiffness? Not particularly worried, concerned 
[…] is this the beginning of something worse. But I don’t go worrying about it for 
hours when there’s nothing you can do at that time […] when they put worried in, 
it’s concerned would be my word for that more” [2405] 
 
On review of earlier qualitative work (Chapter 5), ‘worry’ was the word that was used 
by participants. However, following discussion it was felt that by including both worry 
and concern the item may have broader relevance to participants (Box 7.18). 
 
Box 7.18: Changes to item 30 
 
7.5.2.2.17 Have you felt embarrassed because of stiffness? (item 31): 
Understanding 
This item was not identified as problematic for participants and although only one 
participant identified uncertainty regarding the wording, it generated some further 
discussion.  
 
“No, it’s awkwardness. Awkwardness, I think, and slowness, yes. No, I don’t know 
embarrassed” [2403] 
 
Previous work on fatigue in RA had found that the word ‘embarrassed’ was difficult to 
translate (Nicklin et al, 2014). Synonyms included ‘awkward’, as suggested by one 
participant. However, the word ‘awkward’ was used in earlier qualitative work in 
general stiffness descriptions in the context of lacking ease of movement rather than 
in the context of embarrassment (e.g. “[…] walking on stiff feet is just, it feels awkward 
[…]” [102]). Therefore ‘awkward’ was not felt to be an appropriate substitute. A 
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number of other options were discussed and the word ‘self-conscious’ was chosen 
as a substitute (Box 7.19). 
 
Box 7.19: Changes to item 31 
 
7.5.2.2.18 Have you been unable to do your daily activities because of 
stiffness? (item 33): Understanding 
This item was generally well understood by participants although it was identified that 
it captured very similar information to item 32.  
 
“Being unable, didn’t it say that just now as well? To do your daily activities?” [2402] 
 
Another participant suggested that the item was too broad. 
 
“That’s a bit all-encompassing isn’t it […] What, all of them? [Laughs]. It’s unlikely 
that you wouldn’t be able to do any at all” [2405] 
 
This item was removed as it was felt that item 32 captured similar information, as 
reflected in participant suggestion, and as no difficulties were identified with item 32 
it was sensible to retain. On further consideration of item 33, it was recognised that 
the wording ‘unable’ was not suited to response options that gradually increased in 
severity (i.e. you are either able or unable, rather than a bit unable) providing further 
evidence for its removal.  
 
7.5.2.2.19 Have you had to work around stiffness more than usual? (item 35): 
Understanding 
This item was acceptable to participants although one was hesitant about its wording 
and asked for clarification. 
 
“Work around, that mean like fathom out like ways of doing things? […] have you 
had to do things in a different way than usual because of your stiffness, that sounds 
better, doesn’t it, or is that me?” [2406] 
 
As identified earlier (Section 7.5.2.1.4), one participant was uncertain about the use 
of the word ‘usual’. 
Original 
item 
Have you felt embarrassed because of stiffness? 
Refined 
item 
Have you felt self-conscious because of RA stiffness? 




“Yeah. More than usual, but this is usual now […] what used to be usual is not 
what is usual now. You know, before I had arthritis” [2411] 
 
During consideration of this item, it was felt important to retain the original patient 
wording (‘work around’) that led to the development of this item. However, to improve 
clarity an example was added based on participant suggestion. Additionally, the item 
was edited for consistency with other items regarding the use of the word ‘usual’ 
(Section 7.5.2.1.4) (Box 7.20). 
 
Box 7.20: Changes to item 35 
 
7.5.2.2.20 Have you had to spend more time than usual coping (managing, 
dealing with, making do) with stiffness? (item 37) and Have you been able to 
cope (manage, deal, make do) with stiffness? (item 38): Understanding and 
Response 
Items 37 and 38 were identified as capturing similar information. 
 
“I don’t think there’s need for both” [2402] 
 
It was also highlighted by two participants that the response options for item 38 were 
inconsistent with other items in this section. 
 
“Your answers are going to be inverted here […] most of the ‘not at all’ answers 
it’s not affecting you. Here you’re saying you haven’t been able to cope at all […] 
you’re going to get a complete reversal. Here’s me been going down, no, not at 
all, not at all and suddenly it’s this, and have you been able to cope? Very much 
is the answer” [2405] 
 
“Oh dear. Yes that’s right. […] I think it’s difficult because your head at this point 
isn’t reading those [response options], so I didn’t really read what that said […] 
This [Q38] is positive isn’t it? Whereas this [Q37] is negative in a sense” [2407] 
 
These items had originally been developed to capture direct self-management (see 
Appendix O). Different wording had been used given the uncertainty regarding the 
most appropriate wording for such items (Section 6.3.2.1.2.2). The identification of 
the reversed response options was not intentional and was very important. During 
discussion with the supervisory team it was felt that this information was captured in 
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other items within the impact triad (Section 7.5.2.2.21). Therefore both items 37 and 
38 were removed to reduce the number of items and participant burden. 
 
7.5.2.2.21 Impact triad items (39-59) 
Items 39-59 were developed based on the concept of the impact triad (Sanderson et 
al, 2011). As previously discussed (Chapter 6), all items in this section were 
presented in three different formats (NRS, VAS, ordinal scale) and items developed 
to capture the self-management aspect were worded in four different ways. All items 
were discussed with participants to get a better understanding of patient preferences 
and identify the most appropriate format. To minimise repetition and discussion of 
items that were removed, this section will discuss participant comments in three 
respective sections; format, wording, and changes made to retained items.  
 
7.5.2.2.21.1 Format 
Discussion regarding preferences of item formats were broad and participants 
highlighted advantages and disadvantages of all formats. Generally, VAS were felt to 
be easy to complete and two participants suggested that they were accustomed to 
this format as it was often used as part of routine clinical assessment.  
 
“No well that’s [VAS] the same as what you do over the road [in clinic] isn’t it? […] 
we are used to doing this” [2402] 
 
Another participant felt that VAS provided more flexibility than NRS and did not 
require much thought about the appropriate response. 
 
“But I find this easier [VAS] because I don’t have to think about it. I don’t have to 
think about numbers, I can just put a mark on the line” [2407] 
 
One participant felt that VAS allowed greater honesty in response.  
 
“I think sometimes you could be possibly more honest showing the definition on 
the line […] because it is like that you try and think oh well I won’t moan or do the 
box above [on ordinal scale]” [2410] 
 
However, when discussing reasons for aversion to VAS formats, some participants 
felt VAS were imprecise, while others expressed preferences for NRS or ordinal scale 
formats. 
 
“I don’t like the lines no, I don’t mind the circles” [2401] 




“[…] you could like […] put it in the wrong place, do you know what I mean, unless 
you read it […] whereas that is more clear [NRS], and those [ordinal scale]” [2406] 
 
“I think if you grade it up to 10 it is probably easier in people’s minds […] with the 
line I’d be thinking of going into colour coded, you know like the traffic light signal, 
extreme being red” [2409] 
 
When comparing VAS to NRS, generally it was felt that NRS were easy to complete. 
 
“I’m a numbers bloke […] but I still have difficulty in knowing where to put it [NRS], 
but I would, on this [VAS], even worse, I would say” [2405] 
 
Two participants suggested that NRS or ordinal scale may be better for older people 
than VAS. 
 
“I know where I would have to put it, but you get a lot of maybe older people than 
me, they would sooner see a number there” [2404] 
 
“I think either of those [NRS or ordinal scale] is probably better than this [VAS], 
because like that could be quite confusing, especially if it’s an older person” [2406] 
 
Another participant suggested that VAS may be completed as if they were NRS.  
 
“I know really there is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, even though they’re not down 
there” [2403] 
 
Ordinal scales were suggested to be easy to complete and to decide on an 
appropriate response.  
 
“Yeah, actually I think boxes might be better for people […] because sometimes 
when I am over the road [in clinic] then I’ve got to fill one of these [VAS] out […] 
and I can’t decide” [2402] 
 
“I think these are quite easy to do like this […] I can’t imagine too many people not 
being able to read and interpret that sort of thing” [2405] 
 
Although ordinal scales were identified as being clear and easy to complete, the main 
complaint highlighted by three participants was the lack of options and flexibility in 
comparison to VAS or NRS.  
 
“Because in a sense it doesn’t give me a lot of room, does it, because it’s that gap 
in the middle again […] It won’t give me that option I’m looking for” [2403] 
 
“These two [VAS and NRS] give you more flexibility to say a little bit, a lot. So for 
example, Q46 isn’t quite as extreme as Q51, do you see what I mean, whereas if 




I was answering those two on the boxes [ordinal scale], it would be the same box” 
[2407] 
 
In contrast, one participant suggested that fewer options was an advantage.  
 
“[…] some people might not like that [bigger range of options in the NRS], they 
might like that instead [ordinal scale], do you know what I mean, because you’ve 
still got the same answers” [2406] 
 
Overall, given the limitations with VAS formats identified in the literature (Section 
6.3.2.2.1), it would have required an overwhelming preference from patients to be 
considered. Given that this was not achieved, all VAS options were removed. The 
remaining ordinal scale and NRS formats were both supported by participant 
preferences in this study and Study 2 where participants indicated that fewer options 
placed less burden on the responder and also suggested that NRS were clear 
(Section 5.5.2.4.2). However, given the total number of items, it was felt that retaining 
items in both formats would increase participant burden and may influence 




When considering the items worded in different ways, the majority of participants 
indicated that these items were similar or that there was no need for all versions. 
 
“No they mean the same. I think those really are tautology” [2401] 
 
“They’re basically saying the same, aren’t they” [2411] 
 
Only two participants defined these as distinctly different words. 
 
“[…] so this item here about dealing with, you put a 6, and then this item here about 
coping you put a 5 […] what is the difference between these for you?” [Halls] “Well, 
its best how I cope, isn’t it? […] It’s not easy to deal with it but then after that you’ve 
got to cope with it. You’ve got to deal with it first before you can cope with it […] 
because the coping is the action, that’s the way I see it” [2403] 
 
“They are three different things […] We mainly deal with it, okay and we try to cope 
with it and some people find it harder to manage […] You can cope with it, but can 
you manage it?” [2408] 
 
Others indicated slightly different definitions of different wordings but did not feel 
strongly that all three versions were necessary. 




“Managing is more about what have you done about to help yourself, whereas 
coping is, for me, is more about how have you managed to get through” [2407] 
 
“[…] everybody is going to deal, some give in more easier to some things than 
others don’t they and some say well this is a bad day, I’ll do what I got to do and 
then leave some things and I think you have just got to be sensible about it and try 
and do that haven’t you really” [2410] “Yes, so the words to you, it doesn’t matter 
which?” [Halls] “No, I mean I think you’ve put deal with it which I have been fairly, 
I have been honest about that, coping, yeah, and managing it” [2410] 
 
With regard to participant preferences there was no outright favourite. Although two 
participants disliked ‘made do’. 
 
“No I don’t think make do, it sounds a bit like ‘make do and mend’, you don’t 
remember the war when you wanted a skirt a bit longer, you stick something round 
the edge of its bottom and you couldn’t have any material because all clothes were 
rationed” [2401] 
 
“[…] you make do, whatever […] that’s how our parents grew up. They made do 
[…]” [2403]   
 
A further two participants indicated a preference for ‘deal’.  
 
“Which items would you have, if you had to design it?” [Halls] “Deal with […] and 
the others I wouldn’t have” [2402] 
 
“I think it would be just dealing with from day to day […] because it’s all for the 
same thing really isn’t it?” [2404] 
 
However, across participants ‘cope’ or ‘manage’ appeared to be the most consistently 
preferred wording. 
 
“Coping or managing. I think coping. Managing has sort of, slightly bossy lines but 
if you cope, you adapt to what you can do” [2401] 
 
“[…] that’s not bad, deal, but coped I think and managed, people would understand 
better” [2406] 
 
“I think I prefer managed […]. Although all of them do, but managed is best I think” 
[2407] 
 
In discussion and as highlighted earlier (Section 7.5.2.2.21.1), reducing the number 
of items was considered important. Therefore given patient suggestions and evidence 
from previous work where the wording ‘cope’ had been found to be effective (Nicklin 
et al, 2010a; Nicklin et al, 2010b), this item was retained.  
 




7.5.2.2.21.3 Changes made to retained items 
Following the above considerations, only four items (39, 41, 44 and 45) from this 
section were retained for further testing. Of these, minor difficulties were identified 
with items 41, 44, and 45 under the headings of Understanding and Response. These 
difficulties and the subsequent changes made to these items have been detailed 
below. 
 
7.5.2.2.21.3.1 Please circle the number that best describes how well you have 
coped with your RA stiffness (in your joints or your body, and at any time of 
day) during the past 7 days (item 41): Understanding and Response 
There was some discussion regarding the placement of the anchors in this item. 
Some participants identified that the anchors were inconsistent with the other items. 
However, this was also acknowledged as positive with regard to improving the 
accuracy of responses as it would encourage participants to read each item fully.   
 
“And this is the other end because ‘very well’ is at this end not this end this time” 
[2401] “[…] does that make more sense to be there?” [Halls] “It does to me 
because you’ve got all the goods this end and all the bad this end […] I think some 
people might find it a bit complicated […] On the other hand it might make them 
think more […] Perhaps that was why it was done” [2401] 
 
“That’s quite interesting because those are the other way round as well aren’t 
they? […] That’s quite a difficult one because you are sort of answering the same 
thing, it’s just that you are opposite” [2407] 
 
On discussion, it was felt that the anchor format for this item should be retained as it 
had been demonstrated to be effective in a validated scale (Nicklin et al, 2010a; 
Nicklin et al, 2010b). However, in an attempt to reduce any influence of the anchor 
placement on response to other items, this item was placed at the end of the section. 
Minor changes were also made to the wording of all items in this section for 
consistency (Box 7.21). 
 
7.5.2.2.21.3.2 Please circle the number that best describes the effect RA 
stiffness (in your joints or your body, and at any time of day) has had on your 
life during the past 7 days (item 44) and Please circle the number that best 
describes the overall impact on your life of RA stiffness (in your joints or your 
body, and at any time of day) during the past 7 days (item 45): Understanding 
Three participants were uncertain about the wording of this item.  
 




“[…] not everyone knows what effect is do they […] can’t you put it more simpler 
like?” [2402] “I mean we can ask how important has RA stiffness been to you?” 
[Halls] “Yeah. I think that would be better than putting effect you know” [2402] 
 
Others identified uncertainty regarding the difference between item 44 (importance) 
and item 45 (impact).  
 
“My way of thinking it is quite similar” [2409] 
 
Following discussion, the wording of item 44 was changed with ‘effect’ replaced by 
‘important’ to enhance distinction between the items. Minor changes to all impact triad 
items were made for consistency and to enhance clarity (Box 7.21). 
 
Box 7.21: Refined impact triad items (39, 41, 44, 45) 
Please circle the number that best describes the impact that RA stiffness has 










Please circle the number that best describes the severity of your RA stiffness 
over the past 7 days 
No 
stiffness 
0 1 2 3 4 5 6 7 8 9 10 
Extreme 
stiffness 
Please circle the number that best describes how important RA stiffness has 









Please circle the number that best describes how well you have coped with your 
RA stiffness over the past 7 days 
Not well  
at all 
0 1 2 3 4 5 6 7 8 9 10 Very well 
 
 
7.5.2.3 Attribution items (60-68) 
Items 60-68 (Appendix S) were developed to explore the contribution of aspects 
identified as relevant to the patient experience of stiffness in Study 1 and 2 (Chapters 
4 and 5). However, these items did not perform well during cognitive interviews. 
Although the ideas that each of the items attempted to capture were relevant to the 




patient experience, they did not appear to be effective in a measurement format and 
participants identified a number of difficulties with them. Firstly these items were 
highlighted as being worded in a difficult way. 
 
“I think ‘contributed to your experience’ is a little bit hard to get my mind round” 
[2401] 
 
“I am not quite understanding this item, I mean I do understand, I do but I don’t 
you know […] I am picking it up but I am not picking it up as easily as I was 
everything else” [2402] 
 
One participant was uncertain about the word ‘moderate’ used in the response 
options. While others suggested the wording was unnecessarily repetitive making it 
complicated. 
 
“I’ve read contribution five times and I am at two inches down the page” [2402] 
 
“The only thing I’m not so sure about though is moderate. What does moderate 
mean? […] moderate to me seems like oh only moderate, like in between” [2403] 
 
As discussed above (Section 7.5.2.1.5), participants identified difficulties with items 
that required factual information. This was highlighted in relation to the item regarding 
the influence of the weather. 
 
“[…] well do we really know? It does sometimes seem it’s the weather” [2401]  
 
This was also highlighted regarding the item about joint damage where participants 
were uncertain whether they had joint damage making it difficult to respond. 
 
“I don’t know what joint damage I’ve got, I don’t know” [2402] 
 
“Joint damage. That one is a bit hard to know because unless you have an x-ray 
or something you don’t really necessarily know, unless it is so visually obvious” 
[2409] 
 
Uncertainty was also highlighted in relation to making factual statements about the 
effect of medications. 
 
“I wouldn’t want to go into [Consultant in clinic] now and say my RA medications 
aren’t controlling my symptoms, my disease because I don’t think we know yet” 
[2407] 
 
Participants found the inexplicit nature of item 65 difficult. 




“What other RA symptoms are there?” [2401] “What would other RA symptoms 
include for you?” [Halls] “Ha ha good answer, apart from stiffness and pain, I can’t 
think of any” [2401] 
 
“Other, well, does that include pain?” [2411]  
 
Finally, some participants felt that if items were not currently relevant to them, there 
was no appropriate response option. 
 
“[…] this is a horrid one in a way to answer because I haven’t been in an RA flare 
so I suppose no contribution is what one would put” [2401] 
 
“No, see this bit don’t apply because I am not actually taking the medication that 
they required me to” [2409] 
 
Given the numerous difficulties with these items, considerable thought was given to 
their inclusion. It was decided that although these items helped understand the 
context of the patient experience of stiffness they did not provide information that 
would be useful for measurement because they were difficult to answer. Given these 
considerations and other concerns regarding the length of the overall questionnaire 
they were removed.   
 
7.5.2.4 Traditional stiffness items (69-74) 
The traditional stiffness items from the literature were included for cognitive 
interviewing as cognitive debrief did not appear to have been performed before. 
Although this process was not intended to result in changes to items as it was 
important to retain their traditional wording and format, it was felt that information 
generated here may provide information to aid decision making regarding the 
subsequent retention or removal of items in Study 4. However, given the large volume 
of items taken to cognitive interviews and that this was not the key objective of this 
study, less time was spent exploring these items than was anticipated and less data 
were generated regarding these items than other sections in the questionnaire pack. 
Despite this, a number of participant comments relating to the headings of 
Understanding and Response are described below.  
 
7.5.2.4.1 How would you describe the overall level of morning stiffness you 
have had from the time you wake up? (item 69 (VAS), item 70 (NRS), item 
71(ordinal scale)): Understanding and Response 
Some uncertainty was reported regarding the wording of ‘overall level of morning 
stiffness’.   




“How would you describe the overall morning, overall? Overall stiffness?” [2411] 
 
One participant appeared to relate the item to duration rather than severity.  
 
“Because how would you describe the overall level? […] because there’s no like 
hours there. Although down here [item 73] there is” [2409] “So would something 
like that be easier to do you think?” [Halls] “I think so, yes” [2409]  
 
Despite these considerations, no further difficulties were identified. For consistency 
with earlier discussion (Section 7.5.2.2.21.1), the item using a VAS format was 
removed. This was reinforced as appropriate by participant comments indicating that 
items with NRS and ordinal scale formats were easy to answer.  
 
7.5.2.4.2 How long does your morning stiffness last from waking until 
maximum improvement occurs? (item 72 (minutes and hours), item 74 (ordinal 
scale)): Understanding and Response 
Participants disclosed some uncertainty regarding response to this item, particularly 
in relation to item 72. One participant suggested this format was acceptable but 
imprecise and could be improved by removing the specified units of time.  
 
“Yeah, I’m not sure whether you’ll be able to put the exact amount down […] I think 
you could just put down there how long, I don’t think minutes or hours is relevant 
really” [2402] 
 
Another response suggested that the format was not clear enough that participants 
had to specify the amount of each unit.  
 
“Minutes, hours, that could be hours, okay, not minutes” [2408] 
 
Another participant highlighted that it was difficult to respond to this item for 
individuals with no stiffness because the item does not inherently provide a ‘none’ 
option. 
 
“[…] you’re leading you see, how long does your morning stiffness last?” [2405]  
As in earlier qualitative work, some participants queried the focus on morning 
stiffness, highlighting the broader nature of the experience of stiffness.  
 
“[…] it can last more or less all the day, but it usually eases up within about four 
hours” [2411] 
 




Other participants were uncertain about ‘maximum improvement’.  
 
“Maximum improvement, well, what’s maximum improvement?” [2411] 
 
In contrast, for some participants no difficulties were reported.  
 
“[…] it’s marred, you know, it gets marred or less. What I do, I got my own way of 
dealing with it. I just sit in the chair in the morning, and like come to yourself […]” 
[2406] 
 
7.5.2.4.3 Were your joints stiff when you woke up today? If yes, how long did 
this stiffness last? (item 73) 
This item was presented in one format only and appeared acceptable to participants.  
 
“About an hour” [2403] “Are those easy to answer?” [Halls] “Yes, because […] I’m 
sort of bringing it all together quickly and […] [giving the] first answer that comes 
into your head” [2403] 
 
Although large amounts of data were not collected in relation to traditional items, 
these data combined with data collected in Study 2 will inform decision making in 
Study 4. All the traditional items were taken forward for inclusion in Study 4 apart from 
item 69 which was replaced by another severity item. The item was taken from the 
preliminary flare questionnaire (PFQ) and has been demonstrated to be able to 
distinguish patients in flare from those not in flare (Bykerk et al, 2012; Bykerk et al, 
2014b). This item was not identified in the systematic literature review (Section 2.4.1) 
but was highlighted during discussion at OMERACT. Although not cognitively 
debriefed with patients it appears to be the only traditional stiffness item which 
focuses on ‘stiffness’ rather than EMS/MS, which fits with patient descriptions from 
Studies 1 and 2. Given this, and that the item was clearly defined it was felt relevant 
to include as another traditional severity item to test in Study 4. 
 
7.5.2.5 Response shift items (75-77) 
Items 75-77 were developed in an attempt to explore the response shift. Like the 
impact triad items (Section 7.5.2.2.21) these items shared wording but were tested in 
three formats (NRS, VAS, ordinal scale). Generally these items were well responded 
to by participants. Minor difficulties under the headings of Understanding and 
Response were discussed. Firstly there was uncertainty regarding a ‘usual week’ and 
the ability to identify flare.  
 




“Usual week, is there with arthritis anything such as a usual week?” [2401] 
 
“I mean I am not used to identifying the flares really” [2401]   
 
Another participant answered the item based on the anchors being reversed but this 
was clarified through discussion. Although identified as being potentially difficult, the 
item was retained but the wording was made simpler and only the NRS format was 
retained (Box 7.22). 
 
Box 7.22: Changes to response shift items 
Original: 
Thinking about a usual week when you are not in a flare (flare-up) of your RA 
please circle the number that shows your usual RA stiffness (in your joints or 









Please circle the number that best describes the severity of your RA stiffness 









7.5.2.6 Instructions, formatting and consistency  
In addition to discussion regarding specific items, it was clear that other aspects 
including wording and format also required clarification. This included the 
introduction, and general formatting and consistency aspects where changes were 
made to enhance clarity and ease of completion. These have been described below. 
 
7.5.2.6.1 Questionnaire introduction: Understanding and Judgement 
There were some difficulties regarding understanding the introduction. One 
participant was uncertain about the term joint damage due to its factual nature, as 
highlighted previously (Sections 7.5.2.1.5 and 7.5.2.3). 
 
“Yes, the only thing what throws me a little bit, it says, due to joint damage. Well 
[…] have I got joint damage or has it just grown?” [2403] 
 
Another three participants were uncertain about the instructions being given in the 
introduction and therefore what to include in their answer.  




“I could do the questionnaire […] but am I really clear in my mind […] what that’s 
asking? […] Because I wouldn’t know what to put, to be honest, now I’ve read that 
bit in brackets especially” [2403] 
 
“Don’t include the fact that I can’t straighten my arm or anything like that then?” 
[2405] 
 
Four participants questioned whether they needed to write anything in the space 
underneath the introduction. One participant had to clarify ‘RA’ and another 
questioned whether this questionnaire took pain into account. 
 
“[…] what’s RA stiffness? Oh rheumatoid arthritis! [Laughs]” [2404] 
 
“[…] do you want to know about [...] the difficulties in movement, regardless of 
pain?” [2411] 
 
It was clear that the questionnaire introduction required changes to enhance clarity. 
Refined wording was generated through discussion with the supervisory team, in 
particular with one patient partner (GB) (Box 7.23). Minor formatting changes, 
including the removal of the space below the introduction and the use of emphasis 
were made to enhance clarity.  
 
Box 7.23: Changes to questionnaire introduction 
 
In addition to the changes to the introduction, suggestions from the team indicated 
that it would be important to explore the relevance and influence of joint damage. 
Therefore two items to capture its presence and how it is reported by patients were 
developed (Box 7.24). The first additional item was developed to capture the 
presence of joint damage and was placed at the beginning of the questionnaire. The 
second additional item was developed to capture the amount of reported stiffness that 
was a result of joint damage and was placed at the end of the questionnaire. Item 
Original 
item 
This questionnaire is about stiffness related to your rheumatoid 
arthritis or RA stiffness. It will help us understand how active your 
disease is. Some people have joints that are always difficult to move 
whether their RA is good or bad (for example, due to joint damage). 
Please do not include this sort of stiffness when you answer this 
questionnaire. We would like to know how RA stiffness has affected 
you during the past 7 days 
Refined 
item 
This questionnaire is about RA stiffness that comes and goes. It is 
not about joints that are permanently stuck (for example, due to an 
operation). However, we do appreciate that sometimes even 
permanently stuck joints do get stiffer (for example, when your 
disease is bad). Please just try to think about the stiffness that comes 
and goes as you answer this questionnaire. 




wording was developed from patient descriptions from Studies 1 and 2 and the 
supervisory team including considerable input from one patient partner (GB). 
 
Box 7.24: Additional items related to the introduction 
Additional 
item 







How much of the stiffness you have reported in the items above is 
about joints that are permanently stuck? 
None of the stiffness I have reported 
 
A little of the stiffness I have reported 
 
Quite a lot of the stiffness I have reported 
 
All of the stiffness I have reported 
 
 
7.5.2.6.2 General instructions, format and consistency 
A number of changes were made to the overall questionnaire based on comments 
from cognitive interview participants and discussion with the supervisory team. Firstly, 
in relation to the layout of the questionnaire, in some instances participants found that 
they had marked the wrong response option. Consequently the layout was edited to 
include boxes for clarity and ease of response.  
 
“Oh, did you say that one was very much so?” [Halls] […] “Oh yes, got it in the 
wrong one, haven’t I?” [2406] 
 
“I think now that I’m getting down to this level here, I think you probably could do 
with a line down here as well” [2407] 
 
Secondly, as identified earlier (Studies 1 and 2), participants highlighted relationships 
between symptoms such as stiffness and pain, and between different conditions such 
as OA and RA.  
 
“I am not too sure if the stiffness affects my sleep, it is more if I am in a bit of pain 
but like I said again it is the combination of the two […]. Is it the pain or is it because 
I am stiff?” [2409] 
 
In discussion about these relationships it was felt important to reinforce the topic of 
stiffness in the context of RA throughout the questionnaire. ‘RA stiffness’ was 
incorporated into each stem question to reinforce the topic throughout the 




questionnaire. Thirdly, it was identified that some items contained the word ‘over’ 
while others used the word ‘during’ to describe the timeframe. For consistency, ‘over’ 
was decided upon and used throughout the questionnaire. Finally, other minor 
changes were made for consistency and clarity. These included replacing any double 
reinforcement with single reinforcement using bold only, and clarifying and ensuring 
appropriate placement of all instructions 
 
7.5.2.7 Final set of draft items 
During the process of cognitive interviews and subsequent review with the 
supervisory team, 36 items (5, 7, 18, 26, 27, 33, 37, 38, 40, 42, 43, 46-68, 76 and 77) 
were removed and four items were added. The final 45 draft items included 39 new 




Overall, the results from the cognitive interviews indicated that the draft RA stiffness 
PROM items were acceptable and understandable to patients with only minor 
difficulties identified. This demonstrates a key strength of the development of these 
items which involved a rigorous process of qualitative investigation that was informed 
at all stages by patients. The majority of difficulties identified fell under the heading of 
Understanding and mainly related to the identification of minor but necessary 
improvements regarding the wording and clarity of items. Although identified 
difficulties were minor, this study demonstrates the importance of using cognitive 
interviews to enhance understanding of PROM items in the intended population and 
in PROM development.  
 
Although cognitive interviewing will not identify all problems with survey items, it is 
considered that the most significant problems will be highlighted by their use (Beatty 
and Willis, 2007). If cognitive interviewing had not been performed in this study, 
difficulties would not have been detected which may have led to inaccuracies in future 
data collection. The use of cognitive interviewing is also consistent with 
recommendations in the development of PROM instruments, particularly in relation to 
the content validity (Patrick et al, 2011b). The rigorous tracking of the development 
of items within previous Chapters (4-6) was especially useful where problems were 
identified with items. The transparent item development process enabled the 
researcher to return to earlier qualitative data to check ideas and wording to ensure 




that the relevant concept was being captured or that appropriate patient language 
was included, again enhancing content validity. In addition, data generated from this 
study has provided further evidence directly from patients, regarding the format and 
wording of draft items. These results add to data generated from Study 2 and provide 
evidence to support the current literature (e.g. Section 6.3.2.2). Cognitive interviews 
also provided the opportunity to further explore patient preferences regarding the use 
of different item formats and wording. This was important to enable informed decision 
making regarding the tradeoff between rewording and removing items. An interesting 
observation from the cognitive interview process was the detection of no difficulties 
under the analysis heading of Retrieval. This is consistent with other recent work 
(Murtagh, Addington-Hall and Higginson, 2007; Nicklin et al, 2010a) and it has been 
suggested that the short timeframe (past week) employed in all these studies may 
explain this finding (Murtagh, Addington-Hall and Higginson, 2007; Nicklin et al, 
2010a). 
 
Taking forward only the items in an NRS format was a key decision. This was 
advantageous from the perspectives of practicality (Akad et al, 2013) and given the 
suggested improved psychometric properties compared with VAS (van Tubergen et 
al, 2002; Franchignoni et al, 2014). It will also reduce participant burden in Study 4. 
However, the use of an NRS scale is inconsistent with the optimal number of 
response options recommended by the seven (plus or minus two) rule (Miller, 1956, 
reprinted in 1994; Streiner and Norman, 2008) where it is suggested that participants 
are unable to discriminate responses over this recommendation. Although it was 
decided that only items in NRS format would be taken forward for further testing, both 
ordinal scale and NRS formats appeared to be acceptable to patients. Some scales 
such as the WOMAC are validated in multiple formats (Bellamy, 2005). Further 
investigation regarding item format could be explored in future research.  
 
Despite the advantages of cognitive interviewing, there are limitations of the 
approach. The value of information generated from cognitive interviews has been 
questioned given that they involve artificial environments and small sample sizes 
(Drennan, 2003). The artificial environment created by cognitive interviewing may 
result in differences in the completion of items once the researcher is not present. For 
example, each cognitive interviews lasted approximately one hour but it is unlikely 
that participants would spend that amount of time completing items in applied 
environments. Despite this, this study was just one part of an extensive PROM 
development process involving earlier qualitative (Chapters 4 and 5) and subsequent 




quantitative (Chapters 8 and 9) studies. Therefore, rather than producing entirely 
independent evidence, they instead provide evidence as part of a broader body of 
work, and cognitive interviews are most effective when used in combination with other 
validity and reliability assessment methods (Drennan, 2003).  
 
In relation to sample size, it is acknowledged that the information generated from 
cognitive interviews is qualitative rather than quantitative in nature (Drennan, 2003; 
Willis, 2005), and therefore inherently associated with small samples. As expected in 
cognitive interview studies (Willis, 2005), the participant sample in this study was 
small (n=11), although it did include participants with a range of age, gender and 
disease duration. Also acknowledging the qualitative nature of cognitive interviewing 
data, the principal of data saturation (Guest, Bunce and Johnson, 2006) was used. 
Data saturation was felt to have been reached in this study although given the 
deductive analysis approach this was based on the generation of no new difficulties 
rather than no new themes.  
 
Other limitations also relate to participant demographics. The ‘think aloud’ process 
has been suggested to be difficult for participants (von Thurn and Moore, 1994), 
particularly for certain groups of individuals such as those with low educational levels 
(Wellens, 1994). Although participants in this study did not appear to find the process 
difficult, participants were all required to be able to speak English unaided to be 
eligible to take part, and all participants indicated that they had at least a school level 
of education (Table 7.1). Therefore, the draft items have currently not been cognitively 
tested in individuals with self-defined lower levels of education or English language 
ability. However, attempts were made previously to ensure that the items were as 
understandable and accessible as possible, and met recommendations regarding 
readability (Section 6.3.2.4). Although, as acknowledged in Chapter 6, readability 
recommendations themselves have inherent limitations (e.g. Adams et al, 2013). The 
study sample is also limited by the lack of collection of information relating to ethnicity. 
Although no formal information was captured, all participants for all studies were 
recruited from hospitals in South West England and were Caucasian. Despite this, 
local colloquialisms were avoided during item development. Furthermore it would be 
expected that the conceptual underpinning of items would be relevant in broader 
populations. As discussed in Chapter 4, conceptual consistencies have been 
identified between this work and other research targeting the same topic, which also 
involved an ethnically heterogeneous participant sample (Orbai et al. 2014). 
Therefore data generated in this and preceding qualitative studies provide a good 




basis for further item development and testing. However, further development of any 
new PROM may include translation and cultural adaption (USDHHS FDA, 2009).  
 
A key strength of this study was the discussion of results with members of the 
supervisory team allowing enhanced interpretation, from a range of perspectives. 
Identifying problems with multiple reviewers is considered good practice and has 
been suggested to combat some limitations of cognitive interview such as ambiguity 
of participant responses (Conrad and Blair, 2009). Although the items were not 
cognitively debriefed in their final format, detailed discussion with the team’s patient 
partners (GB and AE) enabled development and review of items from expert patient 
perspectives. Finally the use of the COREQ reporting framework enhanced the 
transparency of the study (Tong, Sainsbury and Craig, 2007) (Appendix U). 
 
7.7 Conclusions 
This study has allowed testing and refinement of the draft RA stiffness PROM items. 
Although predominantly the changes made to these items were minor, they were 
crucial in ensuring that they were understandable and acceptable to the intended 
population. This study has demonstrated the benefits of cognitive interviewing to 
reduce reporting errors during the completion of questionnaires. The 45 draft PROM 
items are now suitable for quantitative testing and validation (Study 4). 
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Chapter 8: Developing the structure and content for an RA 
stiffness PROM (Study 4, part 1) 
Preceding chapters have described the process of development and testing of draft 
items for a new RA stiffness PROM using qualitative approaches to enhance content 
validity, and resulting in 45 draft items (39 new and six traditional). This chapter is the 
first of two describing quantitative methods to develop the most effective item 
structure for a novel RA stiffness PROM. It reports data collection and demographic 
description, then focuses on the identification of the most appropriate analysis to use 
for these data, describing the theoretical underpinning and presenting a worked 
example comparing two analytical approaches.  
 
8.1 Background 
8.1.1 Questionnaire development methodology 
The importance of combining qualitative and quantitative methods in the development 
of PROMs has been emphasised in the literature (Patrick et al, 2011b). Consistent 
with recommendations (USDHHS FDA, 2009), previous qualitative studies were 
followed by a quantitative study to test the draft items. Surveys provide an opportunity 
to systematically collect information from large samples (Groves et al, 2009). 
Therefore in this study, a survey enabled collection of responses to the draft items 
from a sample of RA patients. The development of a new PROM was based on CTT. 
CTT is grounded on the idea that a participant’s observed score is the result of true 
score plus error (DeVellis, 2012) and has traditionally dominated the field of scale 
development (Streiner and Norman, 2008). The theory of CTT is broadly applicable 
in many testing situations because its assumptions are considered easy to meet, but 
weak (not stringent) (Hambleton and Jones, 1993), which highlights some of the 
advantages and limitations of this approach. The newer, IRT framework broadly aims 
to overcome the limitations of CTT, and includes models such as Rasch (Streiner and 
Norman, 2008). The implications of using CTT are discussed in Section 8.5. The 
development of PROM using CTT requires a series of statistical analyses including 
initial assessment of the suitability of items for inclusion and exploration of whether 
the PROM contains different groups of items. This is then followed by analyses to 
identify the smallest combination of items that work well together to effectively 
evaluate stiffness (item reduction) (Pett, Lackey and Sullivan, 2003). This chapter 
describes data collection and demographic description, followed by a comparison of 
two analytical approaches to establish the most appropriate method which will then 
be used to develop and test the RA stiffness PROM (Chapter 9).  
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8.1.2 Multivariate analysis 
The family of factor analysis techniques are often used in scale development to 
identify groups of related items (Pallant, 2010). The primary functions of what is 
broadly referred to as factor analysis are 1) understanding the relationships in a set 
of items; 2) development of a structure to assess the concept of interest; 3) reducing 
the number of items by retaining only necessary items without losing information 
(Field, 2009). There are different approaches to factor analysis including confirmatory 
factor analysis (CFA) and exploratory factor analysis (EFA). CFA is useful for 
hypothesis testing, when looking to test how well an a priori model fits the data (Pett, 
Lackey and Sullivan, 2003; Field, 2009). EFA is better suited to exploring data, when 
looking to understand the most appropriate factor structure from the data (Pett, 
Lackey and Sullivan, 2003; Field, 2009). As this study was exploratory in nature, it 
adopted an EFA approach. Within EFA there are a number of different techniques 
including principal component analysis (PCA), principal axis factoring, and image 
factoring (Field, 2009). As PCA is a straightforward, well recognised and commonly 
employed approach to factor analysis (Pett, Lackey and Sullivan, 2003) it was used 
here. However, it is important to acknowledge that although PCA falls under the 
umbrella term factor analysis, it has a different underpinning mathematical method 
(Field, 2009). There is considerable debate within the methodological literature about 
the strengths and limitations of the two approaches, where some do not even perceive 
PCA to be a member of the factor analysis family (Schmitt, 2011). However, the 
method of PCA is robust and less complex than factor analysis (Field, 2009) enabling 
better understanding in applied rather than methodological contexts. Furthermore, the 
two approaches have been found to produce similar results (Stevens, 2002). With 
regards to terminology, although PCA was the approach employed in this study, much 
of the literature refers to factor analysis to describe the many approaches within the 
family of factor analysis techniques. Therefore, subsequent references to factor 
analysis refer to PCA (under the broad umbrella of factor analysis). 
 
8.1.3 The appropriateness of PCA 
PCA has many advantages including being straightforward, well recognised, 
common, accessible and stable (Pett, Lackey and Sullivan, 2003; Field, 2009; Linting 
and van der Kooij, 2012). However, there are considerations regarding its 
appropriateness. Statistical tests require certain assumptions to be met to produce 
accurate results (Field, 2009). Generally, the assumptions of parametric tests are 
appropriate for PCA (Pett, Lackey and Sullivan, 2003) which assumes that there are 
linear relationships between variables (items), and that variables are scaled at an 
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interval or ratio measurement level (Linting and van der Kooij, 2012). As the variables 
to be assessed in Study 4 were collected on a combination of scales (dichotomous, 
4-point ordinal scale, 5-point Likert scale, and 11-point NRS), it is unlikely that these 
assumptions would be met. Although variables assessed using Likert scales of five 
categories and more are often treated as continuous (e.g. Bollen and Barb, 1981), 
implications of the use of PCA with inappropriate data have been documented in the 
literature. For example, the use of Pearson’s correlation coefficients has been 
questioned (Choi, Peters and Mueller, 2010) as they can underestimate correlations 
(Olsson, 1979) and lead to inaccurate factor loadings (Bernstein and Teng, 1989). 
Given these considerations, different approaches for performing factor analysis with 
non-continuous data have been recommended. One recommendation is the use of 
polychoric correlation coefficients for variables with ordered categories and 
tetrachoric correlation coefficients for dichotomous variables, to create the correlation 
matrix (Streiner and Norman, 2008; Field, 2009). The use of tetrachoric correlations 
were clearly inappropriate for these data as only two of the 45 draft items were 
dichotomous. Polychoric correlations can be viewed as a transformation that 
stretches the response scale to produce “corrected” correlations (Lorenzo-Seva and 
Ferrando, 2014, p.884). This makes polychoric correlations more appropriate for 
dichotomous and ordinal data (Streiner and Norman, 2008). However, there are 
limitations with polychoric correlations including that they are suggested to be less 
stable than Pearson’s correlation coefficients because they are generated from a 
model-based estimate rather than generated directly (Chen and Choi, 2009). 
Furthermore, the option to produce these correlation coefficients is not provided in 
many traditional software packages (Baglin, 2014). Programmes that are available to 
generate polychoric correlations are often very basic and are unable to deal with 
missing data (BayesPCC, Choi, Chen and Kim, 2009; FACTOR, Lorenzo-Seva and 
Ferrando, 2013), and importantly expect all variables to have the same number of 
response categories (i.e. be assessed on the same scales) (Lorenzo-Seva and 
Ferrando, 2013). 
 
Another recommendation for use with ordinal data is nonlinear principal component 
analysis (NLPCA) (Linting and van der Kooij, 2012). Consistent with the aims of PCA, 
the aim of NLPCA is to understand the structure of and reduce the number of items 
in a data set (Linting and van der Kooji, 2012). The strengths of NLPCA include that 
the approach can take into account non-linear relationships between variables and 
can include items with different levels of measurement (Linting and van der Kooji, 
2012). A key limitation of NLPCA is that, similar to polychoric correlations, NLPCA is 
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not as stable as a PCA solution (Linting et al, 2007a; Linting et al, 2007b), where 
stability is defined as “[…] the degree of sensitivity of an analysis to changes in the 
data” (Linting et al, 2007b). Despite this, NLPCA does not have the same restrictions 
as polychoric correlations with regard to the number of response categories and 
missing data, enabling retention of as much information as possible. Both polychoric 
correlations and NLPCA are limited by the focus in the literature on guidance centered 
on the performance of factor analysis with continuous data (Gaskin and Happell, 
2013). Expert advice was sought through discussion with Dr. Mariëlle Linting, 
Associate Professor at Leiden University in the Netherlands, who recommended 
NLPCA as appropriate for the purposes of this study (Linting, 2015, email 
communication). Although not originally included in the plan for this research, given 
the uncertainty in the literature it was decided to run the initial analysis twice using 
both NLPCA and PCA in parallel to test their appropriateness by exploring the 
differences between the outputs of the two approaches. Following comparison and 
determination of the most appropriate analysis method, further development of the 
RA stiffness PROM and preliminary validity testing would be performed (Chapter 9).  
 
8.2 Aims and objectives 
The overall aim of this study was to use the responses to the candidate items in a 
survey of participants to develop and then test the structure of a new RA stiffness 
PROM. The specific objectives of this chapter were: 
 To present the details of the data collection survey 
 To compare PCA and NLPCA 
 To decide whether PCA or NLPCA is the most appropriate method for analysis 
of this dataset to take forward into Chapter 9 for further analysis to develop 
the structure of a new RA stiffness PROM 
 
8.3 Methods 
8.3.1 Postal survey 
Although computer assisted approaches such as internet surveys are appealing as 
they can limit measurement error and provide a time efficient survey option (Streiner 
and Norman, 2008; Groves et al, 2009), daily computer use in the target population 
(mostly >65 years) is only 42% (Office of National Statistics, 2014). Recruiting patients 
in clinic or using a postal survey enables completion of the questionnaire in paper 
format, which is likely how it would be used in research or clinical settings. The clinic 
system in the local rheumatology department is one where RA patients initiate 
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appointments when required rather than being offered them routinely (Hewlett et al, 
2005). Therefore when patients attend clinic appointments they are likely to be more 
unwell and so recruitment would sample patients with a narrower range of disease 
activity than in a postal survey. A postal survey was therefore used to sample a wider 
range of patients, and allow more rapid recruitment, as demonstrated in two previous, 
locally completed survey studies (Nicklin, 2009; Sanderson, 2009).  
 
8.3.2 Patient identification and sampling 
Ethics approval was obtained from the University of the West of England REC 
(HAS/14/10/35) and from Wales REC 4 following proportionate review (14/WA/1162). 
Inclusion criteria were a confirmed diagnosis of RA (Arnett et al, 1988; Aletaha et al, 
2010) and aged ≥18 years. Exclusion criteria were participation in earlier studies 
within this research and lack of capacity to consent. The absence of current RA 
stiffness was not an exclusion criteria, as any PROM developed needs to be able to 
differentiate those with stiffness from those without.  
 
Recruitment took place between January and March 2015 from NHS patient 
databases at the BRI and Weston General Hospital. At the BRI, the new patient 
pathway and direct access databases were used thus providing a range of disease 
duration and likely disease activity. Databases were checked for duplicate patient 
entries. Each patient was assigned a random number and patients were then selected 
in sequence until recruitment was completed. For each patient, medical records were 
checked to ascertain the inclusion criteria were met and they were not recently 
deceased. Each patient was assigned a unique identification code.   
 
Questionnaire packs (Section 8.3.3) were sent out in batches so as to meet the 
recruitment target (Section 8.3.2.1) and to ensure ease of monitoring recruitment. 
Patients were sent a questionnaire pack via post, inviting them to complete and return 
the pack in the enclosed prepaid envelope. If questionnaire packs were not returned 
within three weeks, a reminder pack was sent.  
 
8.3.2.1 Sample size 
The sample size for this study was based on considerations relating to the sampling 
and analysis approaches. A 50% response rate was expected given previous, local 
research on a similar patient population (Wilson, 2016). Published sample size 
recommendations for factor analysis are inconsistent (MacCallum et al, 1999). 
Recommendations include the minimum number of participants and the ratio of 
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participants to items. The recommended minimum number of participants vary. Some 
describe 100 as acceptable (Gorsuch, 1983) while others suggest that 100 is poor 
(Comrey and Lee, 1992), 300 is acceptable (Tabachnick and Fidell 2001), or good 
(Comrey and Lee, 1992), and >1000 is excellent (Comrey and Lee, 1992). 
Recommendations regarding the ratio of participants to items also differ, ranging from 
five to 10 (Tinsley and Tinsley, 1987) to 10-15 (Pett, Lackey and Sullivan, 2003) 
participants per item. With a maximum of 45 items (39 draft and six traditional stiffness 
items) that could be included in the analysis, approximately 225 completed and 
returned questionnaire packs would be required to meet minimum recommendations 
of five participants per item. Therefore, recruitment targeted approximately 450 
participants.  
 
8.3.3 Questionnaire pack 
A questionnaire pack was developed considering recommendations regarding 
maximising questionnaire return rates (Streiner and Norman, 2008), and with input 
from the supervisory team and patient partners. The pack contained a site-specific 
invitation letter, a patient information sheet, a questionnaire booklet, and a stamped 
return envelope. The questionnaire pack (Appendix V) included a brief introduction, 
two consent forms (one of which could be removed from the pack for the participant 
to keep for their own records) and items in three key sections; 1) clinical items; 2) 
stiffness items; and 3) demographic items. Table 8.1 provides description and 
justification of each questionnaire pack component. It also includes the full and 
abbreviated wording for each stiffness item as included in the final questionnaire pack 
(Appendix V). In subsequent reference to stiffness items, the full item wording is used 
in the text while abbreviated item wording is used in tables. The final questionnaire 
pack was reviewed on two occasions, once with the supervisory team and once with 
a patient partner (GB).  
 
Two versions of the questionnaire pack were developed with the items in different 
orders to attempt to combat bias as a result of order effect (Oppenheim, 1992). 
Questionnaire pack A was printed in blue and questionnaire pack B was printed in 
green for clarity. Questionnaire pack A was ordered as described above while in 
questionnaire pack B, half of the clinical items were included before the stiffness items 
and the rest were included before the demographic items. As the content was 
identical, only questionnaire pack A is presented (Appendix V). Alternate packs were 
sent to the randomly sequenced patients (Section 8.3.2). 
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Table 8.1: Questionnaire pack contents, full item wording, abbreviated item wording and rationale  
Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
1 Patient Global 
Assessment 
(PtG VAS) (van 
der Heijde et al, 
1993) 
Considering all the ways that 
your arthritis affects you, 
mark an X on the scale for 




The PtG is a 10cm VAS which asks 
patients to indicate how well they are 
doing with their arthritis from 0 (very 
well) to 10 (very badly). The PtG is 
taken from the validated DAS28. As 
has been identified, different wordings 
of the PtG are often used (Section 
1.4). The specific wording used in this 
study was consistent with the arthritis 
impact measurement scales (AIMS) 




Although often classified as a 
measure of disease activity 
(Anderson et al, 2011), it is also 
suggested that the PtG captures 
general health or arthritis impact 
(Kalyoncu et al, 2009; French et al, 
2013). The PtG wording used is 
consistent with the AIMS (Meenan, 
Gertman and Mason, 1980) which 
aims to capture impact. This item is 
commonly used clinically and the 
specific PtG wording is used locally 
(French et al, 2013) thus will be 
recognisable to patients. It will be 
used for describing the patient 
sample and exploring the validity of 
the draft stiffness items. 
 
Pain NRS 
(Farrah et al, 
2001; Hawker et 
al, 2011) 
Please circle the number 
which shows how much pain 




This pain item is an 11-point NRS 
which asks patients to indicate how 
much pain they have experienced 
within the last week from 0 (no pain) 
to 10 (worst possible pain). 
The pain NRS will provide a patient 
report of an important patient 
symptom. Previous research and 
earlier qualitative studies suggested 
a relationship between pain and 
stiffness therefore, this item will be 
used for describing the patient 
sample and exploring the validity of 
the draft stiffness items. The 
timeframe for this item varies 
although a 24 hour timeframe is most 
commonly used (Hawker et al, 
2011). A seven day timeframe has 
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Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
been used here for consistency with 








(Nicklin et al, 
2010a; Nicklin et 
al, 2010b)  
 
Please circle the number 
which shows your average 
level of fatigue during the 




The BRAF-NRS severity item is a 
patient self-report of fatigue severity 
over the past seven days. The item 
asks patients to circle the number 
representing their average level of 
fatigue from 0 (no fatigue) to 10 (totally 
exhausted).  
The BRAF-NRS severity item will 
provide a patient report of fatigue 
severity. Fatigue is an important 
patient symptom which has been 
suggested to relate to stiffness 
therefore, this item will be used for 
describing the patient sample and 








et al, 2012; 
Bykerk et al, 
2014b) 
 
Are you having a flare (flare-





This item was taken from the PFQ 
(Bykerk et al, 2012; Bykerk et al, 
2014b). It asks patients to report 
whether they consider their RA to be 
in flare at the present time using a 
‘Yes’ or ‘No’ response. 
 
The flare question will provide a 
patient report of whether patients 
consider their RA to be in flare at 
present. As qualitative work 
indicated that stiffness related to 
flare this item will be used for 
describing the patient sample and 







et al, 1983) 
NA NA 
 
The MHAQ is short version of the 
original 20 item HAQ (Fries et al, 
1980) assessing disability. The MHAQ 
includes 8 items, one from each of the 
8 categories in the HAQ (dressing and 
grooming, rising, eating, walking, 
hygiene, reach, grip, activities). 
However unlike the HAQ the MHAQ 
does not address the use of aids or 
The MHAQ will provide a patient 
report of perceived disability. It will 
be used for describing the patient 
sample and exploring the validity of 
the draft stiffness items. Although 
the original HAQ (Fries et al, 1980) 
was used in earlier studies, the 
MHAQ will be used here because it 
forms part of the PDAS2 scoring 
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Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
assistive devices. Patients rate each 
question with a score between 0 
(without any difficulty) and 3 (unable 
to do) with higher total scores 
indicating worse function and greater 
disability. These scores are summed 
and averaged to give a total MHAQ 
score between 0-3. 
 
algorithm (see below) and its 
condensed format reduces 





(Choy et al, 




The PDAS2 is a composite measure 
to assess patient reported RA disease 
activity. The PDAS2 includes four 
items; a PtG VAS, an EMS duration 
item with 6 response options (see 
traditional stiffness duration item D 
(item no. 6.2)), a 28-SJC on a 
mannequin displaying individual 
joints, and the MHAQ (see above). A 
simplified PDAS2 algorithm can also 
be calculated without EMS (Choy and 
Leung, 2016). The PDAS2 without 
EMS was utilised in this study to avoid 
circular reasoning. 
The PDAS2 will provide a patient 
report of disease activity. Patient 
reported assessment is essential 
given that the study is based on a 
survey where clinician based 
assessments is not possible. It will 
be used for describing the patient 
sample and exploring the validity of 
the draft stiffness items. The PDAS2 
was developed to provide 
comparable information to that 
gained in the DAS28 (Choy et al, 
2008; Choy et al, 2015; Anderson et 
al, 2011) and has demonstrated 
strong correlations with DAS28 
(rs=0.76, p not reported) (Choy et al, 
2008).  
 
2 Draft stiffness 
items 
Please circle the number 
that best describes the 
severity of your RA stiffness 
over a usual week when you 




The draft stiffness items have been 
developed during previous qualitative 
studies, as described in earlier 
chapters. 
The 45 draft stiffness items are 
included to develop the structure of 
the final combination of items that 
work best together, followed by 




Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
Do you have any joints that 
are permanently stuck? 
 
Draft item stuck 
joints 
Over the past 7 days when 





Have you experienced RA 
stiffness in your joints over 
the past 7 days? 
 
Draft item in 
joints 
Over the past 7 days have 
you experienced RA 
stiffness all over? 
 
Draft item all 
over 
Over the past 7 days has 
your RA stiffness been 






Over the past 7 days has 
your RA stiffness been as 
variable (coming and going) 




Over the past 7 days have 
you experienced RA 
stiffness after a period of 
immobility (for example, 
after sitting for a while)? 
 
Draft item after 
immobility 
Have you experienced RA 
stiffness in your body 




Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
(outside of your joints) over 
the past 7 days? 
 
Has RA stiffness affected 
your sleep? 
 
Draft item sleep 
Has RA stiffness made it 
difficult to dress or undress 
yourself? 
 
Draft item dress 
Has RA stiffness made it 
difficult to wash yourself (for 
example, have a shower)? 
 
Draft item wash 
Has RA stiffness made it 






Has RA stiffness made it 
difficult to do your daily tasks 
or activities? 
 
Draft item daily 
tasks 
Has RA stiffness made it 
difficult to chew? 
 
Draft item chew 
Has RA stiffness made it 
difficult to do hobbies or 




Has RA stiffness made it 
difficult to get out of bed? 
 
Draft item get 
out of bed 
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Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
Has RA stiffness made it 
difficult to get up after sitting 
for a while? 
 
Draft item get 
up after sitting 
Have your daily tasks and 
activities required more 
effort because of RA 
stiffness? 
 
Draft item effort 
Has RA stiffness made you 
slower (for example, unable 




Has RA stiffness made it 
difficult to do fine 
movements (for example, 
write with a pen)? 
 
Draft item fine 
movement 
Has RA stiffness made it 
difficult to grip or hold 
things? 
 
Draft item grip 
Has RA stiffness made it 





Has RA stiffness reduced 




Has your movement been 







Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
Has RA stiffness made it 






Have you had to concentrate 
to move your body because 




Have you felt frustrated 




Have you felt worried or 





Have you felt self-conscious 




Has it taken you longer to do 
your daily tasks or activities 
because of RA stiffness? 
 
Draft item take 
longer 
Have you had to change 
your plans or behaviour 




Have you had to work 
around your RA stiffness (or 
do things in a different way)? 
 




Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
Have you needed help (from 
others or gadgets) because 
of RA stiffness? 
 
Draft item need 
help 
Please circle the number 
that best describes the 
impact that RA stiffness has 





Please circle the number 
that best describes the 
severity of your RA stiffness 




Please circle the number 
that best describes how 
important RA stiffness has 
been in your life over the 




Please circle the number 
that best describes how well 
you have coped with your 





How much of the stiffness 
you have reported in the 
questions above is about 
joints that are permanently 
stuck? 
 














How would you describe the 
overall level of morning 
stiffness you have had from 
the time you wake up? 
Traditional item 
severity A 
This is an 11-point NRS which asks 
patients to indicate the overall level of 
MS from waking from 0 (no stiffness) 
to 10 (very severe stiffness). The 
specific wording comes from the Bath 
Ankylosing Spondylitis Disease 
Activity Index (BASDI) which is a 
validated composite score used in AS 
(Garrett et al, 1994). The NRS 
anchors have been used in previous 
studies (e.g. Rhind, Unsworth and 
Haslock, 1987; Hazes, Hayton, and 
Silman, 1993). 
 
As described earlier (Section 
6.3.2.1.4) it has been suggested that 
stiffness assessed in the form of 
severity has better measurement 
properties than duration (e.g. 
Westhoff et al, 2008; Lie et al, 2014) 
despite being less commonly 
assessed (Cutolo, 2011).  
 
Poor definition of stiffness items is 
common in the literature (Section 
2.3.1). Wordings, response options 
and formats of traditional severity 
items used in this study have been 
based on defined items used in the 
literature where possible. 
Adjustments have been in 
circumstances where items were not 
defined. For example the use of the 
wording from the BASDAI (Garrett et 
al, 1994) which has also been used 
in studies involving RA patients (e.g. 
Lie et al, 2014). The stiffness 
severity item B which was based on 
a VAS has not been included here 
for reasons discussed in Chapter 7.  
 
These traditional stiffness severity 
items will be included in further 
testing to identify the smallest 
combination of items that perform 
most effectively to assess stiffness.  
Circle the number that best 
describes the stiffness (all 
over or in your joints) you felt 
due to your rheumatoid 
arthritis during the last week 
Traditional item 
severity G 
This is an 11-point NRS which asks 
patients to indicate stiffness during the 
last week from 0 (no stiffness) to 10 
(extreme stiffness). This item is taken 
from the PFQ and has been 
suggested to be able to distinguish 
patients reporting being in flare from 
those reporting not being in flare 
(Bykerk et al, 2012; Bykerk et al, 
2014b). This item was not originally 
included for testing (Chapter 6) 
however, as detailed previously 
(Section 7.5.2.4) the wording for this 
item is clearly defined and fits with 
patient descriptions of stiffness 





Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
How would you describe the 
overall level of morning 
stiffness you have had from 
the time you wake up? 
Traditional item 
severity C 
This item asks patients to indicate the 
overall level of MS from waking using 
the same wording as item 12.1, 
derived from the BASDAI (Garrett et 
al, 1994). The response options are a 
5-point Likert scale from no stiffness 
to very severe stiffness, as used in 
previous studies (e.g. Rhind, 
Unsworth and Haslock, 1987). 
 
Were your joints stiff when 
you woke up today? If yes, 





This item asks patients to indicate 
whether their joints were stiff on 
waking today, and if so the 
subsequent duration within six 
possible response options between 
‘less than 30 minutes’ to ‘all day’. This 
item has been included in a number of 
validated composite scales including 
the RADAI (Stucki et al, 1995; 
Fransen et al, 2000; which was 
modified from RADAR (Mason et al, 
1992)), and the PDAS2 (Choy et al, 
2008; Choy et al, 2015). 
 
Stiffness assessed in the form of 
duration is recommended in the ACR 
guidelines for RA management 
(American College of Rheumatology 
subcommittee on rheumatoid 
arthritis guidelines, 2002) and is the 
most common stiffness assessment 
method in trials (Cutolo, 2011). This 
is despite the suggestion that 
stiffness assessed by severity has 
better measurement properties (e.g. 
Westhoff et al, 2008).  
 
Traditional duration items have used 
a number of different wordings and 
formats, although the exact wording 
and format are rarely described in 
studies (Section 2.3.1). Wordings, 
response options and formats of 
traditional severity items used in this 
study have been based on defined 
items used in the literature where 
possible. 
How long does your morning 
stiffness last from waking 




This item asks patients to indicate the 
duration of MS from waking to 
maximum improvement. The wording 
is in accordance with ARA guidelines 
(Arnett et al, 1988), has been 
employed in other research (e.g. Vliet 
Vlieland et al, 1997; Khan et al, 2009), 
and was found to be most effective 
compared to other similar items 
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Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
(Hazes et al, 1994). The item provides 
three possible response options (‘up 
to 1 hour’, ‘1-3 hours’, and ‘more than 
3 hours’). These options had been 
used in categorisation of responses in 
the literature (Hazes et al, 1994). 
 
 
As with the traditional stiffness 
severity items, these traditional 
duration items will be included in 
further testing to identify the smallest 
combination of items that perform 
most effectively to assess stiffness.  
 
 
How long does your morning 
stiffness last from waking 




This item asks patients to indicate the 
duration of MS from waking to 
maximum improvement and is 
consistent with the wording of item 
12.2. The item provides response 
options in minutes and/or hours. This 
format has been used in previous 
studies (e.g. Rhind, Unsworth and 
Haslock, 1987; Vliet Vlieland et al, 
1997).  
 
3 Gender Are you male or female?  
 
NA Simplified wording for this item was 
adapted from the 2011 census 
 
The demographic items are required 
to enable description of the sample. 
Specifically, it is important to be able 
to compare the sample in this study 
to the samples involved in 
questionnaire development and also 
compare responders and non-
responders to inform the 
generalisability of the study findings.  
 
Age What is your date of birth? 
 
NA Simplified wording for this item was 




Approximately how long 
have you had rheumatoid 
arthritis (RA)?  
 
NA Wording of this item was adapted from 




What medications are you 
taking for your RA?   
NA Wording of this item was adapted from 




Section Item/scale Full wording Abbreviated 
wording 
Source/content Rationale 
Co-morbidities Do you have any other 
medical conditions for which 
you are receiving treatment? 
 
NA Wording of this item was adapted from 
a recent survey conducted within the 
department 
Work status What is your work status?  
 
NA Simplified wording for this item was 
adapted from the 2011 census and a 
recent survey conducted within the 
department 
 
Education level What is your level of 
education? 
NA Simplified wording for this item was 
adapted from the 2011 census and a 
recent survey conducted within the 
department 
 
Postcode What is your postcode? NA Wording of this item was adapted from 
a recent survey conducted within the 
department 




8.3.3.1 Index of multiple deprivation 
Postcode data were collected to obtain a measure of deprivation. Socioeconomic 
factors were recognised as an important topic in relation to outcome measures in the 
OMERACT equity special interest group (O’Neil et al, 2014). These data, alongside 
other demographic data, characterised the patient sample in which the new stiffness 
PROM was developed. This information will be useful to identify areas for future 
development and validation of any new PROM.  
 
Deprivation information was collected using the index of multiple deprivation (IMD). 
The IMD is a measure of deprivation calculated from seven weighted domains; 
income (22.5%), employment (22.5%); health and disability (13.5%); education, skills 
and training (13.5%); barriers to housing and services (9.3%); crime (9.3%); and living 
environment (9.3%) (Department for Communities and Local Government, 2011). The 
IMD represents the level of deprivation in specific geographical areas or ‘lower layer 
super output areas’ (LSOA’s). There are 32,482 LSOA’s in England which are ranked 
from one (most deprived) to 32,482 (least deprived). IMD scores represent the whole 
LSOA and may not be directly applicable to an individual within that area. GeoConvert 
(GeoConvert, 2007), a free online tool that can match postcodes to measures of 
deprivation was used to generate IMD 2010 scores. IMD scores for the whole sample 
were converted into categories with category one representing the least deprived 
scores (lowest 20%) and category five the most deprived scores (81-100%), (other 
categories; category two (21-40%); category three (41-60%); category four (61-
80%)). These categories are therefore relative, limited to the geographical area in 
which the participants live.  
 
8.4 Analysis and results 
A 4-stage analysis plan was devised to ensure an organised and directed approach 
to data analysis. Stage 1 involved data cleaning and descriptive statistics. Stage 2 
involved identification of an appropriate analysis method. Stage 3 and 4 focused on 
the development of the new RA stiffness PROM and preliminary validity testing and 
are presented in Chapter 9. The description of each analysis stage is followed directly 
by its results. 
 
8.4.1 Stage 1 analysis: Data cleaning and descriptive statistics 
An Excel spreadsheet was developed for study management to monitor the sending 
and return of questionnaire packs. SPSS for Windows (version 21) was used for data 




management and analysis. Each questionnaire pack was reviewed by hand by the 
researcher. Data gathered using existing instruments (PDAS2 and MHAQ) were 
scored according to the authors’ instructions using Excel formulae. All data were then 
entered into SPSS according to a codebook which was developed to aid consistent 
data input (Pallant, 2010). Within SPSS, descriptives and frequencies, correlations, 
and the factor analysis and categorical principal component analysis (CATPCA) 
programmes were used.  
 
8.4.1.1 Data cleaning 
The dataset was inspected for error as a result of data input. Frequency distributions 
were generated for each variable and inspected for minimum and maximum values, 
and missing values. Identified potential errors were checked in the original 
questionnaire pack and if necessary corrected in the database. Following correction, 
frequencies and descriptives were repeated for each variable.   
 
8.4.1.2 Descriptive statistics 
Descriptive statistics were performed to enable characterisation of the sample and to 
compare responders and non-responders. Given the nature of these data, medians 
and interquartile ranges (IQR) were reported and variables were described using 
frequencies and percentages. As some variables were continuous in nature (e.g. 
age), or could be classed as interval (e.g. pain assessed on an 11-point NRS), the 
extent to which these variables met the assumptions of normality was explored using 
measures of skew and kurtosis, and the Kolmogorov-Smirnov statistic. However, in 
large samples, these tests are often too sensitive and inspection of the histogram is 
recommended (Tabachnick and Fidell, 2007). Where variables demonstrated 
reasonably normal distributions and values on the Q-Q plot fell near to or on the 
straight line, mean and standard deviations were also reported.  
 
8.4.1.3 Missing data 
Errors such as missing information are common in self-completed surveys (Silman 
and Macfarlane, 2002), although the pattern of missing data may be more relevant 
than the amount (Tabachnick and Fidell, 2007). For this study, it was important to 
identify any items with large amounts of missing data as this would be taken into 
account during decision making about the usefulness of items during analysis stages 
2 and 3. It was also relevant for analyses where decisions are required regarding the 
use of listwise (include only cases with a complete dataset across all variables) or 




pairwise (include only cases with a complete dataset for specific variables) treatment 
of missing values (Pallant, 2010). Frequency outputs and pattern analysis were used 
to identify missing values. Missing values up to 5% were defined as acceptable as 
this amount is not likely to cause serious problems in large datasets (Tabachnick and 
Fidell, 2007). Items that were marked by participants as not being relevant were 
coded differently (8888) from items that were left blank (9999). As the reason for an 
item being left blank is unknown these were always treated as missing (9999).  
 
8.4.2 Stage 1 results: Data cleaning and descriptive statistics 
8.4.2.1 Data cleaning 
Seven variables had incorrectly entered values which were corrected. Histograms and 
investigation into normality (e.g. Q-Q plots) for non-stiffness variables are available in 
Appendix W. Frequency and distribution graphs for all draft stiffness items are 
presented in Section 8.4.4.1.2. 
 
8.4.2.2 Descriptive statistics 
8.4.2.2.1 Study population 
Of 645 questionnaire packs sent in seven batches, 197 were returned without a 
reminder, a further 80 were returned following a reminder and two were duplicates, 
giving an overall response rate of 43.1% (n=277) (Figure 8.1). 
 
 
Figure 8.1: Recruitment flow diagram 




8.4.2.2.2 Responder and non-responder demographic information 
Frequencies and percentages for gender, age and social deprivation were similar 
between responders (participants) and non-responders (Table 8.2).  
 
Table 8.2: Demographic information across whole sample 
  Whole 
sample  
(n = 643)* 
Responders  
(n = 277)* 
Non-
responders  
(n = 366)* 
Gender 
count (%) 
Female  465 (72.3%) 186 (67.1%) 279 (76.2%) 































2 197 (31.1%) 84 (30.8%) 113 (31.3%) 
3 80 (12.6%) 28 (10.3%) 52 (14.4%) 
4 52 (8.2%) 15 (5.5%) 37 (10.2%) 
5 (Most deprived) 32 (5.0%) 12 (4.4%) 20 (5.5%) 
*GeoConvert unable to match 9 postcodes (whole sample n=634; responders n=273; non-
responders n=361) 
 
8.4.2.2.3 Participant disease and medication demographic information 
Participants were representative of an RA population; mostly female and >45 years 
of age. Gender and age were similar to reports from other recent surveys (74% 
female, mean age=63.5 years, Wilson et al, 2015; 75% female, mean age=60 years, 
Hammond et al, 2015). Participants had a range of disease duration (n=271, 
median=6 years, IQR=3.0-15.0 years) and most frequently reported taking DMARDS, 
while 20% were taking biologics. The majority (80.2%) reported taking medication for 
other comorbidities (Table 8.3). A small number of participants reported that they had 
conditions where stiffness was a feature, including OA (n=4), PMR (n=1), AS (n=1). 
This will be addressed in the discussion. 
 
Disease activity was assessed using PDAS2 (Choy et al, 2008, Choy et al, 2015). 
PDAS2 scores demonstrated a range of disease activity (range 2.7-6.9, median=4.1, 
IQR=3.2-5.0). Categorisation of scores was based on established cut-offs from 
previous validation work (Leung et al, 2012). Although 38.5% (n=106) were in 








Table 8.3: Participant demographic information 
Variable Frequency Percent Missing 
Gender   0 
Male 91 32.9%  
Female 186 67.1%  
Age   0 
<44 16 5.8%  
45-64 119 43.0%  
65-74 78 28.2%  
>74 64 23.1%  
Disease duration   6 
≤2 45 16.6%  
3-<5 60 22.1%  
5-<10 58 21.4%  
10-20 68 25.1%  
>20 40 14.8%  
Medications   8 
Analgesics and NSAIDS 104 38.7%  
DMARDs 219 81.4%  
Glucocorticoids 98 36.4%  
Biologics 55 20.4%  
Comorbidities   33 
None  






2 other conditions 64 26.2%  
3 or more other conditions 35 14.3%  
Disease activity (PDAS2)   0 
Remission (<3.8) 106 38.3%  
Low disease activity (3.8-4.5) 65 23.5%  
Moderate disease activity (4.6-5.0) 26 9.4%  
High disease activity (>5.0) 80 28.9%  
Disability (MHAQ)   0 
Normal (<0.3) 112 40.4%  
Mild functional loss (0.3-<1.3) 120 43.3%  
Moderate functional loss (1.3-1.8) 32 11.6%  
Severe functional loss (>1.8) 13 4.7%  
Patient global assessment (PtG)   2 
0-39 (mild) 141 51.3%  
40-69 (moderate) 89 32.4%  
70-100 (severe) 45 16.4%  
Pain    0 
0-3 (mild) 104 37.5%  
4-6 (moderate) 87 31.4%  
7-10 (severe) 86 31.0%  
Fatigue (BRAF-NRS)   0 
0-3 (mild) 75 27.1%  
4-6 (moderate) 94 33.9%  
7-10 (severe) 108 39.0%  
 
Patient reports of perceived disability were captured using the MHAQ (Pincus et al, 
1983), demonstrating a range of disability (range 0-2.5, median=0.5, IQR=0.1-1.1). 
Categorisation of scores was based on established cut-offs from previous validation 




work (Maska, Anderson and Michaud, 2011). Mild functional loss (n=120, 43.3%) was 
most frequently reported. A range of scores in relation to pain (NRS, median=5.0, 
IQR=2.0-7.0), fatigue (NRS, median=6.0, IQR=3.0-7.0) and PtG (100cm VAS, 
median=36.0, IQR=16.0-59.0) were also reported, and 102 (37%) participants 
reported being in flare. These variables will be explored further in Chapter 9. 
 
8.4.2.2.4 Participant sociodemographic information 
Most participants were retired (n=146, 52.9%) but 80 (29.0%) were in paid work 
(Table 8.4). A small group of participants reported a combination of responses (n=17, 
6.2%), most commonly retired and receiving incapacity benefits (n=11). Of the 257 
participants who reported their education level, 54.1% had a school education. A 
range of IMD scores were included in the sample (range 0.99-69.65, median=14.2, 
IQR=9.4-25.7), although most participants resided in areas of low deprivation (Table 
8.2).  
 
Table 8.4: Participant sociodemographic information 
 Frequency Percent Missing 
Work status    1 
Student 0 0.0%  
Paid work 80 29.0%  
Homemaker 4 1.4%  
Unemployed 7 2.5%  
Retired 146 52.9%  
Receiving incapacity benefits 22 8.0%  
Combination of responses 17 6.2%  
Education level    20 
Did not complete school 2 0.8%  
School education 139 54.1%  
College/apprenticeship 62 24.1%  
University 54 21.0%  
 
8.4.2.3 Missing data  
Overall the number of missing values for the draft stiffness items was small with only 
232 of the 12,465 total values missing (1.9%), although 40 of the 45 draft stiffness 
items (88.9 %), and 104 of the 277 participants (37.6%) had at least one missing 
value. Pattern analysis identified only two items with >5% missing data. Both were 
traditional stiffness items asking ‘How long does your morning stiffness last from 
waking until maximum improvement occurs?’, one on a ordinal scale (n=39, 14.1%), 
the other with minutes and hours as the response option (n=56, 20.2%). Most 
participants had no missing stiffness values (n=173, 62.5%). Of the 104 participants 
with missing values, most (n=80, 76.9%) had <5% (representing one or two missing 




values). The remainder had three to eight missing values (n=24, 23.1%), except one 
participant who had 26, accounting for 11.2% of all missing stiffness values.  
 
For non-stiffness items, pattern analysis identified only one item (13.7, education 
level) with missing data over >5% (n=20, 7.2%). Missing data was therefore generally 
limited to specific items or participants. As information on missing data was being 
considered in item suitability decision making (Section 8.4.4.1.1), data were not 
imputed. Given the spread of missing data across approximately one third of 
participants, pairwise treatment of missing data was used to maximise the dataset.  
 
8.4.3 Stage 2 analysis: Identification of an appropriate analysis method 
Given the considerations regarding the appropriateness of PCA for this dataset 
(Section 8.1.3), it was important to test the two proposed approaches and select the 
most appropriate method. To do this, both PCA and NLPCA were performed in 
parallel. This involved five steps: 1) assess item suitability; 2) preliminary analysis; 3) 
component extraction; 4) component rotation; 5) compare the approaches. The 
sections that follow describe each step. Aspects relevant to both PCA and NLPCA 
have been described together, aspects specific to each analytical approach have 
been addressed separately where relevant. 
 
8.4.3.1 Assess item suitability  
The aim of this step was to ensure that items were suitable to take forward for PCA 
and NLPCA and before moving on to preliminary analysis, a decision was made about 
whether to retain or remove items. Decisions were based on the acceptability of items 
for both PCA and NLPCA but removal of items was conservative to ensure that as 
many items as possible were retained for further analysis. A consideration relevant 
for both analyses was missing data therefore items with large amounts of missing 
data were considered for removal.  
 
8.4.3.1.1 PCA  
The premise of PCA is the identification of different groups of related items (Pallant, 
2010). Items assessing the same concept will correlate with each other whilst items 
addressing different concepts will correlate poorly. A Pearson’s correlation coefficient 
matrix is one of the first parts of a PCA output and can be used to explore the 
relationship between items. It is recommended that the correlation matrix is screened 
for very low (r<0.30) or very high (r≥0.80) correlations (Pett, 1997; Pett, Lackey and 




Sullivan, 2003; Field, 2009). However, as multicollinearity (very high correlation) does 
not affect PCA (Field, 2009), only items with many correlations below <0.3 were 
considered for removal (Field, 2009). Recognising that this is an arbitrary cut-off 
(Field, 2009), for the purpose of this study any item which had correlations <0.3 with 
more than 36 of the 45 items (80%) was considered for removal. 
 
Other considerations are the frequency and distribution of data. Factor analysis 
requires roughly normal distributions (Field, 2009) and discussion with a statistician 
(Rosemary Greenwood, Research Design Service) highlighted that items with a large 
number of responses in one response category only may cause difficulties with 
analysis and are unlikely to be useful. Frequency tables and distribution graphs were 
performed for each item and inspected for the spread of responses across categories. 
Any item with a response category containing 50% or more of the responses to that 
item was considered for removal.  
 
8.4.3.1.1 NLPCA 
Although both NLPCA and PCA generate a correlation matrix, in NLPCA calculations 
are not based on the correlation matrix as in PCA but are generated directly from the 
data themselves (Linting and van der Kooij, 2012) so the correlation matrix is not as 
important. To assess item suitability in NLPCA, the key consideration is the frequency 
of responses in each category as low frequencies can lead to unstable solutions or 
inflated influence on the quantification process. The number of observations per 
category to ensure stability may vary (Linting and van der Kooij, 2012) but a minimum 
of eight has been recommended (Markus, 1994, in Linting and van der Kooij, 2012). 
Frequency tables and distribution graphs were therefore used to identify items with 
response categories with low frequencies.  
 
Overall, the suitability criteria for items across PCA and NLPCA included missing 
responses, distributions and frequencies, and correlations. These data are 
consolidated in Section 8.4.4.1.4.  
 
8.4.3.2 Preliminary analysis 
This step reviewed the initial output from each analysis method. This provided an 
indication as to whether the data were appropriate from a statistical perspective, in 
other words to explore whether the data were factorable (Pett, Lackey and Sullivan, 
2003). 
 





Two criteria were reviewed: Bartlett’s test of sphericity and Kaiser-Meyer-Olkin (KMO) 
measure of sampling adequacy (Kaiser, 1970, in Field, 2009). Bartlett’s test of 
sphericity assesses whether the correlation matrix is an identity matrix, meaning there 
is no correlation among items, and should be large and significant (Pett, Lackey and 
Sullivan, 2003; Field, 2009). The KMO is an indicator of the strength of the overall 
relationship between items (Pett, Lackey and Sullivan, 2003) and is useful given the 
variable sample size recommendations for factor analysis (Section 8.3.2.1). It is 
suggested that KMO values between 0.5-0.7 are ‘mediocre’, values between 0.7-0.8 
are ‘good’, values between 0.8-0.9 are ‘great’, and values >0.9 are ‘superb’ 
(Hutchenson and Sofroniou, 1999). As recommended, the KMO was also inspected 
for individual items using the anti-image matrices output and items with diagonal 
elements <0.5 were considered for removal (Field, 2009). 
 
8.4.3.2.2 NLPCA 
One of the advantages of NLPCA is the ability to take into account data at different 
levels of measurement (e.g. ordinal). The specification of the level of analysis defines 
the freedom allowed in the category quantifications (Linting and van der Kooij, 2012). 
Whilst the level of analysis does not need to match the level of measurement of a 
variable, it is a relevant consideration because increased freedom reduces the 
stability of solutions (Linting and van der Kooij, 2012). The nominal analysis level 
allows the most freedom and is useful if exploring nonmonotonic relationships (where 
variables do not increase or decrease at the same rate as each other). The ordinal 
analysis level allows slightly less freedom, allowing maintenance of category order, 
but assumes relationships between variables may not be linear. Numeric analysis 
level allows the least freedom and as in PCA assumes linear relationships between 
variables (Linting and van der Kooij, 2012).  
 
Expert advice recommended that variables should only be given enough freedom to 
adequately describe the data, thus initially the lowest level of analysis (nominal) 
should be specified and gradually restricted if appropriate (Linting, 2015, email 
communication). Therefore as recommended, the analysis level was initially specified 
as nominal for all variables but was also tested with more restricted analysis levels. 
Variance accounted for (VAF) is an important indicator of fit that is represented by 
eigenvalues (Field, 2009; Linting and van der Kooij, 2012).  Eigenvalues are indicators 
of the size of a component (Field, 2009) as they represent the VAF by all of the items 
that make up that component (Pett, Lackey and Sullivan, 2003). If VAF does not show 




significant improvement as a result of allowing more freedom then a more restricted 
analysis level would provide more stability, simpler interpretation of the relationship 
between variables, and less risk of capitalising on chance (Linting and van der Kooij, 
2012). 
 
8.4.3.3 Component extraction 
This step involved determination of whether separate factors or components were 
present (the term ‘component’ is used for consistency across PCA and NLPCA). 
Components are subsets or groups of the original items and are based on 
eigenvalues (Pett, Lackey and Sullivan, 2003). Both PCA and NLPCA define the 
number of components present in the dataset but use slightly different approaches. 
In NLPCA, the number of components is specified for the analysis but in PCA it is 
generated by the analysis (Field, 2009; Linting and van der Kooij, 2012). However, as 
the number of components to retain was not directly relevant to decisions regarding 
the most appropriate analytical approach to use, this has not been explored in detail 
here but is discussed in Chapter 9. 
 
8.4.3.4 Component rotation 
Unrotated solutions are often not meaningful or easy to interpret (Pett, Lackey and 
Sullivan, 2003) and rotation produces a simpler and more interpretable solution by 
maximising high item loadings and minimising low item loadings (Field, 2009). The 
goal of rotation is a simple structure where each item has a high or meaningful loading 
on one component, and each component has high or meaningful loadings for only 
some of the items (Pedhazur and Schmelkin, 1991). Weak loadings have been 
defined as ≤0.30 (Hair et al, 1995) or <0.30 (Comrey and Lee, 1992), but Pett et al. 
(2003) suggest suppressing loadings <0.40 when evaluating outputs. In this study, 
loadings ≥0.40 are defined as high or meaningful.  
 
There are two types of component rotation; orthogonal and oblique. Within each type 
of rotation there are different methods, which have different ways of rotating the 
components (Field, 2009). As the appropriateness of different approaches to rotation 
have been discussed in the literature (e.g. Pett, Lackey and Sullivan, 2003), both 
orthogonal (varimax) and oblique (promax) approaches to rotation were tested and 
compared (Pett, Lackey and Sullivan, 2003; Field, 2009). Varimax is the most 
common orthogonal rotation method (Pett, Lackey and Sullivan, 2003) which works 
by maximising high loadings and minimising low loadings to improve interpretability 




(Tabachnick and Fidell, 2001; Field, 2009). Promax aims to produce a clear structure 
but allows correlations between components (Tabachnick and Fidell, 2001). 
 
The options for rotation can be selected during the PCA procedure but, for NLPCA 
the CATPCA programme does not allow rotation. As recommended (Linting and van 
der Kooij, 2012), the transformed variables produced in NLPCA were saved and 
subject to rotation within the factor analysis programme.  
 
8.4.3.5 Comparing the two statistical approaches 
This step compared the findings from PCA and NLPCA to inform the decision about 
the analysis method to take forward to stage 3 analysis. Four aspects of PCA and 
NLPCA are directly comparable; eigenvalues; component loadings; communalities; 
and component scores (Linting and van der Kooij, 2012).  
 
As explained earlier, eigenvalues are indicators of the importance of a component 
(Field, 2009) as they represent the VAF by all of the items that make up that 
component (Pett, Lackey and Sullivan, 2003). As VAF is an important indicator of fit 
(Linting and van der Kooij, 2012), eigenvalues and VAF were compared across 
analyses. Following discussion with the supervisory team it was also considered 
important that VAF across rotated components was similar to reflect the conceptual 
importance of the components and enhance stability and robustness of components 
in further testing. Rotated component loadings demonstrate the correlations between 
the quantified variables and the components (Linting and van der Kooij, 2012). Given 
that rotated solutions are more meaningful and easier to interpret (Pett, Lackey and 
Sullivan, 2003), the rotated solutions were compared across analyses. Communality 
is the proportion of common variance in a (quantified) variable that is shared with 
other variables (Field, 2009; Linting and van der Kooij, 2012). As communalities are 
indicators of shared common variance (Field, 2009), communalities for each item 
were compared across analyses. Although component scores are consistent outputs 
across methods, they are particularly useful for interpretive purposes and primarily 
used for investigation at an individual participant level for example, whether groups of 
participants with certain characteristics score highly on certain components. Given 
the purpose of this part of the analysis, this was not felt to be relevant at this stage 
therefore, component scores were not considered. Therefore, four criteria were used 
to compare PCA and NLPCA; 1) eigenvalues and VAF; 2) VAF across components 
3) component loadings; and 4) communalities. 
 




8.4.4 Stage 2 results: Identification of an appropriate analysis method 
8.4.4.1 Assess item suitability 
8.4.4.1.1 Missing responses 
Due to missing data, both traditional stiffness items asking ‘How long does your 
morning stiffness last from waking until maximum improvement occurs?’ using 
different response options (ordinal scale and minutes and hours) were considered for 
removal. 
 
8.4.4.1.2 Distribution and frequencies 
Frequency and distribution graphs were generated for each of the 45 items, including 
the draft stiffness items (Figures 8.3-8.41) and traditional stiffness items (Figures 
8.42-8.47). Response categories containing over 50% of all responses, or less than 
eight responses per category are highlighted in red and are listed in Table 8.5. 
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distribution graph 
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Figure 8.7: Frequency and 
distribution graph 
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Figure 8.9: Frequency and 
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distribution graph 









Figure 8.13: Frequency and 
distribution graph 
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distribution graph 
  
Figure 8.15: Frequency and 
distribution graph 
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distribution graph 









Figure 8.19: Frequency and 
distribution graph 
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distribution graph 









Figure 8.25: Frequency and 
distribution graph 
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Figure 8.29: Frequency and 
distribution graph 









Figure 8.31: Frequency and 
distribution graph 
Figure 8.32: Frequency and 
distribution graph 
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distribution graph 
Figure 8.34: Frequency and 
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Figure 8.35: Frequency and 
distribution graph 









Figure 8.37: Frequency and 
distribution graph 
Figure 8.38: Frequency and 
distribution graph 
  
Figure 8.39: Frequency and 
distribution graph 
Figure 8.40: Frequency and 
distribution graph 
  
Figure 8.41: Frequency and 
distribution graph 
Figure 8.42: Frequency and 
distribution graph 
 





Figure 8.43: Frequency and 
distribution graph 
Figure 8.44: Frequency and 
distribution graph 
  
Figure 8.45: Frequency and 
distribution graph 
















In the Pearson’s correlation matrix of all variables (Appendix X) only items ‘Do you 
have any joints that are permanently stuck?’ and ‘How long does your morning 
stiffness last from waking until maximum improvement occurs?’ had very low 
correlations (r<0.30) in ≥36 (80%) of the 45 items. Three other items (‘Over the past 
7 days has your RA stiffness been as variable (coming and going) as usual for you?’, 
‘Has RA stiffness made it difficult to chew?’, ‘How much of the stiffness you have 
reported in the questions above is about joints that are permanently stuck?’) had very 
low correlations close to this threshold (>67%).  
 
8.4.4.1.4 Consolidation of evidence regarding item suitability  
Table 8.5 consolidates the information gathered from missing responses, distributions 
and frequencies, and correlations. Seven of the 45 draft items were identified as 
unsuitable at this stage: ‘Please circle the number that best describes the severity of 
your RA stiffness over a usual week when you are not in a flare?’, ‘Do you have any 
joints that are permanently stuck?’, ‘Over the past 7 days has your RA stiffness been 
as variable (coming and going) as usual for you?’, ‘Has RA stiffness made it difficult 
to chew?’, ‘How much of the stiffness you have reported in the questions above is 
about joints that are permanently stuck?’, ‘How long does your morning stiffness last 
from waking until maximum improvement occurs?’ (ordinal scale and minutes and 
hours). These are briefly reviewed below.  
 
Although ‘Please circle the number that best describes the severity of your RA 
stiffness over a usual week when you are not in a flare?’ was developed as a draft 
stiffness item, on discussion it was decided that it should not be included in the 
questionnaire, therefore it was removed. Although ‘Do you have any joints that are 
permanently stuck?’ and ‘How much of the stiffness you have reported in the 
questions above is about joints that are permanently stuck?’ correlated moderately 
with each other (r=0.517, n=266, p<0.01), both demonstrated correlations <0.3 with 
most other items. The number of correlations <0.3 was over the 80% threshold for 
‘Do you have any joints that are permanently stuck?’ and just under for ‘How much of 
the stiffness you have reported in the questions above is about joints that are 
permanently stuck?’, therefore both were considered unsuitable. ‘Over the past 7 
days has your RA stiffness been as variable (coming and going) as usual for you?’ 
and ‘Has RA stiffness made it difficult to chew?’ had many but <80% correlations <0.3 
with other items but had large percentages of responses in one response category, 
and small response ranges, and were removed. In contrast, while ‘Over the past 7 




days have you experienced RA stiffness all over?’ and ‘Over the past 7 days has your 
RA stiffness been different to usual for you?’ had similar percentages of responses in 
one response category, they had considerably fewer correlations <0.3 with other 
items and therefore were retained. Both traditional items asking ‘How long does your 
morning stiffness last from waking until maximum improvement occurs?’ on different 
response scales (ordinal scale and minutes and hours) were removed because they 
had considerably higher amounts of missing data than other items and the concept of 
duration was captured in ‘Were your joints stiff when you woke up today? If yes, how 




Table 8.5: Draft items (n=45) and rationale for retention (n=38) or removal (n=7) based on response rate, distribution and 
correlations (assessing item suitability, Section 8.4.4.1) 
Items 
 





other items <0.3  
(n=45) 




Categories with <8 
responses (no. of 




Draft stiffness items 











Draft item timing 6 6   Retain 
Draft item in joints 1 4  (63.8%)  (1, n=7) Retain 
Draft item all over 0 17  (83.4%)  Retain 
Draft item different to usual 9 11  (60.8%)   (1, n=7) Retain 
Draft item variable 10 33  (69.3%)   (1, n=8) Remove 
Draft item after immobility 0 6   Retain 
Draft item in body 4 8  (50.5%)  (1, n=6) Retain 
Draft item sleep 4 3   Retain 
Draft item dress 4 5   Retain 
Draft item wash 4 4  (51.3%)  Retain 
Draft item responsibilities 9 4   Retain 
Draft item daily tasks 4 3   Retain 
Draft item chew 3  30  (89.4%)  (2, n=6, n=3) Remove 
Draft item hobbies 8 5   Retain 
Draft item get out of bed 1 6   (1, n=7) Retain 
Draft item get up after sitting 2 6   Retain 
Draft item effort 4 5   Retain 
Draft item slower 4 4   Retain 
Draft item fine movement 3 5   Retain 
Draft item grip 2 6   Retain 
Draft item open/close fist 2 6   Retain 
Draft item strength 0 6   Retain 










other items <0.3  
(n=45) 
 >50% of all 
responses in 
one category 
Categories with <8 
responses (no. of 





Draft item balance 1 8   Retain 
Draft item concentrate 3 5   (1, n=8) Retain 
Draft item frustrated 0 4   Retain 
Draft item worried 1 4   Retain 
Draft item self-conscious 3 8   Retain 
Draft item take longer 1 5   Retain 
Draft item change plans 1 7   Retain 
Draft item work around 1 4   Retain 
Draft item need help 0 9   Retain 
Draft item impact 2 2   Retain 
Draft item severity 3 2   (1, n=6) Retain 
Draft item importance 5 3   Retain 
Draft item coped 9 22   (2, n=6, n=7) Retain 
Draft item stuck joints B 10 35  (62.2%)  Remove 
Draft item response shift 
Traditional stiffness items 
















Traditional item severity A 3 3   (1, n=8) Retain 
Traditional item duration E 39* 11  (52.5%)  Remove 
Traditional item severity G 2 4   (1, n=4) Retain 
Traditional item severity C 1 3   (1, n=7) Retain 
Traditional item duration F 56* 40^   (16, n=<8 in all) Remove 
*=>5% missing values; ^>80% cut-off 




8.4.4.2 Preliminary analysis 
8.4.4.2.1 PCA 
PCA on the 38 retained draft items gave a KMO measure of sampling adequacy of 
0.98, which is defined as ‘superb’ (Kaiser, 1974, in Field, 2009). The diagonal 
elements of the anti-image matrices output for each of the KMO values for individual 
items were >0.94 and therefore above the recommended value (Field, 2009). 
Bartlett’s test of sphericity was significant (Χ2(703 degrees of freedom)=10892.48, 
p=<0.001) confirming that the correlations between items were sufficiently large to 
perform PCA (Pett, Lackey and Sullivan, 2003; Field, 2009). 
 
8.4.4.2.2 NLPCA 
NLPCA was performed three times on the 38 retained draft items specifying a 4-
component solution and using different analysis levels giving the following VAF: 
nominal (73.28%), ordinal (73.09%) and numeric (71.19%). Only very slight 
improvement in VAF was seen by allowing non-linear (nominal or ordinal) 
transformations. Although an ordinal analysis level would be considered the most 
appropriate for these data, a numeric analysis level would provide greater stability, 
simpler interpretation, and less likelihood of results occurring by chance (Linting and 
van der Kooij, 2012). 
 
8.4.4.3 Component extraction 
PCA of the 38 retained draft items indicated a 4-component solution explaining 
71.19% of the variance. NLPCA was performed specifying an ordinal analysis level 
and a 4-component solution which explained 73.09% of the variance.  
 
8.4.4.4 Component rotation 
PCA and NLPCA were performed on the 38 retained draft items first specifying 
orthogonal varimax rotation. Rotation clarified that each of the 4-components 
identified in component extraction were made up of a cluster of items with loadings of 
≥0.40. The rotated solutions (Table 8.6) were very similar and most items loaded 
highest onto the same components across analyses. There were some minor 
differences including that items ‘Have you had to work around your RA stiffness (or 
do things in a different way)?’, ‘Has it taken you longer to do your daily tasks or 
activities because of RA stiffness?’, ‘Has RA stiffness affected your sleep?’, and 
‘Please circle the number that best describes how well you have coped with your RA 
stiffness over the past 7 days’ did not load highest onto the same components across 




analyses. ‘Have you had to work around your RA stiffness (or do things in a different 
way)?’ and ‘Has it taken you longer to do your daily tasks or activities because of RA 
stiffness?’ had loadings ≥0.40 on both components 1 and 3 but the highest was 
different between analyses. ‘Has RA stiffness affected your sleep?’ loaded ≥0.40 on 
both component 1 and 4 in PCA but only on component 1 in NLPCA. ‘Please circle 
the number that best describes how well you have coped with your RA stiffness over 
the past 7 days’ failed to load ≥0.40 on any component in PCA but loaded ≥0.40 on 
component 2 in NLPCA. 
 
PCA and NLPCA were also performed specifying oblique promax rotation. The 
rotated pattern and structure matrices (Appendix Y) were similar to the orthogonal 
varimax rotation, with items loading on similar components. As varimax rotation is 
more commonly used and is easier to interpret as it produces a single matrix (Pett, 








Rotated component loadings Communalities 
PCA NLPCA* 
PCA NLPCA* 
1 2 3 4 1 2 3 4 
Draft item wash .791 .219 .199 .274 .823 .234 .134 .184 .774 .769 
Draft item dress .742 .281 .202 .345 .790 .295 .114 .281 .789 .790 
Draft item grip .688 .362 .313 .139 .683 .394 .305 .047 .722 .718 
Draft item responsibilities .679 .372 .337 .219 .734 .327 .311 .167 .761 .765 
Draft item balance .669 .161 .328 .182 .723 .177 .219 .131 .614 .621 
Draft item daily tasks .668 .437 .296 .263 .728 .381 .271 .199 .795 .785 
Draft item fine movement .659 .341 .273 .160 .703 .299 .234 .103 .651 .648 
Draft item get out of bed .647 .182 .222 .472 .679 .262 .128 .413 .724 .709 
Draft item need help .611 .226 .485 .186 .671 .205 .435 .119 .695 .710 
Draft item movement .608 .358 .465 .241 .699 .352 .413 .180 .773 .774 
Draft item strength .606 .344 .466 .130 .622 .360 .456 .062 .720 .736 
Draft item concentrate .583 .207 .442 .242 .649 .229 .335 .209 .636 .631 
Draft item open/close fist .581 .448 .248 -.040 .590 .397 .272 -.040 .601 .587 
Draft item effort .564 .435 .456 .282 .632 .411 .426 .221 .795 .794 
Draft item hobbies .562 .301 .471 .315 .640 .307 .409 .264 .734 .728 
Draft item slower .549 .464 .486 .194 .618 .421 .479 .107 .791 .795 
Draft item get up after sitting .543 .255 .290 .490 .574 .376 .228 .398 .984 .664 
Draft item severity .368 .690 .401 .347 .353 .774 .383 .170 .893 .908 
Draft item different to usual .121 .689 .047 .124 .181 .593 -.143 .103 .507 .510 
Traditional item severity G .380 .677 .388 .338 .354 .802 .341 .157 .869 .961 
Traditional item severity C .395 .672 .260 .345 .336 .778 .288 .157 .794 .831 
Draft item impact .398 .628 .477 .338 .423 .689 .445 .192 .895 .896 
Traditional item duration D .245 .626 .320 .231 .331 .653 .294 .180 .608 .672 





Rotated component loadings Communalities 
PCA NLPCA* 
PCA NLPCA* 
1 2 3 4 1 2 3 4 
Draft item importance .354 .598 .529 .326 .396 .614 .537 .198 .870 .861 
Draft item timing .243 .598 .529 .326 .169 .796 .159 .210 .585 .704 
Draft item in joints .341 .598 .529 .326 .199 .830 .044 .095 .620 .759 
Draft item coped -.215 -.362 -.215 .026 -.225 -.537 -.397 -.005 .224 .459 
Draft item worried .228 .234 .771 .221 .351 .205 .714 .250 .750 .741 
Draft item self-conscious .323 .155 .743 .252 .419 .160 .670 .235 .745 .702 
Draft item frustrated .412 .313 .679 .277 .474 .351 .639 .219 .806 .809 
Draft item change plans .475 .225 .678 .151 .577 .164 .609 .219 .759 .766 
Draft item work around .572 .243 .602 .187 .636 .241 .550 .144 .784 .792 
Draft item take longer .569 .373 .577 .211 .651 .341 .535 .151 .840 .859 
Draft item all over .066 .050 .174 .764 .128 .104 .129 .805 .620 .696 
Draft item in body .178 .248 .229 .672 .246 .231 .190 .726 .597 .679 
Draft item after immobility .319 .331 .224 .599 .356 .464 .195 .485 .621 .621 
Draft item sleep .443 .344 .267 .451 .505 .376 .225 .371 .590 .583 
Initial eigenvalues 22.98 1.80 1.18 1.10 22.87 2.47 1.35 1.08   
Initial VAF 60.47% 4.73% 3.09% 2.90% 60.19% 6.50% 3.56% 2.83%   
Rotated eigenvalues 9.62 6.64 6.40 4.40 11.12 8.35 5.49 2.82   
Rotated VAF 25.31% 17.47% 16.84% 11.58% 29.26% 21.97% 14.45% 7.41%   
Total VAF 71.19% 73.09%   
NB bold loadings=highest loading; underlined loadings=other loadings ≥0.4; *Specifying an ordinal analysis level   
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8.4.4.5 Comparing the two statistical approaches 
The output from PCA was compared to the output generated from NLPCA specifying 
an ordinal analysis level which was considered most appropriate for these data. Four 
criteria were used to compare PCA and NLPCA; 1) eigenvalues and VAF; 2) VAF 
across components 3) component loadings; and 4) communalities (Table 8.6). 
 
As expected, initial eigenvalues for both solutions were large for the first component 
(22.98 and 22.87 for PCA and NLPCA respectively) and much smaller for the following 
three components. Following rotation, the eigenvalues and VAF in both solutions 
demonstrated a more even spread across components. Total VAF was 71.19% and 
73.09% for PCA and NLPCA respectively. PCA demonstrated slightly more even VAF 
across components which was considered preferable from the perspective of 
conceptual importance and stability and robustness for further testing. Component 
loadings were similar, despite small differences in the loadings of some items between 
solutions, items generally loaded on the same components. Similarly, communalities 
were not identical but were consistent across methods (e.g. items with low 
communalities were generally low in both PCA and NLPCA).  
 
Benefits of PCA include increased stability, simpler interpretation, and less risk of 
occurring by chance (Linting and van der Kooij, 2012). A further advantage of PCA is 
that calculations are generated from the correlation matrix whereas in NLPCA 
calculations are generated directly from the data (Linting and van der Kooij, 2012). As 
a result, in NLPCA, the solution can be “over fitted” to the particular dataset in which 
a solution is developed, which may influence the stability of the solution when tested 
in other populations. PCA also provides all aspects of a rotated analysis as part of 
one programme and has the additional benefit of familiarity in the literature which may 
also improve the accessibility of the results. Although in theory PCA is less 
appropriate for the data available here, the comparison between PCA and NLPCA 
shows similarity between the outputs regardless. Overall, given the similarity between 
the PCA and NLPCA outputs and the advantages of PCA, PCA was taken forward to 
perform further testing to develop a new RA stiffness PROM (Chapter 9). 
 
8.5 Discussion 
8.5.1 Postal survey 
The survey sample reflected the characteristics of patients in other recent survey 
research (e.g. Wilson et al, 2015; Hammond et al, 2015) and included a range of 
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participants from disease related and sociodemographic perspectives. The response 
rate of 43.1% was slightly lower than that found in the aforementioned studies, but 
similar to other questionnaire development studies (e.g. Goodacre et al, 2007). 
However, response rate may have been affected by the data collection approach 
where information including consent was collected altogether.  
 
A strength of the survey is the collection of non-responder data. Non-response bias 
occurs when those who do not participate are different from those who do participate 
in respect to the topic under investigation (Silman and Macfarlane, 2002). Collection 
of non-responder data in this study enabled demonstration that the frequencies and 
percentages of gender, age, and social deprivation were similar in responders and 
non-responders. A limitation of the survey was that the questionnaire pack was not 
piloted prior to use. An implication of this could have been reducing the amount of 
missing data. However, the draft stiffness items and traditional unvalidated stiffness 
items had been tested with patients in cognitive interviews (Chapter 7), and the 
questionnaire pack was developed with patient partner (GB) involvement. Despite 
this, a small pilot of the questionnaire would likely have enhanced data completion 
and response rates, provided valuable information and been consistent with 
recommendations (e.g. Silman and Macfarlane, 2002).  
 
A small number of participants (n=6, 2.4%) reported that they had other conditions in 
addition to RA, where stiffness was also a feature (Section 8.4.2.2.3). That patients 
with other rheumatic conditions were not excluded from this study may be perceived 
as a limitation. However, this study did not exclude patients with other conditions so 
as to not limit the sample and reduce the questionnaires application clinically and in 
research. For example, OA is very common in the general population, with recent 
figures indicating that one third of individuals >45 years have sought treatment for OA 
(Arthritis Research UK, 2013b). Such figures indicate crossover with the age of an RA 
population and could have reduced the sample considerably. In addition, the final 
questionnaire will need to be robust enough to be used in the target population, which 
will likely contain individuals with other conditions such as OA. Interestingly, the 
numbers reported in this study were much lower than expected based on the OA 
figures reported by Arthritis Research UK (2013b), but were consistent with those 
found in another recent survey study where 8.2% of the sample (n=413) reported 
having other rheumatic conditions, specifically 19 (5%) reported OA (Wilson, 2016). 
It must be acknowledged however that both studies were based on patient self-
reported information. The accuracy of patient self-reports of rheumatic conditions 
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have been challenged by some authors (e.g. Kvien et al, 1996) yet reported as 
accurate by others (e.g. Barlow, Turner and Wright, 1998). Overall, further 
consideration of the study population could be explored in more detail in future 
validation studies and is certainly relevant in future research directions relating to the 
universal or specific nature of stiffness assessment tools (Section 2.4.2 and Chapter 
10). Regardless, the careful development of the draft items, for example the inclusion 
of RA stiffness in each stem question, will enhance clarity and specificity, and 
hopefully aid the robustness of items in such situations. 
 
8.5.2 Analysis approach 
Although not originally considered within the plan for this research, the recognition of 
and exploration into the debate surrounding the methodological appropriateness of 
different analytical approaches has turned into a strength of this work. As discussed 
earlier (Section 8.1.3), when performing PCA, current recommendations suggest the 
use of alternative approaches to producing Pearson’s correlations, such as polychoric 
correlations, when working with data that are not continuous (Streiner and Norman, 
2008). Despite this, these recommendations are not routinely employed in practice. A 
recent review of EFA (and PCA) in nursing studies identified 54 analyses in 28 papers, 
all of which were performed using methods suited to continuous data despite all being 
based on ordinal (91%) or nominal (9%) data (Gaskin and Happell, 2014). The authors 
suggest that this may be expected given the limited guidance regarding performing 
factor analysis with ordinal and nominal data in comparison to guidelines for 
continuous data. In combination with other restrictions including the poor accessibility 
of programmes for these purposes (Baglin, 2014) and limitations of their use (e.g. 
Lorenzo-Seva and Ferrando, 2014), this may provide some explanation for the poor 
uptake of recommendations in practice. Given the lack of guidance and difficulties 
regarding implementation of non-traditional approaches to PCA, it is rare to see 
comparisons of different methodological approaches, especially in practical rather 
than theoretical examples. This chapter has described a novel comparison of two 
analytical approaches; the traditional approach suited to the analysis of continuous 
data (PCA), and an approach suited to the analysis of non-continuous data (NLPCA). 
It has provided evidence of consistent results across analyses and enabled evidence 
based decision making regarding PCA as acceptable for further analysis, a decision 
which would otherwise be inconsistent with current recommendations (e.g. Streiner 




Another consideration is the use of CTT (Section 8.1.1) as a basis for PROM 
development. Although CTT is broadly applicable and well used (Hambleton and 
Jones, 1993), the newer IRT is considered by some to be a better alternative as it 
overcomes the limitations of CTT (Streiner and Norman, 2008). The advantages of 
IRT models include true interval properties, more precise estimation of measurement 
error, and test-free measurement (comparison of subjects regardless of the items 
completed) (Streiner and Norman, 2008). Despite these advantages, IRT models do 
not directly improve item wording or construction (DeVellis, 2012), therefore the use 
of CTT does not detract from the careful development of items in this study. Within 
the PROM development literature, recommendations for the use of IRT models are 
now common place. For example, the FDA recently stated that they recognise the 
benefits of modern approaches to scale development such as IRT methods over more 
traditional approaches. However, they also recommend that sponsors include 
assessment of both traditional and novel approaches to demonstrate links between 
methods (Patrick et al, 2007). This dual-method recommendation is reflected in the 
theoretical literature where rather than IRT methods replacing more traditional 
approaches, it is recognised that both approaches have advantages (DeVellis, 2012). 
IRT and CTT have been described as “complementary approaches” (de Champlain, 
2010, p.117) which “should be integrated in a comprehensive approach to 
measurement issues” (Embretson and Hershberger, 1999, p.252). Given the above 
considerations, any stiffness PROM developed from this research would benefit from 
further exploration in future research using newer IRT models such as Rasch analysis 
(e.g. Tennant and Conaghan, 2007). 
 
8.6 Conclusion 
This chapter has described the demographics of participants involved in the postal 
survey and found the sample to be similar to other recent survey studies and 
representative of the RA population. The comparison of PCA and NLPCA identified 
considerable similarities in the outputs which facilitated the decision that PCA was the 
most appropriate method to further analyse the dataset given its improved stability, 
familiarity, and practicality. Of the 45 draft stiffness items, seven were established as 
being unsuitable for further analysis and were therefore removed. The remaining 38 
draft stiffness items will now be taken forward to Chapter 9 for further development 
and testing using PCA to identify the smallest and most effective item structure for a 
new RA stiffness PROM. 




Chapter 9: Developing and testing the structure of an RA 
stiffness PROM (Study 4, part 2) 
The previous chapter reported on the survey methods and sample demographics, and 
addressed which analytical approach would be most appropriate for the development 
of a new RA stiffness PROM. PCA was identified as the most appropriate method. 
This chapter now describes the use of PCA to develop the smallest and most effective 
item structure utilising the remaining 38 draft items, and then describes preliminary 
testing of the resulting RA stiffness PROM. 
 
9.1 Background 
9.1.1 Developing the provisional RA stiffness PROM 
In using PCA to develop a provisional RA stiffness PROM, the smallest item structure 
was sought for feasibility (Boers et al, 1998) in clinical and research environments. 
This required attention to internal consistency which is concerned with the 
homogeneity of the items that make up an instrument (Field, 2009; DeVellis, 2012) 
(Section 2.3.1.3). To investigate the coherence of the whole item structure and each 
individual component, and to identify items that contribute least, Cronbach’s alpha 
was performed in combination with PCA. This was supplemented by performing 
successive PCAs on each individual component to investigate whether items 
constitute a single component or a number of smaller components (Pett, Lackey and 
Sullivan, 2003). Consideration of statistical criteria, theoretical appropriateness and 
simplicity are recommended during solution refinement in PCA (Nunnally and 
Bernstein, 1994; Pett, Lackey and Sullivan, 2003). Therefore, all decisions regarding 
item reduction and the final structure of the provisional RA stiffness PROM were 
tempered with information from statistical tests and expert (clinical and patient) 
judgement. 
 
9.1.2 Concepts of measurement 
As appropriate measurement properties are required for PROMs to be useful (Terwee 
et al, 2007), following the development of the provisional RA stiffness PROM, 
preliminary testing of some measurement properties was performed. A valid measure 
(one which measures what it intends to measure (SACMOT, 2002; Frost et al, 2007)) 
would have appropriate relationships with other measures of RA (construct validity, 
Section 2.3.1.1). Relationships have been highlighted in the qualitative literature (e.g. 
Lineker et al, 1999; Orbai et al, 2014; Halls et al, 2015) between stiffness and 
disability, pain, fatigue, and flare. Therefore, moderate correlations would be expected 




between the provisional RA stiffness PROM and measures capturing these 
constructs. Stiffness is also considered an indicator of inflammatory activity in RA (e.g. 
Lansbury, 1956; Scott, 1986; Hazes et al, 1994; Soubrier et al, 2006). Therefore, 
moderate to strong correlations would be expected between the provisional RA 
stiffness PROM and measures capturing disease activity. Correlation cut-offs were as 
defined previously (Section 2.3.1.1.1) and testing of expected relationships used data 
that were not involved in decisions regarding PROM development.  
 
9.2 Aims and objectives 
The overall aim of this study was to develop and test the structure of a provisional RA 
stiffness PROM. The specific objectives of this chapter were: 
 From the 38 provisional stiffness items, to identify the smallest and most 
effective item structure to form a new provisional RA stiffness PROM 
 To test the validity of the provisional RA stiffness PROM by investigating its 
correlations with other measures of RA 
 To provide recommendations on the most appropriate tool to use to assesses 
stiffness in research and clinical situations  
 
9.3 Methods 
The methods for the survey in Study 4 were described in Chapter 8 (Section 8.3).  
 
9.4 Analysis and results 
Analysis stages 1 and 2 were described in Chapter 8 (Section 8.4). Stage 3 analysis 
involved statistical analysis guided by expert (clinical and patient) judgement to 
reduce the number of items into the smallest and most effective item structure (item 
reduction and structure development). Stage 4 involved testing of the provisional RA 
stiffness PROM using comparisons with other measures of RA (validity testing). The 
description of each analysis stage is followed directly by its results. 
 
9.4.1 Stage 3 analysis: Item reduction and structure development 
Item reduction and structure development was performed in seven steps: 1) explore 
the whole structure; 2) explore each component individually; 3) test item removal; 4) 








9.4.1.1 Explore the whole structure 
In Chapter 8, loadings ≥0.40 were defined as high or meaningful. However, the aim 
of stage 3 analysis was to refine the solution therefore, stricter item loading criteria 
were adopted. Guidelines suggest that 0.45=‘fair’, 0.55=‘good’, 0.63=‘very good’, 
0.71=‘excellent’, and it is recommended that the more ‘very good’ or ‘excellent’ 
loadings the better (Comrey and Lee, 1992). Therefore, ‘good’ item loadings (≥0.55) 
were targeted to seek the optimal model. 
 
Even after rotation, it is common for PCA solutions to include items with high loadings 
on several components, and items with weak loadings on all components. There is 
conflicting advice about what to do with such items (Pett, Lackey and Sullivan, 2003). 
Some suggest removing items with high loadings on many components to reduce 
difficulties with interpretation (Kline, 2000). Others recommend careful consideration 
of their placement (Hair et al, 1995), taking into account the conceptual relationship 
between item and component (Pett, Lackey and Sullivan, 2003). Given the 
importance of the conceptual perspective of the item structure and to retain as much 
useful information as possible, the latter approach was implemented.  
 
Consistent with the idea that PCA aims to identify groups of related items (Pallant, 
2010), it is also important that those items are homogenous (DeVellis, 2012) and 
‘hang together’ well. This can be assessed by Cronbach’s alpha coefficient which 
evaluates internal consistency (Pett, Lackey and Sullivan, 2003). In questionnaires 
with different components, it is also recommended that the internal consistency of 
each component is investigated (Field, 2009). Therefore Cronbach’s alpha coefficient 
was explored in the whole structure and each individual component. The output from 
these analyses provide information about the effect that the deletion of each item 
would have on the internal consistency of the scale (Pallant, 2010), and aids decisions 
about item removal. The correlation of an item with the component having removed 
that item (corrected item total correlation) will be strong and positive if internal 
consistency is demonstrated (Pett, Lackey and Sullivan, 2003). This can be explored 
further using the correlation matrix of all items within the component. The correlation 
matrix generated from PCA rather than from internal consistency analysis was used 
as PCA can be performed pairwise while internal consistency analysis can only be 








9.4.1.2 Explore each component individually 
PCA was performed on each individual component to establish whether items 
constituted a single component or a number of smaller components (Pett, Lackey and 
Sullivan, 2003). Investigation into item loadings and internal consistency was also 
performed as described above. 
 
9.4.1.3 Test item removal 
Items that do not contribute to the homogeneity of the scale can be removed without 
loss of information, and it is recommended that items with low loadings are removed 
and analyses rerun without them (Hair et al, 1995). A series of rotated PCA were 
performed alongside internal consistency analyses. During each round, items with the 
lowest component loading or which, if removed, would increase the overall alpha were 
considered for removal. Decisions about which item to remove (or replace) at each 
iteration were based on the output of the PCA at that iteration, information identified 
above (Sections 9.4.1.1 and 9.4.1.2), and in previous examination of items (Section 
8.4.4). Following removal of an item, PCA was repeated and the resulting solution 
was reviewed. This process was continued until an appropriate solution, from both 
statistical and conceptual perspectives, was identified (Section 9.4.1.4).  
 
9.4.1.4 Decide on the final component structure 
Decisions made during item removal (Section 9.4.1.3) were based on statistical 
information (e.g. component loadings). It was also important to identify whether this 
could be improved upon by consideration from a conceptual perspective. Therefore, 
following item removal, the component structure was discussed with the supervisory 
team. Discussions considered whether the content of the individual components 
made sense conceptually and corresponded with results from the qualitative studies 
(Chapters 4, 5 and 7), informed how components should be labelled to reflect their 
content, and influenced further item removal testing for example by identifying items 
with similar wording. 
 
9.4.1.5 Bootstrapping 
The provisional RA stiffness PROM structure was then tested for stability and 
robustness using bootstrapping. Bootstrapping involved performing 20 repeated PCA 
analyses on randomly selected subsets of data (approximately 50% of the whole 
sample per subset) to establish whether the component structure was retained. 
 





Consideration was given to how to combine the responses to each item in a 
meaningful way, or score the scale (Streiner and Norman, 2008). Scores can be 
generated using simple summation or based on factor scores generated in PCA. The 
simple summation approach involves adding together the response to each item as 
assigned during coding. Factor scores are generated from standardised participant 
scores, which are weighted by a generated coefficient and then summed across items 
(Pett, Lackey and Sullivan, 2003). Factor scores can be performed in three ways; 
regression method, Bartlett method, Anderson-Rubin method. Although 
recommendations regarding the appropriate approach vary it has been suggested 
that for most studies, the three approaches will produce similar factor scores (Kim and 
Mueller, 1978). As the regression method is commonly employed (Pett, Lackey and 
Sullivan, 2003), it was used in this study. To investigate the relationship between 
scores generated from simple summation and from factor scores, correlations and 
scatterplots were produced and compared. 
 
9.4.1.7 Formatting 
Finally, discussion with the supervisory team and patient research partners developed 
names and other formatting aspects such as the layout, font, and order of items in the 
provisional RA stiffness PROM. 
 
9.4.2 Stage 3 results: Item reduction and structure development 
9.4.2.1 Explore the whole structure 
When reviewing the whole item structure, component loadings could be generally 
described as ‘good’ (≥0.55). However, three items (‘Has RA stiffness affected your 
sleep?’, ‘Has RA stiffness made it difficult to get up after sitting for a while?’ and ‘Has 
RA stiffness made you slower (for example, unable to do things quickly)?’) 
demonstrated loadings just below this threshold and one item (‘Please circle the 
number that best describes how well you have coped with your RA stiffness over the 
past 7 days’) demonstrated weak loadings on all components (Table 9.5). The 
strongest loading for ‘Has RA stiffness made it difficult to get up after sitting for a 
while?’ (0.543) and ‘Has RA stiffness made you slower (for example, unable to do 
things quickly)?’ (0.549) were marginally below the ‘good’ threshold, and ‘Has RA 
stiffness affected your sleep?’ (0.451) just met the criteria of a ‘fair’ loading (>0.45). 
‘Please circle the number that best describes how well you have coped with your RA 
stiffness over the past 7 days’ had a weak loading on all components. 





The whole 38-item 4-component structure indicated a homogenous set of items 
(Cronbach’s alpha=0.961). The removal of ‘Please circle the number that best 
describes how well you have coped with your RA stiffness over the past 7 days’ would 
result in a slight improvement to internal consistency (Cronbach’s alpha=0.971). 
 
9.4.2.2 Explore each component individually 
PCA was performed on each of the four individual components to establish whether 
they were made up of more than one component and to investigate internal 
consistency. 
 
9.4.2.2.1 Component 1 
A single component was identified and all item loadings were ‘excellent’ (Table 9.1). 
The Cronbach’s alpha coefficient for the 17-items was 0.973 which could not be 
improved by item removal. Generally, correlations between items were moderate or 
strong, apart from between ‘Has RA stiffness made it difficult to open and close your 
fist?’ and ‘Has RA stiffness made it difficult to get out of bed?’, ‘Has RA stiffness made 
it difficult to get up after sitting for a while?’ and ‘Has RA stiffness made it difficult to 
balance without physically supporting yourself?’ which were weak (r=≤0.46). ‘Has RA 
stiffness made it difficult to open and close your fist?’ also demonstrated the lowest 
component loading and Cronbach’s alpha coefficient. From a conceptual perspective, 
component 1 appeared to contain items capturing impact on physical tasks and daily 

















Table 9.1: Item loadings and Cronbach’s alpha coefficient for 
component 1 (“Physical”) 
Item Loading Cronbach’s alpha 
coefficient 
Draft item effort .884 .872 
Draft item daily tasks .884 .868 
Draft item movement .879 .867 
Draft item slower  .871 .863 
Draft item responsibilities .868 .846 
Draft item dress  .855 .835 
Draft item hobbies  .852 .831 
Draft item grip  .841 .841 
Draft item strength  .841 .836 
Draft item wash .834 .816 
Draft item need help  .813 .797 
Draft item fine movement  .796 .779 
Draft item get out of bed  .794 .767 
Draft item concentrate   .791 .772 
Draft item get up after sitting  .783 .773 
Draft item balance  .768 .746 
Draft item open/close fist  .715 .698 
 
9.4.2.2.2 Component 2 
A single component was identified and item loadings were generally ‘excellent’, 
although ‘Over the past 7 days has your RA stiffness been different to usual for you?’ 
was ‘good’, and ‘Please circle the number that best describes how well you have 
coped with your RA stiffness over the past 7 days’ was ‘weak’ (Table 9.2). The weak 
loading of ‘Please circle the number that best describes how well you have coped with 
your RA stiffness over the past 7 days’ (-0.414) in component 2 was consistent with 
the poor loading identified for that item within the whole item structure (-0.362). The 
overall Cronbach’s alpha coefficient for the 11-item component was 0.926. If ‘Have 
you experienced RA stiffness in your joints over the past 7 days?’ or ‘Over the past 7 
days has your RA stiffness been different to usual for you?’ were removed the overall 
Cronbach’s alpha coefficient would increase slightly to 0.929. If ‘Please circle the 
number that best describes how well you have coped with your RA stiffness over the 
past 7 days’ was removed the overall Cronbach’s alpha coefficient would increase to 
0.935. Generally, correlations between items were moderate or strong, apart from 
between ‘Please circle the number that best describes how well you have coped with 
your RA stiffness over the past 7 days’ and ‘Over the past 7 days has your RA stiffness 
been different to usual for you?’ and all other items which were weak. From a 
conceptual perspective, this component appeared to contain items capturing stiffness 
severity and broad stiffness impact, as such this was initially labelled as ‘Severity’. 
 




Table 9.2: Item loadings and Cronbach’s alpha coefficient for 
component 2 (“Severity”) 
Item Loading Cronbach’s alpha 
coefficient 
Draft item severity .955 .935 
Traditional item severity G .947 .924 
Draft item impact .942 .924 
Traditional item severity A .924 .896 
Draft item importance .921 .908 
Traditional item severity C .901 .864 
Traditional item duration D .769 .684 
Draft item in joints  .728 .618 
Draft item timing  .700 .600 
Draft item different to usual  .587 .543 
Draft item coping  -.414 .404 
 
9.4.2.2.3 Component 3 
A single component was identified and all item loadings were ‘excellent’ (Table 9.3). 
The overall Cronbach’s alpha coefficient for the 6-item component was 0.941 which 
could not be improved by item removal. Correlations between all items were moderate 
or strong. Conceptually this component appeared to capture psychosocial impact, 
including emotional aspects and daily management, and was initially labelled as 
‘Psychosocial’. 
 
Table 9.3: Item loadings and Cronbach’s alpha coefficient for 
component 3 (“Psychosocial”) 
Item Loading Cronbach’s alpha 
coefficient 
Draft item frustrated  .903 .856 
Draft item work around  .902 .853 
Draft item ADLs take longer  .897 .847 
Draft item change plans  .888 .835 
Draft item self-conscious  .851 .788 
Draft item worried  .833 .763 
 
9.4.2.2.4 Component 4 
A single component was identified and all item loadings were ‘excellent’ (Table 9.4). 
The overall Cronbach’s alpha coefficient for the 4-item component was 0.761 which 
despite being ‘acceptable’, was lower than that of other components. Removal of any 
item failed to improve the overall Cronbach’s alpha coefficient, and correlation 
between items were weak or moderate. From a conceptual perspective, this 
component was not as clear as other components as it contained items capturing 
stiffness location but also items capturing impact and severity. Initially this was 




labelled as ‘Location’ but these results raise questions regarding this component in 
the model. 
 
Table 9.4: Item loadings and Cronbach’s alpha coefficient for 
component 4 (“Location”) 
Item Loading Cronbach’s alpha 
coefficient 
Draft item in body  .819 .625 
Draft item after immobility  .790 .613 
Draft item sleep  .778 .595 
Draft item all over  .733 .533 
 
9.4.2.3 Test item removal 
Box 9.1 describes each round of item removal including the rotated PCA output 
(Tables 9.5-9.25), justification for the item removed at each round and internal 
consistency analyses. As the item loadings changed and components moved position 
during the process, components are referred to by their initial label rather than by their 
number, and are distinguished by colour (as per the key). Only loadings >0.40 were 
reported for clarity, unless important for description. For all items, the highest loading 
has been illustrated in bold. For items which loaded on more than one component, 
underlining is used to illustrate all other loadings >0.40.
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Box 9.1: Rotated PCA and internal consistency analyses for item removal  
Description of item removal Rotated PCA output 
The first rotated PCA (Table 9.5) represents the 38-item, 4-
component solution with a Cronbach’s alpha coefficient of 0.961 
(Chapter 8). Here ‘Please circle the number that best describes 
how well you have coped with your RA stiffness over the past 7 
days’ (Draft item coped) was considered for removal as it had the 
lowest component loading in the PCA. ‘Please circle the number 
that best describes how well you have coped with your RA 
stiffness over the past 7 days’ had been identified earlier as falling 
under the weak component loading threshold (<0.40) (Section 
9.4.2.1) and performing poorly within examination of individual 
components (Section 9.4.2.2). It had also been identified in 
Chapter 8 as having a number (n=22) of poor correlations (<0.3) 
with other items (Section 8.5.2.1.3). When considering internal 
consistency, the removal of this item would slightly improve the 
overall Cronbach’s alpha coefficient (to 0.971). Therefore, ‘Please 
circle the number that best describes how well you have coped 
with your RA stiffness over the past 7 days’ was removed (Table 
9.6). 





Description of item removal Rotated PCA output 
Rotated PCA 2 (Table 9.6) comprised 37-items and retained the 
4-component structure. The Severity and Psychosocial 
components remained consistent while the Location component 
was reduced to three items as ‘Has RA stiffness affected your 
sleep?’ (Draft item sleep) loaded highest in the Physical 
component. The lowest loading item was ‘Has RA stiffness 
affected your sleep?’ However, internal consistency analyses 
indicated that the overall Cronbach’s alpha coefficient of 0.971 
could be improved very slightly (0.972) by the removal of ‘Over 
the past 7 days have you experienced RA stiffness all over?’ 
(Draft item all over) On further consideration, this item had 
demonstrated the lowest component loading during examination 
of individual components (Section 9.4.2.2.4). It had also been 
considered for removal during investigation into item suitability 
(Chapter 8) where it was identified as having a number (n=17) of 
poor correlations (<0.3) with other items and a large percentage 
of responses in one response category (Section 8.5.2.1.3). In 
contrast, ‘Has RA stiffness affected your sleep?’ during individual 
component investigation (Section 9.4.2.2) had demonstrated a 
slightly higher component loading than ‘Over the past 7 days have 
you experienced RA stiffness all over?’ (Table 9.4), and had not 
been considered for removal previously (Chapter 8). For these 
reasons, ‘Over the past 7 days have you experienced RA stiffness 
all over?’ was removed (Table 9.7). 
Table 9.6: Rotated PCA 2 (‘Please circle the number that best 
describes how well you have coped with your RA stiffness over 




Description of item removal Rotated PCA output 
 
Rotated PCA 3 (Table 9.7) retained a 4-component structure and 
its Cronbach’s alpha coefficient was .972, but the content of the 
Location component had changed considerably. The two items 
that remained from the original Location component (‘Have you 
experienced RA stiffness in your body (outside of your joints) over 
the past 7 days?’ (Draft item in body) and ‘Over the past 7 days 
have you experienced RA stiffness after a period of immobility (for 
example, after sitting for a while)?’ (Draft item after immobility)) 
were joined by four other items (‘Has RA stiffness made it difficult 
to get out of bed?’ (Draft item get out of bed), ‘Has RA stiffness 
made it difficult to get up after sitting for a while?’ (Draft item get 
up after sitting), ‘Have you had to concentrate to move your body 
because of RA stiffness?’ (Draft item concentrate), and ‘Has RA 
stiffness made it difficult to balance without physically supporting 
yourself?’ (Draft item balance)), which had previously loaded 
highest on the Physical component. Although this change in 
content challenged the original label of the Location component, 
its original name was retained for consistency. As in rotated PCA 
2 (Table 9.6), ‘Has RA stiffness affected your sleep?’ (Draft item 
sleep) again demonstrated the lowest component loading. This 
item had also demonstrated inconsistent component placement 
having loaded (>0.40) on the Location (rotated PCA 1), Physical 
(rotated PCA 2), and Severity (rotated PCA 3) components. 
Therefore ‘Has RA stiffness affected your sleep?’ was removed 
(Table 9.8). 
Table 9.7: Rotated PCA 3 (‘Over the past 7 days have you 





Description of item removal Rotated PCA output 
 
Rotated PCA 4 (Table 9.8) retained a 4-component structure and 
had a Cronbach’s alpha coefficient of 0.971. The structure was 
similar to the solution identified in rotated PCA 3 although the 
Physical and Severity components changed places. The content 
of the Physical and Psychosocial components remained 
consistent while the Severity component gained ‘Have you 
experienced RA stiffness in your body (outside of your joints) over 
the past 7 days?’ (Draft item in body) which originally loaded 
highest in the Location component. This item also demonstrated 
the lowest overall component loading. As a result, ‘Have you 
experienced RA stiffness in your body (outside of your joints) over 
the past 7 days?’ was removed (Table 9.9). 
Table 9.8: Rotated PCA 4 (‘Has RA stiffness affected your 




Description of item removal Rotated PCA output 
Rotated PCA 5 (Table 9.9) retained a 4-component structure and 
its Cronbach’s alpha coefficient was 0.971. Again the structure 
was similar to the previous two solutions (rotated PCA 3 and 4), 
however the Physical, Psychosocial and Severity components 
changed places. The Severity component remained consistent in 
content while the other components varied slightly as a result of 
changes in the highest loading of some items. The Psychosocial 
component gained ‘Has your movement been restricted because 
of RA stiffness?’ (Draft item movement) and ‘Have your daily 
tasks and activities required more effort because of RA stiffness?’ 
(Draft item effort) from the Physical component. The Physical 
component gained ‘Has RA stiffness made it difficult to get out of 
bed?’ (Draft item get out of bed) from the Location component but 
lost ‘Has RA stiffness made it difficult to dress or undress 
yourself?’ (Draft item dress) and ‘Has RA stiffness made it difficult 
to wash yourself (for example, have a shower)?’ (Draft item dress) 
back to the Location component. Overall, ‘Have your daily tasks 
and activities required more effort because of RA stiffness?’ was 
the lowest loading item and was removed (Table 9.10).  
Table 9.9: Rotated PCA 5 (‘Have you experienced RA stiffness 
in your body (outside of your joints) over the past 7 days?’ 





Description of item removal Rotated PCA output 
Rotated PCA 6 (Table 9.10) contained 33-items across 4-
components, with an overall Cronbach’s alpha coefficient of 
0.969. This solution was comparable to the rotated solution 
produced in rotated PCA 5 except that in the Physical and 
Location components, ‘Has RA stiffness made it difficult to get out 
of bed?’ (Draft item get out of bed) now loaded highest in the 
Location component. ‘Has your movement been restricted 
because of RA stiffness?’ (Draft item movement) had the lowest 
component loading overall, therefore it was removed (Table 9.11). 
Table 9.10: Rotated PCA 6 (‘Have your daily tasks and activities 






Description of item removal Rotated PCA output 
Rotated PCA 7 (Table 9.11) retained a 4-component structure 
and had an overall Cronbach’s alpha coefficient of 0.968. Again 
the Severity and Psychosocial components remained consistent 
however, the Physical component lost ‘Has RA stiffness made 
you slower (for example, unable to do things quickly)?’ (Draft item 
slower) to the Location component. ‘Has RA stiffness made it 
difficult to do hobbies or activities you enjoy?’ (Draft item hobbies) 
had the lowest component loading overall and was removed 
(Table 9.12). 
Table 9.11: Rotated PCA 7 (‘Has your movement been 






Description of item removal Rotated PCA output 
Rotated PCA 8 (Table 9.12) contained 31-items and its overall 
Cronbach’s alpha coefficient was 0.966. However, the 4-
component solution reduced to a 3-component solution where the 
original Location component was lost. The content of the three 
remaining components incorporated items that had loaded 
highest in the Location component in the previous solution. All 
items apart from ‘Has RA stiffness made it difficult to open and 
close your fist?’ (Draft item open/close fist) had component 
loadings defined as ‘good’ or better which was an improvement 
on previous solutions. The lowest loading item was ‘Has RA 
stiffness made it difficult to open and close your fist?’ However on 
consideration of internal consistency analyses, Cronbach’s alpha 
coefficient (0.966) could have been increased very slightly (0.967) 
by removing ‘Over the past 7 days has your RA stiffness been 
different to usual for you?’ (Draft item different to usual). This item 
was the second lowest loading during examination of individual 
components (Section 9.4.2.2.2). It had also been considered for 
removal during investigation into item suitability (Chapter 8) 
where it was identified as having a number (n=11) of poor 
correlations (<0.3) with other items and a large percentage of 
responses in one response category (Section 8.5.2.1.3). ‘Has RA 
stiffness made it difficult to open and close your fist?’ had the 
lowest component loading and Cronbach alpha coefficient during 
examination of individual components. It also was the only item to 
demonstrate any weak correlations with other items within the 
component (Section 9.4.2.2.1). Both items had evidence to justify 
their removal. However, as ‘Over the past 7 days has your RA 
stiffness been different to usual for you?’ had evidence of poor 
suitability (Chapter 8) it was removed first (Table 9.13). 
Table 9.12: Rotated PCA 8 (‘Has RA stiffness made it difficult to 







Description of item removal Rotated PCA output 
The rotated PCA 9 (Table 9.13) contained 30-items and retained 
a 3-component solution with the Cronbach’s alpha coefficient also 
remaining stable at 0.967. The components remained steady with 
rotated PCA 8 (Table 9.12) apart from ‘Has RA stiffness made it 
difficult to get up after sitting for a while?’ (Draft item get up after 
sitting) which loaded highest within the Severity component. 
Consistent with rotated PCA 8 (Table 9.12), ‘Has RA stiffness 
made it difficult to open and close your fist?’ (Draft item 
open/close fist) demonstrated the lowest component loading. 
Given the poor performance of ‘Has RA stiffness made it difficult 
to open and close your fist?’ discussed above, it was removed 
(Table 9.14).  
Table 9.13: Rotated PCA 9 (‘Over the past 7 days has your RA stiffness 







Description of item removal Rotated PCA output 
Rotated PCA 10 (Table 9.14) contained 3-components and had 
an overall Cronbach’s alpha coefficient of 0.967. Consistent with 
rotated PCA 9 (Table 9.13), all item loadings could be defined as 
‘good’ or better. There were slight changes to the solution 
including ‘Has RA stiffness made it difficult to get up after sitting 
for a while?’ (Draft item get up after sitting) loading highest in 
Physical component instead of the Severity component. These 
components also swapped places. ‘Has RA stiffness reduced 
your strength to do tasks?’ (Draft item strength) loaded highest 
within the Psychosocial component rather than the Physical 
component. Overall, ‘Has RA stiffness reduced your strength to 


















Table 9.14: Rotated PCA 10 (‘Has RA stiffness made it difficult 







Description of item removal Rotated PCA output 
Rotated PCA 11 (Table 9.15) comprised 28-items over 3-
components and had an overall Cronbach’s alpha coefficient of 
0.965. All components remained consistent and ‘Has RA stiffness 
made you slower (for example, unable to do things quickly)?’ 
(Draft item slower) was the lowest loading item. Both ‘Has RA 
stiffness made you slower (for example, unable to do things 
quickly)?’ and ‘Has it taken you longer to do your daily tasks or 
activities because of RA stiffness?’ (Draft item take longer) also 
demonstrated acceptable component loadings (>0.45) on all 
components which can cause difficulties with interpretation. 
Therefore, ‘Has RA stiffness made you slower (for example, 
unable to do things quickly)?’ was removed (Table 9.16).  
Table 9.15: Rotated PCA 11 (‘Has RA stiffness reduced your 









Description of item removal Rotated PCA output 
Rotated PCA 12 (Table 9.16) retained 3-components and had a 
Cronbach’s alpha coefficient of 0.964. The components again 
remained consistent. Although ‘Has it taken you longer to do your 
daily tasks or activities because of RA stiffness?’ (Draft item take 
longer) continued to demonstrate acceptable component loadings 
(>0.45) on all components, ‘Has RA stiffness made it difficult to 
get up after sitting for a while?’ (Draft item get up after sitting) had 
the lowest component loading overall and was removed (Table 
9.17).  
Table 9.16: Rotated PCA 12 (‘Has RA stiffness made you slower 









Description of item removal Rotated PCA output 
Rotated PCA 13 (Table 9.17) contained 26-items and maintained 
the 3-component structure. The overall Cronbach’s alpha 
coefficient was 0.963. The components remained consistent. 
‘Have you had to concentrate to move your body because of RA 
stiffness?’ (Draft item concentrate) had the lowest loading and 
was removed (Table 9.18).  
Table 9.17: Rotated PCA 13 (‘Has RA stiffness made it difficult 







Description of item removal Rotated PCA output 
Rotated PCA 14 (Table 9.18) retained the 3-component solution 
and had a Cronbach’s alpha coefficient of 0.962. All components 
continued to remain consistent. Overall, ‘Has it taken you longer 
to do your daily tasks or activities because of RA stiffness?’ (Draft 
item take longer) had the lowest loading, and had consistently 
demonstrated loading >0.45 on all components in previous 
solutions, therefore it was removed (Table 9.19).  
Table 9.18: Rotated PCA 14 (‘Have you had to concentrate to 










Description of item removal Rotated PCA output 
Rotated PCA 15 (Table 9.19) retained 3-components and had a 
Cronbach’s alpha coefficient of 0.959. ‘Have you needed help 
(from others or gadgets) because of RA stiffness?’ (Draft item 
need help) and ‘Have you had to work around your RA stiffness 
(or do things in a different way)?’ (Draft item work around) loaded 
lowest and both had a loading of 0.615 on their respective 
components. To identify which of these items to remove, internal 
consistency analyses were inspected. The removal of either item 
would reduce Cronbach’s alpha coefficient slightly to .958 thus 
not differentiating between items. However, ‘Have you had to 
work around your RA stiffness (or do things in a different way)?’ 
had a slightly higher corrected item total correlation (r=0.787) than 
‘Have you needed help (from others or gadgets) because of RA 
stiffness?’ (r=0.760), therefore ‘Have you needed help (from 
others or gadgets) because of RA stiffness?’ was removed (Table 
9.20).  
Table 9.19: Rotated PCA 15 (‘Has it taken you longer to do your 
daily tasks or activities because of RA stiffness?’ (Draft item 









Description of item removal Rotated PCA output 
Rotated PCA 16 (Table 9.20) contained 23-items in a 3-
component solution which had a Cronbach’s alpha coefficient of 
0.958. All components continued to remain consistent. As 
identified in rotated PCA 15 (Table 9.19), ‘Have you had to work 
around your RA stiffness (or do things in a different way)?’ (Draft 
item work around) still had the lowest component loading, 
therefore it was removed (Table 9.21). 
Table 9.20: Rotated PCA 16 (‘Have you needed help (from 











Description of item removal Rotated PCA output 
Rotated PCA 17 (Table 9.21) contained 22-items in a 3-
component solution which had a Cronbach’s alpha coefficient of 
0.956. The components retained their structure and it was 
identified that item ‘Over the past 7 days have you experienced 
RA stiffness after a period of immobility (for example, after sitting 
for a while)?’ (Draft item after immobility) had the lowest 
component loading, therefore it was removed (Table 9.22). 
Table 9.21: Rotated PCA 17 (‘Have you had to work around 
your RA stiffness (or do things in a different way)?’ (Draft item 











Description of item removal Rotated PCA output 
Rotated PCA 18 (Table 9.22) retained the 3-component solution 
with a Cronbach’s alpha coefficient of 0.955. In addition to 
consistency of the structure of the solution, all item loadings could 
be defined as ‘very good’ or ‘excellent’. Despite this, for the 
purpose of testing item removal, the process was continued and 
‘Has RA stiffness made it difficult to balance without physically 
supporting yourself?’ (Draft item balance) was identified as having 
the lowest component loading, and was removed (Table 9.23). 
Table 9.22: Rotated PCA 18 (‘Over the past 7 days have you 
experienced RA stiffness after a period of immobility (for 











Description of item removal Rotated PCA output 
Rotated PCA 19 (Table 9.23) contained 20-items and retained the 
3-component solution with a Cronbach’s alpha coefficient of 
0.954. Component consistency was retained and ‘Has RA 
stiffness made it difficult to do fine movements (for example, write 
with a pen)?’ (Draft item fine movement) had the lowest 
component loading, and was removed (Table 9.24). 
Table 9.23: Rotated PCA 19 (‘Has RA stiffness made it difficult 













Description of item removal Rotated PCA output 
Rotated PCA 20 (Table 9.24) contained 19-items and retained the 
consistent 3-component solution with a Cronbach’s alpha 
coefficient of 0.952. ‘Has RA stiffness made it difficult to grip or 
hold things?’ (Draft item grip) had the lowest loading, thus it was 
removed (Table 9.25). 
Table 9.24: Rotated PCA 20 (‘Has RA stiffness made it difficult 
to do fine movements (for example, write with a pen)?’ (Draft 













Description of item removal Rotated PCA output 
Following the removal of item 10.21, the 3-component solution 
that had been stable for 13 rounds of item removal, reduced to a 
2-component solution containing 18-items. Although the internal 
consistency remained high with a Cronbach’s alpha coefficient of 
0.951, 12 items loaded on both the Physical and Severity 
components, which made interpretation difficult. Here it appeared 
that the Severity component remained stable from the solution 
generated in rotated PCA 20 (Table 9.24). However, the Physical 
and Psychosocial components appeared to merge into one 
component. This was labelled as the Physical component given 
the slightly higher number of items from the earlier defined 
Physical component.  
 
Testing of item removal was continued with the removal of the 
lowest loading item in each round. The 2-component structure 
was sustained for six further rounds of item removal after which a 
single component solution was formed containing 11-items. 
Subsequent PCA solutions have not been presented as given the 
above solutions it appeared likely that a multi-dimensional 
solution was present and would be most appropriate to represent 
the available items.  
 
Table 9.25: Rotated PCA 21 (‘Has RA stiffness made it difficult 
to grip or hold things?’ (Draft item grip) removed) 
 
 




9.4.2.3.1 Review item removal 
In the initial 4-component structure, components 1, 2 and 3 (“Physical”, “Severity”, 
and “Psychosocial”) not only had a strong statistical basis but also appeared to 
generally capture items assessing related concepts (Section 9.4.2.2). However, 
component 4 (“Location”) had weaker statistical evidence and conceptual clarity. 
During early rounds of item removal, three items (7.4, 8.8, and 9.9) originally 
contained within “Location” were removed indicating that this component contained 
poorly performing items and the content was inconsistent. The revised content of the 
component (Tables 9.7-9.11) at that stage did not lead to clarity from a conceptual 
perspective as items that loaded highest within the component were inconsistent 
across iterations and it did not appear to capture a unified concept. After this, a 
conceptually coherent 3-component structure emerged (Table 9.12) and remained for 
13 rounds of item removal. The component loadings could be described as ‘good’ or 
better, improving in later solutions and there was less movement of items between 
components than seen during the first seven rounds of item removal. 
 
The 2-component solutions generated after PCA 21 (Table 9.25) retained the 
conceptual essence of the 3-component solution but did not make it clearer. The 
merging of the “Physical” and “Psychosocial” components and the large number of 
items that loaded substantively on both components, reduced distinctiveness and 
interpretation from a conceptual perspective. Although item reduction was pursued 
further to test whether a smaller and clearer item structure resulted, this did not 
happen. Given the consistency and conceptual relevance of the 3-component 
solution, its individual components were re-examined.  
 
9.4.2.3.2 Re-examine each component individually (3-component solution) 
The first iteration of the 3-component solution (Table 9.12) was used to re-examine 
each component. 
 
9.4.2.4.1 Component 1 (“Physical”) 
A single component was identified and all item loadings were ‘excellent’ (Table 9.26). 
The Cronbach’s alpha coefficient for the 13-items was .960 which could not be 
improved by item removal. This was only slightly lower than that for “Physical” in the 
4-component solution (0.973). Correlations between items were moderate or strong. 
However, correlations between ‘Has RA stiffness made it difficult to open and close 
your fist?’ and ‘Has RA stiffness made it difficult to get out of bed?’, ‘Has RA stiffness 




made it difficult to get up after sitting for a while?’ and ‘Has RA stiffness made it difficult 
to balance without physically supporting yourself?’ were ‘weak’ (r=≤0.46). ‘Has RA 
stiffness made it difficult to open and close your fist?’ had the lowest loading and 
Cronbach’s alpha coefficient. 
  
Table 9.26: Item loadings and Cronbach’s alpha coefficient for 
component 1 (“Physical”) 
Item Loading Cronbach’s alpha 
coefficient 
Draft item daily tasks .876 .850 
Draft item dress .868 .838 
Draft item responsibilities .866 .827 
Draft item wash .854 .828 
Draft item grip .847 .831 
Draft item strength .836 .821 
Draft item need help .820 .795 
Draft item get out of bed .808 .766 
Draft item fine movement .807 .773 
Draft item concentrate  .790 .760 
Draft item get up after sitting .780 .750 
Draft item balance  .776 .744 
Draft item open/close fist .720 .682 
 
9.4.2.4.2 Component 2 (“Severity”) 
A single component was identified and all item loadings were ‘excellent’ apart from 
item 8.5 which was ‘good’ (Table 9.27). The Cronbach’s alpha coefficient for the 11-
items was 0.935 which was slightly higher than that for “Physical” in the 4-component 
solution (0.926). The separate removal of each of three items would slightly improve 
the Cronbach’s alpha coefficient (7.3=0.938, 8.5=0.938, and 8.7=0.936). Correlations 
between items were generally moderate or strong. However, correlations were weak 
between ‘Were your joints stiff when you woke up today? If yes, how long did this extra 
stiffness last?’ and ‘Over the past 7 days have you experienced RA stiffness after a 
period of immobility (for example, after sitting for a while)?’ (r=0.459) and ‘Over the 
past 7 days when have you experienced RA stiffness?’ (r=0.479). ‘Over the past 7 
days has your RA stiffness been different to usual for you?’ demonstrated weak 









Table 9.27: Item loadings and Cronbach’s alpha coefficient for 
component 2 (“Severity”) 
Item Loading Cronbach’s alpha 
coefficient 
Draft item severity .951 .949 
Traditional item severity G .946 .939 
Draft item impact .941 .935 
Traditional item severity A .925 .909 
Draft item importance .918 .911 
Traditional item severity C .895 .865 
Traditional item duration D .764 .930 
Draft item in joints .734 .636 
Draft item after immobility .724 .654 
Draft item timing .710 .621 
Draft item different to usual .582 .536 
 
9.4.2.4.3 Component 3 (“Psychosocial”) 
A single component was identified and all item loadings were ‘excellent’ (Table 9.28). 
The Cronbach’s alpha coefficient for the 7-item component was 0.948 which could 
not be improved by item removal. This was slightly higher than that for “Psychosocial” 
in the 4-component solution (0.941). All correlations between items were moderate or 
strong. 
 
Table 9.28: Item loadings and Cronbach’s alpha coefficient for 
component 3 (“Psychosocial”) 
Item Loading Cronbach’s alpha 
coefficient 
Draft item take longer .913 .936 
Draft item work around .902 .937 
Draft item frustrated .896 .937 
Draft item change plans .884 .939 
Draft item slower .864 .941 
Draft item self-conscious .834 .944 
Draft item worried .819 .946 
 
9.4.2.4 Decide on the final component structure  
The first 3-component solution (Table 9.12) was identified as being consistent and 
effective when considering both the whole structure and individual components. 
Subsequent testing of the 3-component solution indicated that it was statistically 
stable and conceptually sound. It was next important to review the above solutions in 
order to decide which of the 3-component solutions should be retained to ensure that 
the chosen solution was as good as it could be both statistically and conceptually. In 
all 3-component solutions there were a number of items within “Severity” that 




appeared to be capturing similar information. Two items both captured MS severity 
asking ‘How would you describe the overall level of morning stiffness you have had 
from the time you wake up?’ but were measured on different scales (NRS and 5-
option ordinal scale) while ‘Please circle the number that best describes the severity 
of your RA stiffness over the past 7 days’ and ‘Circle the number that best describes 
the stiffness (all over or in your joints) you felt due to your rheumatoid arthritis during 
the last week’ both captured stiffness severity on NRS but were worded differently. 
Given this, it was important to test the removal of conceptually similar items to identify 
the smallest component structure. Secondly, the components contained different 
numbers of items yet did not differ in importance. Therefore, the removal of items was 
influenced by consideration of the number of items per component. 
 
To consider these aspects, the 3-component solutions were reviewed again to identify 
the point at which all poorly performing items had been removed, and all item loadings 
met the target of ‘good’ (≥0.55). However, given that item loadings were generally 
‘good’, a higher target of ‘very good’ (>0.63) was set in order to retain the smallest set 
of items. The variance explained by each solution was also considered. In the first 
iteration of the 3-component solution (Table 9.12), all but one item (10.22) had ‘good’ 
loadings and the solution explained 71.14% of the variance. In rotated PCA 17 (Table 
9.21), the solution explained 75.10% of the variance and all item loadings were ‘very 
good’. However, in the previous solution (Table 9.20), which explained 75.14% of the 
variance, ‘Have you had to work around your RA stiffness (or do things in a different 
way)?’ had been identified for removal as it had the lowest loading. The removal of 
‘Have you had to work around your RA stiffness (or do things in a different way)?’ had 
led to a reduction in size of the smallest component (“Psychosocial”). As the loading 
of ‘Have you had to work around your RA stiffness (or do things in a different way)?’ 
(.620) was very close to the ‘very good’ cut-off and retaining it would preserve the 
number of items in an already small component, rotated PCA 16 (Table 9.20), with 23 
items, was identified as the most appropriate 3-component solution from the 
combined perspective of component loadings and explained variance. 
 
Having identified which 3-component solution to retain, an attempt was made to 
enhance it by testing the removal of similar items and trying to even up the size of the 
components. Firstly, the two items capturing MS severity (‘How would you describe 
the overall level of morning stiffness you have had from the time you wake up?’ (NRS 
and 5-option ordinal scale)) were investigated. When reviewing the retained 3-
component solution (Table 9.20) the component loadings of ‘How would you describe 




the overall level of morning stiffness you have had from the time you wake up?’ on 
both response scales (NRS and 5-option ordinal scale) were ‘excellent’, although the 
loading of the NRS item (0.750) was very slightly higher than the loading of the 5-
option ordinal scale item (0.749). When looking at previous 3-component solutions, 
the NRS item loaded higher than the 5-option ordinal scale item on more occasions 
(n=6, n=3). Furthermore, when looking at the loadings of items within the individual 
components (Section 9.4.2.4.2), the NRS item loaded higher (0.925) than the 5-option 
ordinal scale item (0.895). As a result, the 5-option ordinal scale item was removed.  
 
The resulting solution (Table 9.29) included 22-items, retained the 3-component 
structure, and explained 75.04% of the variance. All item loadings were ‘very good’ 
and the Cronbach’s alpha coefficient was 0.955. Next, the two items capturing 
stiffness severity (‘Please circle the number that best describes the severity of your 
RA stiffness over the past 7 days’ and ‘Circle the number that best describes the 
stiffness (all over or in your joints) you felt due to your rheumatoid arthritis during the 
last week’) were explored. In rotated PCA 16 (Table 9.20) the loadings of both items 
were ‘excellent’, although the loading of ‘Please circle the number that best describes 
the severity of your RA stiffness over the past 7 days’ (0.765) was higher than for 
‘Circle the number that best describes the stiffness (all over or in your joints) you felt 
due to your rheumatoid arthritis during the last week’ (0.761). When looking back at 
the loadings of these items in the 3-component solutions, ‘Please circle the number 
that best describes the severity of your RA stiffness over the past 7 days’ loaded 
higher than ‘Circle the number that best describes the stiffness (all over or in your 
joints) you felt due to your rheumatoid arthritis during the last week’ on all occasions 
(n=9). Furthermore, when looking at the loadings of items within the individual 
components (Section 9.4.2.4.2), it was again found that ‘Please circle the number that 
best describes the severity of your RA stiffness over the past 7 days’ loaded slightly 
higher (0.951) than ‘Circle the number that best describes the stiffness (all over or in 
your joints) you felt due to your rheumatoid arthritis during the last week’ (0.946). As 
a result, ‘Circle the number that best describes the stiffness (all over or in your joints) 











Table 9.29: Rotated PCA (‘How would you describe the overall level of 
morning stiffness you have had from the time you wake up?’ (5-option 
ordinal scale) removed) 
 
The resulting solution (Table 9.30) included 21-items and retained the 3-component 
structure (although the “Severity” and “Physical” switched places). The solution 
explained 74.53% of the variance. All item loadings were ‘very good’ and the 
Cronbach’s alpha coefficient was .951. The components were also slightly more equal 
in size (“Severity” and “Physical” n=8, “Psychosocial” n=5). The solution did 
demonstrate seven items which loaded >.40 on more than one component however 
this is fewer than in previous solutions such as rotated PCA 16 (Table 9.20) which 
had 12 multiple loading items. This solution provided a good performing, well 
balanced, conceptually sound set of items that was felt to be an improvement on that 
identified by statistics alone. Therefore it was taken forward as the best structure for 
the provisional RA stiffness PROM for further testing. As before, in subsequent 
reference to stiffness items, the full item wording is used in the text while abbreviated 




Item 1 2 3 
Draft item severity .750  .446 
Traditional item severity G .744  .436 
Draft item timing .743   
Traditional item severity A .725 .424  
Draft item in joints .719   
Draft item impact .697  .518 
Draft item importance .661  .569 
Draft item after immobility .650   
Traditional item duration D .641   
Draft item wash  .823  
Draft item dress  .775  
Draft item responsibilities   .714  
Draft item daily tasks  .460 .696  
Draft item get out of bed   .671  
Draft item grip  .658  
Draft item fine movement  .648  
Draft item balance  .644  
Draft item worried   .809 
Draft item self-conscious   .770 
Draft item frustrated    .708 
Draft item change plans  .487 .700 
Draft item work around  .572 .622 
Component key: Physical; Severity; Psychosocial 




Table 9.30: Rotated PCA (‘Circle the number that best describes the 
stiffness (all over or in your joints) you felt due to your rheumatoid 
arthritis during the last week’) removed) 
Component key: Physical; Severity; Psychosocial 
 
9.4.2.5 Bootstrapping 
The most appropriate solution (Table 9.30) was then subject to bootstrapping to test 
whether the components within the structure were retained during repeated PCA of 
subsets of the original data, indicating stable components. Twenty rounds of rotated 
PCA were performed, each time with randomly selected subsets of 50% of the dataset 
(Table 9.31). On five occasions bootstrapping produced a 2-component solution 
similar to that identified in rotated PCA 21 (Table 9.25). However, on 15 occasions, a 
3-component solution was produced indicating good stability. On seven occasions the 
solution was identical to the final solution. During the remaining eight rounds of 
bootstrapping, there was some movement of items between components, as a result 
of items which loaded >0.40 on more than one component. This meant that the 
number of items in some components did change however, the component structure 
was retained. This demonstrated the strength of the individual components, 
particularly “Severity” and “Physical” which were slightly larger than “Psychosocial”.  
 
Item 1 2 3 
Draft item wash .826   
Draft item dress .776   
Draft item responsibilities  .719   
Draft item daily tasks  .703 .447  
Draft item get out of bed  .668   
Draft item balance  .664   
Draft item grip .660   
Draft item fine movement .645   
Draft item timing  .763  
Draft item in joints  .734  
Draft item severity  .716 .458 
Traditional item severity A .441 .698  
Draft item impact  .668 .531 
Draft item after immobility  .664  
Traditional item duration D  .632  
Draft item importance  .631 .581 
Draft item worried   .815 
Draft item self-conscious   .775 
Draft item frustrated    .716 
Draft item change plans .493  .702 
Draft item work around .574  .624 
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Table 9.31: Component structure and item placement during rotated PCA on 20 randomly selected subsets of the dataset  
Round FS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
No. of components 3 3 2 3 3 3 2 3 3 3 3 3 2 3 3 3 3 2 2 3 3 
Final item timing  Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Ph Se Se 
Final item in joints  Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Ph Se Se 
Final item after immobility  Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Ph Se Se 
Final item dress  Ph Ph Ph Ph Ph Ph Se Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph 
Final item wash Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph 
Final item responsibilities  Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph 
Final item daily tasks  Ph Ph Ph Ph Ph Ph Se Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph 
Final item get out of bed Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph 
Final item fine movement   Ph Ph Se Ph Ph Ph Ph Ph Ph Ph Ph Ph Se Ph Ph Ph Ph Ph Ph Ph Ph 
Final item grip  Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Se Ph Ph Ph 
Final item balance  Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph Ph 
Final item frustrated  Ps Ps Ph Ps Ps Ps Ph Ps Ps Ps Ps Ps Ph Ps Ps Ps Ps Ph Ps Ps Ps 
Final item worried  Ps Ps Ph Ps Ps Ps Ph Ps Ps Ps Ps Ps Ph Ps Ps Ps Ps Ph Ps Ps Ps 
Final item self-conscious  Ps Ps Ph Ps Ps Ps Ph Ps Ps Ps Ps Ps Ph Ps Ps Ps Ps Ph Ps Ps Ps 
Final item change plans  Ps Ph Ph Ps Ps Ps Ph Ps Ps Ps Ps Ps Ph Ps Ps Ph Ps Ph Ps Ps Ps 
Final item work around  Ps Ph Ph Ph Ps Ps Ph Ph Ps Ps Ps Ps Ph Ps Ph Ph Ps Ph Ps Ps Ph 
Final item impact  Se Se Se Se Se Se Se Se Se Ps Se Se Se Se Se Se Se Se Ps Se Se 
Final item severity  Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Ph Se Se 
Final item importance  Se Se Se Ps Se Se Ph Ps Se Ps Se Se Se Se Se Se Ps Ph Ps Se Ps 
Final item severity A  Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Ph Se Se 
Final item duration D  Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Se Ps Se Ps 
FS = Final solution; Ph = Physical component; Se = Severity component; Ps = Psychosocial component 




9.4.2.6 Scoring  
All items within “Physical” and “Psychosocial” were assessed on the same scale while 
items within “Severity” were assessed on different scales. Scores using simple 
summation are shown in Table 9.32. Factor scores were also generated using the 
regression method in SPSS. Scores were generated for all participants for the 
“Severity” and “Psychosocial” and 276 scores for “Physical” because one participant 
provided no responses to any item in that component. 
 
Table 9.32: Each component and the scale each item was scored on 
Physical component  Severity component  Psychosocial component 
Item Score Item Score Item Score 
Final item wash  0-3 Final item timing  0-4 Final item worried 0-3 
Final item dress  0-3 Final item in joints  0-3 Final item self-conscious  0-3 
Final item responsibilities  0-3 Final item severity  0-0 Final item frustrated  0-3 
Final item daily tasks  0-3 Final item severity A 0-10 Final item change plans 0-3 
Final item get out of bed  0-3 Final item impact  0-10 Final item work around  0-3 
Final item balance  0-3 Final item after immobility  0-3   
Final item grip  0-3 Final item duration D  0-6   
Final item fine movement   0-3 Final item importance  0-10   
Range 0-24  Range 0-56 Range 0-15 
Total possible range of score=0-95 
 
To compare the simple summation and factor score methods, correlations (Table 
9.33) and scatterplots (Figures 9.1-9.3) were produced comparing each participant’s 
component simple summation scores with their factor scores.  
 
Table 9.33: Correlation between simple summation and regression 










REGR factor score F1  .784 .394 .460 
REGR factor score F2 .445 .760 .377 
REGR factor score F3 .436 .523 .809 









Figure 9.1: “Physical” sum score 
plotted against “Physical” 
regression factor score 
Figure 9.2: “Severity” sum plotted 




Figure 9.3: “Psychosocial” sum 
plotted against “Psychosocial” 
regression factor score 
 
 
As would be expected, the correlations between the scores generated using the 
simple summation method and the regression factor scores were strong between the 
same components, and weak or moderate between different components. The scores 
generated using the simple summation method were significantly related to those 
generated using the regression factor score method (Table 9.33). The strong 
correlation between the scores suggested similarities in approaches. The surprising 
effectiveness of simple summation has been demonstrated in the literature (Dawes, 
1979), and has the advantage of ease of application in clinical or research 
environments. The factor score method produces a more accurate indication of the 
relationship between each item and the component (Field, 2009). However, it would 








9.4.2.6.1 Whole scale or individual component scoring 
Discussion with the supervisory team regarding the scale scoring highlighted two 
areas for consideration. Firstly, given the identification of three individual components, 
the principal of a total score was questioned in favor of scores for each individual 
component. However, regardless of the most appropriate scoring of the scale it was 
still considered important to provide the option to generate a sum of all components. 
Secondly, it was highlighted that neither scoring approach represented the PCA 
output. As the range of possible scores for “Severity” was much larger (0-56) than the 
other components (“Physical”=0-24; “Psychosocial”=0-15), it may appear that it was 
more important and its influence dominated the total score calculation. Therefore, to 
ensure that all components were comparable, and that generation of a sum of all 
components was possible, item scores were rescaled using percentages (Tables 
9.34-9.36). A percentage score for each individual component could then be 
generated, which could be used to create a total percentage score for the new RA 
stiffness PROM by adding together the percentage scores for each individual 
component and dividing them by three. This approach provided balanced scores 
across components. The scoring protocol can be viewed in Appendix Z.  
 
Table 9.34: Rescaled percentage score for “Physical” 
Item Original score Percentage score 







Final item dress 
Final item responsibilities 
Final item daily tasks 
Final item get out of bed 
Final item balance 
Final item grip 
















Table 9.35: Rescaled percentage score for “Severity” 
Item Original score Percentage score 





Final item after immobility 

























Final item impact 
Final item severity 
Final item importance 
 
Table 9.36: Rescaled percentage score for “Psychosocial” 
Item Original score Percentage score 
Final item worried 
Final item self-conscious 
Final item frustrated 
Final item change plans 







9.4.2.6.2 Dealing with missing data 
Simple summation and factor scores had been generated with all available data 
regardless of the amount of missing data. However, for use in applied situations a 
more accurate approach was required. Similar to guidance provided in other scales 
such as the HAQ (Fries et al, 1980), it was decided that when scoring the scale, one 
missing item per component was acceptable. Here, individual component percentage 
scores could be generated by adding together the item percentages from the available 
data and dividing that by the number of item percentages provided. A score for each 




individual component would be required for the generation of a sum of all 
components. Future work investigating the treatment of missing data using other data 
sets is required. 
 
In this dataset, six participants had more than one missing item on some components 
therefore, scores were not calculated for these participants for these components 
(“Physical” n=272, “Severity” n=274, “Psychosocial” n=277). A sum of all components 
was only calculated for participants with a score for each component (n=271).  
 
9.4.2.6.3 Frequency and distribution of the components and total score 
Frequency and distributions of each individual component and the sum of all 
components were generated based on the percentage scores described above 
(Figures 9.4-9.7).  
 
 
Figure 9.4: Frequency and distribution for “Physical”  
 









Figure 9.6: Frequency and distribution for “Psychosocial” 
 





Figure 9.7: Frequency and distribution for the sum of all components 
 
Frequency and distributions indicated that participants reported a range of scores on 
each component and the sum of all components, although there were higher 
frequencies at the lower end of each. 
 
9.4.2.7 Formatting 
Component names used thus far (“Physical”, “Severity”, and “Psychosocial”) had 
been developed based on consideration of their content following discussion with the 
supervisory team. Discussion with one patient partner (GB) reinforced the 
appropriateness of these component names from the patient perspective. As 
recommended by GB, a summary sentence that captured the content of each 
component was added for clarity. Items within each component were presented in 
individually marked boxes. This layout ensured that the individual components could 
retain their distinct nature. Discussion of the final PROM items with one member of 
the supervisory team (JK) highlighted the importance of item placement specifically 
in relation to two items (‘How would you describe the overall level of morning stiffness 
you have had from the time you wake up?’ and ‘Were your joints stiff when you woke 
up today? If yes, how long did this extra stiffness last?’) which had different timeframes 
to other items within the questionnaire. Rational placement of these items was 
important in order to retain them as tested during the survey. The order that the items 
were tested in was retained where possible. The layout and font of the final PROM 
was also discussed with one patient partner (GB) to ensure appropriateness from the 




patient perspective. The final layout, now called the RA stiffness (RAST) PROM is 
detailed in Appendix AA.  
 
9.4.3 Stage 4 analysis: Validity testing 
The clinical data captured in the survey, but so far not used in the development of the 
RAST, provided the opportunity for preliminary validity testing. Spearman’s rank order 
correlations were used to investigate whether the RAST demonstrated expected 
relationships with other measures of RA. Correlation coefficients between the RAST 
(each individual component and total percentage scores) and clinical measures 
capturing disease activity (PDAS2, Choy et al, 2008; Choy et al, 2015), disability 
(MHAQ, Pincus et al, 1983), pain (Pain NRS, Farrah et al, 2001; Hawker et al, 2011), 
fatigue (BRAF severity-NRS, Nicklin et al, 2010a; Nicklin et al, 2010b), patient global 
assessment (PtG VAS, van der Heijde et al, 1993) and current flare (PFQ, Bykerk et 
al, 2012; Bykerk et al, 2014b) were calculated and shared variance reported. The 
PDAS2 (Choy et al, 2008; Choy et al, 2015) without EMS (Choy and Leung, 2016) 
was used here to avoid circular reasoning. 
 
Given that there has been little robust investigation to date into stiffness assessment, 
Spearman’s rank order correlations and shared variance were also used to 
investigate the relationships between traditional stiffness severity (‘How would you 
describe the overall level of morning stiffness you have had from the time you wake 
up?’ on NRS and 5-option ordinal scale and ‘Circle the number that best describes 
the stiffness (all over or in your joints) you felt due to your rheumatoid arthritis during 
the last week’) and duration (‘Were your joints stiff when you woke up today? If yes, 
how long did this extra stiffness last?’ and ‘How long does your morning stiffness last 
from waking until maximum improvement occurs?’ on 3-option ordinal scale and in 
minutes and hours) items and other measures of RA (as above). 
 
9.4.4 Stage 4 results: Validity testing 
Descriptive statistics for the non-stiffness items were reported during description of 
the study population (Chapter 8) and histograms and investigation into normality for 
these data are available in Appendix W.  
 
9.4.4.1 Comparison between RAST and clinical measures  
Table 9.37 reports the correlation coefficients (r) and shared variance (R2) and 
demonstrated strong correlations with disease activity and moderate to strong 




correlations with other measures of disease, apart from current flare which 
demonstrated moderate or weak correlations.  
 
Correlations between RAST and other measures of disease were higher than the 
expected moderate correlations. However, these appeared appropriate when 
considering the pattern across components, which also provided support for the 3-
component structure. “Physical” shared the most variance with disability (rs=0.886, 
R2=78.5%), which may be expected given the overlap in concepts and the response 
option format with the MHAQ (Pincus et al, 1983). “Severity” shared the most variance 
with pain (rs=0.851, R2=72.4%) and PtG (rs=0.826, R2=68.2%), which would be 
expected and may in part be due to similarities in assessment format (e.g. NRS or 
VAS). “Psychosocial” shared less variance with the disease related measures than 
other components. This may indicate that it is capturing aspects not currently being 
assessed (Pincus et al, 1983). 
 
When considering these results specifically in terms of shared variance, while RAST 
(individual components and sum score) appears related to other measures of disease, 
it does not appear to be capturing the same information. Shared variance between 
RAST (individual components and sum score) and pain (R2=44.9-72.4%) and fatigue 
(R2=43.2-55.2%) varied depending on the component. The relationship between 
RAST (individual components and sum score) and the PtG (R2=48.2-68.2%) may be 
expected given the suggestion that the PtG provides a patient report of the impact of 
RA rather than disease activity (Kalyoncu et al, 2009; French et al, 2013). Therefore, 
the shared concept of impact may increase this relationship. The relatively weak 
relationship between RAST (individual components and sum score) and self-reported 
current flare (rs=0.455-0.532, R2=20.7-28.3%) was unexpected and is considered 



















Pain Fatigue PtG Flare 
1 r (n) - .835 (271) .836 (272) .942 (271) .829 (272) .886 (272) .752 (272) .699 (272) .764 (270) .455 (271) 
R2 (%) - 69.7% 69.7% 88.7% 68.7% 78.5% 56.6% 48.9% 58.4% 20.7% 
2 r (n)  - .804 (274) .927 (271) .882 (274) .766 (274) .851 (274) .741 (274) .826 (272) .532 (273) 
R2 (%)  - 64.6% 85.9% 77.8% 58.7% 72.4% 54.9% 68.2% 28.3% 
3 r (n)   - .945 (271) .746 (277) .744 (277) .670 (277) .657 (277) .694 (275) .458 (276) 
R2 (%)   - 89.3% 55.7% 55.4% 44.9% 43.2% 48.2% 21.0% 
Sum 
r (n)    - .868 (271) .848 (271) .810 (271) .743 (271) .804 (269) .521 (270) 
R2 (%)    - 75.3% 71.9% 65.6% 55.2% 64.6% 27.1% 
DA 
r (n)     - .792 (277) .617 (276) .609 (276) .596 (274) .444 (275) 
R2 (%)     - 62.7% 38.1% 37.1% 35.5% 19.7% 
Dis 
r (n)      - 713 (277) .646 (277) .728 (275) .369 (276) 
R2 (%)      - 50.8% 41.7% 53.0% 13.6% 
Pain 
r (n)       - .693 (277) .827 (275) .576 (276) 
R2 (%)       - 48.0% 68.4% 33.2% 
Fatigue 
r (n)        - .700 (275) .445 (276) 
R2 (%)        - 49.0% 19.8% 
PtG 
r (n)         - .511 (274) 
R2 (%)         - 26.1% 
Flare 
r (n)          - 
R2 (%)          - 
All significant at p<.01; Physical (1)=Physical component % score; Severity (2)=Severity component % score; Psychosocial (3)=Psychosocial component % 
score; DA=Disease activity (PDAS2, Choy et al, 2008; Choy et al, 2015; Choy and Leung, 2016); Dis.=Disability (MHAQ, Pincus et al, 1983); Fat.=Fatigue 
(BRAF severity-NRS, Nicklin et al, 2010a; Nicklin et al, 2010b) 




9.4.4.2 Comparison between RAST and disease activity measures 
Strong correlations and a range of shared variance (rs=0.746-.882, R2=55.7-77.8%) 
were reported between RAST (individual components and sum score) and disease 
activity suggesting that RAST is assessing an aspect of patient reported disease 
activity as assessed by the PDAS2 (Choy et al, 2008; Choy et al, 2015). Interestingly, 
SJC individually only explained 31.4-41.5% of the variance in RAST (individual 
components and sum score). This indicates that that RAST may capture something 
not currently included within this aspect of disease activity assessment. It also reflects 
earlier qualitative work where some patients reported that inflammation was 
independent of stiffness and some stated they were unable to recognise inflammation 
(Section 4.5.2.1.3). 
 
9.4.4.3 Comparison between traditional stiffness items and clinical measures  
Traditional stiffness items demonstrated moderate to strong correlations with disease 
activity and weak to strong correlations with other measures of disease (Table 9.38). 
As demonstrated in the literature, generally stronger correlations were reported for 
traditional severity items than for traditional duration items (Section 2.4.1). Traditional 
item duration D (‘Were your joints stiff when you woke up today? If yes, how long did 
this extra stiffness last?’) demonstrated moderate correlations with all measures of 
disease apart from flare, whilst traditional items duration E and F (‘How long does 
your morning stiffness last from waking until maximum improvement occurs?’ on 3-
option ordinal scale and in minutes and hours) only demonstrated weak to moderate 
correlations. Similarly when considering the relationship between traditional stiffness 
items and disease activity, all traditional severity items demonstrated strong 
correlations with disease activity, while the traditional duration items (‘How long does 
your morning stiffness last from waking until maximum improvement occurs?’ on 3-
option ordinal scale and in minutes and hours) or strong (‘Were your joints stiff when 
you woke up today? If yes, how long did this extra stiffness last?’) demonstrated 
moderate correlations with disease activity. When considered another way, traditional 
items duration E and F (‘How long does your morning stiffness last from waking until 
maximum improvement occurs?’ on 3-option ordinal scale and in minutes and hours) 
only shared a quarter of the variance in disease activity while all other items shared 
over half. 
 
Furthermore, when looking at correlations between items, whilst traditional severity 
items correlated strongly with each other and traditional duration items correlated 
strongly with each other, traditional severity and duration items only correlated 




moderately with each other. This reinforces that these concepts may capture different 
information and supports the inclusion of both within RAST. In contrast, RAST 
demonstrated strong internal correlations between individual components and the 




Table 9.38: Correlation coefficients (r) and shared variance (R2) between traditional stiffness items and clinical measures 
  A G C D E F DA Dis. Pain Fat. PtG Flare 
A 
r (n) - .888 (273) .864 (274) .718 (273) .497 (237) .564 (219) .830 (274) .729 (274) .814 (274) .718 (274) .798 (272) .441 (273) 
R2 (%) - 78.9% 74.6% 51.6% 24.7% 31.8% 68.9% 53.1% 66.3% 51.6% 63.7% 19.4% 
G 
r (n)  - .844 (275) .706 (274) .536 (237) .552 (221) .850 (275) .721 (275) .858 (275) .707 (275) .806 (273) .508 (274) 
R2 (%)  - 71.2% 49.8% 28.7% 30.5% 72.3% 52.0% 73.6% 50.0% 65.0% 25.8% 
C 
r (n)   - .706 (275) .527 (238) .564 (221) .784 (276) .667 (276) .770 (276) .654 (276) .745 (274) .475 (275) 
R2 (%)   - 49.8% 27.8% 31.8% 61.5% 44.5% 59.3% 42.8% 55.5% 22.6% 
D 
r (n)    - .699 (237) .753 (237) .726 (276) .595 (276) .656 (276) .628 (276) .641 (274) .462 (275) 
R2 (%)    - 44.8% 56.7% 52.7% 35.4% 43.0% 39.4% 41.1% 21.3% 
E 
r (n)     - .779 (211) .508 (238) .371 (238) .543 (238) .435 (238) .516 (237) .354 (237) 
R2 (%)     - 63.8% 25.8% 13.8% 29.5% 18.9% 26.6% 12.5% 
F 
r (n)      - .551 (221) .424 (221) .521 (221) .458 (221) .552 (221) .333 (220) 
R2 (%)      - 30.4% 18.0% 27.1% 21.0% 30.6% 11.1% 
DA 
r (n)       - .792 (277) .812 (277) .706 (277) .824 (275) .532 (276) 
R2 (%)       - 62.7% 65.9% 49.8% 67.9% 28.3% 
Dis. 
r (n)        - .713 (277) .646 (277) .728 (257) .369 (276) 
R2 (%)        - 50.8% 41.7% 53.0% 13.6% 
Pain 
r (n)         - .693 (277) .827 (275) .576 (276) 
R2 (%)         -  68.4% 33.2% 
Fat. 
r (n)          - .700 (275) .445 (276) 
R2 (%)          -  19.8% 
PtG 
r (n)           - .511 (274) 
R2 (%)           - 26.1% 
Flare 
r (n)            - 
R2 (%)            - 
All significant at p<.01; A=Traditional item severity A (MS severity NRS); G=Traditional item severity G (stiffness severity NRS); C=Traditional item severity 
C (MS severity 5-point Likert scale); D=Traditional item duration D (MS duration 6 ordinal response options); E=Traditional item duration E (MS duration 3 
ordinal response options); F=Traditional item duration F (MS duration minutes/hours); DA=Disease activity (PDAS2, Choy et al, 2008; Choy et al, 2015; Choy 
and Leung, 2016); Dis.=Disability (MHAQ, Pincus et al, 1983); Fat.=Fatigue (BRAF severity-NRS, Nicklin et al, 2010a; Nicklin et al, 2010b) 





A rigorous examination of the draft stiffness items in relation to component structure 
and internal consistency, and from statistical and conceptual perspectives, led to the 
specification of the smallest and most effective combination of items reflecting the 
patients’ experience of stiffness. This enabled the development of a proposed new 
RA stiffness PROM (RAST) containing 21-items across three components (“Physical”, 
“Severity”, and “Psychosocial”) which reflect the patient experience of stiffness. 
During preliminary validity testing, the RAST demonstrated stronger correlations for 
every variable, apart from PtG where very similar strong correlations were 
demonstrated (Table 9.37 and 9.38). Furthermore, its rigorous item development 
process, consistent with PROM development guidelines (USDHHS FDA, 2009; 
Patrick et al, 2011a; Patrick et al, 2011b), provides superior face and content validity 
in comparison to traditional stiffness items and is a novel characteristic of the new 
RAST. 
 
In relation to the conceptual development of the RAST, the final content and structure 
reflects the patient experience of stiffness identified in earlier qualitative studies 
(Chapter 4 and 5). Most items in RAST were based on stiffness over a seven day 
timeframe. However, the inclusion of traditional stiffness items (‘How would you 
describe the overall level of morning stiffness you have had from the time you wake 
up?’ and ‘Were your joints stiff when you woke up today? If yes, how long did this extra 
stiffness last?’) in the final RAST resulted in items with different timeframes. ‘Were 
your joints stiff when you woke up today? If yes, how long did this extra stiffness last?’ 
asks about stiffness today and ‘How would you describe the overall level of morning 
stiffness you have had from the time you wake up?’ did not specify a timeframe. It is 
proposed that as both traditional stiffness items (‘How would you describe the overall 
level of morning stiffness you have had from the time you wake up?’ and ‘Were your 
joints stiff when you woke up today? If yes, how long did this extra stiffness last?’) 
related to MS specifically, short timeframes such as ‘today’ may be more appropriate, 
especially given the variability in the experience (Chapters 4 and 5). Furthermore, it 
was proposed that as both ‘Please circle the number that best describes the severity 
of your RA stiffness over the past 7 days’ and ‘How would you describe the overall 
level of morning stiffness you have had from the time you wake up?’ captured severity 
but over different timeframes, it may be that the combination of both items captures 
stiffness variability (e.g. a low score on ‘Please circle the number that best describes 
the severity of your RA stiffness over the past 7 days’ and a high score on ‘How would 




you describe the overall level of morning stiffness you have had from the time you 
wake up?’ could suggest that stiffness severity has been low over the last 7 days but 
is severe today). The concept of variability was originally identified as relevant in the 
patient experience of stiffness (Chapter 4) and was captured in an item (Chapter 6), 
but was later removed for poor performance (Chapter 8). However, further qualitative 
work is required to fully understand the concept and timeframe that ‘How would you 
describe the overall level of morning stiffness you have had from the time you wake 
up?’ is capturing. The variation in timeframes across items also had implications on 
the placement of the items in the final questionnaire to ensure that the neutral 
timeframe was retained. 
 
RAST includes three aspects of the impact triad (Sanderson et al, 2011), severity, 
importance and impact, but not coping. ‘Please circle the number that best describes 
how well you have coped with your RA stiffness over the past 7 days’ demonstrated 
poor item loadings in the initial exploration of the component structure (Chapter 8) 
and performed poorly during investigations into the whole and individual component 
structure, and was removed in the first round of item reduction testing. As discussed 
during item development (Chapter 6) the impact triad items were developed based on 
previous work (Nicklin, 2009; Nicklin et al, 2010a; Nicklin et al, 2010b). Specifically in 
relation to the coping item, a reversed anchor layout had been suggested as being 
more appropriate by patients (Nicklin, 2009), and was implemented here. Although 
the inconsistency of the anchors in comparison to other items was highlighted by 
some participants in cognitive interviews (Chapter 7), the feedback was not all 
negative and it was felt that the anchor format should be retained given the evidence 
in support of it from previous work (Nicklin et al, 2010a; Nicklin et al, 2010b). However, 
on review of responses to this item during the survey it appeared likely that some 
participants had marked the opposite response to that intended, although it was not 
possible to tell which patients marked responses inadvertently and those who did it 
intentionally. It is likely that this affected the correlations between this item and other 
items and was a contributing factor to its exclusion. A very recent study investigated 
the use of cognitive interviews in the translation of the BRAF (Nicklin et al, 2010a; 
Nicklin et al, 2010b) and RAID (Gossec et al, 2009; Gossec et al, 2011) 
questionnaires into six European languages (Hewlett et al, 2016a). The study found 
that there were difficulties with capturing and interpreting coping. It also highlighted 
problems with the anchor placement in the BRAF coping question as seven of the 10 
Dutch participants marked the item in the opposite way to that verbally conveyed. To 
investigate this further, a survey study was performed including both the original and 




a revised coping item, which found that the revised item with anchors in the traditional 
place performed better (Hewlett et al, 2016b). This provides evidence to support the 
suggestion that responses to the coping item in this study were influenced by the 
anchor placement. Further work into the concept of coping and how to assess it may 
have implications for the RAST. 
 
A final consideration relating to RAST is the appropriateness of a sum score. To reflect 
the three components identified during PCA, a score was generated for each 
individual component that could be used for different purposes. If the purpose was to 
assess the severity of stiffness then “Severity” could be used. If the purpose was to 
assess specific types of stiffness impact then the respective impact components 
(“Physical” and “Psychosocial”) could be employed. It was recognised that in some 
circumstances, all components would be used, therefore the option was provided to 
enable a sum score of all components if required.  
 
As reported earlier (Section 2.4), there is currently no clear evidence regarding the 
most appropriate measure to use to assess stiffness in RA. This work provides the 
first comprehensive and robust evaluation of stiffness assessment involving the RAST 
and traditional stiffness items. One key finding was the relationship between stiffness 
and disease activity where RAST (individual components and sum score) 
demonstrated strong correlations. Strong correlations were also reported for 
traditional severity items while moderate or strong correlations were reported for 
traditional duration items. Correlations between stiffness items and disease activity 
assessed using the PDAS2 (Choy et al, 2008) have not been demonstrated before. 
Although MS is traditionally considered an indicator of inflammatory activity in RA (e.g. 
Lansbury, 1956; Hazes et al, 1994; Soubrier et al, 2006), there is little evidence of this 
relationship in the literature. Two previous studies specifically exploring the 
relationship between stiffness and disease activity demonstrated weak or moderate 
correlations (Westhoff et al, 2008; Khan et al, 2009). Khan et al. (2009) reported weak 
correlations between MS duration and DAS28 (rs=0.46, p<0.001) while Westhoff et 
al. (2008) reported weak or moderate correlations between DAS28 and MS severity 
(baseline rs=0.47, follow up rs=0.58, both p<0.001). The MS duration results are 
similar to results from this study where ‘How long does your morning stiffness last 
from waking until maximum improvement occurs?’ reported in minutes and hours (the 
same item as used by Khan et al. (2009)) correlated only moderately with disease 
activity (rs=0.508, p<0.01). However, despite similarities, disease activity was 
assessed differently. The results for MS severity identified by Westhoff et al. (2008) 




were much lower than the strong correlations identified in this study. However, 
stiffness items were not directly comparable across studies.   
 
The consideration of different disease activity assessment is important. This study 
assessed disease activity using the PDAS2 without EMS which is a validated patient 
report of disease activity (Choy et al, 2008; Choy et al, 2015). Although the PDAS2 
demonstrated strong correlations with the DAS28 (rs=0.76) during validation (Choy et 
al, 2008), the DAS28 is still the recommended tool for assessment of disease activity 
(e.g. Luqmani et al, 2009). Research suggests that self-reported measures are more 
closely associated with other self-reported measures than with laboratory or 
physician-reported measures, specifically in relation to stiffness (Khan et al, 2009; 
Westhoff et al, 2008), but also more broadly in RA (Pincus et al, 1989; Taal et al, 
1998). In this study, the self-reported nature of all data may have influenced the 
demonstrated relationship between disease activity and stiffness. An important area 
for further testing of RAST includes comparison with other disease activity 
assessments that contain objective items, such as the DAS28 and blood tests for 
inflammatory markers. 
 
Another important result was the demonstration of the poor performance of traditional 
stiffness duration items (‘How long does your morning stiffness last from waking until 
maximum improvement occurs?’ on 3-option ordinal scale and in minutes and hours). 
Stiffness assessment in research trials is most common in the form of MS duration 
(Kalyoncu et al, 2009), yet there are difficulties with its assessment (e.g. Vliet Vlieland 
et al, 1997), and some literature suggests that stiffness severity items have better 
measurement properties than duration items (e.g. Lie et al, 2014) (Section 2.4.1.4). 
One previous study reported that despite assessing both MS severity and duration, 
only MS severity was used in analyses because it was more responsive and MS 
duration had a high proportion of missing data (Westhoff et al, 2008). This was 
consistent with the findings in the present study where ‘How long does your morning 
stiffness last from waking until maximum improvement occurs?’ on 3-option ordinal 
scale and in minutes and hours had large amounts of missing data (Section 8.4.2.3) 
and were excluded from PROM development analyses. Some was a result of 
inaccurate item completion where survey participants marked the minutes or hours 
response options provided rather than stating a specific duration. One participant 
during the cognitive interviews (Chapter 7) had suggested that item 12.5 was not clear 
enough that an amount of time had to be specified (“minutes, hours, that could be 
hours, okay, not minutes” [2408]). When reviewing ‘How long does your morning 




stiffness last from waking until maximum improvement occurs?’ on 3-option ordinal 
scale and in minutes and hours with the supervisory team, it was discussed that these 
items do not provide clear options to respond ‘none’ or ‘no stiffness’. This was 
proposed as a reason for the large amounts of missing data and thus poor correlations 
demonstrated by these items. It may also explain why tradition duration item ‘Were 
your joints stiff when you woke up today? If yes, how long did this extra stiffness last?’ 
(which provides an option for ‘no stiffness’) demonstrated higher amounts of complete 
data, and superior correlations than the two other duration items. As the concept of 
duration had been challenged by patients (Chapter 5), it was interesting that 
traditional stiffness duration item ‘Were your joints stiff when you woke up today? If 
yes, how long did this extra stiffness last?’ was retained as an item in the final RAST. 
It may be that because duration is so commonly used to assess stiffness, patients are 
familiar with the concept and used to completing it. Additionally, although the concept 
of duration was suggested to be difficult for patients, the timing of stiffness was 
important to patients (Chapter 4). Furthermore, the retained duration item (‘Were your 
joints stiff when you woke up today? If yes, how long did this extra stiffness last?’) was 
the only traditional duration item included in this study that did not focus specifically 
on MS. Although the item asks about stiffness on waking, the response options allow 
patients to describe any experience in the following 24 hour period which was 
consistent with the patient experience of stiffness (Chapter 4). Despite the poor 
performance of some traditional items, others performed well as individual items. Like 
many of the RAST items, the wording of ‘Circle the number that best describes the 
stiffness (all over or in your joints) you felt due to your rheumatoid arthritis during the 
last week’ reflects the patient suggestion that stiffness is not only relevant in the 
morning period (Chapters 4 and 5). Although it was not included in the RAST, ‘Circle 
the number that best describes the stiffness (all over or in your joints) you felt due to 
your rheumatoid arthritis during the last week’ demonstrated appropriate relationships 
with other measures of disease which were comparable with those reported for the 
RAST severity component. This provides support of the use of this item within the 
work into flare and within the currently unvalidated PFQ (Bykerk et al, 2012; Bykerk 
et al, 2014b). 
 
An unexpected finding in this study were the low correlations between self-reported 
flare and all stiffness items. However, given the strong correlations demonstrated 
between stiffness items and disease activity, poor correlations in relation to flare may 
be a result of the question used to explore this relationship. The flare item used in the 
questionnaire pack was taken from the PFQ (Bykerk et al, 2012; Bykerk et al, 2014b). 




However, the PFQ is as yet unvalidated and work into the definition and assessment 
of flare is ongoing, and while a core domain set for flare assessment has been 
endorsed at OMERACT (Bykerk et al, 2014a), the most appropriate way to assess 
these domains has not yet been established (Bartlett et al, 2015). Importantly, one of 
the RA flare core set domains is stiffness, and is one of the domains which has been 
identified as requiring work into most appropriate assessment (Bingham et al, 2011; 
Bykerk et al, 2014a). Different definitions and assessments of flare have been used 
in other work (Bingham et al, 2009; Lie et al, 2014). In further development and 
validation of RAST it would be relevant to consider the relationship with flare using 
different flare assessments. This may include the complete PFQ once it is validated. 
Additionally, as stiffness featured in the flare score set (Bykerk et al, 2014a), the use 
of RAST may be relevant in the context of flare assessment.  
 
This discussion has reviewed aspects relevant to the development of the final 
structure and content of the RAST. Importantly this highlighted that the RAST 
captures the patient perspective of stiffness which is essential in PRO’s. It has also 
identified a number of key areas for further validation and development of the RAST. 
Firstly, as preliminary validation was performed in the population in which it was 
developed, validity testing must be repeated in a new set of RA patients. This may 
provide an opportunity to further explore aspects of validity such as the relationship 
between the RAST and disease activity (e.g. the DAS28, blood tests, and flare). It 
would also enable exploration of the performance of RAST in relation to other 
psychometric properties including test-retest reliability, ability to detect change, floor 
and ceiling effects, and other quality criteria for evaluating questionnaires (Terwee et 
al, 2007).  
 
9.6 Conclusion 
This study has described the development of the 21-item, 3-component RAST. The 
process of development was rigorous and involved careful investigation from both 
statistical and conceptual perspectives. RAST demonstrated appropriate 
relationships with other measures of disease which were as good as or better than 
traditional stiffness items. However, the novel characteristic of RAST is its superior to 
face and content validity. The new RAST appears suitable for use in the assessment 
of stiffness and for further development and validation. Chapter 10 will now provide a 
summary of the key findings, strengths and limitations and implications of this body 
of research. 




Chapter 10: Summary and discussion 
This chapter summarises and draws together the main findings from the studies 
presented earlier and discusses the implications of this work. 
 
10.1 Thesis aims 
Stiffness is a key patient symptom for people with RA and is regularly used as an 
outcome measure in clinical and research settings, but currently its patient-reported 
assessment is variable, non-standardised, and has not been developed according to 
current guidelines (e.g. USDHHS FDA, 2009). The overall aim for this thesis was to 
explore the experience of stiffness in people with RA and use this to develop and test 
a new RA stiffness PROM. PROM provide an assessment of a patient’s health 
condition that comes directly from a patient and as such are useful in the assessment 
of concepts that are best understood by patients, such as disease symptoms 
(USDHHS FDA, 2009). The justification for the development of a new stiffness PROM 
was the provision of a standardised assessment that captures this patient relevant 
symptom, and could be used in clinical and research environments. To achieve this 
a mixed methods approach was employed which first aimed to qualitatively 
understand the experience of stiffness in people with RA and then explore which 
aspects might be relevant in the patient-reported assessment of stiffness. Further 
qualitative work developed a set of items that captured those patient relevant aspects 
using appropriate wording and formatting and ensured the acceptability of the draft 
items to the target population. Using these items a quantitative survey was 
undertaken to provide data on which to perform multivariate analysis to develop the 
smallest and most internally consistent set of items to form an RA stiffness PROM 
and then to test how these items perform compared to current stiffness assessments. 
From these results it was possible to make recommendations about the most 
appropriate way to assess stiffness in clinical and research environments. 
 
10.2 Contributions to knowledge 
This thesis contributed to knowledge in the following ways: 
 A systematic literature review of currently available stiffness assessment tools 
and their measurement properties identified that current stiffness assessment 
is based on non-standardised and poorly defined items that do not appear to 
have been developed in accordance with PROM development guidelines 
 Investigation into the experience of stiffness for people with RA confirmed that 
stiffness was a significant patient symptom but also enhanced understanding 




of stiffness from the patient perspective and enabled the development of a 
conceptual model of stiffness in RA 
 Rigorous item development and testing resulted in a novel stiffness 
questionnaire (RAST) which was acceptable to patients, demonstrated validity 
during preliminary testing, and is likely to be useful in future assessment of RA 
stiffness in a research context 
 Testing of two multivariate analytical methods (PCA and NLPCA) provided 
novel evidence that the two approaches produced similar results when 
analysing the same dataset 
 
10.2.1 Current stiffness assessment tools and measurement properties 
The systematic literature review (Chapter 2) found 19 articles all assessing stiffness 
from only two concepts (duration or severity), yet 37 different stiffness assessment 
tools were identified. This highlighted the need for standardisation of stiffness 
assessment in RA. On review of the measurement properties of the available tools, 
there was no clear evidence regarding the most appropriate measurement tool to use 
to assess stiffness. Additionally, no identified tools appeared to have been developed 
in accordance with current standards (USDHHS FDA, 2009), and there was no 
evidence of an appropriate conceptual framework for stiffness in RA on which to 
constitute stiffness assessment. Therefore the need for an RA stiffness measure with 
appropriate content validity was highlighted. 
 
10.2.2 Understanding stiffness 
A better understanding of the patient experience of stiffness is important because it 
has been a poorly understood and under-researched topic and because it is crucial 
for PROM development. Prior to Study 1, little was known about the patient 
experience of stiffness and only one previous study on the topic had been performed 
(Lineker et al, 1999), which focused on the development of a patient-centred definition 
of MS. Study 1 investigated the patient experience of stiffness using semi-structured 
interviews, and from it a conceptual model of the patient experience of stiffness was 
developed. This model was reinforced by data generated in Study 2 involving a 
different sample of patients and a different data collection method (focus groups). A 
qualitative study in a US-population (Orbai et al, 2014) was performed at a similar 
time to Study 1 which reported similar results (presented orally at OMERACT 12 and 
in a collaborative publication (Orbai et al, 2015)). The key similarities were that 
stiffness was variable within and between participants, and with respect to location 




and disease activity, and was particularly important in flare. Both studies reported that 
participants did not experience stiffness exclusively during the morning period, and 
highlighted similar factors that exacerbated or alleviated stiffness. Importantly both 
stated that stiffness was described in terms of its impact on patients’ lives. This 
comparison recognised important considerations in relation to stiffness assessment 
including investigation into cross-study aspects (impact, severity, timing, location and 
duration) and how these might fit into measurement, and identification of the most 
appropriate way to assess stiffness (Orbai et al, 2015). PROM development 
guidelines highlight the importance of underpinning qualitative studies such as these 
to identify relevant concepts and inform item development (USDHHS FDA, 2009). 
The conceptual model that emerged from Chapters 4 and 5 was supported by the 
similarities between the results from Study 1 and the study by Orbai et al. (2014) and 
provided a basis for PROM development. Furthermore, it identified inconsistencies 
between the patient experience of stiffness and current assessment (e.g. focus on 
EMS and limited to duration and severity).  
 
It is helpful to consider the RA patient experience of stiffness within a broader 
rheumatology context, and recently published work in PMR has explored this further. 
PMR is a condition in which stiffness is a central symptom. Qualitative work involving 
eight focus groups (Mackie et al, 2015) previously reported in an abstract only 
(Hughes et al, 2012), developed a conceptual model of stiffness in PMR where 
stiffness was integral to PMR, linked to function and pain, and often discussed by 
patients in relation to how it impacted on their daily lives (Mackie et al, 2015). Twohig 
et al. (2015a) investigated the patient experience of PMR and identified ‘pain, 
stiffness, and weakness’ as one resulting theme. The similarities between the RA and 
PMR patient experience of stiffness were accentuated in a comment by Twohig et al. 
(2015b) published in response to the article capturing the Study 1 results (Halls et al, 
2015). This highlighted cross-condition similarities with regards to the relationship 
between stiffness and pain, the conflict between the biomedical understanding and 
patient descriptions of the timing of stiffness, and the relevance of impact to patients 
(Twohig et al, 2015b). The adequacy of MS duration as a stiffness measure was 
challenged in PMR (Twohig et al, 2015a; Mackie et al, 2015) and RA (Orbai et al, 
2014; Halls et al, 2015; Studies 1 and 2). Variability in PMR MS duration was reported 
and patients did not suggest the use of MS duration as a method of stiffness 
assessment (Mackie et al, 2015). Furthermore, the pattern of stiffness described by 
PMR patients was often much broader than the traditionally accepted concept of ‘MS’ 
and it was suggested that ‘stiffness’ may be more relevant than ‘MS’ (Twohig et al, 




2015a). This was reinforced in a recent Delphi study in the development of a core 
domain set for PMR where patients articulated a preference for ‘stiffness’ rather than 
‘MS’ (Helliwell et al, 2015). This is also consistent with the finding that the RA patient 
experience is not limited to the morning (Studies 1 and 2; Orbai et al, 2014; Halls et 
al, 2015). The use of the broader term ‘stiffness’ was highlighted as appropriate and 
acceptable to patients during Study 2. This is also supported by older RA literature 
where stiffness was found to present in the morning but also after a period of 
immobility (Hazes, Hayton, and Silman, 1993) and where ‘immobility’ was included in 
a patient-generated definition of ‘MS’ (Lineker et al, 1999). 
 
The suggestion that stiffness measurement could be based on the concept of impact 
(Halls et al, 2015; Study 1) was reinforced in the work by Orbai et al. (2014) as impact 
was an area of common language in an otherwise varied symptom. It was also 
supported by both PMR studies (Twohig et al, 2015a; Mackie et al, 2015). 
 
Given the similarities in the experience of stiffness and apparent shared concepts 
between patients with PMR and RA, there would be value in exploring the possibility 
of shared measurement. The specific or general nature of stiffness assessment within 
rheumatology is an important area for further research. The OMERACT stiffness 
special interest group aims to enable investigation of stiffness assessment across 
conditions (Orbai et al, 2015). Given the criticisms of traditional stiffness assessment 
in RA and PMR populations, an area for future research would be exploration into 
stiffness assessment in other rheumatic populations. 
 
10.2.3 Development and content of a novel stiffness PROM (RAST) 
The combination of qualitative (Studies 1, 2 and 3) and quantitative (Study 4) methods 
in the development and subsequent testing of the RAST is a key strength. The 
development process was congruent with recommended PROM development 
methodology (USDHHS FDA, 2009; Patrick et al, 2011a; Patrick et al, 2011b). The 
inclusion of the patient perspective throughout the studies is consistent with practices 
of groups such as OMERACT who advocate and implement patient involvement in 
outcome assessment in rheumatology (Hewlett et al, 2006; de Witt et al, 2011). It also 
fits with recent work highlighting the importance of patient participation in PROM 
development (de Wit, Kvien and Gossec, 2015). Specifically, the initial qualitative 
work (Studies 1 and 2) developed understanding of stiffness from the patient 
perspective. These data informed the iterative item development process (Chapter 6) 
which involved the perspectives of clinicians, patients and researchers and 




considered current literature. Item content, wording and format were checked with 
patients during Study 3. Subsequent item reduction involved consideration of 
statistical criteria, theoretical appropriateness and simplicity (Nunnally and Bernstein, 
1994; Pett, Lackey and Sullivan, 2003) to identify the smallest and most effective item 
structure (Study 4). The large VAF (71.19%) reported in the initial 38-item model 
(Chapter 8) emphasised the strength of the items prior to item refinement (Chapter 9) 
where a 21-item, three component model was defined and tested. 
 
The PROM development process, embedded within the patient perspective, enabled 
the content of the RAST to reflect the patient experience of stiffness. The final RAST 
contained three individual components capturing stiffness severity, physical impact 
and psychosocial impact. The severity component contained items relating to the 
timing and location of stiffness, stiffness after immobility, stiffness duration and 
severity, and the broad impact of stiffness. The two specific impact components 
contained items capturing physical and daily life impact and psychosocial impact of 
stiffness. The content of RAST reflects the concepts identified by patients in Studies 
1 and 2 and within the literature (Orbai et al, 2014; Orbai et al, 2015; Twohig et al, 
2015a; Twohig et al, 2015b; Mackie et al, 2015). Also in relation to content, there is 
overlap between RAST and traditional stiffness assessment as RAST includes two 
traditional stiffness assessment items; one capturing duration (‘Were your joints stiff 
when you woke up today? If yes, how long did this extra stiffness last?’) and one 
capturing MS severity (‘How would you describe the overall level of morning stiffness 
you have had from the time you wake up?’). This was particularly interesting given 
that the concept of duration had been challenged by patients (Studies 1 and 2). Both 
traditional items demonstrated acceptable statistical performance (Study 4) and as 
suggested previously, despite patients’ difficulties in reporting duration, its inclusion 
in the final RAST may be due to familiarity with the concept or the option provided to 
report ‘no stiffness’. The systematic literature review (Chapter 2) reported different 
relationships between traditional stiffness items which varied across and within 
concepts (severity and duration) and also across items using different wording or 
timeframes. In contrast, Study 4 revealed strong correlations between severity items 
and moderate or strong correlations between duration items, while correlations across 
concepts were weaker. Overall, correlations between all traditional stiffness items 
(apart from ‘How would you describe the overall level of morning stiffness you have 
had from the time you wake up?’ vs ‘How long does your morning stiffness last from 
waking until maximum improvement occurs?’ (3-option ordinal response), rs=0.497) 
were moderate or strong regardless of concept or item format. Given the consistency 




in these results, it may be that the varied relationships between items in the systematic 
literature review were a result of differences in wording, format and timeframe. This 
strengthens the argument for stiffness assessment standardisation. In another recent 
study, Boers et al. (2015) reported that MS duration and severity items correlated 
moderately (r=0.50, p<0.001). These results were comparable to Study 4 where 
severity and duration items correlated between rs=0.497 and rs=0.718. The authors 
suggested the different concepts of severity and duration, capture different aspects 
of RA (Boers et al, 2015). This suggestion is supported by Studies 1 and 2 where 
duration and severity were both identified within the conceptual model, and provides 
support for the inclusion of ‘Were your joints stiff when you woke up today? If yes, how 
long did this extra stiffness last?’ and ‘How would you describe the overall level of 
morning stiffness you have had from the time you wake up?’ within RAST. It may also 
explain the differences found between concepts in previous literature (Vliet Vlieland 
et al, 1997). This work also reported that the severity of MS demonstrated less 
variability than the duration of MS over 12-weeks (Vliet Vlieland et al, 1997), which 
may provide some explanation for the importance of a shorter timeframe for ‘Were 
your joints stiff when you woke up today? If yes, how long did this extra stiffness last?’ 
Given the variability in MS duration, assessment over a shorter timeframe (e.g. today) 
is likely to enhance accuracy. This was also reported in work in PMR (Mackie et al, 
2015) where given the variability in MS duration reported by participants, it was 
suggested that this fluctuation was a possible reason for poor performance in 
measurement as seen in other PMR literature (e.g. Matteson et al, 2012). This 
provides further justification for the shorter timeframe for ‘Were your joints stiff when 
you woke up today? If yes, how long did this extra stiffness last?’ compared to other 
items included in the RAST. However, it would be worthwhile to investigate the 
different timeframes in RAST items and establish the most relevant timeframe for 
‘How would you describe the overall level of morning stiffness you have had from the 
time you wake up?’ 
 
It is important to note that the RAST does not capture stiffness as a result of 
permanent damage to joints. Some patients in Study 1 suggested that damaged joints 
(mechanical process) may be perceived to be stiff, and were different in severity and 
persistence from stiffness as a result of disease activity (inflammatory process). As it 
is traditionally considered that stiffness is an indicator of inflammatory activity in RA 
(e.g. Lansbury, 1956; Hazes et al, 1994; Soubrier et al, 2006), during item 
development (Chapter 6) it was felt important to clarify that this was the focus of the 
questionnaire as part of the introduction. However, two items concerned the 




relationship between stiffness and damaged joints and it was hypothesised that some 
items may naturally group (or factor) with those items thus potentially capturing 
stiffness as a result of different processes. Despite this, these items performed poorly 
in early investigation into item suitability and were removed from subsequent testing. 
It may have been that this was not relevant to enough patients to be distinguished in 
the survey. Although, a recent study investigating radiological damage and disease-
related variables reported that MS duration was associated with radiological damage 
(Celepkolu et al, 2015), these results are not consistently demonstrated in other 
research (van Nies et al, 2015). There was no significant difference between MS 
duration in patients with high (Larsen score <28, n=32) and low (Larsen score ≥28, 
n=58) erosion scores (high Larsen scores indicate more damage), and highlighted 
that the mechanism for the relationship is uncertain (Celepkolu et al, 2015). Future 
research could investigate whether there are differences in RAST responses between 
patients with different amounts of radiological damage.  
 
10.2.4 Measurement property evidence for stiffness assessment tools 
Correlations between all stiffness items (RAST and traditional stiffness items) and 
other measures of disease were higher than expected (Study 4). The relationship 
between stiffness and disability is perhaps unsurprising when considering previous 
work that concluded that MS was more associated with disability than with laboratory 
measures such as ESR (Yazici et al, 2004). This may be related to the observation 
that self-reported measures are more closely associated with other self-reported 
measures than with laboratory or physician-reported measures (Pincus et al, 1989; 
Taal et al, 1998; Westhoff et al, 2008; Khan et al, 2009). Interestingly, in PMR it was 
suggested that the HAQ or MHAQ could be used for assessment of stiffness impact 
(Mackie et al, 2015). Although there was an overlap in concepts and response option 
format between the RAST physical component and the MHAQ (Pincus et al, 1983), 
correlations were slightly lower for other components indicating that they capture 
different information.  
 
Qualitative research has consistently highlighted a relationship between the patient 
perspective of pain and stiffness in RA (Orbai et al, 2014) and PMR (Mackie et al, 
2015; Twohig et al, 2015a; Twohig et al, 2015b). Very strong correlations between 
morning pain and MS severity (r=0.91, p<0.0001) were reported in a recent study 
(Boers et al, 2015), although these may have been influenced by the consistency 
between question timeframes and the diary-based data collection. Moderate or strong 
relationships between all stiffness items (RAST and traditional stiffness items) and 




pain were reported in Study 4. However the relationship between RAST and pain 
varied between components and the shared variance suggested that different 
components capture different information. Furthermore, moderate or strong 
relationships were also reported between other measures of disease and pain 
indicating that this was not just the case for stiffness. It has been suggested that 
stiffness and pain represent different concepts and that the underlying 
pathophysiology of the two symptoms may differ (Boers et al, 2015). This suggestion 
is reinforced by other recent work which reported that MS severity was associated 
with changes in PtG assessment independent of changes in pain, indicating that pain 
cannot be used as a substitute assessment of stiffness (Ward, Guthrie and Alba, 
2015). The close relationship between symptoms in RA has been demonstrated in 
other work into fatigue where it was reported that some participants found it difficult 
to separate symptoms (Salmon, 2015). However, this does not detract from the need 
to assess these symptoms. Added to which, patients in Study 2 disliked the proposal 
that given the correlation between stiffness and pain, these could be assessed using 
a combined question (Boers et al, 2015). It is hoped that developing a stiffness 
assessment tool with acceptable content validity will provide better assessment of this 
symptom to enable proper investigation into the relationship between these 
symptoms. Furthermore, in an attempt to capture stiffness yet acknowledge its close 
relationship with pain, RAST includes ‘RA stiffness’ in every stem question to enhance 
specificity and focus on the relevant symptom.  
 
Study 4 also provided novel evidence of a relationship between stiffness and patient-
reported disease activity. This had not been investigated in detail in previous literature 
and the systematic literature review only identified two studies (Westhoff et al, 2008; 
Khan et al, 2009) that had specifically examined this relationship. Both studies 
demonstrated weak correlations between composite disease activity assessment and 
stiffness. In contrast, Study 4 demonstrated strong correlations between all stiffness 
items (RAST and traditional stiffness items) and patient-reported disease activity 
(PDAS2, Choy et al, 2008). It is acknowledged that this could have been influenced 
by the patient-reported nature of both stiffness and disease activity (Pincus et al, 
1989; Taal et al, 1998; Westhoff et al, 2008; Khan et al, 2009).  However, a strength 
is the use of the PDAS2 without EMS (Choy et al, 2008; Choy et al, 2015; Choy and 
Leung, 2016) to avoid circular reasoning. More recent research (Boers et al, 2015) 
has specifically investigated the relationship between MS (duration and severity) and 
disease activity. The study collected information using a daily diary that asked 
participants to record the time they woke and if they were stiff on waking (‘Yes’ or 




‘No’). If participants responded ‘Yes’ they were required to indicate the severity of MS 
on a 100mm VAS (0=not severe at all, 100=extremely severe) and also the time that 
MS subsided, from which the duration of MS was calculated (the difference between 
the time of waking and time MS subsided). Patients also reported pain severity on a 
100mm VAS (0=no pain, 100=very severe pain) and collected disease activity 
information using the ACR core set, DAS28, and HAQ. The study reported 
correlations between disease activity (DAS28, ACR20) and MS duration (r=0.28, 
r=0.24) and MS severity (r=0.48, r=0.45), indicating that the assessment of MS adds 
to what is currently captured in the current RA core set (Boers et al, 2015). These 
correlations are comparable to those reported in the earlier studies (Westhoff et al, 
2008; Khan et al, 2009) but different to those reported in Study 4. It may be that the 
differences in correlations are a result of different assessment of disease activity (e.g. 
DAS28 is mostly physician-reported and includes blood tests for inflammatory 
markers). Therefore, further investigation into the relationship between the RAST and 
different measures of disease activity is an important area for future research. It is 
also important to consider that the stiffness assessment methods, question 
timeframes, and data collection methods were different across studies, making direct 
comparison difficult. This provides further evidence for the need to standardise 
stiffness assessment. Given that RAST performed as well as or better than traditional 
stiffness items and has superior content validity, it would be an appropriate tool for 
future use.  
 
The study by Boers et al. (2015) also reported that MS was common in patients with 
low (DAS28 ≤3.2) and minimal (DAS28 <2.6) disease activity. Eighty-one participants 
achieved low disease activity and of these, 26% reported MS duration ≥1 hour and 
37% reported MS severity >10mm. Thirty-four participants achieved minimal disease 
activity and of these, 18% reported MS duration ≥1 hour and 30% reported MS 
severity >10mm. These results are similar to results reported in previous work (Hazes, 
Hayton, and Silman, 1993; Khan et al, 2009). They call into question the traditionally 
accepted relationship between stiffness and disease activity as they question the 
value of the use of stiffness assessment purely as an indicator of inflammatory activity 
and make the case for its use more broadly as part of routine assessment in addition 
to composite scores, as recommended by Boers et al. (2015). Furthermore, this 
emphasises the importance of the use of PROMs to capture the patient experience, 
which is valuable information in its own right. Unlike the traditional stiffness items, 
RAST was developed based on qualitative research with patients, consistent with 
recommendations regarding the development of content validity of PROMs (USDHHS 




FDA, 2009; Patrick et al, 2011a; Patrick et al, 2011b). The superior content validity of 
RAST compared to traditional stiffness assessment is therefore advantageous from 
the perspective of capturing patient relevant information regardless of its relationship 
with other measures of disease. 
 
10.3 Implications for PRO methodology 
The RAST was developed following PROM development guidelines (USDHHS FDA, 
2009). Although initially conceived for measures used to support pharmaceutical 
labelling claims, these guidelines provided a rigorous framework for all PROM 
development and for structuring this thesis. Data generated in Studies 1, 2 and 3 have 
supported the emphasis the guidelines place on qualitative underpinning. The 
guidelines regarding the development of content validity (Patrick et al, 2011a, Patrick 
et al, 2011b) were particularly influential, especially for tracking the development of 
items (Chapter 6).  
 
Many investigators apply PCA to multivariate analysis without consideration of the 
nature of the dataset to which it is being applied. The statistical literature calls 
attention to the potential errors related to different analytical methods, and so attention 
was paid to the characteristics of the items. Recommended alternatives (NLPCA and 
polychoric correlations) were identified and two analytical methods (PCA and NLPCA) 
were compared in theory and practice (using the survey data) in Chapter 8. This novel 
approach provided evidence demonstrating similarities between results on the 
dataset to be analysed here. This investigation underpinned the decision to use PCA 
in the development of the new RA stiffness PROM, in spite of published 
recommendations (e.g. Streiner and Norman, 2008). This challenges those 
concerned with theoretical differences to explore further the circumstances in which 
they have practical consequences.  
 
One reason for the similarities in results across analyses is that, although the 
assumptions of parametric tests (such as distribution normality) are relevant to factor 
analysis (Pett, Lackey and Sullivan, 2003), both exploratory and confirmatory factor 
analysis may be robust in circumstances when normality is violated (Gorsuch, 1983). 
However, this does not explain the results from the perspective that some items in the 
dataset were not at an interval or ratio level of measurement. This could be 
investigated further in future research using IRT or Rasch analysis (Tennant and 
Conaghan, 2007). It would also be interesting to explore whether similar RAST 




content and structure emerged using polychoric correlations (Streiner and Norman, 
2008; Field, 2009). If similar results were gained from all three methods (PCA, 
NLPCA, and polychoric correlations), this may challenge the application of 
approaches considered most theoretically appropriate. However, the present dataset 
was generated from a questionnaire which had been rigorously developed and was 
accounted for very well (>70% VAF) by the analysis model. It may be that theoretical 
differences of greater practical consequence are present in the analysis of datasets 
where more ‘noise’ is present. This could be tested in future work by adding ‘noise’ 
(e.g. random samples of data) to the current dataset. 
 
An additional methodological implication of this work is related to the accessibility of 
polychoric correlations. As options to run polychoric correlations are not included in 
many standard software packages (and despite being accessible to download e.g. 
POLYMAT-C, Lorenzo-Seva and Ferrando, 2014), this process has been described 
as complicated (Gaskin and Happell, 2014). Therefore, additional accessibility may 
improve implementation of such approaches.  
 
10.4 Implications for research 
Stiffness is commonly (Kalyoncu et al, 2009), although decreasingly (Labitigan et al, 
2010) measured in rheumatology research. One new area of use is research into 
timed-release (delayed-release) glucocorticoids, as in the CAPRA-1 and CAPRA-2 
trials (Buttgereit et al, 2008; Buttgereit et al, 2013). These RCTs have demonstrated 
reductions in MS severity and duration following a course of TRT prednisone 
specifically designed for this purpose. 
 
Further research on the CAPRA datasets has also recently been published 
investigating MS from the perspective of its relationship with disease activity (Boers 
et al, 2015), response following change in treatment (Alten et al, 2015), and 
improvement thresholds (Buttgereit et al, 2015). The study by Boers et al. (2015) has 
been described previously (10.2.3 and 10.2.4). The study by Alten et al. (2015) 
investigated patients who demonstrated no improvement in MS while taking 
immediate-release (IR) prednisone (in CAPRA-1), and were switched to delayed-
release (DR) prednisone. The authors reported significant reductions in MS at 3, 6, 
and 9 months and stated that responses were comparable to patients who had 
continued on DR during the original study (Buttgereit et al, 2008). It was concluded 
that DR prednisone may be appropriate for use in patients who continue to experience 




MS while taking IR prednisone (Alten et al, 2015). Buttgereit et al. (2015) investigated 
the reduction in MS duration in patients receiving IR prednisone compared to DR 
prednisone. The authors reported significantly higher numbers of MS reductions at all 
thresholds (25%, 50% and 75%) in patients receiving DR compared to IR prednisone. 
It was also suggested that the defined thresholds could be useful in future work 
regarding treatment effectiveness (Buttgereit et al, 2015). MS duration has also been 
used recently as an outcome in research into DMARD initiation. Here, MS continued 
to be reported in 69.2% of patients despite DMARD initiation (Strand et al, 2015). 
Although it should be remembered that MS (≥45 minutes) was an inclusion criterion 
for the above trials, they indicate that research using stiffness as a primary outcome 
measure is continuing to be performed and the results inform the development of 
treatment in clinical practice. MS duration remains commonly employed in these 
recent studies, which is problematic given the poor performance of MS duration items 
(‘How long does your morning stiffness last from waking until maximum improvement 
occurs?’ on a 3-option ordinal scale or in minutes and hours) in Study 4. Poor 
performance of such traditional items may result in inability to demonstrate treatment 
effects in clinical trials. Although the remaining traditional stiffness items and RAST 
demonstrated appropriate relationships with other measures of disease, RAST is the 
only PROM with content validity. Therefore it would be important to investigate 
whether similar results are demonstrated in trials using stiffness assessment that 
captures the patient experience of stiffness. RAST may be appropriate for such a task 
given its appropriate validity and that it contains assessment of MS duration, enabling 
comparison. Therefore, use in clinical trials may be a key area of future use of the 
new RAST. Additionally, although considerable further testing would be required, the 
measurement property evidence for all stiffness items (apart from ‘How long does 
your morning stiffness last from waking until maximum improvement occurs?’ on a 3-
option ordinal scale or in minutes and hours) could lead to reconsideration of the 
decision to exclude stiffness from the ACR core set from which it was omitted (Felson 
et al, 1993). This is supported by a statement by Yazici et al. (2004) that study 
inclusion criteria often include MS yet not HAQ or pain, which unlike stiffness are both 
included within the ACR core set (Felson et al, 1993). 
 
A final implication for research relates to the work on the assessment of flare. 
Although it has been proposed that stiffness should be included as a core domain to 
assess RA flare (Bykerk et al, 2014a), Study 4 demonstrated an unexpectedly poor 
relationship between RAST and flare. As discussed (Chapter 9), this may have been 
due to the flare assessment method used, or the study population which generally 




represented patients at the lower end of the disease activity spectrum (Chapter 8). 
Given the considered relevance of stiffness in relation to flare, this is an area requiring 
further research. This should include testing the PFQ (Bykerk et al, 2012; Bykerk et 
al, 2014b) or other flare assessments in the same population of patients to provide 
further validation evidence for the new RAST and also to further explore the 
relationship between stiffness and flare.  
 
10.5 Implications for clinical practice 
A key implication for clinical practice relates to health professional and patient 
discourse regarding stiffness. This work has highlighted that stiffness is a relevant 
patient symptom, is an important part of the patient experience of RA, and has a 
significant impact on daily life. This reinforces the need for health professional 
awareness of this symptom and the importance of its recognition during clinical 
consultations. It was apparent that stiffness was particularly problematic for some 
patients, which is consistent with work in PMR where some patients reported that 
stiffness was the dominant symptom (Twohig et al, 2015a). Therefore it is important 
that health professionals have an awareness of the relevance of stiffness to individual 
patients. This work also emphasises that discussions should be worded using 
‘stiffness’ rather than ‘MS’ or ‘EMS’. ‘Stiffness’ is acceptable and relevant to patients, 
both in RA (Orbai et al, 2014; Halls et al, 2015) and PMR (Twohig et al, 2015a; Mackie 
et al, 2015). 
 
Given completion times for the 20-item HAQ (White, Wilson and Keysor, 2011), it is 
estimated that the RAST will also take <10 minutes to complete. Despite attempting 
to identify the smallest set of items for feasibility (Boers et al, 1998), the 21-items may 
still have implications for the ease of implementation of RAST in clinical practice 
settings from a time perspective. Further research investigating a shorter version of 
RAST for use in clinical practice would be an important development of the tool. This 
may be facilitated by qualitative research with health professionals to help shape an 
improved RAST format specifically suitable for application in clinical practice. 
Additionally, the identification of the best performing traditional items (Study 4) 
provides evidence for items that could be used in this context. On the other hand, the 
consequence of a shorter tool would be reduced precision, especially when being 
used with individual (rather than groups) of patients. Therefore, this tradeoff would 
need to be tested as part of future work.  
 




Additionally, the use of stiffness for diagnostic purposes has been re-evaluated in 
recent research by van Nies et al. (2015). That study included data from large 
European cohort studies and investigated the diagnostic value of MS in 5202 patients 
with arthralgia and early arthritis. In patients with arthralgia, MS duration ≥60 minutes 
was found to be associated with the presence of arthritis (OR 1.49 (95% CI 1.001-
2.20)-2.21 (95% CI 1.33-3.69)), but the discriminatory ability was low (AUC=0.52-
0.57). In patients with early arthritis, MS was associated with RA independent of other 
variables such as SJC (OR 1.68-1.72 (95% CI 1.03-2.74), AUC=0.64-0.68). MS 
duration ≥30 minutes was reported to have the optimal, although only moderate, 
discriminatory ability (sensitivity=74-77%, specificity=48-52%) for RA. The study 
concluded that in clinical practice, stiffness is useful for diagnostic purposes given its 
moderate discriminative ability. The acceptable performance of the MS duration item 
contrasts with the results from Study 4 which demonstrated poor performance of 
traditional duration items (‘How long does your morning stiffness last from waking until 
maximum improvement occurs?’ on a 3-option ordinal scale or in minutes and hours). 
However, the question used to evaluate MS duration provided an initial option for 
participants to report ‘no stiffness’ (similar to ‘Were your joints stiff when you woke up 
today? If yes, how long did this extra stiffness last?’), which may explain the difference 
in the performance of this item. Furthermore, providing patients with the option to 
report ‘no stiffness’ would seem an important implication during clinical questioning. 
In addition, the study recognised that the use of traditional stiffness assessment using 
severity and duration does not appropriately capture the patient experience (Orbai et 
al, 2014). Yet it was highlighted that a tool that did capture the patient experience was 
not currently available and suggested that if it were, it may improve the performance 
of stiffness for diagnostic purposes (van Nies et al, 2015), therefore emphasising an 
important potential area of application of the new RAST.   
 
The clinical relevance of stiffness was also emphasised in recently published 
recommendations regarding stiffness in Asian RA patients (Mok et al, 2015). These 
suggested routine clinical assessment of stiffness, pain and function to ensure 
accurate patient assessment, yet focused on ‘MS’ and did not provide any 
suggestions regarding assessment in clinical situations. The recommendations were 
developed specifically for an Asian population but were based on a systematic 
literature review including international publications, and expert opinion which 
predominantly involved rheumatologists based in Asia but did included a European 
contributor. Therefore, it is likely that they would be relevant to other populations. 
However, whether RAST would be appropriate for use in populations external to the 




population in which it was developed would require work on translation, including 
investigation into whether items are conceptually equivalent across cultures (Streiner 
and Norman, 2008).  
 
10.6 Future research 
10.6.1 Further development and validation of RAST 
Preliminary validity evidence for the RAST has been demonstrated, but further 
research using different measures of disease activity would enhance this. This would 
include comparison between RAST and DAS82 (van der Heijde et al, 1990), and also 
blood tests for common inflammatory markers such as CRP. 
 
Although Study 4 provided some measurement property evidence for RAST, it is 
necessary to further this in future work. In particular it is vital to investigate the 
measurement properties of test-retest reliability and ability to detect change (Streiner 
and Norman, 2008). These are key components that require evidence in FDA 
guidelines (USDHHS FDA, 2009). Test-retest reliability would involve the 
administration of the questionnaire at two separate time points (Streiner and Norman, 
2008) to test the stability of questionnaire responses over a period where the target 
of measurement is not expected to have changed (USDHHS FDA, 2009). Ability to 
detect change would test whether the questionnaire can detect changes where the 
target of measurement has changed (USDHHS FDA, 2009). This could be explored 
by using RAST in a drug intervention study such as the CAPRA trials (Buttgereit et al, 
2008; Buttgereit et al, 2013). Further development in relation to measurement 
properties could also investigate floor and ceiling effects of RAST (whether highest or 
lowest scores can be achieved, Terwee et al, 2007) and interpretability (can 
qualitative meaning be interpreted from scores, SACMOT, 2002). These 
investigations should be performed in new samples of patients, providing further 
evidence in populations who were not involved in the development of the scale. 
Although it is important to remember that the preliminary validity testing data, though 
derived from the same population, did not contribute to the development of the RAST. 
 
As addressed in Chapter 9 further research is required to develop the protocol for the 
use of RAST. Regarding scoring, it would be relevant to investigate the performance 
of the individual components in more detail. For example, are there differences in the 
characteristics of patients who score high or low on different components and do the 
components respond differently to change? Regarding the treatment of missing data 




it would be important to test different approaches such as data imputation methods. 
This would provide evidence to enable informed decision making about 
recommendations regarding acceptable levels and appropriate treatment of missing 
data when using RAST.   
 
Further testing using IRT would also be worthwhile. The RAST development was 
based on CTT which is well used and accepted in scale development (Streiner and 
Norman, 2008). IRT is often recommended for use within the PROM development 
literature (Patrick et al, 2011b) as it overcomes the limitations of CTT (Streiner and 
Norman, 2008). However, CTT and IRT can be considered complementary, therefore  
further investigation of RAST using IRT or Rasch analysis (Tennant and Conaghan, 
2007) would enhance our understanding of the structure of RAST, and if necessary 
could be used to explore the response categories, and to transform ordinal level data 
into linear level data (Tennant and Conaghan, 2007).  
 
10.6.2 Specific or general nature of stiffness assessment  
Given the similarities in the patient experience of stiffness in RA and PMR, stiffness 
measurement may also be relevant in other rheumatological patient populations. 
Initial investigation into stiffness assessment across conditions is the current focus of 
the OMERACT stiffness special interest group, informed by this thesis. Recent special 
interest group discussion at OMERACT 2016 suggested that stiffness was relevant 
across rheumatic conditions and that there would be value in universal stiffness 
assessment. However, this would need to reflect potential differences in the patient 
experience across conditions. For example, patients within the special interest group 
highlighted that the location of stiffness would differ for those with PMR and RA and 
this should be reflected in the wording of items. It was also highlighted that this would 
be furthered by improved understanding of stiffness pathophysiology, although this is 
currently another area limited by lack of appropriate outcome assessment (Halls et al, 
2016, manuscript in preparation). Stiffness assessment is also relevant more broadly, 
for example stiffness is reported in healthy, older populations (Sokka et al, 2007). The 
RAST may play a part in collecting normative data, possibly for populations from 
different communities or different age groups.  
 
10.7 Strengths and limitations 
This overview of strengths and limitations highlights the main points discussed in 
detail within preceding chapters.  




One of the key strengths is that this work has followed published guidelines on the 
development of PROMs (USDHHS FDA, 2009) particularly in relation to content 
validity (Patrick et al, 2011a; Patrick et al, 2011b). These have provided a rigorous 
and systematic framework for PROM development, highlighting the importance of an 
underpinning of qualitative research. This enabled the development of content validity 
in RAST, differentiating it from other traditional stiffness assessment approaches. 
Furthermore the qualitative work was performed in a rigorous and transparent way 
including independent analysis of data by the supervisory team and patient partners 
(Mays and Pope, 1995; Cohen and Crabtree, 2008), and utilising COREQ guidelines 
to enhance rigor and transparency (Tong, Sainsbury and Craig, 2007).  
 
Further strengths relate to the quantitative development of RAST including the 
comprehensive approach to deciding upon and implementing PCA, and the 
substantial testing of the provisional RAST for internal consistency and robustness, 
including repeated testing on subsets of data to ensure it was not overly dependent 
on the particular dataset used for development. Another strength is the careful and 
detailed approach to wording, presentation and comprehension of questionnaire 
items, ensuring each question is likely to be understood and answers will reflect 
patient intentions. 
 
There are some limitations with the work presented here. Although study samples 
were generally representative of an RA population in the descriptives collected, a 
number of aspects were not considered which might influence the generalisability of 
results. Culture and ethnicity were not captured, few participants had low levels of 
education and the ability to speak English unaided was a required inclusion criterion. 
Furthermore, most of the subjects in the population surveyed resided in areas of 
relatively low deprivation. Despite this, given the consistency of results with studies 
containing a more diverse sample (Orbai et al, 2014), it is likely that the conceptual 
underpinning is relevant in broader populations, and efforts to address the 
accessibility and readability of items for a broad population were made during item 
development (Chapter 6). Further development and validation of RAST would include 
testing it in different populations (e.g. with lower education levels or English language 
ability) and translation and cultural adaption (Streiner and Norman, 2008). 
 
The content and format of the RAST was primarily directed towards and derived from 
patients. It may be that understanding more explicitly the perspective of practicing 
clinicians would have resulted in some differences that might increase the utility of the 




instrument in routine clinical practice. However, the perspectives of clinicians were 
included as part of the supervisory team and informal feedback was gained during 
presentation and discussion within the local clinical department. However, this is an 
area that should be considered as part of future development of RAST. 
 
Finally, full validity testing of the RAST has not been carried out. While the preliminary 
validity testing results are promising, further validation work will be required before 
the RAST can be confidently recommended.  
 
10.8 Personal reflection 
Undertaking this research project and writing this thesis has been a challenging but 
rewarding journey. I came to this PhD process from a non-clinical background, and 
with limited research experience and a basic understanding of RA. Over the past four 
years I have learnt a great deal and developed personally and as a researcher.  
 
I was concerned that my non-clinical background would reduce my ability to undertake 
this project, especially as I had very little experience of working directly with patients. 
However, I learnt a considerable amount from the team’s patient research partners 
who were very open in sharing their personal experiences and helping me understand 
the patient perspective of RA at a human level. It was also important that I 
acknowledged my personal position so that I could understand my weaknesses and 
work to my strengths. Although I attempted to remain neutral to this during the 
performance of each study, especially the qualitative work, my personal background 
will have influenced the research process. The development of awareness, reflection 
on my personal background and increasing understanding of how to take account of 
this during qualitative studies were important while performing this work. This was 
supported by the input of the patient research partners and supervisory team in all 
aspects of this research.  
 
The completion of Masters-level modules in critical appraisal and qualitative methods 
in addition to other research training opportunities through the University have 
enabled me to develop skills as a researcher. One of the biggest challenges for me 
during this process has been presentation and communication. This was an important 
area for personal development especially given the importance of disseminating 
results and sharing knowledge in research. 
 




The research within this thesis has been presented at local and departmental events. 
In addition, Study 1 was presented as an oral presentation at BSR 2014 (published 
abstract available in Appendix BB) and has also been published as a journal article 
(Halls et al, 2015). This work has also been presented as an invited talk at the 
international OMERACT conference 2014 which has led to a collaborative publication 
(Orbai et al, 2015). This collaboration is currently being furthered by the stiffness 
special interest group who held a discussion session at OMERACT 2016 and involved 
further presentation of this work (Halls et al, 2016, manuscript in preparation). An 
overview of the work within this thesis was presented as an invited talk within a 
session convened by the researcher at BSR 2016. The systematic literature review 
was presented orally and as a poster at OMERACT 2016 (abstract available in 
Appendix CC) and Study 4 has been published as abstracts at EULAR 2016 
(Appendix DD and EE). I hope to continue to present and publish other work within 
this thesis and to continue to develop my skills as a researcher. 
 
10.9 Thesis summary 
Stiffness is commonly experienced by people with RA and is relevant in both clinical 
and research contexts. Despite this, a systematic review identified that there is no 
clear evidence regarding the most appropriate way to assess stiffness in RA. Current 
stiffness assessment is not standardised, and often involves the use of unvalidated 
and poorly defined items, none of which appear to have been developed according to 
current standards including collaboration with patients. This project developed a new 
assessment approach based on the patient experience of stiffness. The content and 
structure of the new RAST was developed during a series of qualitative and 
quantitative studies involving people with RA.  
 
Preliminary validity testing supports RAST as an appropriate tool to use to assess 
stiffness. The development of RAST is an early step in recognising stiffness as a 
significant, recordable patient symptom, and is also an important step forward towards 
standardised assessment. Further development and validation work is now required 
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Appendix A: Data extraction form 
 















 Yes/No/? Notes/Evidence 
Does the paper include populations with 
RA?* 
  
Does the paper report on measurement 






Stiffness as an outcome in 
relation to other core set 
disease activity measures+ 
  
The development of a patient 
reported tool to measure 
stiffness+ 
  
A comparison of two or more 
different tools to measure 
aspects of stiffness+ 
  
Include the study in the review?  















































   





   
 
 
For each of the below criteria please report: 
 Whether each was reported on in the paper or not 
 If it was reported please detail how (including: what was compared, what 
tests were used, what the results were, what population/s this was 
performed in, and any other relevant information) 
 Complete one report for every item; if there is more than 1 item per paper, 
please report for each item individually 
 In circumstances where studies refer to other papers to describe the item 
development (e.g. particularly for content validity), or validation (e.g. 
particularly for construct validity) process. State what information is provided 
by the original paper and then perform a separate review on the referenced 














Face validity (credibility; does the instrument look sensible?) 
Consider: 
i. The concept being assessed, 
on what anchors 
ii. The length and complexity of 
the tool 














Content validity (comprehensiveness; does the instrument contain all 
relevant content that is important to the intended populations?) 
Consider: 
i. Qualitative evidence that 
items and domains are 
relevant to the intended 
population, the measurement 
concept, and for the tools 














Criterion validity (accuracy; does the instrument perform well against a gold 
standard?) 
Consider: 
i. How the concept was 
assessed in the different 
methods 
ii. Are the methods correlated? 
iii. Do the methods perform 




























Construct validity (biological sense; do results agree with expected 
hypotheses?) 
Convergent validity (does the 
instrument demonstrate 
relationships where they would be 
expected?) 
Consider: 






Divergent validity (does the 
instrument demonstrate no 
relationship when no relationship is 
expected?) 
Consider: 






Discriminant/known groups validity 
(does the instrument demonstrate 
ability to differentiate between 
expected groups? E.g. inflam (RA) 
and non-inflam (OA)) 
Consider: 











Test-retest reliability (reproducibility)  
Consider: 












Internal consistency (agreement among items in subscales) 
Consider: 















Ability to detect change 
 
Ability to detect change (responsiveness; when patient experiences 
change, does the instrument score reflect that change?) 
Consider: 
i. Is change in the instrument 
score also seen in similar 
measures that indicate the 
patient state has changed? 
ii. Sensitivity 
iii. Full range 













Floor and ceiling effects  
 
Floor and ceiling effects (can the instrument distinguish responders with 
lowest or highest possible score?) 
Consider: 
i. Do more than 15% 
responders achieve lowest or 















Interpretability (can the instrument provide information about what change 
in score would be clinically meaningful?) 
Consider: 
i. Means and SDs 














Appendix B: Patient information sheet (Study 1) 
 
A research study to explore stiffness in people with rheumatoid arthritis (Phase 1) 
 
Patient information sheet 
 
You are being invited to take part in a research study. Before you decide whether to take 
part, it is important for you to understand why the research is being done, and what it will 
involve. Please take time to read the following information leaflet carefully and discuss it 
with others if you wish. If anything is not clear or you would like more information please 
ask one of the team. 
 
What is the purpose of the study? 
One of the problems commonly experienced by people with rheumatoid arthritis is 
stiffness. Stiffness is a term used by patients and health professionals, but it is not very 
well understood. The aim of this study is to understand your experience of stiffness and 
the language that you use to describe it. Your knowledge will help improve the current 
understanding of stiffness. It will also help to develop a way of measuring stiffness for 
people with rheumatoid arthritis. 
 
Why have I been chosen? 
You have been chosen because you have rheumatoid arthritis.  
 
Who is asking me to take part? 
I am Serena Halls, a PhD student at the University of the West of England. This research 
study is the first of three studies which will form part of my PhD. 
 
What will I be asked to do if I take part? 
You will be asked to attend an informal one to one interview with the researcher (Serena 
Halls) at the rheumatology department you attend. Before the interview starts, the 
researcher will ask you to read and sign the consent form and ask you some questions 
about your medical history. In the interview, she will invite you to discuss your experience 
of stiffness. You can say as much or as little as you like, there are no right or wrong 
answers - we are looking for your own individual experience. The interview will last for 
about an hour and we will offer you refreshments and are happy to pay your travel costs. 
We will ask your permission to audio-record the interview, which we will type up 
(transcribe) and then analyse after the interview.  
 
Do I have to take part? 
No, taking part is voluntary. It is up to you to decide whether or not to take part. If you 
decide not to take part you do not need to give a reason, nobody will be upset and the 
standard of care you receive will not be affected. If you decide to take part we will ask you 
to sign a consent form, and will give you a copy of this information sheet and the consent 
form to keep.  
 
For general advice about taking part in research, you can contact the local Patient Advice 
and Liaison Service on 0117 900 3433 or pals@bristolpct.nhs.uk. 
 
What if I wish to withdraw at a later stage? 






What are the risks of taking part in the study? 
We do not believe there are any risks in being involved in this study. We appreciate that 
there may be some inconvenience to you by having to come into the hospital for the 
interview but we will try and reduce this by arranging a convenient date and time for you 
to come. 
 
What are the benefits of taking part in the study? 
The benefits of taking part in this study are that you will be helping us to gain a better 
understanding of stiffness in people with rheumatoid arthritis. This will help us to improve 
decisions made about treatment and management of rheumatoid arthritis.   
 
Will my taking part in the study be kept confidential? 
Yes. Your name will be replaced by a code. All other identifying information (such as 
people’s names, locations or specific descriptions) will be replaced with code numbers or 
a generalised summary. No one will be able to identify you from any analysis or report. 
The study reports will include quotations from the interviews but no names will be used. 
The recordings will be kept securely for 6 years and then destroyed, in accordance with 
best practice in research guidelines.   
 
What will happen to the results of this research study? 
Research team members will analyse the anonymous transcripts and discuss our 
findings. The findings of this study will influence the design of later research studies within 
this PhD. We hope the results will be reported in professional journals and at meetings 
(but participants will not be identified by name). We will send you a summary of the results 
if you would like. 
 
Who is organising, funding and reviewing the research? 
The study is coordinated by a team from the university of the West of England (UWE) 
based at the Academic Rheumatology Unit at the Bristol Royal Infirmary. It is funded by 
UWE and has been peer reviewed by the local and UWE Research Ethics Committees.  
 
What do I do now? 
Thank you for considering taking part in this research. Please return the reply slip 
provided if you would like to take part by returning it in the pre-paid reply envelope to 
Serena Halls. Serena will then contact you in a few days with further information and to 




Serena Halls, PhD Student Researcher, UWE Bristol 
Professor Sarah Hewlett, Professor of Rheumatology Nursing, UWE Bristol 
Professor John Kirwan, Professor of Rheumatic Diseases, UoB Bristol 
Dr Jon Pollock, Reader in Epidemiology, UWE Bristol 
Dr Emma Dures, Research Fellow, UWE Bristol 
Mrs Avis Edmunds, Patient Research Partner 




Serena Halls  0117 342 4972  Serena.Halls@uwe.ac.uk 




Appendix C: Interview topic guide with prompts (Study 1) 
 
A. Can you tell me about your experience of stiffness in relation to RA? 
a. Definition? 
b. Sensation? Is there anything that feels similar to the feeling of 
stiffness? 
c. Is stiffness the right word to describe how you feel?  
d. If you were to describe stiffness to someone who didn’t have 
rheumatoid arthritis and didn’t really know what it was, what would 
you say? 
e. Where in your body do you feel stiff? Is it always the same place? 
Does it feel the same? 
 
B. How does this vary in a 24 hour period? 
a. Does it gradually go away or is it sudden? 
b. Is it different during the day or night? 
c. Causes? 
d. Differences at different times of disease activity? 
 
C. Has stiffness changed over the course of your disease?  
a. Before you had rheumatoid arthritis did you ever experience that 
same feeling? 
b. Before you had rheumatoid arthritis did you experience a different 
feeling that you would call/class as stiffness?  
c. Do you have any other diseases that make you stiff? 
 
D. How does stiffness differ from other RA symptoms? 
a. Pain/fatigue/other 
b. What is the relationship between symptoms? 
c. How relevant is stiffness in relation to other symptoms? 
 
E. What are the consequences of stiffness? 
 
F. How do you deal with stiffness? 
a. Influence of medications? 
 
G. How to you assess stiffness? 
a. When you are asked in clinic by a consultant or nurse about stiffness, 
what do you say? 
b. What are your thoughts about stiffness measurement?  
c. How do you know when it is good or bad? 
 
H. Is there anything that you feel is important to stiffness that we have not 
talked about? 
 




Appendix D: Questionnaire pack 
 
Stiffness pre-discussion questionnaire 
 
Date: ________________                          Study ID: ______________                                                
 
Thank you for agreeing to take part in this study 
 
This questionnaire will help the researchers make sure that they talk to a 
wide range of people who experience stiffness. Your answers are 
confidential to the researchers, and although other people will see the results 
of the overall study, they will not be able to link your name to the answers 
you give on this sheet. 
 
A) This section asks about your socio demographic details 
 
1. Gender:         Male           /            Female  (Please circle) 
 
2. Date of birth: __ __ / __ __ / __ __ __ __      (Day/Month/Year) 
 





Receiving incapacity benefits  
Other: _________________ (Please specify) 
 
4. Education:  Did not complete school         (Circle highest level) 
School education 
College / apprenticeship 
University level education 
Other: _________________ (Please specify) 
 
 
B) This section asks about your rheumatoid arthritis 
 
1. How long have you been diagnosed with rheumatoid arthritis? 
 
 _______________ (Years)  
 
 
2. Have you ever experienced stiffness related to your rheumatoid 
arthritis? 
 














4. Have you started or changed medication in the last six weeks? 
 
Yes    No    (Please circle) 
 
 
5. Have you had a steroid injection in the past two months? 
 
Yes    No    (Please circle) 
         
  
6. How much pain have you had because of your arthritis in the 









          
7. Considering all of the ways your arthritis affects you, please 








































1. DRESSING AND GROOMING 
    Are you able to: 
  - Dress yourself, including tying 
    shoelaces and doing buttons? 
 























    Are you able to: 
  - Stand up from an armless    
    straight chair?  
 




























    Are you able to: 
  - Cut your meat? 
 
  - Lift a full cup or glass to your     
    mouth? 
 
  - Open a new carton of milk (or  



































    Are you able to: 
  - Walk outdoors on flat ground?  
 






























Please tick any aids or devices that you usually use for any of these activities: 
_____  Cane   _____  Devices used for dressing (button hook, zipper 
_____  Walking frame  pull, long handled shoe horn etc) 
_____  Crutches  _____  Built-up or special utensils 
_____  Wheelchair  _____  Special or built-up chair 
   
Other: _______________________________________________ (Please specify) 
 
Please tick any categories for which you usually need help from another person:  
_____  Dressing and grooming _____  Eating 









5.  HYGIENE      
    Are you able to: 
  - Wash and dry your entire      
     body? 
 
  - Take a bath? 
 















































6. REACH      
    Are you able to: 
  - Reach and get down a 5lb    
    object (e.g. a bag of potatoes)    
    from just above your head? 
 
  - Bend down to pick up clothing  






































7. GRIP      
    Are you able to: 
  - Open car doors? 
 
  - Open jars which have been  
    previously opened? 
 


































8. ACTIVITIES      
    Are you able to: 
  - Run errands and shop? 
 
  - Get in and out of a car? 
 
  - Do chores such as vacuuming,  



































Please tick any aids or devices that you usually use for any of these activities: 
_____  Raised toilet seat _____  Bath rail  
_____  Bath seat  _____  Long handled appliances for reach 
_____  Jar opener (for jars previously opened)  
 
Other: ________________________________________________ (Please specify) 
  
Please tick any categories for which you usually need help from another person:  
 _____  Hygiene  _____  Gripping and opening things 
 _____  Reach   _____  Errands and housework 
 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE
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Appendix E: Study 1 coding tree 
Codes Level 1 groups Level 2 groups Theme 
Stiffness is normal Stiffness is normal 
Stiffness is a normal 
consequence of RA 





























No stiffness prior to RA No stiffness prior to 
RA 
Stiffness is an obvious symptom of RA Stiffness is an 
obvious symptom of 
RA 
Stiffness is part of a bigger picture in the morning specifically 
Stiffness is part of a bigger picture 
RA stiffness is different – General 
RA stiffness is 
specific 
RA stiffness is different to exercise stiffness 
RA stiffness is different to overuse stiffness 
RA stiffness is different to OA stiffness 
RA stiffness is not different to OA stiffness 
During a period of flare you cannot move 






























During a period of flare it is difficult to move and you can’t do ADLs 
Can’t do anything in a flare up 
Stiffness affects sleep when it’s bad 
During a period of flare pain and stiffness more related 
During a period of flare stiffness and inflammation more related  
During a period of flare all symptoms are worse 
During a period of flare stiffness does not go away 
During a period of flare stiffness sticks around  
During a period of flare stiffness is quick/sudden 
In flare stiffness lasts longer 
In flare stiffness is more frequent in occurrence 
During a period of flare stiffness affects more joints 
During a period of flare stiffness severity is high 
During a period of flare stiffness is an exaggeration of itself 
During a period of flare stiffness is acute 
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Codes Level 1 groups Level 2 groups Theme 













Harder to ease in flare 
Damaged joints cause stiffness 
Stiffness relates to 
damaged joints 
You can’t move damaged joints 
Causes of damaged joints 
Stiffness from damage and flare are different 
Pain and stiffness are normal 
















Pain and stiffness are related 
Pain and stiffness are different concepts 
Pain comes with baggage 
Pain is easier to deal with than stiffness 
Pain is harder to deal with than stiffness 
Pain and stiffness more related during flare 
Pain effects sleep 
You feel stiff when you try  to move but pain you feel when you don’t 
move 
If you stay in one position for too long you get pain 
You can tell pain and stiffness limitations apart 
Stiffness and fatigue are related 
Patient symptoms - 
Fatigue 
Stiffness is more fatigue than pain 
Stiffness and fatigue are different 
Stiffness and fatigue are distinguishable by the time they occur 
Stiffness is related to inflammation 
Medical symptoms – 
Inflammation 
 
Stiffness is unrelated to inflammation 
Inflammation causes stiffness 
Inflammation relates to a flare 
Stiffness is the same as inflammation 
 393 
 
Codes Level 1 groups Level 2 groups Theme 
Both stiffness and inflammation cause functional loss 
Patients don’t recognise inflammation 
All symptoms are intertwined 
All symptoms are 
intertwined 
All symptoms are intertwined when its bad but unrelated when it’s not 
All symptoms are worse [in a flare] 
Symptoms are not just related when disease is bad 
Stiffness was an early symptom of RA Stiffness relevant in 
early RA Varying prominence 
of stiffness during 
course of the disease 
Stiffness was severe at disease onset 
Stiffness was not relevant in early disease Stiffness not relevant 
in early RA Stiffness more relevant later in disease duration 
Stiffness affects certain parts of the body Stiffness affects 
certain locations 
Location within body 
Local and 
widespread 
Stiffness feels the same in different part of the body 
Stiffness moves around the body Stiffness affects 
variable locations Stiffness feels different in different parts of the body 
During a flare/bad day stiffness affects more joints 
Stiffness all over 
In the morning stiffness affects more joints/all over 
Joints are the problem 
Stiffness affects 
particular structures Affected body 
structures 
Muscles are the problem 
Tendons are the problem 
Uncertainty about what structure is the problem Uncertainty about 
affected structures 











Being in a restricted position causes stiffness 
Should be less stiff when have been more active in the night but not the 
case 
Legacy of activity causes stiffness 
Overdoing it 
Overdoing it and not resting causes stiffness 
Medications are beneficial for stiffness – Non-specific 
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Codes Level 1 groups Level 2 groups Theme 
Medications are beneficial for stiffness – Infusion Medications have an 
impact on stiffness 
Medications and 
stiffness 
Medications are beneficial for stiffness – Steroids 
Medications are beneficial for stiffness – DMARD 
Medications are beneficial for stiffness - Anti-TNF 
Medications reduce stiffness duration 
Medications reduce 
stiffness 
Medications reduce stiffness severity 
Medications reduce stiffness which allows normality 
Medications get rid of stiffness 
Only steroids reduce stiffness in flare 
Medications reduce stiffness but it’s a lost entity because it’s never 
measured 
Medications impact 
on stiffness is lost 
Medications do not target stiffness Medications are not 
beneficial for 
stiffness 
Medications do not work when you have a flare up 
Some medications work better than others 
Medications effects 
can be variable 
Sometimes the same medications work better than other times 
You have transition periods between medications 
Medications have side effects 
Medications have 
other considerations 
Not wanting to take medications 
You don’t have a choice but to take medications 





Certain foods cause stiffness to be worse 
Air conditioning causes joints to be stiff and painful 
Weather 
The weather has an impact on stiffness – Hot weather 
The weather has an impact on stiffness – Cold weather 
The weather has an impact on stiffness – Humid weather 
Stiffness does not affect sleep 
Sleep 
Stiffness does affect sleep 
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Codes Level 1 groups Level 2 groups Theme 
Poor sleep impacts on stiffness 
Stiffness is individual/subjective  Individual experience 








Stiffness is different for different people Different experience 
Stiffness does relate to mornings 
Morning 




Stiffness does not relate to mornings 
You notice stiffness when you get up/wake up 
Stiffness relates to other times of day 
Other times of day Stiffness doesn’t relate to a particular time of day 
Best time of day is afternoon/evening 
Timing of stiffness has changed through the course of the disease Timing changes 
Duration of stiffness – Varies within people 
Varies 
Duration of stiffness 
Duration of stiffness – Varies between people 
Duration of stiffness - Different amount of time 
Duration of stiffness - Gradually eases off 
Duration of stiffness - Similar amount of time 
Constant 
Stiffness never completely goes away 
Stiffness is constant now (it doesn’t change) 
Some joints stick all day 
Time is not a relevant factor Time is not relevant 
General stiffness – Expected 
General stiffness 
Severity of stiffness 
General stiffness – Impact on function 
General stiffness – Manageable 
Severe stiffness – Cramp stiffness 
Severe stiffness Severe stiffness – Not expected [harder to manage] 
Can’t function when its bad 
Damage related stiffness – Element of severity in damaged joints Damage related 
stiffness 
Can’t do ADL's or simple tasks Daily life impact 
 
Impacts on daily 
life Restricts hobbies 
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Codes Level 1 groups Level 2 groups Theme 
Can’t eat Impact on activities 




























































Getting up from a chair is difficult 
Stairs 
Restricts family life 
Cant plan 
Difficult to get out of bed 
Unnatural/awkward walking 
Can’t get comfortable 
Stiffness a problem at night 
Stiffness not a problem at night 
Impact on life 
Restriction 
Disabling 
Affects work Impact on work 
Loose normality Impact on normality 
Stiffness in different places is worse because it has different impact 
Impact differs in 
different locations 
Location of stiffness affects the impact [worse in hands] 
Certain movements 
Difficult to move 
General impact 
Physical impact 







Don’t have mobility 
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Codes Level 1 groups Level 2 groups Theme 
Slow/can’t rush/actions take me longer 
Physically have to unbend limbs 
No flexibility 
Need physical support 
Forget how to walk properly 
Cognitive impact Cognitive impact 
Have to think about doing actions 
Psych impact/general wellbeing 
Psychological impact Psychological impact 
Mood affects symptoms 
Stiffness doesn’t affect mood 
Stiffness makes you frustrated 
Stress and anxiety impacts on symptoms 
Restricts image – vanity  
You lose the good part of the day 
Pain on movement 
Pain impact Pain impact 
If you force movements you get pain 
Pain on movement is accentuated in flare 
























Supporting joints  
Physically manipulating your joints 
Balancing rest and movement 
Exercise Exercise 
Gadgets/aids 
Gadgets and splints Other strategies Splints are effective for stiffness 
Splints are not effective for stiffness 
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Codes Level 1 groups Level 2 groups Theme 
Splints are not compatible with other self-management strategies 
Hot/cold therapy is effective 
Heat and cold 
Shower in the morning 
Hot/cold therapy is not effective 
Hydrotherapy 
Alternative therapy - Changing diet 
Alternative therapies Alternative therapy - Aromatherapy 
Alternative therapy - Relaxation techniques 
Take medication in the morning to get going 
Medications and 
painkillers 
Take medication to function 
Take painkillers 
Family and friends – Physically help with jobs/housework 




Family and friends - Facilitate use of self-management strategies 
Family and friends - Are flexible 
Normalise/accept stiffness Internal – Normalise 
Adapt and adjust behaviours generally - Have to find other ways to do 
things 
Internal – Adapt and 
adjust 
Adapt and adjust behaviours generally - You can work round stiffness 
Adapt and adjust behaviours in the morning - You just adapt in the 
morning 
Adapt and adjust behaviours in the morning - Perform activities later in 
day 
Adapt and adjust behaviours in the morning - Use gadgets at difficult 
times 
Prepare/plan for stiffness - Compensate for slow movement by getting 
up earlier Internal – Prepare 
and plan Prepare/plan for stiffness - Not too restrictive if pace and plan 
Self-management is easier since stopping work 
Ensure RA and stiffness does not take over life [RA general] 
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Codes Level 1 groups Level 2 groups Theme 
Self-management is individual/knowing your limitations/your body 
[general RA] 
Internal – Part of 
general RA 
management Do what you can to help yourself [general RA] 
Self-management and understanding RA develops over time [RA 
general] 




 Appendix F: COREQ checklist (Study 1) 
No.  Item  Guide questions/description How was this component addressed 
Domain 1: Research team and reflexivity   
Personal Characteristics   
1. Interviewer Which author/s conducted the interview or focus group?  Identified in Section 4.3.4. 
2. Credentials What were the researcher’s credentials?  The characteristics of the supervisory team 
were identified in Section 3.4.2 and the 
researchers (Halls) background was 
highlighted in Section 3.2.1 
3. Occupation What was their occupation at the time of the study?  
4. Gender Was the researcher male or female?  
5. Experience and training What experience or training did the researcher have?  
Relationship with participants   
6. Relationship established Was a relationship established prior to study commencement?  
Identified in Section 4.3.4. 7. Participant knowledge of 
the interviewer  
What did the participants know about the researcher?  
8. Interviewer 
characteristics 
What characteristics were reported about the interviewer?  The researchers (Halls) background, 
experience and research interests were 
highlighted in Section 3.2.1 
Domain 2: study design   
Theoretical framework   
9. Methodological 
orientation and theory  
What methodological orientation was stated to underpin the 
study?  
The methodological approach to the study was 
discussed in Section 3.3.1 and the method and 
analysis approaches were discussed in 
Sections 4.3.1 and 4.4.1  
Participant selection   
10. Sampling How were participants selected?  
Identified in Section 4.3.2 and 4.5.1 11. Method of approach How were participants approached?  
12. Sample size How many participants were in the study?  
13. Non-participation How many people refused to participate or dropped out? 
Reasons?  
Identified in Section 4.3.4 
Setting  
14. Setting of data 
collection 
Where was the data collected?  
Identified in Section 4.3.4 
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No.  Item  Guide questions/description How was this component addressed 
15. Presence of non-
participants 
Was anyone else present besides the participants and 
researchers?  Identified in Section 4.3.4 and 4.5.1 
16. Description of sample What are the important characteristics of the sample?  
Data collection   
17. Interview guide Were questions, prompts, guides provided by the authors? Was it 
pilot tested?  
Identified in Section 4.3.3 and Appendix C 
18. Repeat interviews Were repeat interviews carried out? If yes, how many?  This was not performed  
19. Audio/visual recording Did the research use audio or visual recording to collect the data?  Identified in Section 4.3.4 
20. Field notes Were field notes made during and/or after the interview or focus 
group? 
Identified in Section 4.3.4 
21. Duration What was the duration of the interviews or focus group?  Identified in Section 4.3.4 
22. Data saturation Was data saturation discussed?  Identified in Section 4.3.2 
23. Transcripts returned Were transcripts returned to participants for comment and/or 
correction?  
This was not performed as part of Study 1 
however, the findings were validated in Study 2 
Domain 3: analysis and findings   
Data analysis   
24. Number of data coders How many data coders coded the data?  Identified in Section 4.4.1.1.2 
25. Description of the 
coding tree 
Did authors provide a description of the coding tree?  
Identified in Section 4.5.2 and Appendix E 
26. Derivation of themes Were themes identified in advance or derived from the data?  Identified in Sections 4.4.1.1 and 4.5.2 
27. Software What software, if applicable, was used to manage the data?  Identified in Sections 4.4.1.1.2 
28. Participant checking Did participants provide feedback on the findings?  This was not conducted as part of Study 1 
however, the findings were validated in Study 2 
Reporting   
29. Quotations presented Were participant quotations presented to illustrate the themes? 
Was each quotation identified?  
Identified in Section 4.5.2 
30. Data and findings 
consistent 
Was there consistency between the data presented and the 
findings?  
31. Clarity of major themes Were major themes clearly presented in the findings?  




Appendix G: Patient information sheet (Study 2) 
 
A research study to develop a questionnaire for stiffness in rheumatoid arthritis 
(Phase 2) 
 
Patient information sheet 
 
You are being invited to take part in a research study. Before you decide whether to take 
part, it is important for you to understand why the research is being done, and what it will 
involve. Please take time to read the following information leaflet carefully and discuss it 
with others if you wish. If anything is not clear or you would like more information please 
ask one of the team. 
 
What is the purpose of the study? 
One of the problems commonly experienced by people with rheumatoid arthritis is 
stiffness. Stiffness is a term used by patients and health professionals, but it is not very 
well understood. The aim of this study is to develop a way of measuring stiffness in 
rheumatoid arthritis. With the help of other people like yourself we have developed a 
better understanding of what stiffness means to people. We would now like your help to 
develop this further by working towards a way of measuring stiffness in a questionnaire.  
 
Why have I been chosen? 
You have been chosen because you have rheumatoid arthritis.  
 
Who is asking me to take part? 
I am Serena Halls, a PhD student at the University of the West of England. This research 
study is the second of three studies which will form part of my PhD. 
 
What will I be asked to do if I take part? 
You will be asked to attend a group discussion with the researcher (Serena Halls) and 
between 4 and 6 other people like yourself at the rheumatology department you attend. 
Before the focus group starts, the researcher will ask you to read and sign the consent 
form and ask you some questions about your medical history. In the group discussion, 
she will invite you to discuss your thoughts about stiffness and how to measure it. You 
can say as much or as little as you like, there are no right or wrong answers. The 
discussion will last for about an hour and we will offer you refreshments and are happy to 
pay your travel costs. We will ask your permission to audio-record the discussion, which 
we will type up (transcribe) and then analyse after the discussion finishes.  
 
Do I have to take part? 
No, taking part is voluntary. It is up to you to decide whether or not to take part. If you 
decide not to take part you do not need to give a reason, nobody will be upset and the 
standard of care you receive will not be affected. If you decide to take part we will ask you 
to sign a consent form, and will give you a copy of this information sheet and the consent 
form to keep. For general advice about taking part in research, you can contact the local 
Patient Advice and Liaison Service on 0117 900 3433 or pals@bristolpct.nhs.uk. 
 
What if I wish to withdraw at a later stage? 







What are the risks of taking part in the study? 
We do not believe there are any risks in being involved in this study. We appreciate that 
there may be some inconvenience to you by having to come into the hospital for the 
discussion but we will try and reduce this by arranging a convenient date and time for you 
to come. 
 
What are the benefits of taking part in the study? 
The benefits of taking part in this study are that you will be helping us to gain a better 
understanding of stiffness in people with rheumatoid arthritis. This will help us to improve 
decisions made about treatment and management of rheumatoid arthritis.   
 
Will my taking part in the study be kept confidential? 
Yes. Your name will be replaced by a code. All other identifying information (such as 
people’s names, locations or specific descriptions) will be replaced with code numbers or 
a generalised summary. No one will be able to identify you from any analysis or report. 
The study reports will include quotations from the discussion but no names will be used. 
The recordings will be kept securely for 6 years and then destroyed, in accordance with 
best practice in research guidelines.   
 
What will happen to the results of this research study? 
Research team members will analyse the anonymous transcripts and discuss our 
findings. The findings of this study will influence the design of later research studies within 
this PhD. We hope the results will be reported in professional journals and at meetings 
(but participants will not be identified by name). We will send you a summary of the results 
if you would like. 
 
Who is organising, funding and reviewing the research? 
The study is coordinated by a team from the university of the West of England (UWE) 
based at the Academic Rheumatology Unit at the Bristol Royal Infirmary. It is funded by 
UWE and has been peer reviewed by the local and UWE Research Ethics Committees.  
 
What do I do now? 
Thank you for considering taking part in this research. Please return the reply slip 
provided if you would like to take part by returning it in the pre-paid reply envelope to 
Serena Halls. Serena will then contact you in a few days with further information and to 





Serena Halls, PhD Student Researcher, UWE Bristol 
Professor Sarah Hewlett, Professor of Rheumatology Nursing, UWE Bristol 
Professor John Kirwan, Professor of Rheumatic Diseases, UoB Bristol 
Dr Jon Pollock, Reader in Epidemiology, UWE Bristol 
Dr Emma Dures, Research Fellow, UWE Bristol 
Mrs Avis Edmunds, Patient Research Partner 




Serena Halls  0117 342 4972  Serena.Halls@uwe.ac.uk 












 Researchers introduce themselves 
 Thank patients for coming 
 Explain purpose of study  
 
Introduction (patients): 
 Names/duration of RA  
 
Main body:  
Part A: The experience of stiffness and how you describe it 
 What is your experience of stiffness?                      (take notes) 
 What words do you use to describe stiffness?   
 Liked and disliked descriptors                            (separate piles) 
 What is your definition of stiffness? 
 
Part B: Measure development - designing RA stiffness PROM 
 What do you think about these items?                  (see flipchart) 
 What do you like/dislike about them? 
 How could they be improved? 
 Discuss 
o Wording and format 




 Overview and last thoughts 
 Thank patients for coming  
 
Other general prompts 
Can you give me an example? 
Can you explain that a bit more? 
Why do you say that? 
1. Check tape recorder works 
2. Obtain written consent 
3. Explain the purpose of the session 
4. Explain the background of stiffness 
5. Explain ground rules: confidentiality, anonymity, and respect 













 Researchers introduce themselves 
 Thank patients for coming 
 Explain purpose of study  
 
Introduction (patients): 
 Names/duration of RA  
 
Main body:  
Part A: The experience of stiffness and how you describe it 
 What is your experience of stiffness?                      (take notes) 
 What words do you use to describe stiffness?  (here or at end) 
 Liked and disliked descriptors 
 
Include key discussion point prompts where relevant: 
Is stiffness specific? 
 Stiffness a patient word 
 Stiffness and pain 
 Changes in disease activity 
Stiffness location 
Changes over disease duration 
 Change in impact or change in severity? 
 
Part B: Measure development - designing RA stiffness PROM 
 Study 1 results overview 
 Present impact triad concept 
 Discuss thoughts on measurement based on aspects of impact 
triad 
 Consider 
o Stem questions 
o Response options 




 Overview and last thoughts 
 Thank patients for coming
1. Check tape recorder works 
2. Obtain written consent 
3. Explain the purpose of the session 
4. Explain the background of stiffness 
5. Explain ground rules: confidentiality, anonymity, and respect 




Appendix J: Study 1 coding tree with Study 2 codes added 
Codes Level 1 codes Level 2 codes Theme 
Stiffness is normal 
Stiffness is normal 
Stiffness is a normal 
consequence of RA 





























Stiffness is a normal part of getting older [FG] 
No stiffness prior to RA No stiffness prior to 
RA 
Stiffness is an obvious symptom of RA [reinforced in FG] Stiffness is an 
obvious symptom of 
RA 
Stiffness is part of a bigger picture in the morning specifically 
Stiffness is part of a bigger picture 
RA stiffness is different – General 
RA stiffness is 
specific 
RA stiffness is different to exercise stiffness 
RA stiffness is different to overuse stiffness 
RA stiffness is different to OA stiffness 
RA stiffness is not different to OA stiffness [reinforced in FG] 
Pain is different in RA and OA – but stiffness is the same [FG] 






























During a period of flare it is difficult to move and you can’t do ADLs 
Can’t do anything in a flare up 
Stiffness affects sleep when it’s bad 
During a period of flare pain and stiffness more related 
During a period of flare stiffness and inflammation more related  
During a period of flare all symptoms are worse 
During a period of flare stiffness does not go away 
During a period of flare stiffness sticks around  
During a period of flare stiffness is quick/sudden 
In flare stiffness lasts longer 
In flare stiffness is more frequent in occurrence 
During a period of flare stiffness affects more joints 
During a period of flare stiffness severity is high 
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Codes Level 1 codes Level 2 codes Theme 











During a period of flare stiffness is acute 
During a period of flare stiffness you can’t use manage it in the 
same way 
Harder to ease in flare 
Damaged joints cause stiffness 
Stiffness relates to 
damaged joints 
You can’t move damaged joints 
Causes of damaged joints 
Stiffness from damage and flare are different 
Pain and stiffness are normal 
















Pain and stiffness are related [reinforced in FG] 
Pain and stiffness are different concepts [reinforced in FG] 
Pain comes with baggage 
Pain is easier to deal with than stiffness 
Pain is harder to deal with than stiffness 
Pain and stiffness more related during flare 
Pain effects sleep 
You feel stiff when you try  to move but pain you feel when you don’t 
move 
If you stay in one position for too long you get pain 
You can tell pain and stiffness limitations apart 
Management targets pain and stiffness differently [FG] 
You should separate pain and stiffness [FG] 
You might stiffness as a protective instinct against pain [FG] 
The feeling/sensation of stiffness is a type of pain [FG] 
Hard to define in words the difference between symptoms [FG] 
Uncertainty about the difference between pain and stiffness [FG] 
Stiffness is more physically restrictive than pain [FG] 
 408 
 
Codes Level 1 codes Level 2 codes Theme 
Stiffness and fatigue are related 
Patient symptoms - 
Fatigue 
Stiffness is more fatigue than pain 
Stiffness and fatigue are different 
Stiffness and fatigue are distinguishable by the time they occur 
Stiffness is related to inflammation 
Medical symptoms – 
Inflammation 
 
Stiffness is unrelated to inflammation 
Inflammation causes stiffness 
Inflammation relates to a flare 
Stiffness is the same as inflammation 
Both stiffness and inflammation cause functional loss 
Patients don’t recognise inflammation 
All symptoms are intertwined 
All symptoms are 
intertwined 
All symptoms are intertwined when its bad but unrelated when it’s not 
All symptoms are worse [in a flare] 
Symptoms are not just related when disease is bad 
Stiffness was an early symptom of RA 
Stiffness relevant in 
early RA Varying prominence 
of stiffness during 
course of the disease 
Stiffness was severe at disease onset 
Stiffness changes over disease duration [FG] 
Stiffness was not relevant in early disease Stiffness not relevant 
in early RA Stiffness more relevant later in disease duration 
Stiffness affects certain parts of the body Stiffness affects 
certain locations 
Location within body Local and 
widespread 
Stiffness feels the same in different part of the body 
Stiffness moves around the body Stiffness affects 
variable locations Stiffness feels different in different parts of the body 
During a flare/bad day stiffness affects more joints [reinforced in FG] 
Stiffness all over In the morning stiffness affects more joints/all over [reinforced in FG] 
Stiffness affects whole body [FG] 
Joints are the problem 
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Codes Level 1 codes Level 2 codes Theme 
Muscles are the problem Stiffness affects 
particular structures Affected body 
structures 
Tendons are the problem 
Uncertainty about what structure is the problem Uncertainty about 
affected structures 











Being in a restricted position causes stiffness 
Should be less stiff when have been more active in the night but not the 
case 
Legacy of activity causes stiffness 
Overdoing it 
Overdoing it and not resting causes stiffness 
Medications are beneficial for stiffness – Non-specific 
Medications have an 
impact on stiffness 
Medications and 
stiffness 
Medications are beneficial for stiffness – Infusion 
Medications are beneficial for stiffness – Steroids 
Medications are beneficial for stiffness – DMARD 
Medications are beneficial for stiffness - Anti-TNF 
Medication improvements - now prevent damage [reinforced in FG] 
Medications reduce stiffness duration 
Medications reduce 
stiffness 
Medications reduce stiffness severity 
Medications reduce stiffness which allows normality 
Medications get rid of stiffness 
Only steroids reduce stiffness in flare 
Medications reduce stiffness but it’s a lost entity because it’s never 
measured 
Medications impact 
on stiffness is lost 
Medications do not target stiffness Medications are not 
beneficial for 
stiffness 
Medications do not work when you have a flare up 
Some medications work better than others 
Medications effects 
can be variable 
Sometimes the same medications work better than other times 
You have transition periods between medications 
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Codes Level 1 codes Level 2 codes Theme 
Medications have side effects 
Medications have 
other considerations 
Not wanting to take medications 
You don’t have a choice but to take medications 





Certain foods cause stiffness to be worse 
Air conditioning causes joints to be stiff and painful 
Weather 
The weather has an impact on stiffness – Hot weather 
The weather has an impact on stiffness – Cold weather 
The weather has an impact on stiffness – Humid weather 
Air pressure has an impact on stiffness [FG] 
The weather does not influence stiffness for everyone [FG] 
Stiffness does not affect sleep 
Sleep Stiffness does affect sleep [reinforced in FG] 
Poor sleep impacts on stiffness 
Stiffness is individual/subjective  Individual experience 








Stiffness is different for different people Different experience 
Stiffness does relate to mornings 
Morning 




Stiffness does not relate to mornings 
You notice stiffness when you get up/wake up 
Stiffness relates to other times of day 
Other times of day 
Stiffness doesn’t relate to a particular time of day 
Best time of day is afternoon/evening 
Stiffness relates to the night time [FG] 
Timing of stiffness has changed through the course of the disease Timing changes 
Duration of stiffness – Varies within people 
Varies Duration of stiffness 
Duration of stiffness – Varies between people 
Duration of stiffness - Different amount of time 
Duration of stiffness - Gradually eases off 
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Codes Level 1 codes Level 2 codes Theme 
Duration of stiffness - Similar amount of time 
Constant 
Stiffness never completely goes away 
Stiffness is constant now (it doesn’t change) 
Some joints stick all day 
Time is not a relevant factor Time is not relevant 
General stiffness – Expected 
General stiffness 
Severity of stiffness 
General stiffness – Impact on function 
General stiffness – Manageable 
Different levels of stiffness [reinforced in FG] 
Severe stiffness – Cramp stiffness 
Severe stiffness Severe stiffness – Not expected [harder to manage] 
Can’t function when its bad 
Damage related stiffness – Element of severity in damaged joints Damage related 
stiffness 
Can’t do ADL's or simple tasks Impact on activities 
















































Dressing or undressing [added in FG] 
Causes difficulties 
Getting up from a chair is difficult 
Stairs 
Restricts family life 
Can’t plan 
Difficult to get out of bed 
Unnatural/awkward walking 
Can’t get comfortable [reinforced in FG] 
Stiffness a problem at night 
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Codes Level 1 codes Level 2 codes Theme 
















Impact on life  
Restriction 
Disabling 
Stiffness makes everything an effort [FG] 
Affects work Impact on work 
Loose normality Impact on normality 
Stiffness in different places is worse because it has different impact 
Impact differs in 
different locations 
Location of stiffness affects the impact [worse in hands] 
Certain movements 
Difficult to move 
General impact 
Physical impact 







Don’t have mobility 
Slow/can’t rush/actions take me longer 
Physically have to unbend limbs 
No flexibility 
Need physical support 
Loss of strength [FG] 
Forget how to walk properly 
Cognitive impact Cognitive impact 
Have to think about doing actions 
Bits of my body won’t move when I am expecting them to [FG] 
Automatic instinct is gone [FG] 
Psych impact/general wellbeing 
Psychological impact Psychological impact Mood affects symptoms 
Stiffness doesn’t affect mood 
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Codes Level 1 codes Level 2 codes Theme 
Stiffness makes you frustrated/angry [added in FG] 
Stress and anxiety impacts on symptoms 
Restricts image – vanity  
You lose the good part of the day 
I worry about stiffness [FG] 
I don’t worry about stiffness [FG] 
Stiffness makes me embarrassed [FG] 
Pain on movement 
Pain impact Pain impact 
If you force movements you get pain 
Pain on movement is accentuated in flare 
Must move to relieve stiffness which means you go through the pain 
barrier 

















Moving while still in bed 







Supporting joints  
Physically manipulating your joints 
Balancing rest and movement 
Exercise 
Exercise 
Debate about the benefit of exercise [FG] 
Gadgets/aids 
Gadgets and splints 
Other strategies 
Splints are effective for stiffness 
Splints are not effective for stiffness 
Splints are not compatible with other self-management strategies 
Hot/cold therapy is effective Heat and cold 
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Codes Level 1 codes Level 2 codes Theme 
Shower in the morning 
Hot/cold therapy is not effective 
Hydrotherapy 
Alternative therapy - Changing diet 
Alternative therapies Alternative therapy - Aromatherapy 
Alternative therapy - Relaxation techniques 
Take medication in the morning to get going 
Medications and 
painkillers 
Take medication to function 
Take painkillers 
Family and friends – Physically help with jobs/housework 




Family and friends - Facilitate use of self-management strategies 
Family and friends - Are flexible 
Normalise/accept stiffness Internal – Normalise 
Adapt and adjust behaviours generally - Have to find other ways to do 
things 
Internal – Adapt and 
adjust 
Adapt and adjust behaviours generally - You can work round stiffness 
Adapt and adjust behaviours in the morning - You just adapt in the 
morning 
Adapt and adjust behaviours in the morning - Perform activities later in 
day 
Adapt and adjust behaviours in the morning - Use gadgets at difficult 
times 
Prepare/plan for stiffness - Compensate for slow movement by getting 
up earlier Internal – Prepare 
and plan Prepare/plan for stiffness - Not too restrictive if pace and plan 
Self-management is easier since stopping work 
Ensure RA and stiffness does not take over life [RA general] 
Internal – Part of 
general RA 
management 
Self-management is individual/knowing your limitations/your body 
[general RA] 
Do what you can to help yourself [general RA] 
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Codes Level 1 codes Level 2 codes Theme 
Self-management and understanding RA develops over time [RA 
general] 
Self-management can be difficult especially when you enjoy things 
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Appendix K: Study 2 coding tree 
Coding 
frame 





Relevant to the 
individual 
Stiffness is very individual and 
measurement should reflect that 
 Stem questions and anchors: 
Individual 
Questions should be worded around 
the individual (“to you”) to appreciate 
whether this is usual  
 
Questions need to consider individual 
response shift 
 Stem questions and anchors: 
Individual; Response shift 
Wording questions around the 
individual can be difficult because of 
variability 
 Stem questions and anchors: 
Individual 
Impact Relevant consequences are just 
normal everyday tasks 
 Stem questions and anchors: 
Impact 
Possible impact questions worded 
around daily tasks or movement 
 
Impact around taking longer to do 
things  
 
Comes down to impact on QoL  
Difficulties with impact questions Some impact questions are 
gender specific 
Capture difficulty not completion 
Time and location specific 
Liked the impact triad as a concept 
around which to base measurement 
Impact triad mirrors real life 
experiences 
Stem questions and anchors: 
Impact triad 
Impact triad accounts for 





Level 1 codes  Level 2 codes Level 3 codes Key areas  
Stiffness after a 
period of 
immobility 
  Stem questions and anchors: 




Time is relevant   Stem questions and anchors: 
Duration is relevant but 
difficult 
Current duration questions are difficult 
answer 
Difficult to quantify 
It is hard to remember 
What is the start and endpoint? 
It depends what you are doing 
Duration of other symptoms not 
considered  
Questions about morning stiffness are 
limited 
Morning stiffness is not relevant 
to patients 
Stem questions and anchors: 
When do you get stiff is better 
to ask  Morning stiffness is important but 
should be separated from 
daytime stiffness 
Difficulties answering questions 
about the morning 
When is a more appropriate question  
 
Need to ask when stiffness 
occurs rather than about the 
morning? 
Need to ask about stiffness 
during the night 
Location Ask where you are stiff 
 
Number of joints affected Stem questions and anchors: 
Where do you get stiff 
Reflects individual experience 
Relates to usual experience 
You could look at structure and 





Level 1 codes  Level 2 codes Level 3 codes Key areas  
Location relates to severity  Could ask both where and how 
bad 
 Assessment of more joints does 
not indicate and increase in 
severity for everyone 
Assess each joint individually for 
severity? 
Different joints might have 
different severities 
 




Would like to be asked about pain and 
stiffness but it must be separate 
 Stem questions and anchors: 
Other symptoms (esp. pain) 
Need to ask about pain and stiffness 
separately or it is confusing  
 
Asking about ‘painful stiffness’ 
separates mechanical stiffness from 
inflammatory stiffness  
 








VAS lines are imprecise  Response options: Difference 
in opinion about 
VAS/NRS/VRS 
VAS are easy to respond to  
NRS - numbers are preferable to lines  
NRS provide too many options  
Less options are better  
Response option 
preference 
Fewer response options  
Free text  
Timeframe Debate about 
appropriate 
timeframe 
Timeframe must be recent   Timeframe: Debate about 
appropriate timeframe Stiffness over the last week con - 
might not capture the worst times/daily 
variability 
 
Stiffness over the last week pro – 






Level 1 codes  Level 2 codes Level 3 codes Key areas  
Stiffness now pro – takes a snapshot 
of you now 
 
Stiffness now pro – captures the worst 
for those on direct access 
 
Stiffness now con – might not capture 




Patients want to 
know why you are 
asking  
Provide explanation to improve 
accuracy  
 Layout and format: Purpose 
Visual aspects 
might be effective 
Clock face  Layout and format: Visual 
elements Body image  
It must be short 
and simple 
Give examples to help simplify  Layout and format: Succinct 
Fewer response options  
Questions must be 
up to date and not 
old fashioned   





Room for free text boxes to make it 
individual 
 Layout and format: 
Practicality of different 
approaches Practicality of lists – you need to use 
general categories to shorten the 
process 
 
Words to circle or tick are better than 
lots to write  
 
Circles are hard to draw  
Specific wording Joint stiffness?  Layout and format: Specific 
wording Flare vs seize up stiffness  
Severity or level  
Stiffness in every stem?  
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Appendix L: COREQ checklist (Study 2) 
No.  Item  Guide questions/description How was this component addressed 
Domain 1: Research team and reflexivity   
Personal Characteristics   
1. Interviewer Which author/s conducted the interview or focus group?  Identified in Section 5.3.4 
2. Credentials What were the researcher’s credentials?  The characteristics of the supervisory team 
were identified in Section 3.4.2 and the 
researchers (Halls) background was 
highlighted in Section 3.2.1 
3. Occupation What was their occupation at the time of the study?  
4. Gender Was the researcher male or female?  
5. Experience and training What experience or training did the researcher have?  
Relationship with participants   
6. Relationship established Was a relationship established prior to study commencement?  
Identified in Section 5.3.4 7. Participant knowledge of the 
interviewer  
What did the participants know about the researcher?  
8. Interviewer characteristics What characteristics were reported about the interviewer?  The researchers (Halls) background, 
experience and research interests were 
highlighted in Section 3.2.1 
Domain 2: study design   
Theoretical framework   
9. Methodological orientation 
and theory  
What methodological orientation was stated to underpin the 
study?  
The methodological approach to the study 
was discussed in Section 3.3.1 and the 
method and analysis approach were 
discussed in Sections 5.3.1 and 5.4 
Participant selection   
10. Sampling How were participants selected?  
Identified in Section 5.3.2 11. Method of approach How were participants approached?  
12. Sample size How many participants were in the study?  
13. Non-participation How many people refused to participate or dropped out? 
Reasons?  
Identified in Section 5.5.1 
Setting  
14. Setting of data collection Where was the data collected?  Identified in Section 5.3.4 
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15. Presence of non-
participants 




Identified in Section 5.5.1 16. Description of sample What are the important characteristics of the sample?  
Data collection   
17. Interview guide Were questions, prompts, guides provided by the authors? Was it 
pilot tested?  
Identified in Section 5.3.3 and Appendices 
H and I 
18. Repeat interviews Were repeat interviews carried out? If yes, how many?  This was not performed 
19. Audio/visual recording Did the research use audio or visual recording to collect the data?  Identified in Section 5.3.4 
20. Field notes Were field notes made during and/or after the interview or focus 
group? 
Identified in Section 5.4 
21. Duration What was the duration of the interviews or focus group?  Identified in Section 5.5.2  
22. Data saturation Was data saturation discussed?  Identified in Section 5.3.2 
23. Transcripts returned Were transcripts returned to participants for comment and/or 
correction?  
This was not performed 
Domain 3: analysis and findings   
Data analysis   
24. Number of data coders How many data coders coded the data?  Identified in Section 5.4 
25. Description of the coding 
tree 
Did authors provide a description of the coding tree?  Identified in Sections 5.5.2.2, 5.5.2.4, and 
Appendices J and K 
26. Derivation of themes Were themes identified in advance or derived from the data?  Identified in Section 5.4 
27. Software What software, if applicable, was used to manage the data?  Identified in Section 5.4 
28. Participant checking Did participants provide feedback on the findings?  This was not performed 
Reporting   
29. Quotations presented Were participant quotations presented to illustrate the themes? 
Was each quotation identified?  
Identified in Section 5.5 
30. Data and findings 
consistent 
Was there consistency between the data presented and the 
findings?  
31. Clarity of major themes Were major themes clearly presented in the findings?  
32. Clarity of minor themes Is there a description of diverse cases or minor themes?       
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Appendix M: Identifying what is relevant to measure 









































Stiffness is normal As a result of 
stiffness being 
considered to be 
normal in RA and 
part of having RA 
coupled with 
stiffness also being 
relevant in other 
conditions such as 
OA, the use of 
specific wording 
may be important. 
This would also aid 
keeping the focus 
on stiffness during 







Stiffness is a normal part of getting older [FG] 
No stiffness 
prior to RA 
No stiffness prior to RA 




Stiffness is an obvious symptom of RA [reinforced in 
FG] 
Stiffness is part of a bigger picture in the morning 
specifically 
Stiffness is part of a bigger picture 
RA stiffness is 
specific 
RA stiffness is different – General 
RA stiffness is different to exercise stiffness 
RA stiffness is different to overuse stiffness 
RA stiffness is different to OA stiffness 
RA stiffness is not different to OA stiffness [reinforced 
in FG] 
























fluctuating disease it 
would be important 
to capture this 
change in stiffness 





During a period of flare it is difficult to move and you 
can’t do ADLs 
Can’t do anything in a flare up 
Stiffness affects sleep when it’s bad 
During a period of flare pain and stiffness more 
related 
During a period of flare stiffness and 
inflammation more related  
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During a period of flare stiffness does not go away 
During a period of flare stiffness sticks around  
During a period of flare stiffness is quick/sudden 
In flare stiffness lasts longer 
In flare stiffness is more frequent in occurrence 
During a period of flare stiffness affects more 
joints 
During a period of flare stiffness severity is high 
During a period of flare stiffness is an exaggeration of 
itself 
During a period of flare stiffness is acute 
During a period of flare stiffness you can’t use 
manage it in the same way 





Damaged joints cause stiffness It would also be 
important to 
differentiate 






You can’t move damaged joints 
Causes of damaged joints 













Pain and stiffness are normal The relationship 
between stiffness 
and other symptoms 
was clear and this 








Pain and stiffness are related [reinforced in FG] 
Pain and stiffness are different concepts [reinforced in 
FG] 
Pain comes with baggage 
Pain is easier to deal with than stiffness 
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Pain is harder to deal with than stiffness development. As 
above the use of 
specific language 
will ensure that the 
topic of stiffness is 
reinforced. Other 
symptoms will be 
assessed as part of 
the questionnaire 















Pain and stiffness more related during flare 
Pain effects sleep 
You feel stiff when you try  to move but pain you feel 
when you don’t move 
If you stay in one position for too long you get pain 
You can tell pain and stiffness limitations apart 
Management targets pain and stiffness differently 
[FG] 
You should separate pain and stiffness [FG] 
You might stiffness as a protective instinct against 
pain [FG] 
The feeling/sensation of stiffness is a type of pain 
[FG] 
Hard to define in words the difference between 
symptoms [FG] 
Uncertainty about the difference between pain and 
stiffness [FG] 




Stiffness and fatigue are related 
Stiffness is more fatigue than pain 
Stiffness and fatigue are different 





Stiffness is related to inflammation 
Stiffness is unrelated to inflammation 
Inflammation causes stiffness 
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 Inflammation relates to a flare 
Stiffness is the same as inflammation 
Both stiffness and inflammation cause functional loss 




All symptoms are intertwined 
All symptoms are intertwined when its bad but 
unrelated when it’s not 
All symptoms are worse [in a flare] 










Stiffness was an early symptom of RA Could explore 
differences in 
response between 
newly diagnosed vs 
experienced 
patients in Study 4 
 
Stiffness was severe at disease onset 




Stiffness was not relevant in early disease 





















Stiffness affects certain parts of the body This may capture 
aspects of severity 
and/or impact that 
have not been 

















Stiffness moves around the body 
Stiffness feels different in different parts of the body 
Stiffness all 
over 
During a flare/bad day stiffness affects more joints 
[reinforced in FG] 
In the morning stiffness affects more joints/all over 
[reinforced in FG] 
Stiffness affects whole body [FG] 
 426 
 














Joints are the problem This may be 
relevant from a 
severity perspective 
and also in stiffness 
assessment across 
conditions e.g. PMR 




Muscles are the problem 
































Stiffness is caused by being immobile Important to 
consider stiffness 
after immobility, and 






Being in a restricted position causes stiffness 
Should be less stiff when have been more active in 
the night but not the case 
Overdoing it 
Legacy of activity causes stiffness 



















Medications are beneficial for stiffness – Non-specific Patient relevant to 
discuss 
medications. If this 
is the way that 
some patients 
assess stiffness 
then it may be 
important to test. 
Could consider 
about medications 
are working as 
effectively as usual? 















Medications are beneficial for stiffness – Infusion 
Medications are beneficial for stiffness – Steroids 
Medications are beneficial for stiffness – DMARD 
Medications are beneficial for stiffness - Anti-TNF 
Medications are better than they were - now prevent 




Medications reduce stiffness duration 
Medications reduce stiffness severity 
Medications reduce stiffness which allows normality 
Medications get rid of stiffness 
Only steroids reduce stiffness in flare 
Medications 
impact on 
Medications reduce stiffness but it’s a lost entity 
because it’s never measured 
 427 
 
















































Medications do not target stiffness 
Medications do not work when you have a flare up 
Medications 
effects can be 
variable 
Some medications work better than others 
Sometimes the same medications work better than 
other times 




Medications have side effects Purely experiential 
and not relevant to 
measurement 
 
Not wanting to take medications 





Certain drinks cause stiffness to be worse As with 
medications, if 
these are the ways 
that patients use to 
talk about and 
assess stiffness 
then they may need 
consideration in 
assessment. 
Although again this 









Certain foods cause stiffness to be worse 
Weather 
Air conditioning causes joints to be stiff and painful 
The weather has an impact on stiffness – Hot 
weather 
The weather has an impact on stiffness – Cold 
weather 
The weather has an impact on stiffness – Humid 
weather 
Air pressure has an impact on stiffness [FG] 













Stiffness does not affect sleep 
Stiffness does affect sleep [reinforced in FG] 

























Stiffness is individual/subjective  This was very 
important to patients 
and reinforced by 
patient partners. 
This may influence 















Stiffness does relate to mornings Key to capture 
temporality in 
assessment bearing 
in mind patient 
experience being 








Stiffness does not relate to mornings 
You notice stiffness when you get up/wake up 
Other times of 
day 
Stiffness relates to other times of day 
Stiffness doesn’t relate to a particular time of day 
Best time of day is afternoon/evening 
Stiffness relates to the night time [FG] 
Timing 
changes 





Duration of stiffness – Varies within people See above. Plus 
could consider 
assessing duration 
in relation to impact 
e.g. it takes me long 




Duration of stiffness – Varies between people 
Duration of stiffness - Different amount of time 
Duration of stiffness - Gradually eases off 
Constant 
Duration of stiffness - Similar amount of time 
Stiffness never completely goes away 
Stiffness is constant now (it doesn’t change) 
Some joints stick all day 
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Time is not 
relevant 









usual baseline level 
and maybe severity 




General stiffness – Impact on function 
General stiffness – Manageable 
Different levels of stiffness [reinforced in FG] 
Severe 
stiffness 
Severe stiffness – Cramp stiffness 
Severe stiffness – Not expected [harder to manage] 






















































Can’t do ADL's or simple tasks The key aspect from 
the interviews and 
focus groups and a 
very natural way for 
patients to discuss 
stiffness. Important 
to ensure that every 
aspect here is 




























Dressing or undressing [added in FG] 
Causes difficulties 
Getting up from a chair is difficult 
Stairs 
Restricts family life 
Can’t plan 
Difficult to get out of bed 
Unnatural/awkward walking 
Can’t get comfortable [reinforced in FG] 
Stiffness a problem at night 
Stiffness not a problem at night 
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Stiffness in different places is worse because it has 
different impact 



















Don’t have mobility 
Slow/can’t rush/actions take me longer 
Physically have to unbend limbs 
No flexibility 
Need physical support 





Forget how to walk properly As above Impacts on  
Have to think about doing actions 
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Bits of my body won’t move when I am expecting 
them to [FG] 
daily life: 
Cognitive 









Mood affects symptoms 
Stiffness doesn’t affect mood 
Stiffness makes you frustrated/angry [added in FG] 
Stress and anxiety impacts on symptoms 
Restricts image – vanity  
You lose the good part of the day 
I worry about stiffness [FG] 
I don’t worry about stiffness [FG] 





Pain on movement This may be an idea 




and pain this may 




If you force movements you get pain 
Pain on movement is accentuated in flare 
Must move to relieve stiffness which means you go 
through the pain barrier 
Stiffness is a warning – telling you to slow down 

















Moving Important to capture 
this in assessment 
as was relevant to 
patients. It also 
forms part of the 
impact triad so can 
be tested within that 










Moving while still in bed 
Uncertainty as to whether movement always helps 






Supporting joints  
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Balancing rest and movement 
Exercise 
Exercise 









Splints are effective for stiffness 
Splints are not effective for stiffness 
Splints are not compatible with other self-
management strategies 
Heat and cold 
Hot/cold therapy is effective 
Shower in the morning 




Alternative therapy - Changing diet 
Alternative therapy - Aromatherapy 
Alternative therapy - Relaxation techniques 
Medications 
and painkillers 
Take medication in the morning to get going 





























Family and friends - Facilitate use of self-
management strategies 




Adapt and adjust behaviours generally - Have to find 
other ways to do things 
 433 
 
















Adapt and adjust behaviours generally - You can 
work round stiffness 
Adapt and adjust behaviours in the morning - You just 
adapt in the morning 
Adapt and adjust behaviours in the morning - Perform 
activities later in day 
Adapt and adjust behaviours in the morning - Use 




Prepare/plan for stiffness - Compensate for slow 
movement by getting up earlier 
Prepare/plan for stiffness - Not too restrictive if pace 
and plan 
Self-management is easier since stopping work 
Internal – Part 
of general RA 
management 
Ensure RA and stiffness does not take over life [RA 
general] 
Purely experiential 
and not relevant to 
measurement 
 
Self-management is individual/knowing your 
limitations/your body [general RA] 
Do what you can to help yourself [general RA] 
Self-management and understanding RA develops 
over time [RA general] 




Appendix N: Mapping the experience of stiffness to the measurement perspective 







Summary of measurement ideas Discussion with team 
Part of having 





A suggestion was made about specifying 
stiffness in each question to reinforce the topic 
of the question/s 
 Given the complexity of stiffness and how it 
fits within a complex disease it is important 
to include stiffness in every stem to avoid 
distraction and keep on topic? 
 Keep stiffness or RA stiffness in every stem 
[JK] 
Part of having 
RA: Fluctuation 
with disease 
   Capture via specific aspects of stiffness in 
periods of fluctuating disease (detailed in 
Appendix L) 





Suggested differences between stiffness from 
different processes. 
 
One suggestion about different wording for 
different experiences of stiffness  
 Any different wording to distinguish 
mechanical/inflammatory? [JK] e.g. 
constant (fused joints) [ED] 
 Consider what is used clinically e.g. physio 
- distinction between active and passive 
movements -would this or something 
similar work? [JK] 
 Permanence-this never moves vs. 
recent/new/past 7 days? [SHa] Fits with AE 
experience 
 Include a distinction for patients about what 
this is including and excluding e.g. stiffness 
that comes and goes not damaged joints 












Summary of measurement ideas Discussion with team 





















Suggestions about pain and stiffness in 
particular included asking about both but 
separately to avoid confusion. Plus the idea of 
‘painful stiffness’ was suggested as relevant-
could this separate different types of stiffness 
(Part of having RA: Mechanical vs. inflammatory 
stiffness)? 
 
Also it was suggested that inflammation was 
also relevant to ask about in addition to pain and 
stiffness. This lead to the suggestion of what 
contributes to your experience of stiffness. 
 
Visual aspects were encouraged within focus 
group  
 Combined pain and stiffness questions not 
ideal for measurement and difficult for 
patients to answer. Therefore need to think 
about what makes measurement sense 
here [SH] 
 Painful stiffness suggested in FG’s [ED] 
 Need to consider the complex relationship 
between pain and stiffness but bear in mind 
the purpose of this PROM to assess 
stiffness 
 Relevant to measurement because will 
asking about stiffness capture anything 
over and above that already captured by 
pain? [JK] 
 Related to the idea below (see Location) 
about capturing painful, swollen and stiff 
joints on a body and then seeing whether 
that creates another variable. This would 
allow you to explore the relationship 
between all combinations of the above. 
Although difficulties with patients  
accurately identifying swollen joints -
Sarah’s previous work, might influence 
suggestion about identifying swollen, 





























This was suggested as a natural way of thinking 
about stiffness. It was suggested as an indicator 
of worsening stiffness (if you know where you 
usually get stiff then if it is broader than usual 
then that is an indicator of severity (e.g. number 
of joints affected). However it was highlighted 
that this was not an indicator of severity for 
everyone! (See Severity below) 
 
 
Visual aspects were encouraged within focus 
group 
 We currently assess inflammation by 
number of painful and swollen joints. 
Number of stiff joints has not been done 
before but there is precedence [SH] 
 AE’s experience reinforced the idea of 
overall stiffness when struggling 
 Interesting idea, suggested trying the visual 
representation of stiffness with patients 
[might be different with different patients 
e.g. RA vs. PMR] [JK] 
 All over stiffness option - similar to body 
used in the PDAS [ED] 
 Another way of doing this would be ask 
where do you feel stiff-one joint/two 
joints/outside the joints/all joints? Maybe 
look for patterns (similar to McGill pain 
questionnaire). Overall, location of stiffness 













If you asked where you might get a better idea of 
the affected structure  
 
Suggestion about stiffness everywhere  
 
A suggestion was made to specify ‘joint stiffness’  
 
 AE’s experience reinforced the idea of 
overall stiffness when struggling 
 All over stiffness option - similar to body 
used in the PDAS [ED] 
 Include specific wording 
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This is something that is relevant to patients but 
currently not being captured in current 
measurement. Could this separate different 
types of stiffness  
 Capture stiffness after a period of 
immobility  
 Could asking about whether stiffness 
reduces following exercise/movement 
differentiate mechanical and inflammatory 







   Patient relevant to capture aspects like 





Effect of lifestyle 
and environment 
   Patient relevant to capture aspects like 














It was highlighted that questions need to 
appreciate individual differences and reflect 
whether what you have experienced in the 
timeframe is usual for you. However this may be 
difficult given the variability of stiffness. 
 
Response shift highlighted as being an influence 
on perceptions. Maybe this could be explored 
somehow? 
 Look at wording in the PFQ worded around 
normal/usual/average for me [SH] 
 Include individual wording in wording 
questions 
 Capture response shift? 
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When do you get 








The concept of stiffness is broader than just 
morning stiffness for most patients (although 
morning stiffness is relevant, particularly for 
some). The morning is difficult to answer about 
(e.g. what is the morning?). Stiffness during the 
night is also relevant. Maybe WHEN is a better 
way to ask? 
 
Visual aspects were suggested within focus 
group 
 AE suggested that using the term morning 
stiffness excludes other relevant times and 
liked the idea about when  
 Stiffness at night challenges the concept of 
EMS [ED]. 
 Timing graph or clock face as visual 
options - Could measure either using area 
under the curve, digitise it? Lots of 
possibilities but also lots of challenges. 
Overall, some visual way of looking at this 
sounds possible but need to find out what 
is feasible for patients (OMERACT filter) 
[JK] 














When do you get 
stiff is better to 
ask 
It was suggested that duration is relevant to 
patients but it is difficult to answer; it doesn’t 
capture the whole stiffness experience, we don’t 
ask how long pain lasts, it is hard to remember 
and put a time on it, we don’t sit and time it, it 
depends what you are doing, what are the start 
and end points etc. Lots of suggestions about 
how to combat this 
 
Maybe WHEN is a better way to ask? 
 As above – when are you stiff? 
 Address through impact e.g. does it take 
longer to complete certain tasks? 
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Where do you get 
stiff 
it was suggested that number of affected joints 
may indicate severity (See Location above) 
 Address through impact e.g. stiffness is so 
severe I am unable to complete certain 
tasks 
 Capture the number of affected joints (See 
Location above)  
 Consider usual baseline? 
Impacts on daily 























There were suggestions that impact relates to 
normal everyday tasks and activities. Specific 
examples were identified (captured in inductive 
analysis) and impact was also related to taking 
longer to do tasks as well as them being more 
difficult. Difficulties with impact questions were 
highlighted including certain impact elements 
being gender, time (e.g. morning), or location 
(e.g. affected body part) specific, and the input 
of others (e.g. help from significant other). 
 
The impact triad was seen as a relevant concept 
to patients to base measurement around. Each 
aspect of the triad was discussed and was 
relevant. Indicating that the impact triad was 
acceptable to patients as a concept on which to 
base the measurement of stiffness.  
 
Specific wording was also suggested about how 
to word different aspects of the triad 
 The idea of the impact triad being 
acceptable to patients is not surprising as it 
was developed by patients [JK] 
 Captured as part of the impact triad 
 Test items capturing each suggested 
aspect of each area of impact  
Impacts on daily 
life: Physical 
impact 
Impacts on daily 
life: Cognitive 
impact 
Impacts on daily 
life: Psychosocial 
impact 
Impacts on daily 
life: Pain impact 
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   Captured as part of the impact triad 
Requires self-
management: 
Change in ability 
to manage 







As there was difference of opinion as to the most 
appropriate format, different formats could be 
tested in cognitive interviews and even in the 
survey. Also relevant to consider aspects 
highlighted in Format: Practicality of different 
approaches (see below) e.g. circle are difficult 







There was debate about the timeframe that was 
most relevant to stiffness, weighed up against 
what could be reasonably captured in a 
questionnaire  
 Past 7 days preferred by AE 
 Could test questions with different 
timeframes? 
 Consider the usefulness from a clinical 
context 
 Last week is the best for people-captures 
weekly patterns/easy to remember but 











Summary of measurement ideas Discussion with team 
Layout and 
format: Purpose 
As it was suggested that there was uncertainty 
about why this information was being asked for 
and what it would be used for a brief introduction 
could help explain the purpose of the question/s 
 Include introduction to describe purpose 
Layout and 
format: Succinct 
Must ensure that the questionnaire is simple, as 
short as possible and that each question only 
has as many options as necessary. Also provide 
examples if needed to enhance clarity 
 Overall aim is to identify the smallest 
combination of items that work most 
effectively together  
Layout and 
format: Modern 
Ensure that questions are relevant and modern 
(not old-fashioned) 






Relevant to the layout of the question/s e.g. free 
text options, and also to Response options (see 




Appendix O: Early item development 
Key area  Specific 
aspect to 
capture 
Potential wording Origin of 
wording 
Discussion with team 




Specificity No direct question but include the words stiffness 
and or RA in every stem question? 
QD, SH, JK, 
GB 
Important to retain focus on topic of stiffness [JK/SH/GB]. 
Could use ‘stiffness due to your RA’ [JK], ‘RA stiffness’ 
[SHa], or “thinking about stiffness” [GB] 
Normality It was acknowledged that stiffness was part of the 
‘normal’ experience of RA thus maybe we need to 
capture when stiffness is different to normal?  
QD, SH, JK Taking account of normal adaption was important to patients 
in development of PFQ (although didn’t get into final items) 
[SH]. This might be captured by addressing the response 
shift i.e. how patients have reset values. However this would 
have to separate this from the other item so it doesn’t 
influence responses [SH/JK]. Could ask the level of stiffness 
on a normal day using 0-10 [SH] and then use it to 
standardise response [JK] 




Change Capture change in impact? E.g. unable to function 
because of stiffness 
SH, JK No specific question - this will be captured in the impact triad 
(impact and management) and depending on the response 
options for impact items this may be captured there. 
 
Acknowledge variation through timescale – From a 
research/clinical perspective we would be looking at the 
effects of an intervention over weeks/months rather than a 
few days/hours [JK/SH]. Plus from a recall perspective 7 
days is easy to remember as it has a natural social cycle 
[JK] 
Capture change in self-management? 
Is change captured in other items e.g. impact 
items? 
Part of having 
RA: Process 
Process Do you have some joints that are 
always/permanently stiff and do not move? 
(Permanent vs. variable) 
JK, ED, QD Must consider how this information would be used [SH] 
 
Consider something like ‘I have some joints that do not 
move normally whether my arthritis is good or bad’ [JK]. 
Always difficult to move [SH] rather than permanent 
 
The purpose here is to identify mechanical changes in the 
joint that are stopping that joint from moving fully to say to 
patients – we already know about this and we don’t need 
I have some joints that do not move even when I try 
to move them? (Passive vs active) 
JK, ED, QD 
Are you able to reduce stiffness by exercising or 
moving? (Permanent vs. variable) 
QD 
It is usual for some of my joints not to move even 
when I try to move them? (Passive vs active: usual) 
JK, ED, QD 
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Key area  Specific 
aspect to 
capture 
Potential wording Origin of 
wording 
Discussion with team 
It is usual for some of my joints not to move 
permanently? (Permanent vs. variable: usual) 
QD, ED, QD any more information about it - so somehow I think you do 
have to try and either identify it or get patients in their mind 
to identify it but then discount it. Maybe have an introduction 
that introduces these ideas and then a question at the end 
that checks this e.g. how much of the stiffness you have 
reported in these questions do you think is due to 
permanently damaged joints bracket? Having it at the end 
will mean it doesn’t influence the rest of the answers [JK] 
 
Statement rather than direct question e.g. “We 
recognise that sometimes joints do get damaged 
and as a result do not move very much even when 
you try to move them. In this questionnaire, we are 
trying to understand your disease activity rather 
than the consequences of long term disease, so 
please a) only complete the following questions 
about your stiffness that comes and goes or 
changes (i.e. not permanent stiffness) b) do not 
include stiffness as a result of damage in your 
answers to the following questions”. Could be 
included with other questions e.g. “If you answered 
yes to any of the questions above please refer to 
statement” 
QD 





Pain Ask about painful stiffness e.g. In the past [insert 
timeframe] have you experienced painful stiffness? 
QD, GB, ED Although this was suggested by patients, Gill suggested 
avoiding direct discussion about other symptoms to keep the 
focus on stiffness [GB]. Also from a measurement 
perspective this is probably sensible to avoid [JP] plus pain 
will be assessed for validity testing.  
Pain Capture whether stiffness relates to other 
symptoms more than usual to pull out increased 
association between stiffness and other symptoms 
in flare (inflammatory)  
QD Using ‘symptoms’ would be good to capture other symptoms 
rather than just pain – can be interpreted in any way by the 
patient [JK]. This could be a way of characterising the nature 
of stiffness [JK] 





Inflammation Do you experience stiffness with 
inflammation/swelling? 
QD As above, capturing whether stiffness is associated with 
other ‘symptoms’ may be useful [JK]. There could be a 
relevant variable that emerges from the combination of all 
three? [SH]. But there may be difficulty capturing swollen 
joints visually or otherwise is that it has been shown that 
patients can’t identify swollen joints accurately (Hewlett, 
1995) [SH/JK] 
Do you feel stiff because your joints are swollen? QD 
Do your joints feel tight? QD 





Key area  Specific 
aspect to 
capture 
Potential wording Origin of 
wording 














With visual option - how do you quantify this? What image to 
use? E.g. with/out joints? How to mark e.g. shade (patient 
burden), tick (accuracy), mark (different for everyone). 




Location Capture the concept of all over stiffness e.g. In the 
past [insert timeframe] have you experienced all 
over/whole body stiffness? 
QD Could ask ‘over the last 7 days I have experienced stiffness 
in 0 joints/1 joint/2 or 3 joints/all over [SH], 1 joint only/up to 
5 joints/more than 5 joints, none/a few/many [SHa]. Any 
would capture severity [SH/JK] as might all over [SH]  
 
Patients really liked the idea about visual options [ED] but 
there are practical/feasibility considerations – see above. 
When run by GB - visual option would be do-able. Could 
provide people the option if that is easier for them rather 
than for everyone? [GB]  
 
Think about the specific wording for all over/whole body – 
check exact wording in transcripts [SH] As it is it is likely to 
need a Yes/No response. Don’t place together as you could 
have one and not the other (whole body may be different 
from joints). Overall something capturing the number of 
joints, and something separate capturing all over stiffness) 
[JK/SH]   
Capture the concept of number of stiff joints e.g. In 
the past [insert timeframe] where have you felt stiff? 
One joint/two joints/etc 
QD 
I have experienced stiffness affecting more joints 
than usual? 
QD, JK, SH 
Capture the location of stiffness and whether that is 
‘all over’ and ‘usual' visually e.g. 
 
Please mark your 
stiff joints: 
Please tick if the following 
are true for you: 
  
My whole body is stiff 
 
This is usual for me 
 
QD 
Capture a pattern of responses - see McGill pain 




Key area  Specific 
aspect to 
capture 
Potential wording Origin of 
wording 
Discussion with team 
to you in the past [insert timeframe]: all joints/ 
/many joints/some joints/no joints/outside the 




Structure Capture stiffness in body/joints separately? QD, JK, SH, 
ED 
Need to be clearly separated from joints ‘some people 
experience stiffness in their muscles or body in addition to or 
instead of joints. Thinking about your body…’ [SH], or 
‘outside of the joints in the muscles or body’ [JK], or ‘not 
thinking about your joints…’ [SH] These items would need to 
go next to each other to enhance understanding [JK] 
Include specific wording e.g. ‘joint’, ‘all over’, ‘body’ 
depending on the question. Could use PFW 







Immobility Capture stiffness after a period of immobility e.g. 
Have you experienced stiffness after a period of 
immobility? 
QD I think stiffness after immobility is really interesting. I 
definitely think that thinking of the pathophysiological causes 
of stiffness potentially that this could distinguish different 
types of stiffness (different processes?) and so it’s a good 
idea to keep it in for now [JK].  
 
Think about wording - ensure that any item is clear that this 
is talking about immobility over longer than just sitting down 
for 5 minutes [JK]. Suggested wording ‘some time/a period 
of time for example in a chair/in bed’ [SH], ‘after a period of 
immobility (for example sitting still for an hour) my stiffness 
is no different/a little bit worse/a lot worse/much worse’ [JK] 
Movement  Capture whether stiffness reduces following 
exercise or movement e.g. During the past [insert 
timeframe] has your stiffness reduced following 














My current RA medications are having less of an 
effect on stiffness than usual/have not been 
managing stiffness in the way they usually do? 
QD Lots of qualitative discussion so if medications are the way 
that some patients assess stiffness then it could be 
important to test - I think this is something that I can imagine 
patients relating to, this is like a patient’s way of viewing 
things. If that is the way that patients view things [JK] 
 
Is this different from self-management? Think about 
placement [SH/ED] 
 
Could look into something around ‘usual medications having 
less of an effect’ [SH] 
Please indicate the effectiveness of your current RA 
medications in relieving your stiffness 
QD, OS 
(BASDAI) 
Are your current RA medications relieving stiffness 




Key area  Specific 
aspect to 
capture 
Potential wording Origin of 
wording 







Weather During the past [insert timeframe] has the weather 
affected your RA stiffness? 
QD Like medications, if these aspects are the ways that patients 
use to talk about and assess stiffness then they need to be 
considered in assessment e.g. characterising the nature of 
stiffness [JK]. What is the relevance clinically? [SH]. This is 
not about clinical usefulness, it’s about characterising 
stiffness in a patient relevant way [JK]. Although there is 
work into barometric pressure [SH/JK]. Could test and see. 
Overdoing 
things 
Capture stiffness after overdoing things QD 
Other Capture any other aspects relevant to the patient 






Individual No direct question but include individual wording 
e.g. ‘to you’ and/or ‘usual for you’  





Frequency Capture whether stiffness occurs more 
often/frequently e.g. During the past [insert 
timeframe] has stiffness occurred more frequently? 
QD More frequently might be useful [SH]. I prefer does your 
morning stiffness come back more frequently during the day 
(24 hour period) than usual [PAM] 
 
Variability is different from temporal pattern e.g. ‘my stiffness 
varies or comes and goes throughout the day [not at all/a 
little/a lot]’ or ‘my stiffness varies from day to day [not at all/a 
little/a lot]’ [JK]. Temporal pattern is different from variability. 
Timing questions could be over the last 7 days e.g. ‘have 
you had stiffness most mornings, most afternoons, most 
evenings, most nights’ [JK]. The timing question/s are about 
severity - the more times you are stiff = more severity 
because if you are stiff for more times it means the total 
amount of time you are stiff is greater [JK] 
 
Same practical/feasibility considerations with visual options 
– see above 
Variability Has stiffness been more changeable/variable than 
usual? 
QD 
When Has stiffness affected you throughout the day and 
night? 
QD 
When Capture when stiffness occurs rather than how long 
it lasts e.g. During the past [insert timeframe] when 
have you experienced RA stiffness? Night, morning, 
afternoon, evening 
QD 
When Capture when stiffness occurs visually e.g. During 
the past [insert timeframe] when have you 
experienced RA stiffness? 
 Clock face 
 Chart (draw stiffness throughout the day?) 




Duration Capture whether stiffness has lasted longer than 
usual e.g. During the past [insert timeframe] has 
stiffness lasted longer than usual 




Key area  Specific 
aspect to 
capture 
Potential wording Origin of 
wording 
Discussion with team 
Capture duration through impact e.g. During the 
past [insert timeframe] has it taken you longer to 
complete your daily tasks because of stiffness? 
QD Asking about duration through impact could be ok [SH]. 
More about being slower [PR] which comes back to direct 
impact. Suggested wording ‘stiffness makes me slower 
doing usual things’ [PR/SH] 




Severity Capture whether stiffness has been worse than 
usual e.g. During the past [insert timeframe] has 
stiffness been worse than usual 
QD, OS This would capture aspects of fluctuation with disease. 
Capture severity through impact e.g. During the 
past [insert timeframe] have you found it 
difficult/been unable to complete your daily tasks 
because of stiffness? 
 
Capture severity through aspects discussed above 
e.g. no. of affected joints? Frequency, variability  
 See discussion above 
Traditional stiffness items OS Include some standard severity questions [SH] 
Impacts on 
daily life: Daily 
life impact 
Sleep Has stiffness made it difficult to sleep?/Has stiffness 
affected your sleep? 
QD Impact questions look sensible but there are a lot of them 
[JK]. Could be good one liners with similar responses to 
BRAF or other scale [SH]. The amount is disproportionate to 
the amount of other questions [JK]. Poor items will fall out if 
they are not good [SH]. Important to retain range of items 
highlighted in the qualitative work [GB]. Plus one impact 
question would not cover the whole of impact [GB]    
Layout needs to be considered - separate sections for clarity 
and to make a long list of questions look less intimidating 
[GB]. Layout must be appropriate for patients [SH] 
 
Think about the choice of wording to ensure it is accessible 




Has stiffness made it difficult to dress and undress 
yourself? 
QD 
Washing Have you found it difficult to bath or shower 
because of stiffness? 
QD 
Daily tasks or 
chores 
Has stiffness made it difficult to do your usual daily 
tasks and activities? 
QD 
Daily tasks or 
chores: 
Eating 
Has stiffness made it difficult to eat, including 
chewing and cutting food? 
QD 
Daily tasks or 
chores: 
Driving 
Has stiffness made it difficult to drive a car/vehicle? QD 
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Key area  Specific 
aspect to 
capture 
Potential wording Origin of 
wording 
Discussion with team 
Daily tasks or 
chores: 
Walking 
Have you found it difficult to walk because of 
stiffness? 
QD  
Daily tasks or 
chores: 
Brush teeth 
Has stiffness made it difficult brush your teeth? QD 
Work Have you found it difficult to work because of 
stiffness? 
QD 
Hobbies Have you found it difficult to do hobbies and 
activities you enjoy? 
QD 





Have you found it difficult to rise from a chair 
because of stiffness? 
QD 
Effort Have you found doing your usual daily tasks and 
activities requires more effort than usual? 
QD 








Has stiffness made it difficult to perform fine 
movements e.g. use a pen or pencil or do up 
buttons on a shirt or cardigan? 
QD 
Grip Has stiffness made it difficult to grip or hold things 
e.g. opening a bottle of milk 
QD 
Grip: make a 
fist 




Have you lacked strength to complete tasks or 
activities because of stiffness? 
QD 
ROM Has your range of movement been reduced by 
stiffness?/Has stiffness limited your range of 
movement? 
QD 
Flexibility Has stiffness limited your flexibility? QD 
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Key area  Specific 
aspect to 
capture 
Potential wording Origin of 
wording 
Discussion with team 
Balance Has stiffness made it difficult to balance? QD 
Slow Has stiffness made you slow getting 





Has stiffness made it difficult to rush? QD 
Mobility Has stiffness made it difficult to move? Has 




Have you found you are unable to move parts of 
your body because of stiffness? 
QD 





Has stiffness made it difficult to move? QD 
Can’t move 
as expected 
Has your body not moved like your brain expects it 








Has your body not moved like your brain expects it 




Have you had to concentrate to move perform tasks 












Frustration Have you felt frustrated because of stiffness? QD 
Worry Have you felt worried because of stiffness? QD 
Embarrassed Have you felt embarrassed because of stiffness? QD 
Impacts on 
daily life: Pain 
Pain on 
movement 
Has stiffness made it difficult to move without pain? QD See arguments about regarding including pain directly e.g. 
retain focus on stiffness [GB], confusing from measurement 
perspective [JP], pain captured in validity testing already 
Have you been able to self-manage stiffness?  QD  
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Key area  Specific 
aspect to 
capture 
Potential wording Origin of 
wording 






Have you had to spend more time than usual 
managing stiffness? 
QD From the HIT day people said that they don’t use the word 
‘self-manage’ [ED]. That is also true of the qualitative data – 
‘self-management’ was not the term used [SHa]. ‘Cope’ or 
‘deal’ is more of a patient word [PR], or ‘made do’, or ‘work 
around’ but that has more of a problem solving or practical 
slant. Think about the options [SH/ED] 
 
Think about the choice of wording to ensure it is accessible 
to all responders [SH] 
 
Could look at having to use more strategies for example 
medications/hot cold as it might be a level of severity issue 
[SH] 
 
Look at heath foundation for further information on 
measuring self-management [ED] 
Capture self-management in the impact triad QD 




Have you had to change your plans or behaviour 
because of stiffness? 
QD 
Have you had to accept help from others because 
of stiffness? 
QD 
Change plans or behaviour? QD 
Have you been able to self-manage stiffness as 
well as usual? 
QD 
Key: QD = qualitative data, initials (JK, JP, ED, SH, GB, AE, PR) = discussion with supervisory team member, OS = other scale 
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Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
1 Severity Local and 
widespread: 
Location 
Location Thinking about the 
location of your RA 
stiffness: How 
many joints have 
you experienced 
RA stiffness in 
during the last 7 
days? 
4 option ordinal 
scale (none of my 
joints, some of my 
joints, many of my 
joints, all of my 
joints) 
Location is not the 







stiffness in your 
joints during the 
past 7 days? 
4 option ordinal 
scale (not in any of 
my joints, yes, in 
some of my joints, 
yes, in many of my 
joints, yes, in all of 
my joints) 
2 Severity Local and 
widespread: 
Location 
Location Thinking about the 
location of your RA 
stiffness: How 
many parts of the 
body have you 
experienced RA 
stiffness in during 
the last 7 days? 
4 option ordinal 
scale (no parts of 
my body, some 
parts of my body, 
many parts of my 






Clarify that this is 
about stiffness in 
your body but 
outside the joints 
[ED] 
 
Is the ‘whole body’ 
is different to ‘parts 
of the body’ [ED] 
Have you 
experienced RA 
stiffness in your 
body (outside of 
your joints) during 
the past 7 days? 
4 option ordinal 
scale (not in any 
parts of my body, 
yes, in some parts 
of my body, yes, in 
many parts of my 
body, yes, in my 
whole body) 




Variability During the last 7 
days my RA 
stiffness has varied 
(comes and goes) 
throughout the day 
or night/from day to 
day? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
Varied in intensity 
or in number of 
episodes? [ED] 
 






During the past 7 
days have you 
experienced RA 
stiffness coming 
and going as 
frequently as usual 
for you? 
5 option Likert 
scale (it has been 
much less frequent 
than usual, 
it has been less 
frequent than usual, 
it has been the 
same as usual, it 
has been more 







Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
 
Day or night 
sounds like a 
choice – could use 
‘throughout the day’ 
or maybe just get 
rid of that bit and 
end with throughout 
[ED] 
it has been much 
more frequent than 
usual) 




Immobility After a period of 
immobility (e.g. in a 
chair or in bed) my 
stiffness is 
4 option ordinal 
scale (no different, 
a little bit worse, 
quite a bit worse, 
much worse) 
 During the past 7 
days have you 
experienced 
stiffness after a 
period of immobility 
(for example, in a 
chair or in bed)? 
5 option Likert 
scale (I have had 
much less than 
usual, I have had 
less than usual, I 
have had the same 
as usual, I have 
had more than 
usual, I have had 
much more than 
usual) 







My RA medications 
have been affecting 
my RA stiffness 
5 option Likert 
scale (much less 
well than usual, 
less than usual, the 
same as usual, 
better than usual, 
much better than 
usual) 
 During the past 7 
days have your RA 
medications been 
controlling RA 
stiffness as usual 
for you? 
5 option Likert 
scale (it has been 
much less well 
controlled than 
usual, it has been 
less well controlled 
than usual, it has 
been controlled the 
same as usual, it 
has been controlled 
better than usual, it 







Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
much better than 
usual) 




When During the last 7 




4 option ordinal 
scale (During the 
morning, During the 
afternoon, During 





there are two very 
similar items – 
either verbally or 
written [JK] 
During the past 7 
days when have 
you experienced 
RA stiffness (in 
your joints or your 
body)? 
4 option ordinal 
scale (During the 
morning, During the 
afternoon, During 
the evening, During 
the night) 




When Thinking about your 
RA stiffness during 
the last 7 days, 
please mark on the 
clock face the times 
of day when you 
have experienced 
RA stiffness 
Clock face (visual 
option) 
During the past 7 
days when have 
you experienced 
RA stiffness (in 
your joints or your 
body)? 
8 option ordinal 
scale (first thing 
when I wake up, 
when I get out of 
bed, during the first 
few hours after I get 
up, during the late 
morning, during the 
early afternoon, 
during the late 
afternoon, during 
the evening, during 
the night) 
8 Impact  Impacts on 
daily life: Daily 
life impact 
Sleep Has stiffness 
affected your 
sleep? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness 
affected your 
sleep? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
9 Impact Impacts on 




Has stiffness made 
it difficult to dress 
or undress 
yourself? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 
it difficult to dress 
or undress 
yourself? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
10 Impact Impacts on 
daily life: Daily 
life impact 
Wash Has stiffness made 
it difficult to bath or 
shower? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 
it difficult to bath or 
shower? 
4 option ordinal 
scale (not at all, a 








Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
11 Impact Impacts on 




Has stiffness made 
it difficult to work or 
do other daily 
activities? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
Would work need a 
does not apply 
option? [SH] 
 
Would none not 
capture does not 
apply? [ED] 
Has stiffness made 
it difficult to work? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
12 Impact Impacts on 




Has stiffness made 
it difficult to work or 
do other daily 
activities? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 
it difficult to do your 
daily activities? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
13 Impact Impacts on 
daily life: Daily 
life impact 
Eat/cut food Has stiffness made 
it difficult to eat? 
e.g. chewing or 
cutting your food 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
If not trying to save 
space use ‘for 
example’ rather 
than e.g. [JK] 
Has stiffness made 
it difficult to eat? 
For example, chew 
or cut your food 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
14 Impact Impacts on 
daily life: Daily 
life impact 
Hobbies Has stiffness made 
it difficult to do 
hobbies or activities 
you enjoy? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 
it difficult to do 
hobbies or activities 
you enjoy? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
15 Impact Impacts on 
daily life: Daily 
life impact 
Get out of 
bed 
Has stiffness made 
it difficult to get out 
of bed? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 
it difficult to get out 
of bed? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
16 Impact Impacts on 
daily life: Daily 
life impact 
Rise from a 
chair 
Has stiffness made 
it difficult to rise 
from a chair? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 
it difficult to rise 
from a chair? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
17 Impact Impacts on 
daily life: Daily 
life impact 
Effort Do your daily 
activities require 
more effort than 
usual because of 
stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Have your daily 
activities required 
more effort than 
usual because of 
stiffness? 
4 option ordinal 
scale (not at all, a 








Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
18 Impact Impacts on 




Has stiffness had 
an impact/effect on 
your daily life? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness had 
an impact on your 
daily life? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 




Slow Has stiffness made 
you slower doing 
your daily 
activities? 
4 option ordinal 
scale (not at all, a 




think about wording 
[SH] 
Has stiffness made 
you slower? For 
example, unable to 
rush 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 




Dexterity Has stiffness made 
it difficult to do fine 
movements? e.g. 
Do up buttons on a 
shirt or cardigan? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 
it difficult to do fine 
movements? For 
example, do up 
buttons on a shirt or 
cardigan? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 




Grip Has stiffness made 
it difficult to grip or 
hold things? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 
it difficult to grip or 
hold things? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 




Make a fist Has stiffness made 
it difficult to make a 
fist? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 
it difficult to make a 
fist? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 




Strength Have you lacked 




4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Have you lacked 
physical strength to 
do your daily 
activities because 
of stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 









reduced your range 
of movement/ 
flexibility? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
What do you mean 
by flexibility? Go 
back to patient data 
[SH] 
Have you found 




4 option ordinal 
scale (not at all, a 








Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
example, reaching 
to get an item 




Balance Has stiffness 
reduced your 
balance? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 




4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 






Has stiffness made 
it difficult to move? 
(Parts of your body 
or your whole body) 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Has stiffness made 
it difficult to move 
parts of your body 
or your whole 
body? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 






Has your body not 
moved like your 
brain expects it to 
because of 
stiffness? 
4 option ordinal 
scale (not at all, a 




change to ‘tells’ 
[SH] 
Has your body not 
moved like your 
brain tells it to 
because of 
stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 




Concentrate Have you had to 
concentrate more 
than usual to move 
your body because 
of stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Have you had to 
concentrate more 
than usual to move 
your body because 
of stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 




Frustration Have you felt 
frustrated because 
of stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Have you felt 
frustrated because 
of stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 




Worry Have you felt 
worried because of 
stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Have you felt 
worried because of 
stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
31 Impact Impacts on 
daily life: 
Embarrassed  Have you felt 
embarrassed 
4 option ordinal 
scale (not at all, a 
Consider that it is 
difficult to translate 
embarrassed [JK] 
Have you felt 
embarrassed 
4 option ordinal 







Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 



















Has it taken you 
longer to complete 
your daily activities 
because of RA 
stiffness? 
4 option ordinal 
scale (not at all, a 





simple, maybe ‘do’ 
[ED] 
Has it taken you 




4 option ordinal 
scale (not at all, a 










Have you been 
unable to complete 
your daily activities 
because of RA 
stiffness? 
4 option ordinal 
scale (not at all, a 





simple, maybe ‘do’ 
[ED] 
Have you been 




4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 





Have you had to 
change your plans 
or behaviour 
because of RA 
stiffness? 
  Have you had to 
change your plans 
or behaviour 
because of stiffness 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 





   Have you had to 
work around 
stiffness more than 
usual? 
 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 





Have you had to 
accept help from 
others because of 
RA stiffness? 
  Have you had to 
accept help from 
others because of 
stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 





Have you had to 
spend more time 
than usual dealing 
with stiffness? 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
 Have you had to 
spend more time 
than usual coping 
(managing, dealing 
with, making do) 
with stiffness? 
4 option ordinal 
scale (not at all, a 








Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 





Thinking about how 
well you have 
coped with your RA 
stiffness during the 
last 7 days: I have 
been able to deal 
with RA stiffness 
5 option Likert 
scale (much less 
well than usual, 
less well than 
usual, same as 
usual, better than 
usual, much better 
than usual) 
 Have you been 
able to cope 
(manage, deal, 
make do) with 
stiffness? 
4 option ordinal 
scale (not at all, a 








Please circle the 
number/mark the 
line/tick the box that 
best describes your 
level of RA stiffness 
(in your joints or 
your whole body, 
and at any time of 
day) during the past 
7 days 
 
NRS (0 = no 
stiffness, 10 = 
extreme stiffness) 
Think about the 
response options 
for these items [SH] 
 
Could remove 
‘whole’ here for 
consistency with 




options for the 
ordinal response 
options – unsure 










options for the 
Please circle the 
number/mark the 
line/tick the box that 
best describes the 
severity of your RA 
stiffness (in your 
joints or your body, 
and at any time of 
day) during the past 
7 days 
NRS (0 = no 




NRS (0 = no 
stiffness, 10 = 
extreme stiffness) 
VAS (0 = no 
stiffness, 10 = 
extreme stiffness) 
53 4 ordinal options 
(no stiffness “I have 
not been stiff”, 
some stiffness “I 
have been a bit stiff 
in the morning 
and/or have seized 
up a bit during the 
day”, quite a lot of 
stiffness “I have 
been quite stiff in 
the morning and/or 
have seized up 
quite a lot during 
the day”, extreme 
stiffness “I have 
been so stiff I have 
been unable to 
move at all”) 
4 ordinal options 
(no stiffness, a little 









Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
40 
 





Please circle the 
number/mark the 
line/tick the box that 
best describes how 
well you have been 
able to deal with 
your RA stiffness 
(in your joints or 
your whole body, 
and at any time of 
day) during the past 
7 days 
 
NRS (0 = not well 
at all, 10 = very 
well) 
ordinal response 
options – think 
about whether each 
option is a logical 
step up from the 
one before [ED] 
 
Initially used ‘last 7 
days’ then changed 
to ‘during the past 7 
days’ or ‘over the 
past 7 days’ – 
decide which to use 
and keep 
consistent [JK]  
 
Change the 
introduction to the 










– why using all 
these different 
options? Include if 
there is a reason to 
as it is an extra 
Please circle the 
number/mark the 
line/tick the box that 
best describes how 
well you have been 
able to deal with 
your RA stiffness 
(in your joints or 
your body, and at 
any time of day) 
during the past 7 
days 
NRS (0 = not well 




VAS (0 = not well at 
all, 10 = very well) 
VAS (0 = not well at 
all, 10 = very well) 
54 4 ordinal options (I 
have not had any 
stiffness to deal 
with, I have been 
able to deal with my 
stiffness by using 
ways to work 
around it, I have 
been able to deal 
with some of my 
stiffness but I have 
also had to change 
my plans and ask 
for help because of 
it, I have been 
unable to deal with 
my stiffness) 
4 ordinal options 
(not at all well, not 
very well, quite 
well, very well) 





Please circle the 
number/mark the 
line/tick the box that 
best describes how 
well you have been 
able to cope with 
your RA stiffness 
(in your joints or 
your whole body, 
and at any time of 
NRS (0 = not well 
at all, 10 = very 
well) 
Please circle the 
number/mark the 
line/tick the box that 
best describes how 
well you have 
coped with your RA 
stiffness (in your 
joints or your body, 
and at any time of 
day) during the past 
7 days 
NRS (0 = not well 
at all, 10 = very 
well) 
48 VAS (0 = not well at 
all, 10 = very well) 
VAS (0 = not well at 
all, 10 = very well) 
55 4 ordinal options (I 
have not had any 
stiffness to cope 
with, I have been 
able to deal with my 
stiffness by using 
4 ordinal options 
(not at all well, not 
very well, quite 







Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
day) during the past 
7 days 
 
ways to work 
around it, I have 
been able to cope 
with some of my 
stiffness but I have 
also had to change 
my plans and ask 
for help because of 
it, I have been 
unable to cope with 
my stiffness) 
burden on the 
participant [JK] 





Please circle the 
number/mark the 
line/tick the box that 
best describes how 
well you have been 
able to manage 
with your RA 
stiffness (in your 
joints or your whole 
body, and at any 
time of day) during 
the past 7 days 
NRS (0 = not well 
at all, 10 = very 
well) 
Please circle the 
number/mark the 
line/tick the box that 
best describes how 
well you have 
managed your RA 
stiffness (in your 
joints or your body, 
and at any time of 
day) during the past 
7 days 
NRS (0 = not well 
at all, 10 = very 
well) 
49 VAS (0 = not well at 
all, 10 = very well) 
VAS (0 = not well at 
all, 10 = very well) 
56 4 ordinal options (I 
have not had any 
stiffness to 
manage, I have 
been able to 
manage my 
stiffness by using 
ways to work 
around it, I have 
been able to 
manage some of 
my stiffness but I 
have also had to 
change my plans 
and ask for help 
because of it, I 
have been unable 
4 ordinal options 
(not at all well, not 
very well, quite 







Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
to manage my 
stiffness) 





Please circle the 
number/mark the 
line/tick the box that 
best describes how 
well you have been 
able to coped 
(managed, dealt 
with, made do) with 
your RA stiffness 
(in your joints or 
your whole body, 
and at any time of 
day) during the past 
7 days 
NRS (0 = not well 
at all, 10 = very 
well) 
Please circle the 
number/mark the 
line/tick the box that 
best describes how 
well you have 
coped (managed, 
dealt with, made 
do) with your RA 
stiffness (in your 
joints or your body, 
and at any time of 
day) during the past 
7 days 
NRS (0 = not well 
at all, 10 = very 
well) 
50 VAS (0 = not well at 
all, 10 = very well) 
VAS (0 = not well at 
all, 10 = very well) 
57 4 ordinal options (I 
have not had any 
stiffness to cope 
(manage, deal with, 
make do) with, I 
have been able to 
deal with my 
stiffness by using 
ways to work 
around it, I have 
been able to cope 
(manage, deal with, 
make do) with 
some of my 
stiffness but I have 
also had to change 
my plans and ask 
for help because of 
it, I have been 
unable to cope 
(manage, deal with, 
make do) with my 
stiffness) 
4 ordinal options 
(not at all well, not 
very well, quite 
well, very well) 




Please circle the 
number/mark the 
NRS (0 = no effect, 
10 = great effect) 
Please circle the 
number/mark the 
NRS (0 = no effect, 







Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
51 line/tick the box in 
the position that 
best describes the 
effect RA stiffness 
(in your joints or 
your whole body, 
and at any time of 
day) has had on 
your life during the 
past 7 days  
VAS (0 = no effect, 
10 = great effect) 
line/tick the box that 
best describes the 
effect RA stiffness 
(in your joints or 
your body, and at 
any time of day) 
has had on your life 
during the past 7 
days 
VAS (0 = no effect, 
10 = great effect) 
58 4 ordinal options 
(no effect at all, a 
little effect because 
although it has 
been there I have 
been able to get on 
with life, quite a bit 
of an effect 
because it has 
restricted me doing 
my daily activities, 
a great effect 
because I have 
been so stiff I have 
been unable to do 
my usual daily 
activities) 
4 ordinal options 
(no effect, a little 
effect, quite a bit of 
an effect, a great 
effect) 




Please circle the 
number/mark the 
line/tick the box that 
best describes the 
impact of RA 
stiffness (in your 
joints or your whole 
body, and at any 
time of day) during 
the past 7 days 
 
NRS (0 = no 
impact, 10 = a 
great impact) 
Please circle the 
number/mark the 
line/tick the box that 
best describes the 
overall impact on 
your life of RA 
stiffness (in your 
joints or your body, 
and at any time of 
day) during the past 
7 days 
NRS (0 = no 
impact, 10 = a 
great impact) 
52 VAS (0 = no 
impact, 10 = a 
great impact) 
VAS (0 = no 
impact, 10 = a 
great impact) 
59 4 ordinal options 
(no impact, a little 
impact, quite a bit 
of an impact, a 
great impact) 
4 ordinal options 
(no impact, a little 
impact, quite a bit 
of an impact, a 
great impact) 
60 Attribution Linked to 
behaviour and 
environment: 
Weather Thinking about the 
nature of your RA 
stiffness over 
4 option ordinal 
scale (not at all, a 
Think about the 
wording and 
Please indicate 
how much the 
weather has 









Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 





My RA stiffness is 
affected by the 
weather 
little, quite a bit, 
very much) 
response options 
for these items [SH] 
 
What is this trying 
to get at – cause or 
contribution as 
cause sounds 




their perceptions so 
important to 
highlight that e.g. 
‘how much of the 
following has 
contributed to your 




options don’t match 
the questions – 
think about these 








contributed to your 
experience of RA 
stiffness during the 









Immobility Thinking about the 
nature of your RA 
stiffness over 
[insert timescale]. 
My RA stiffness is 
affected by being 
immobile for a 
period of time (e.g. 
in a chair or in bed) 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
Please indicate 
how much being 
immobile for a 
period of time for 
example, in a chair 
or in bed has 
contributed to your 
experience of RA 
stiffness during the 
last 7 days 














Thinking about the 
nature of your RA 
stiffness over 
[insert timescale] 
My RA stiffness is 
affected by other 
RA symptoms (e.g. 
swelling or 
inflammation)  
4 option ordinal 
scale (not at all, a 






contributed to your 
experience of RA 
stiffness during the 
last 7 days 







63 Attribution Part of having 
RA: Process 
Process Thinking about the 
nature of your RA 
stiffness over 
[insert timescale] 
My RA stiffness is 
affected by being in 
a flare 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
Please indicate 
how much being in 
an RA flare (flare 
up) has contributed 
to your experience 
of RA stiffness 
during the last 7 
days 







64 Attribution Part of having 
RA: Process 
Process Thinking about the 
nature of your RA 
4 option ordinal 
scale (not at all, a 
Please indicate 
how much joint 








Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
stiffness over 
[insert timescale] 
My RA stiffness is 
affected by joint 
damage 
little, quite a bit, 
very much) 
Specify what you 
are looking for in 
item 68 e.g. ‘please 
specify anything 
that applies to you 
but is not listed 
above’ [JK] 
damage has 
contributed to your 
experience of RA 
stiffness during the 











Pain Thinking about the 
nature of your RA 
stiffness over 
[insert timescale] 
My RA stiffness is 
affected by other 
RA symptoms (e.g. 
pain) 
4 option ordinal 
scale (not at all, a 
little, quite a bit, 
very much) 
Please indicate 
how much other RA 
symptoms have 
contributed to your 
experience of RA 
stiffness during the 
last 7 days 















Thinking about the 
nature of your RA 
stiffness over 
[insert timescale] 
My RA stiffness is 
affected by 
overdoing things 
4 option ordinal 
scale (not at all, a 




overdoing things for 
example, doing too 
much has 
contributed to your 
experience of RA 
stiffness during the 
last 7 days 














My RA medications 
have been affecting 
my RA stiffness 
5 option Likert 
scale (much less 
well than usual, 
less than usual, the 
same as usual, 
better than usual, 
much better than 
usual) 
Please indicate 




contributed to your 
experience of RA 
stiffness during the 
last 7 days 







68 Attribution Linked to 
behaviour and 
Other Thinking about the 
nature of your RA 
4 option ordinal 
scale (not at all, a 
Please indicate 
how much [please 








Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 







My RA stiffness is 
affected by [please 
insert] 
little, quite a bit, 
very much) 
specify] anything 
that applies to you 
but is not listed 
above has 
contributed to your 
experience of RA 
stiffness during the 











Severity NA NA NA How would you 
describe the overall 
level of morning 
stiffness you have 
had from the time 
you wake up? 
VAS (0 = No 
stiffness 10 = Very 
severe stiffness) 
70 NRS (0 = No 
stiffness 10 = Very 
severe stiffness) 
71 5 ordinal options 





72 Traditional Highly 
variable: 
Duration 
Duration NA NA NA How long does your 
morning stiffness 




Minutes or hours  
74 3 ordinal options 
(up to an hour, 1 – 
3 hours, ≥3 hours) 
73 Traditional Highly 
variable: 
Duration 
Duration NA NA NA Were your joints 
stiff when you woke 
up today? If yes, 
how long did this 
stiffness last? 
6 ordinal options 
(less than 30 
minutes, 30 
minutes–1 hour, 1–
2 hours, 2–4 hours, 








Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
75 Response 
shift 




Normality Thinking about a 
usual week when 
you are not in a 
flare of your RA. 
Please circle the 
number that shows 
your usual level of 
RA stiffness 
NRS (0 = no 
stiffness, 10 = 
extreme stiffness) 
Could test with 
different formats 
[SH] 
Thinking about a 
usual week when 
you are not in a 
flare (flare-up) of 
your RA please 
[mark the response] 
that shows your 
usual RA stiffness 
(in your joints or 
your body, and at 
any time of day) 
NRS (0 = no 
stiffness, 10 = 
extreme stiffness) 
76 VAS (0 = no 
stiffness, 10 = 
extreme stiffness) 
77 4 option ordinal 
scale (no stiffness, 
some stiffness, 





Part of having 
RA: Process 
Process “[…] Although we 
acknowledge that 
some people with 
RA have joints that 
are always difficult 
to move whether 
their RA is good or 
bad (due to joint 
damage), please do 
not include this 
when you answer 
this questionnaire. 
This questionnaire 
will help us 
understand your 
disease activity. We 
will use the 
answers that you 
give alongside 
other tests (e.g. 
blood tests) to build 
NA This is pretty wordy 
– worth trying to 
make it as concise 
as possible [SH] 
 
Shorter is better 
[ED] 
 
The reason for 
doing the 
questionnaire will 




If using underlining 
you need to 
underline the whole 
relevant part – 
change and ensure 
consistent [JK] 
“[…] It will help us 
understand how 
active your disease 
is. Some people 
have joints that are 
always difficult to 
move whether their 
RA is good or bad 
(for example, due 
to joint damage). 
Please do not 
include this sort of 










Key area Specific 
aspect 
Original wording Original response 
options 
Changes 
suggested by team 
Wording taken to 
Study 3 
Response options 
taken to Study 3 
a picture of your 
disease” 




Specificity No specific wording 
but ‘stiffness’ or ‘RA 
stiffness’ used in 
stem questions 
NA Important to 






No specific wording 
but ‘RA stiffness’ 
used in every stem 
question 
NA 
- Wording Local and 
widespread: 
Structure 
Structure No specific wording 
but use relevant 
wording e.g. ‘joint’ 
or ‘all over or in 
your joints’ 
NA   NA 




Individual No specific wording 
but using ‘to you’ or 
other individual 
specific wording 
NA  No specific wording 








Appendix Q: Patient information sheet (Study 3) 
 
A research study to explore stiffness in people with rheumatoid arthritis (Phase 2) 
 
Patient information sheet 
 
You are being invited to take part in a research study. Before you decide whether to take 
part, it is important for you to understand why the research is being done, and what it will 
involve. Please take time to read the following information leaflet carefully and discuss it 
with others if you wish. If anything is not clear or you would like more information please 
ask one of the team. 
 
What is the purpose of the study? 
One of the problems commonly experienced by people with rheumatoid arthritis is 
stiffness. Stiffness is a term used by patients and health professionals, but it is not very 
well understood. The aim of this study is to develop a way of measuring stiffness in 
rheumatoid arthritis. With the help of other people like yourself we have developed a 
better understanding of what stiffness means to people. We would now like your help to 
develop this further by working towards a way of measuring stiffness in a questionnaire.  
 
Why have I been chosen? 
You have been chosen because you have rheumatoid arthritis.  
 
Who is asking me to take part? 
I am Serena Halls, a PhD student at the University of the West of England. This research 
study is the second of three studies which will form part of my PhD. 
 
What will I be asked to do if I take part? 
You will be asked to attend an informal interview with the researcher (Serena Halls) at 
the rheumatology department you attend. Before the interview starts, the researcher will 
ask you to read and sign the consent form and ask you some questions about your 
medical history. During the interview, she will invite you to answer a series of questions 
that have been designed to measure stiffness in rheumatoid arthritis. She will encourage 
you to ‘think aloud’ as you answer the questions and will prompt you about any thoughts 
or preferences you might have about the questions. You can say as much or as little as 
you like, there are no right or wrong answers. The interview will last for about an hour and 
we will offer you refreshments and are happy to pay your travel costs. We will ask your 
permission to audio-record the interview, which we will type up (transcribe) and then 
analyse after the interview.  
 
Do I have to take part? 
No, taking part is voluntary. It is up to you to decide whether or not to take part. If you 
decide not to take part you do not need to give a reason, nobody will be upset and the 
standard of care you receive will not be affected. If you decide to take part we will ask you 
to sign a consent form, and will give you a copy of this information sheet and the consent 
form to keep. For general advice about taking part in research, you can contact the local 
Patient Advice and Liaison Service on 0117 900 3433 or pals@bristolpct.nhs.uk. 
 
What if I wish to withdraw at a later stage? 







What are the risks of taking part in the study? 
We do not believe there are any risks in being involved in this study. We appreciate that 
there may be some inconvenience to you by having to come into the hospital for the 
interview but we will try and reduce this by arranging a convenient date and time for you 
to come. 
 
What are the benefits of taking part in the study? 
The benefits of taking part in this study are that you will be helping us to gain a better 
understanding of how to measure stiffness in people with rheumatoid arthritis. This will 
help us to improve decisions made about treatment and management of rheumatoid 
arthritis.   
 
Will my taking part in the study be kept confidential? 
Yes. Your name will be replaced by a code. All other identifying information (such as 
people’s names, locations or specific descriptions) will be replaced with code numbers or 
a generalised summary. No one will be able to identify you from any analysis or report. 
The study reports will include quotations from the interviews but no names will be used. 
The recordings will be kept securely for 6 years and then destroyed, in accordance with 
best practice in research guidelines.   
 
What will happen to the results of this research study? 
Research team members will analyse the anonymous transcripts and discuss our 
findings. The findings of this study will influence the design of later research studies within 
this PhD. We hope the results will be reported in professional journals and at meetings 
(but participants will not be identified by name). We will send you a summary of the results 
if you would like. 
 
Who is organising, funding and reviewing the research? 
The study is coordinated by a team from the university of the West of England (UWE) 
based at the Academic Rheumatology Unit at the Bristol Royal Infirmary. It is funded by 
UWE and has been peer reviewed by the local and UWE Research Ethics Committees.  
 
What do I do now? 
Thank you for considering taking part in this research. Please return the reply slip 
provided if you would like to take part by returning it in the pre-paid reply envelope to 
Serena Halls. Serena will then contact you in a few days with further information and to 




Serena Halls, PhD Student Researcher, UWE Bristol 
Professor Sarah Hewlett, Professor of Rheumatology Nursing, UWE Bristol 
Professor John Kirwan, Professor of Rheumatic Diseases, UoB Bristol 
Dr Jon Pollock, Reader in Epidemiology, UWE Bristol 
Dr Emma Dures, Research Fellow, UWE Bristol 
Mrs Avis Edmunds, Patient Research Partner 




Serena Halls  0117 342 4972  Serena.Halls@uwe.ac.uk 





Appendix R: Cognitive interview topic guide (Study 3) 
 
Study ID:                    Date:                Start time: _____________ 
 
Instructions for interviewee: 
 
Note to the interviewer: 
a) Either read these instructions in their entirety or paraphrase them  
b) Note that this form is set up to be administered after the interviewee has 
signed the consent form 
 
Thank you for coming in. Let me tell you a little more about what we will be doing 
today 
 
 We are not collecting information about you but are trying our questions out 
on people like you so we can make the questions better  
 Our goal here is to get a better idea of how the questions are working. So I’d 
like you to think aloud as you answer the questions-just tell me everything that 
comes to mind as you go about answering them 
 At times I might ask you about what you think a question is asking about, how 
you come up with your answers and how you interpret the questions  
 Some of the questions might look very similar. This is because we are trying 
to find the best way to word the question, so if there are things you particularly 
like or don’t like please do say! 
 If any question is unclear, hard to answer or doesn’t make sense please tell 
me that – don’t be shy! There are no right or wrong answers.  
 Finally, we will do this for about an hour unless I run out of things to ask you 
before then 
 Do you have any questions before we start? 
(Adapted from Willis, 2005) 
 
TURN TAPE RECORDER ON 
 
Refer to questionnaire: Questions are written on other sheet with space for notes 
 
General probes: 
In your own words, what is this question asking?    
How did you come up with that answer? 
Tell me more about that 
What does the term...mean to you in this question? 
What time period are you thinking of? 
You hesitated a bit there, what are you wondering about? 
How could we phrase that question better? 
 






Appendix S: Draft PROM items for cognitive interviews 
(Study 3) 
 
Rheumatoid Arthritis Stiffness Questionnaire 
(RAST-Q) 
 
This questionnaire is about stiffness related to your rheumatoid arthritis or RA 
stiffness. It will help us understand how active your disease is. Some people 
have joints that are always difficult to move whether their RA is good or bad (for 
example, due to joint damage). Please do not include this sort of stiffness when you 
answer this questionnaire. 
 









































1. Have you experienced RA stiffness in your joints during the past 7 days? 
 
Not in any of my joints 
 
 
Yes, in some of my joints 
 
 
Yes, in many of my joints 
 
 




2. Have you experienced RA stiffness in your body (outside of your joints) 
during the past 7 days? 
 
Not in any of my body 
 
 
Yes, in some parts of my body 
 
 
Yes, in many parts of my body 
 
 




3. During the past 7 days have you experienced RA stiffness coming and going 
as frequently as usual for you? 
 
It has been much less frequent than usual 
 
 
It has been less frequent than usual 
 
 
It has been the same as usual 
 
 
It has been more frequent than usual 
 
 




4. During the past 7 days have you experienced stiffness after a period of 
immobility (for example, in a chair or in bed)? 
 
I have had much less than usual 
 
 
I have had less than usual 
 
 
I have had the same as usual 
 
 
I have had more than usual 
 
 
I have had much more than usual 
 
 







5. During the past 7 days have your RA medications been controlling RA 
stiffness as usual for you? 
 
It has been much less well controlled than usual 
 
 
It has been less well controlled than usual 
 
 
It has been controlled the same as usual 
 
 
It has been better controlled than usual 
 
 









6. During the past 7 days when have you experienced RA stiffness (in your 
joints or your body)? 
 
During the morning 
 
 
During the afternoon 
 
 
During the evening 
 
 




7. During the past 7 days when have you experienced RA stiffness (in your 
joints or your body)? 
 
First thing when I wake up  
 
 
When I get out of bed  
 
 
During the first few hours after I get up 
 
 
During the late morning 
 
 
During the early afternoon 
 
 
           During the late afternoon 
 
 
During the evening 
 
 




































8. Has stiffness affected your sleep? __ __ __ __  
 


























11. Has stiffness made it difficult to work? __ __ __ __ __ 
 













13. Has stiffness made it difficult to eat? For 












14. Has stiffness made it difficult to do 






































17. Have your daily activities required more 

























19. Has stiffness made you slower? For 












20. Has stiffness made it difficult to do fine 
movements? For example, do up buttons 






























22. Has stiffness made it difficult to make a 
fist? 
__ __ __ __  
 
 



























23. Have you lacked physical strength to do 











24. Have you found that your movement is 
restricted because of stiffness? For 
















25. Has stiffness made it difficult to balance 












26. Has stiffness made it difficult to move parts 












27. Has your body not moved like your brain 












28. Have you had to concentrate more than 


















29. Have you felt frustrated because of 
stiffness? 
 
__ __ __ __  
 
30. Have you felt worried because of stiffness?  
 
__ __ __ __  
 













32. Has it taken you longer to do your daily 












33. Have you been unable to do your daily 












34. Have you had to change your plans or 












35. Have you had to work around stiffness 











36. Have you had to accept help from others 












37. Have you had to spend more time than 
usual coping (managing, dealing with, 
















38. Have you been able to cope (manage, deal, 
















Some people with RA have told us that to understand the impact of a symptom we 
should ask about its severity, its effect on the patient’s daily life and the patient’s 
ability to cope (manage, deal with, make do) with it.   
 
We would like to know the impact that RA stiffness has had on your life during the 
past 7 days. 
 
39. Please circle the number that best describes the severity of your RA 
stiffness (in your joints or your body, and at any time of day) during the past 
7 days 
 
40. Please circle the number that best describes how well you have been able to 
deal with your RA stiffness (in your joints or your body, and at any time of 
day) during the past 7 days 
 
 
41. Please circle the number that best describes how well you have coped with 
your RA stiffness (in your joints or your body, and at any time of day) during 
the past 7 days 
 
 
42. Please circle the number that best describes how well you have managed 
your RA stiffness (in your joints or your body, and at any time of day) during 
the past 7 days 
 
 
43. Please circle the number that best describes how well you have coped 
(managed, dealt with, made do) with your RA stiffness (in your joints or 
your body, and at any time of day) during the past 7 days 
 
 
44. Please circle the number that best describes the effect RA stiffness (in your 
joints or your body, and at any time of day) has had on your life during the 
past 7 days 
 
 
45. Please circle the number that best describes the overall impact on your life 
of RA stiffness (in your joints or your body, and at any time of day) during the 






No stiffness 0 1 2 3 4 5 6 7 8 9 10 Extreme stiffness 
Not well at all 0 1 2 3 4 5 6 7 8 9 10 Very well 
Not well at all 0 1 2 3 4 5 6 7 8 9 10 Very well 
Not well at all 0 1 2 3 4 5 6 7 8 9 10 Very well 
Not well at all 0 1 2 3 4 5 6 7 8 9 10 Very well 
No effect 0 1 2 3 4 5 6 7 8 9 10 Great effect 





Some people with RA have told us that to understand the impact of a symptom we 
should ask about its severity, its effect on the patient’s daily life and the patient’s 
ability to cope (manage, deal with, make do) with it. We would like to know the 
impact that RA stiffness has had on your life during the past 7 days. 
 
46. Please mark the line in the position that best describes the severity of your 
RA stiffness (in your joints or your body, and at any time of day) during the 







47. Please circle the number that best describes how well you have been able to 
deal with your RA stiffness (in your joints or your body, and at any time of 







48. Please mark the line in the position that best describes how well you have 
coped with your RA stiffness (in your joints or your body, and at any time of 







49. Please mark the line in the position that best describes how well you have 
managed your RA stiffness (in your joints or your body, and at any time of 







50. Please mark the line in the position that best describes how well you have 
coped (managed, dealt with, made do) with your RA stiffness (in your 







51. Please mark the line in the position that best describes the effect RA 
stiffness (in your joints or your body, and at any time of day) has had on your 







52. Please mark the line in the position that best describes the overall impact on 
your life of RA stiffness (in your joints or your body, and at any time of day) 











Some people with RA have told us that to understand the impact of a symptom we 
should ask about its severity, its effect on the patient’s daily life and the patient’s 
ability to cope (manage, deal with, make do) with it.   
 
We would like to know the impact that RA stiffness has had on your life during the 
past 7 days. 
 
 
53. Please tick the box that best describes the severity of your RA stiffness (in 
your joints or your body, and at any time of day) during the past 7 days 
 
           No stiffness  
 
 
           A little stiffness  
 
 
           Quite a bit of stiffness  
 
 




54. Please tick the box that best describes how well you have been able to deal 
with your RA stiffness (in your joints or your body, and at any time of day) 
during the past 7 days 
 
           Not at all well 
 
 
           Not very well 
 
 
           Quite well 
 
 




55. Please tick the box that best describes how well you have been able to cope 
with your RA stiffness (in your joints or your body, and at any time of day) 
during the past 7 days 
 
           Not at all well 
 
 
           Not very well 
 
 
           Quite well 
 
 














56. Please tick the box that best describes how well you have been able to 
manage your RA stiffness (in your joints or your body, and at any time of 
day) during the past 7 days 
 
           Not at all well 
 
 
           Not very well 
 
 
           Quite well 
 
 




57. Please tick the box that best describes how well you have been able to cope 
(manage, deal with, make do) with your RA stiffness (in your joints or your 
body, and at any time of day) during the past 7 days 
 
           Not at all well 
 
 
           Not very well 
 
 
           Quite well 
 
 




58. Please tick the box that best describes the effect RA stiffness (in your joints 
or your body, and at any time of day) has had on your life during the past 7 
days 
 
           No effect  
 
 
           A little effect  
 
 
           Quite a bit of an effect   
 




59. Please tick the box that best describes the overall impact on your life of RA 
stiffness (in your joints or your body, and at any time of day) during the past 
7 days 
 
           No impact  
 
 
           A little impact  
 
 
           Quite a bit of an impact   
 










Please indicate how much each of the following have contributed to your 
experience of RA stiffness during the last 7 days 
 













60. The weather  
 
__ __ __ __ 
61. Being immobile for a period 
of time for example, in a 










62. Inflammation or swelling  
 
__ __ __ __ 
63. Being in an RA flare (flare-
up)  
 
__ __ __ __ 
64. Joint damage  
 
__ __ __ __ 
65. Other RA symptoms  
 
__ __ __ __ 
66. Overdoing things  










67.  RA medications not 










68. Please specify anything that 
applies to you but is not 





















69. How would you describe the overall level of morning stiffness you have had 








70. How would you describe the overall level of morning stiffness you have had 




0 1 2 3 4 5 6 7 8 9 10 
Very severe 
stiffness 







71. How would you describe the overall level of morning stiffness you have had 


















72. How long does your morning stiffness last from waking until maximum 
improvement occurs?  
 
Minutes ______________ or hours ______________ 
 
73. Were your joints stiff when you woke up today? If yes, how long did this 
stiffness last?  
 
Less than 30 minutes 
 
 
30 minutes–1 hour 
 
 






Over 4 hours 
 
 
All day  
 
 
74. How long does your morning stiffness last from waking until maximum 
improvement occurs?  
 













75. Thinking about a usual week when you are not in a flare (flare-up) of your 
RA please circle the number that shows your usual RA stiffness (in your 




76. Thinking about a usual week when you are not in a flare (flare-up) of your 
RA please mark on the line your usual RA stiffness (in your joints or your 










77. Thinking about a usual week when you are not in a flare (flare-up) of your 
RA please tick the box that best describes your usual RA stiffness (in your 
joints or your body, and at any time of day) 
 
           No stiffness  
 
 
           Some stiffness  
 
 
           Quite a lot of stiffness  
 
 








No stiffness 0 1 2 3 4 5 6 7 8 9 10 Extreme stiffness 






Appendix T: Probes for cognitive interviews (Study 3) 
No. Probes 
Intro.  What does active disease mean to you? 
 What does good/bad disease mean to you? 
 What does joint damage mean to you? 
 How much would you say you know about joint damage?  
 Are you able to exclude that information? 
 What period of time is it asking about/what does that cover for you? 
 How easy/difficult is it to remember stiffness over that period? 
 Can you tell me in your own words what the intro is telling you?  
1  What does stiffness in joints mean to you? 
 How well does this apply to you? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 Tell me why you chose x rather than y? 
2  What does stiffness in your body mean to you? 
 How well does this apply to you? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 Tell me why you chose x rather than y? 
 Is it useful or confusing having Q1 and Q2 as different questions? 
3  What does coming and going as frequently as usual mean to u? 
 How well does this apply to you? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 Tell me why you chose x rather than y? 
4 
 
 What does period of immobility mean to you? 
 What is the instruction telling you? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 Tell me why you chose x rather than y? 
5  What does RA medications mean to you? 
 How well does this apply to you? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 Tell me why you chose x rather than y? 
Inst.  What is the instruction telling you?  
 Is that easy or difficult to follow? 
6  What does in your joints and body mean to you?  
 Tell me what you were thinking when I asked when have you 
experienced stiffness? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 How well does that question apply to you? 
7  What does in your joints and body mean to you?  
 Tell me what you were thinking when I asked when have you 
experienced stiffness? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 How well does that question apply to you? 






Inst.  What is the instruction telling you?  
 Is that easy or difficult to follow? 
8  What is the introduction asking you to do? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 Can you tell me in your own words what the question is asking? 
 How well does this question apply to you? 
9  Can you tell me in your own words what the question is asking? 
10  Can you tell me in your own words what the question is asking? 
11  How well does this apply to you? 
12  What does daily activities mean to you? 
13  In your own words what is the question asking? 
14  What does hobbies or activities you enjoy mean to you? 
15  In your own words what is the question asking? 
16  What does rise from a chair mean to you? 
17  What does more effort than usual mean to you? 
18  Would you say it stays the same or varies? 
19  In your own words what is the question asking? 
20  In your own words what is the question asking? 
 What does fine movement mean to you? 
21  In your own words what is the question asking? 
22  How well does this apply to you? 
23  What does physical strength mean to you? 
 How well does this apply to you? 
24  What does restricted movement mean to you? 
 In your own words what is the question asking? 
25  What does difficult to balance mean to you? 
 What does physically support yourself mean to you? 
 How well does this apply to you? 
26  In your own words what is the question asking? 
27  How well does this apply to you? 
 In your own words what is the question asking? 
28  In your own words what is the question asking? 
29  In your own words what is the question asking? 
30  In your own words what is the question asking? 
31  What does the word embarrassed mean to you? 
 Are their better words e.g. self-conscious? 
 How well does this apply to you? 
32  In your own words what is the question asking? 
33  In your own words what is the question asking? 
34  In your own words what is the question asking? 
35  What does work around mean to you? 
36  How well does this apply to you? 
37  In your own words what is the question asking? 
 How well does this apply to you? 
38  How well does this apply to you? 
Inst.  What does the term impact mean to you? 
 What does the term severity mean to you? 






 What do the terms cope (manage, deal with, make do) mean to you? 
 What is the instruction telling you? 
39-45  What are the instructions telling you to do? 
 What does in your joints or your body, and at any time of day mean 
to you? 
 What does the term severity/deal/cope/manage/effect/impact mean 
to you? 
 How easy or difficult is it to remember the severity/how you have 
dealt/coped/managed/effect/impact of your stiffness over the past 7 
days? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 What are your thought about the format of the question? 
46-52  Same as above 
 What are your thought about the format of the question? 
53-59  Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 What are your thought about the format of the question? 
Inst.  In your own words what is the question asking  
 What does the phrase contributed to your experience of RA 
stiffness mean to you? 
 What is the introduction asking you to do? 
60-68  Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience?  
 Can you tell me in your own words what the question is asking? 
 What does the word contribution mean to you? 
 How well does this question apply to you? 
69-71  What does not in a flare (flare-up) mean to you? 
 What does usual week mean to you? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience? 
 What are your thought about the format of the question? 
72-74  What does the phrase overall level of morning stiffness mean to you? 
 What does morning stiffness mean to you? 
 In your own words what is the question asking? 
 How well does the question apply to you? 
 How easy/difficult is it to remember? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience? 
 What are your thought about the format of the question? 
75  In your own words what is the question asking? 
 What does from waking to maximal improvement mean to you? 
 How well does the question apply to you? 
 How easy/difficult is it to remember? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience? 






76  In your own words what is the question asking? 
 How well does the question apply to you? 
 How easy/difficult is it to remember? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience? 
 What are your thought about the format of the question? 
77  In your own words what is the question asking? 
 How well does the question apply to you? 
 How easy/difficult is it to remember? 
 Was it easy or difficult to decide what answer to give?  
 Do the response options apply to your experience? 
 What are your thought about the format of the question? 
Specific       Impact triad questions 
      Self-management  
 Can you tell me if these questions are the same or different for you?  
 Do they mean the same thing to you?  
 Do you need them all or just one or some?  
 What does each word mean to you?  
      Severity 
 What does severity mean to you? Is there a better word (amount/how 
much/level/other?) 
      Effect 
 What does effect mean to you? Is there a better word 
(importance/other?) 
      Other 
 Was there anything you thought was irrelevant?  
 Is it confusing having the instruction change e.g. tick one/tick all that 
applies? 
 Would you prefer RA stiffness in ever stem question? (What does it 
include/exclude?) 
Layout  Do you like the layout? Would you prefer any sections to be in a different 
order? 
 Do you like the font? 
 Are the words big enough? 
 Are the underlined parts in correct/useful places? 
 Do you like the small boxes for response options? 
 Some of the questions had different formats-do you have any 
preferences for numbers, line or words?  
 Should the short scales be separate from the main questionnaire body? 
General  In your own words, what is this question asking?    
 How did you come up with that answer? 
 Tell me more about that… 
 What does the term...mean to you? 
 What time period are you thinking of? 
 You hesitated a bit there, what are you wondering about? 




Appendix U: COREQ checklist (Study 3) 
No.  Item  Guide questions/description How was this component addressed 
Domain 1: Research team and reflexivity   
Personal Characteristics   
1. Interviewer Which author/s conducted the interview or focus group?  Identified in Section 7.3.5 
2. Credentials What were the researcher’s credentials?  The characteristics of the supervisory team 
were identified in Section 3.4.2 and the 
researchers (Halls) background was 
highlighted in Section 3.2.1 
3. Occupation What was their occupation at the time of the study?  
4. Gender Was the researcher male or female?  
5. Experience and training What experience or training did the researcher have?  
Relationship with participants   
6. Relationship established Was a relationship established prior to study commencement?  
Identified in Section 7.3.5 7. Participant knowledge of the 
interviewer  
What did the participants know about the researcher?  
8. Interviewer characteristics What characteristics were reported about the interviewer?  The researchers (Halls) background, 
experience and research interests were 
highlighted in Section 3.2.1 
Domain 2: study design   
Theoretical framework   
9. Methodological orientation 
and theory  
What methodological orientation was stated to underpin the 
study?  
The methodological approach to the study 
was discussed in Section 3.3.1 and the 
method and analysis approach were 
discussed in Section 7.3 
Participant selection   
10. Sampling How were participants selected?  
Identified in Sections 7.3.3 and 7.5.1 
11. Method of approach How were participants approached?  
12. Sample size How many participants were in the study?  
13. Non-participation How many people refused to participate or dropped out? 
Reasons?  
Setting  
14. Setting of data collection Where was the data collected?  Identified in Section 7.3.5 
 488 
 
15. Presence of non-
participants 




Identified in Section 7.5.1 16. Description of sample What are the important characteristics of the sample?  
Data collection   
17. Interview guide Were questions, prompts, guides provided by the authors? Was it 
pilot tested?  
Identified in Section 7.3.5 and Appendices S 
and T 
18. Repeat interviews Were repeat interviews carried out? If yes, how many?  This was not performed 
19. Audio/visual recording Did the research use audio or visual recording to collect the data?  Identified in Section 7.3.5 
20. Field notes Were field notes made during and/or after the interview or focus 
group? 
NA 
21. Duration What was the duration of the interviews or focus group?  Identified in Section 7.3.5 and Box 7.1 
22. Data saturation Was data saturation discussed?  Sampling discussed in Section 7.3.3.1 
23. Transcripts returned Were transcripts returned to participants for comment and/or 
correction?  
This was not performed 
Domain 3: analysis and findings   
Data analysis   
24. Number of data coders How many data coders coded the data?  
Identified in Section 7.4 25. Description of the coding 
tree 
Did authors provide a description of the coding tree?  
26. Derivation of themes Were themes identified in advance or derived from the data?  Identified in Section 7.4 
27. Software What software, if applicable, was used to manage the data?  Identified in Section 7.4 
28. Participant checking Did participants provide feedback on the findings?  This was not performed 
Reporting   
29. Quotations presented Were participant quotations presented to illustrate the themes? 
Was each quotation identified?  
Identified in Section 7.5 
30. Data and findings 
consistent 
Was there consistency between the data presented and the 
findings?  
31. Clarity of major themes Were major themes clearly presented in the findings?  






Appendix V: Questionnaire pack (Study 4) 
 
Invitation letter from lead consultant (Study 4) 
 










Dear Sir/Madam,  
 
 
Developing and testing a rheumatoid arthritis stiffness questionnaire 
 
 
I am writing to invite you to join a research study which will help us develop 
and test a new questionnaire to measure stiffness in people with rheumatoid 
arthritis. I am writing to many patients with rheumatoid arthritis from this 
department. 
 
Enclosed with this letter is a Patient Information Sheet that explains about 
the research study. We would be grateful if you could read it. Taking part in 
research is quite voluntary. If you would like to take part, please complete the 
questionnaire and return it in the envelope provided. This will go directly to 
Serena Halls, the researcher running the study, and I will not know who 
decides to take part. 
 








Insert consultant name 







Patient information sheet (Study 4) 
 
Developing and testing a rheumatoid arthritis stiffness questionnaire 
 
Patient information sheet 
 
You are being invited to take part in a research study. Before you decide whether to take 
part, it is important for you to understand why the research is being done, and what it will 
involve. Please take time to read the following information leaflet carefully and discuss it 
with others if you wish. If anything is not clear or you would like more information please 
ask one of the study team. 
 
What is the purpose of the study? 
Stiffness is a common problem for people with rheumatoid arthritis (RA). Until recently, 
stiffness was not very well understood but with the help of people like you we have 
developed a better understanding of what stiffness is and what it means to people. We 
would now like your help to develop this further by working towards a better way of 
measuring stiffness. Stiffness measurement currently is not very accurate and has not 
been developed with patient input. The aim of this study is to create and then test a new 
RA stiffness questionnaire that has been developed based on the patient experience of 
stiffness.  
 
Why have I been chosen? 
You have been chosen because you have a diagnosis of RA. We are inviting people with 
RA from Rheumatology Departments in the UK to take part. We would like a range of 
people to complete the questionnaire including those who have lots of stiffness, those 
who have a little bit of stiffness and even those who have none at all. This is because the 
new questionnaire will need to be able to detect different levels of stiffness. 
 
What will I be asked to do if I take part? 
The study involves completing a questionnaire pack. The questionnaire pack includes the 
stiffness questionnaire that we would like to test and some other questions about you and 
your arthritis in general. Once you have completed the questionnaire pack, please return 
it to us in the prepaid envelope, or if you are completing it in clinic, please hand the 
envelope to the receptionist. We will send a written reminder to people who have not 
returned the questionnaire pack within 3 weeks.  
 
At the end of the questionnaire pack we have asked whether you would like to receive a 
summary of the study findings. For this, we will ask you to provide your name and address. 
This will be kept separately from your returned questionnaire. 
 
We would also like to explore the relationship between the answers people give to the 
stiffness questionnaire and their disease activity. To do this we would like permission to 
access your relevant medical records to record the results of your most recent blood test. 
We will not ask you to undergo a blood test to participate in this study. 
 
Who is asking me to take part? 
I am Serena Halls, a PhD research student at the University of the West of England 
(UWE). This research study is the last of three studies which form my PhD. I am based 







Do I have to take part? 
No, you do not have to take part. If you decide not to take part you do not need to give a 
reason, nobody will be upset and the standard of care you receive will not be affected. 
Even if you do decide to take part, you are still free to withdraw from the study at any time 
and do not need to give a reason for doing so.  
 
What are the risks or benefits of taking part in the study? 
We do not believe there are any risks in being involved in this study. Although there are 
no direct benefits to you in taking part, you will be helping us to gain a better 
understanding of how to measure RA stiffness. This could help us to improve decisions 
made about treatment and management of RA.   
 
For general advice about taking part in research, or if you have any concerns or 
complaints about the conduct of the study, you can contact the local Patient Advice and 
Liaison Service (PALS) by phone: 0117 900 3433, email: pals@bristolpct.nhs.uk or post: 
PALS, NHS Bristol, South Plaza, Marlborough Street, Bristol, BS1 3NX. 
 
Will my taking part in the study be kept confidential? 
Yes. Your name will be replaced by a code by the researcher (Serena Halls). No one will 
be able to identify you from the questionnaire or study report. The study records will be 
kept securely for 6 years and then destroyed, in accordance with best practice in research 
guidelines.   
 
What will happen to the results of this research study? 
We hope to report the results at conferences and in professional journals. We will also 
send you a summary of the results at the end of the study if you would like. 
 
Who is organising, funding and reviewing the research? 
The study is coordinated by a team from UWE based at the Academic Rheumatology 
Unit at the Bristol Royal Infirmary. It is funded by UWE. This study has been reviewed 
and approved by Wales Research Ethics Committee 4 and the University Research 
Ethics Committee.  
 
What do I do now? 
Thank you for considering taking part in this study. If you would like to take part, please 





Serena Halls, PhD Researcher, UWE Bristol 
Professor Sarah Hewlett, Professor of Rheumatology Nursing, UWE Bristol 
Professor John Kirwan, Emeritus Professor of Rheumatic Diseases, UoB Bristol 
Dr Jon Pollock, Reader in Epidemiology, UWE Bristol 
Dr Emma Dures, Senior Research Fellow, UWE Bristol 
Mrs Avis Edmunds, Patient Research Partner 
Mrs Gill Baker, Patient Research Partner 
 
Serena Halls 
Academic Rheumatology Unit, 
Bristol Royal Infirmary, 
Bristol, BS2 8HW 
0117 342 4972 
Serena.halls@uwe.ac.uk 
Professor Sarah Hewlett 
Academic Rheumatology Unit, 
Bristol Royal Infirmary, 
Bristol, BS2 8HW 






Questionnaire booklet (Study 4) 
 





We would like to know how rheumatoid arthritis (RA) stiffness has affected 
you in the past 7 days. We would like you to fill this questionnaire out 
whether you have had lots of stiffness, a little bit of stiffness or even no 
stiffness at all. 
 
This questionnaire pack will take about 10 – 20 minutes to complete. When 
you are ready to begin, please turn overleaf and complete the consent form 
on page 2. If you would like to keep a copy, please also fill in the second 
consent form on page 3 which you can tear or cut out for your records. 
 
After you have completed the consent form, please continue through the 
questionnaire pack and answer all of the questions. You may notice that 
some of the questions are very similar. This is because we need to test 
different versions of some of the questions to see which works best, so 
please answer them all. Don’t think too long and hard, just give your first 
reaction - there are no right or wrong answers! 
 
Thank you  
 
 
Today’s date: _____________ 
 
 




Official use only 
 





[INSERT SITE-SPECIFIC HEADER] 
 





Please initial each box 
 
1. I confirm that I have read and understand the information sheet 
dated 10/12/14 (version 1.2) for the above study. 
 
 
2. I understand that my participation is voluntary and that I am free to 




3. I understand information from the questionnaire will be 
anonymised and may be used in publications, conference 
presentations and in a PhD thesis 
 
 
4. I understand that relevant sections of my medical notes and study 
data may be accessed (in confidence) by the study research team, 
regulatory authorities or relevant members of the NHS Trust. I give 
permission for these individuals to have access to my records 
 
 




When you have initialled all of the boxes above, please complete the 
following two lines yourself, including the date. 
                                                                                       




Name or researcher taking consent................................................................. 
 
Signature ........................................................................Date..........................  





[INSERT SITE-SPECIFIC HEADER] 
 





Please initial each box 
 
1. I confirm that I have read and understand the information sheet 
dated 10/12/14 (version 1.2) for the above study. 
 
 
2. I understand that my participation is voluntary and that I am free to 




3. I understand information from the questionnaire will be 
anonymised and may be used in publications, conference 
presentations and in a PhD thesis 
 
 
4. I understand that relevant sections of my medical notes and study 
data may be accessed (in confidence) by the study research team, 
regulatory authorities or relevant members of the NHS Trust. I give 
permission for these individuals to have access to my records 
 
 




When you have initialled all of the boxes above, please complete the 
following two lines yourself, including the date. 
                                                                                       




Name or researcher taking consent................................................................. 
 
Signature ........................................................................Date..........................  





Please tell us about your RA 
 
Overall 
1. Considering all the ways that your arthritis affects you, mark an X on 
the scale for how well you are doing  
Very well  Very poor 
 
Level of pain 
2. Please circle the number which shows how much pain you have had 
in the past 7 days. 





Level of fatigue 
3. Please circle the number which shows your average level of fatigue 
during the past 7 days.  





4. Are you having a flare (flare-up) of rheumatoid arthritis at this time? 
(Please tick) 
 
No  Yes  
 
Stiffness 
5. Please circle the number that best describes the severity of your RA 
stiffness over a usual week when you are not in a flare? 
No 
stiffness 









Please tell us about your abilities this week 
  
Please tick the one response which best describes your 














1 DRESSING AND GROOMING 
    Are you able to: 
  - Dress yourself, including tying   






















2  RISING 
    Are you able to: 


















3  EATING 
    Are you able to: 
  - Lift a full cup or glass to your  






















4  WALKING 
    Are you able to: 


















5  HYGIENE      
    Are you able to: 


















6  REACH      
    Are you able to: 
  - Bend down to pick up clothing  






















7  GRIP      
    Are you able to: 


















8 ACTIVITIES  
   Are you able to: 























Please tell us how active your arthritis is today 
 
1. In general, how active is your arthritis today? 
Mark X on the scale below at the point that best describes the level of 







2. Were your joints stiff when you woke up today?    No               Yes  
  
 If yes, how long did this extra stiffness last? 
 
Less than 30 minutes 
 
 
30 minutes–1 hour 
 
 






Over 4 hours 
 
 
All day  
  
3. Swollen joints 
 
Please indicate with a mark, on the picture below all the joints that are 







Please tell us about your RA stiffness 
This questionnaire is about RA stiffness that comes and goes. It is not about joints 
that are permanently stuck (for example, due to an operation). However, we do 
appreciate that sometimes even permanently stuck joints do get stiffer (for example, 
when your disease is bad). Please just try think about the stiffness that comes and 
goes as you answer this questionnaire. 
 




We would like to know how RA stiffness has affected you over the past 
7 days 
2. Over the past 7 days when have you experienced RA stiffness?  
Please tick all that apply to you 
In the night 
 
 
In the morning 
 
In the afternoon 
 
In the evening 
 
None of these 
 
 
For each of the following questions, please tick the one answer that 
best applies to you 
3. Have you experienced RA stiffness in your joints over the past 7 
days? 
No, not in any of my joints  
Yes, in a few of my joints  
Yes, in many of my joints  
Yes, in all of my joints  
 








5. Over the past 7 days has your RA stiffness been different to usual for 
you? 
It has been much better than usual  
It has been better than usual  
It has been the same as usual  
It has been worse than usual  
It has been much worse than usual  
 
6. Over the past 7 days has your RA stiffness been as variable (coming 
and going) as usual for you? 
It has been much less variable than usual  
It has been less variable than usual  
It has been the same as usual  
It has been more variable than usual  
It has been much more variable than usual  
 
7. Over the past 7 days have you experienced RA stiffness after a 
period of immobility (for example, after sitting for a while)? 
No, not at all  
Yes, a little  
Yes, quite a lot  
Yes, very much  
 
8. Have you experienced RA stiffness in your body (outside of your 
joints) over the past 7 days? 
No, not in any part of my body  
Yes, in a few parts of my body  
Yes, in many parts of my body  







For each of the following questions, please tick the one answer that 
best applies to you 










9. Has RA stiffness affected your sleep? 
    
10. Has RA stiffness made it difficult to 
dress or undress yourself? 
    
11. Has RA stiffness made it difficult to 
wash yourself (for example, have a 
shower)? 
    
12. Has RA stiffness made it difficult to 
carry out your responsibilities or 
commitments? 
    
13. Has RA stiffness made it difficult to do 
your daily tasks or activities? 
    
14. Has RA stiffness made it difficult to 
chew? 
    
15. Has RA stiffness made it difficult to do 
hobbies or activities you enjoy? 
    
16. Has RA stiffness made it difficult to 
get out of bed? 
    
17. Has RA stiffness made it difficult to 
get up after sitting for a while? 
    
18. Have your daily tasks and activities 
required more effort because of RA 
stiffness? 
    
19. Has RA stiffness made you slower 
(for example, unable to do things 
quickly)? 
    
20. Has RA stiffness made it difficult to do 
fine movements (for example, write 
with a pen)? 
    
21. Has RA stiffness made it difficult to 
grip or hold things? 
















22. Has RA stiffness made it difficult to 
open and close your fist? 
    
23. Has RA stiffness reduced your 
strength to do tasks? 
    
24. Has your movement been restricted 
because of RA stiffness? 
    
25. Has RA stiffness made it difficult to 
balance without physically supporting 
yourself? 
    
26. Have you had to concentrate to move 
your body because of RA stiffness? 
    
27. Have you felt frustrated because of RA 
stiffness? 
    
28. Have you felt worried or concerned 
because of RA stiffness? 
    
29. Have you felt self-conscious because 
of RA stiffness? 
    
30. Has it taken you longer to do your daily 
tasks or activities because of RA 
stiffness? 
    
31. Have you had to change your plans or 
behaviour because of RA stiffness? 
    
32. Have you had to work around your RA 
stiffness (or do things in a different 
way)? 
    
33. Have you needed help (from others or 
gadgets) because of RA stiffness? 










34. Please circle the number that best describes the impact that RA 









35. Please circle the number that best describes the severity of your RA 








36. Please circle the number that best describes how important RA 









37. Please circle the number that best describes how well you have coped 
with your RA stiffness over the past 7 days 
 
Not well  
at all 
0 1 2 3 4 5 6 7 8 9 10 Very well 
 
38. How much of the stiffness you have reported in the questions above is 










None of the stiffness I have reported  
A little of the stiffness I have reported  
Quite a lot of the stiffness I have reported  





These questions are also about stiffness. You may be familiar with them from 
clinic or from other questionnaires. We would now like to formally test them 
in this study. 
 
1. How would you describe the overall level of morning stiffness you 
have had from the time you wake up? 
No 
stiffness 












3. Circle the number that best describes the stiffness (all over or in your 








4. How would you describe the overall level of morning stiffness you 








5. How long does your morning stiffness last from waking until maximum 
improvement occurs? 
 
Minutes _____________ or hours _____________ 
 
 
Up to 1 hour  
1 – 3 hours  
More than 3 hours  
No stiffness  
Mild stiffness  
Moderate stiffness  
Severe stiffness  





Please tell us about you 
 
1. Are you male or female?  
(Please tick) 
 
Male                 Female 
2. What is your date of birth? 
 





3. Approximately how long have 
















5. Do you have any other medical conditions for which you are 
















Receiving incapacity benefits 
 
7. What is your level of 




Did not complete school 
School education 
College / apprenticeship 
University level education 







Thank you very much for taking the time to fill in this 
questionnaire! 
 





Serena Halls, PhD Researcher, UWE Bristol 
Professor Sarah Hewlett, Professor of Rheumatology Nursing, UWE Bristol 
Professor John Kirwan, Emeritus Professor of Rheumatic Diseases, UoB Bristol 
Dr Jon Pollock, Reader in Epidemiology, UWE Bristol 
Dr Emma Dures, Senior Research Fellow, UWE Bristol 
Mrs Avis Edmunds, Patient Research Partner 
Mrs Gill Baker, Patient Research Partner 
 
Serena Halls 
Academic Rheumatology Unit, 
Bristol Royal Infirmary, 
Bristol, BS2 8HW 
0117 342 4972 
Serena.halls@uwe.ac.uk 
Professor Sarah Hewlett 
Academic Rheumatology Unit, 
Bristol Royal Infirmary, 
Bristol, BS2 8HW 
0117 342 2903 
Sarah.hewlett@uwe.ac.uk 
If you would like to receive a summary of the results of this study, please 
tick the box below and provide your name and address.  
 
The information you provide here will be kept confidential and will be 
stored separately from your returned questionnaire in a locked cabinet. 
You will not be contacted for any other reason. 
 




Your name: ________________________________________________ 
 










Appendix W: Frequency and distribution graphs (normality 
assessment where relevant) for non-stiffness items (Study 4) 
 
Whole sample: Age 
The variable age for the whole sample was treated as a continuous variable and the 
extent to which it met the assumption of normality was explored. Negative skew (-0.407, 
SE=0.096) and kurtosis (-0.298, SE=0.192) and a significant Kolmogorov-Smirnov 
statistic (D(643)=0.069, p=0.000) indicated violation of the assumption of normality. 
However, in large samples (>200) these tests are too sensitive and results such as these 
are common, thus inspection of the histogram is recommended (Tabachnick and Fidell, 
2007). The histogram appeared to have a reasonably normal distribution and the values 
on the Q-Q plot fell near to or on the straight line (Figure W.1). 
 
  
Figure W.1: Histogram and Q-Q plot for age (whole sample) 
 
Non-responders: Age 
The variable age for the non-responders was explored for the extent to which it met the 
assumption of normality. Negative skew (-0.350, SE=0.128) and kurtosis (-0.518, 
SE=0.254) and a significant Kolmogorov-Smirnov statistic (D(366)=0.073, p=0.000) 
indicated violation of the assumption of normality. The histogram appeared to have a 
reasonably normal distribution and the values on the Q-Q plot fell near to or on the straight 











The variable age for the responders was explored for the extent to which it met the 
assumption of normality. Negative skew (-0.330, SE=0.146) and kurtosis (-0.195, 
SE=0.292) and a significant Kolmogorov-Smirnov statistic (D(277)=0.058, p=0.000) 
indicated violation of the assumption of normality. The histogram appeared to have a 
reasonably normal distribution and the values on the Q-Q plot fell near to or on the straight 
line (Figure W.3). 
 
  
Figure W.3: Histogram and Q-Q plot for age (responders) 
 
Responders: Disease duration 
Responder disease duration was explored for the extent to which it met the assumption 
of normality. Positive skew (1.337, SE=0.148) and kurtosis (1.084, SE=0.295) and a 
significant Kolmogorov-Smirnov statistic (D(271)=0.203, p=0.000) indicated violation of 
the assumption of normality. The histogram was not normally distributed and the values 
on the Q-Q plot fell in an s-shape around the straight line (Figure W.4). 
 
  
Figure W.4: Histogram and Q-Q plot for disease duration (responders) 
 
Responders: Disease activity (PDAS2, Choy et al, 2008) 
Responder disease activity (PDAS2, Choy et al, 2008) was explored for the extent to 
which it met the assumption of normality. Positive skew (0.405, SE=0.146) and negative 
kurtosis (-0.786, SE=0.292) and a significant Kolmogorov-Smirnov statistic 





histogram was not normally distributed and the values on the Q-Q plot dropped off the 
straight line at the ends (Figure W.5). 
 
  
Figure W.5: Histogram and Q-Q plot for disease activity (responders) 
 
Responders: Disability (MHAQ, Pincus et al, 1983) 
Responder disability scores (MHAQ, Pincus et al, 2008) was explored for the extent to 
which it met the assumption of normality. Positive skew (0.796, SE=0.146) and negative 
kurtosis (-0.117, SE=0.292) and a significant Kolmogorov-Smirnov statistic 
(D(277)=0.146, p=0.000) indicated violation of the assumption of normality. The 
histogram was not normally distributed and the values on the Q-Q plot did not fall on the 
straight line (Figure W.6). 
 
  
Figure W.6: Histogram and Q-Q plot for disability (responders) 
 
Responders: Patient global assessment (PtG) 
Patient global assessment (PtG) was explored for the extent to which it met the 
assumption of normality. Positive skew (0.337, SE=0.147) and negative kurtosis (-0.892, 
SE=0.293) and a significant Kolmogorov-Smirnov statistic (D(275)=0.079, p=0.000) 
indicated violation of the assumption of normality. The histogram was not normally 








Figure W.7: Histogram and Q-Q plot for PtG (responders) 
 
Responders: Pain 
Responder pain (NRS) was explored for the extent to which it met the assumption of 
normality. Negative skew (-0.025, SE=0.146) and kurtosis (-1.106, SE=0.292) and a 
significant Kolmogorov-Smirnov statistic (D(277)=0.120, p=.000) indicated violation of the 
assumption of normality. The histogram was quite flat and the values on the Q-Q plot fell 
around the straight line (Figure W.8). 
 
  
Figure W.8: Histogram and Q-Q plot for pain (responders) 
 
Responders: Fatigue (BRAF severity NRS, Nicklin et al, 2010a, Nicklin 
et al, 2010b) 
Responder fatigue (BRAF severity NRS, Nicklin et al, 2010a, Nicklin et al, 2010b) was 
explored for the extent to which it met the assumption of normality. Negative skew (-0.418, 
SE=0.146) and kurtosis (-0.842, SE=0.292) and a significant Kolmogorov-Smirnov 
statistic (D(277)=0.161, p=0.000) indicated violation of the assumption of normality. The 













Appendix X: Pearson’s correlation coefficient (Study 4) 
 7.2 7.3 7.4 8.5 8.7 8.8 9.9 9.10 9.11 9.12 9.13 9.15 9.16 9.17 9.18 9.19 9.20 9.21 10.22 
7.2 1.000 .579 .388 .373 .578 .479 .536 .491 .437 .487 .541 .464 .443 .514 .544 .482 .474 .471 .435 
7.3 - 1.000 .436 .386 .548 .465 .549 .530 .480 .526 .557 .518 .509 .547 .581 .593 .504 .537 .441 
7.4 - - 1.000 .221 .398 .516 .407 .345 .311 .338 .343 .358 .373 .346 .331 .308 .299 .297 .297 
8.5 - - - 1.000 .368 .315 .345 .377 .321 .398 .457 .361 .290 .294 .399 .397 .371 .331 .328 
8.7 - - - - 1.000 .527 .528 .560 .482 .506 .550 .541 .573 .696 .578 .539 .462 .496 .397 
8.8 - - - - - 1.000 .491 .462 .360 .467 .513 .509 .470 .485 .532 .483 .413 .432 .276 
9.9 - - - - - - 1.000 .602 .586 .586 .627 .619 .625 .568 .659 .623 .592 .602 .450 
9.10 - - - - - - - 1.000 .833 .761 .782 .710 .751 .680 .698 .671 .667 .648 .555 
9.11 - - - - - - - - 1.000 .770 .749 .671 .708 .613 .669 .633 .638 .656 .555 
9.12 - - - - - - - - - 1.000 .856 .761 .661 .625 .787 .736 .629 .721 .631 
9.13 - - - - - - - - - - 1.000 .783 .660 .636 .821 .760 .678 .723 .602 
9.15 - - - - - - - - - - - 1.000 .668 .666 .799 .746 .640 .652 .547 
9.16 - - - - - - - - - - - - 1.000 .719 .667 .619 .588 .607 .456 
9.17 - - - - - - - - - - - - - 1.000 .695 .654 .556 .567 .444 
9.18 - - - - - - - - - - - - - - 1.000 .836 .653 .717 .591 
9.19 - - - - - - - - - - - - - - - 1.000 .673 .751 .617 
9.20 - - - - - - - - - - - - - - - - 1.000 .756 .641 
9.21 - - - - - - - - - - - - - - - - - 1.000 .666 
10.22 - - - - - - - - - - - - - - - - - - 1.000 
10.23 - - - - - - - - - - - - - - - - - - - 
10.24 - - - - - - - - - - - - - - - - - - - 
10.25 - - - - - - - - - - - - - - - - - - - 
10.26 - - - - - - - - - - - - - - - - - - - 
10.27 - - - - - - - - - - - - - - - - - - - 
10.28 - - - - - - - - - - - - - - - - - - - 
10.29 - - - - - - - - - - - - - - - - - - - 
10.30 - - - - - - - - - - - - - - - - - - - 
10.31 - - - - - - - - - - - - - - - - - - - 
10.32 - - - - - - - - - - - - - - - - - - - 
10.33 - - - - - - - - - - - - - - - - - - - 
11.34 - - - - - - - - - - - - - - - - - - - 
11.35 - - - - - - - - - - - - - - - - - - - 
11.36 - - - - - - - - - - - - - - - - - - - 
11.37 - - - - - - - - - - - - - - - - - - - 
6.2 - - - - - - - - - - - - - - - - - - - 
12.1 - - - - - - - - - - - - - - - - - - - 
12.3 - - - - - - - - - - - - - - - - - - - 
12.4 - - - - - - - - - - - - - - - - - - - 
All significant at p<.01 
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 10.23 10.24 10.25 10.26 10.27 10.28 10.29 10.30 10.31 10.32 10.33 11.34 11.35 11.36 11.37 6.2 12.1 12.3 12.4 
7.2 .457 .510 .313 .396 .480 .383 .472 .472 .386 .456 .435 .601 .620 .548 -.250 .479 .587 .618 .590 
7.3 .521 .511 .407 .424 .500 .357 .387 .532 .402 .483 .444 .614 .640 .587 -.251 .518 .628 .630 .632 
7.4 .197 .288 .300 .237 .258 .347 .336 .327 .326 .297 .308 .284 .380 .387 -.127 .218 .345 .352 .371 
8.5 .335 .392 .297 .310 .317 .310 .264 .364 .309 .304 .287 .497 .541 .466 -.238 .422 .439 .521 .489 
8.7 .510 .619 .419 .518 .568 .403 .520 .589 .459 .459 .503 .634 .616 .614 -.243 .459 .632 .634 .581 
8.8 .448 .484 .353 .409 .453 .404 .372 .468 .403 .427 .416 .548 .553 .515 -.228 .445 .503 .514 .483 
9.9 .551 .588 .473 .519 .610 .499 .499 .619 .563 .583 .563 .671 .638 .643 -.315 .496 .655 .627 .626 
9.10 .630 .731 .612 .622 .655 .521 .545 .698 .609 .681 .674 .674 .680 .666 -.288 .523 .715 .670 .676 
9.11 .611 .689 .659 .627 .618 .502 .539 .676 .604 .662 .654 .636 .629 .613 -.304 .481 .653 .623 .616 
9.12 .673 .716 .621 .594 .664 .573 .575 .767 .732 .744 .647 .739 .693 .699 -.349 .573 .713 .696 .676 
9.13 .681 .739 .621 .612 .680 .534 .560 .796 .678 .733 .697 .777 .763 .737 -.350 .556 .739 .745 .700 
9.15 .666 .755 .621 .643 .736 .654 .595 .765 .699 .725 .638 .759 .718 .733 -.285 .569 .699 .701 .636 
9.16 .588 .639 .607 .665 .599 .535 .531 .611 .552 .612 .591 .653 .625 .650 -.255 .480 .714 .622 .647 
9.17 .610 .693 .637 .666 .661 .500 .553 .683 .542 .611 .579 .694 .660 .662 -.311 .500 .708 .682 .643 
9.18 .728 .775 .616 .699 .731 .632 .610 .860 .714 .745 .656 .806 .779 .771 -.372 .625 .740 .754 .699 
9.19 .763 .761 .631 .667 .716 .621 .617 .844 .721 .752 .714 .796 .769 .787 -.354 .639 .739 .750 .713 
9.20 .688 .662 .537 .568 .595 .492 .551 .670 .612 .662 .654 .648 .620 .634 -.322 .491 .597 .617 .576 
9.21 .786 .701 .563 .592 .632 .515 .550 .734 .624 .692 .727 .679 .650 .675 -.361 .496 .646 .662 .615 
10.22 .688 .638 .457 .503 .583 .460 .468 .600 .509 .568 .521 .602 .566 .554 -.291 .494 .557 .549 .570 
10.23 1.000 .761 .590 .635 .688 .593 .622 .760 .645 .751 .738 .711 .670 .685 -.360 .534 .619 .653 .623 
10.24 - 1.000 .683 .710 .746 .615 .645 .800 .699 .731 .710 .757 .748 .743 -.333 .565 .698 .749 .667 
10.25 - - 1.000 .755 .591 .456 .524 .657 .569 .588 .636 .603 .601 .562 -.262 .461 .564 .613 .532 
10.26 - - - 1.000 .654 .562 .595 .697 .612 .636 .605 .660 .651 .648 -.307 .517 .601 .642 .558 
10.27 - - - - 1.000 .738 .748 .786 .726 .760 .683 .764 .728 .783 -.355 .568 .682 .720 .645 
10.28 - - - - - 1.000 .726 .644 .655 .653 .552 .645 .600 .672 -.343 .495 .556 .583 .540 
10.29 - - - - - - 1.000 .677 .676 .677 .659 .644 .593 .658 -.266 .458 .586 .600 .527 
10.30 - - - - - - - 1.000 .787 .823 .753 .814 .770 .786 -.336 .610 .718 .762 .683 
10.31 - - - - - - - - 1.000 .830 .687 .704 .645 .705 -.284 .508 .602 .638 .553 
10.32 - - - - - - - - - 1.000 .714 .720 .673 .704 -.306 .486 .651 .673 .629 
10.33 - - - - - - - - - - 1.000 .689 .657 .680 -.291 .459 .633 .662 .577 
11.34 - - - - - - - - - - - 1.000 .920 .921 -.338 .703 .878 .906 .810 
11.35 - - - - - - - - - - - - 1.000 .908 -.344 .711 .872 .934 .831 
11.36 - - - - - - - - - - - - - 1.000 -.360 .664 .867 .888 .759 
11.37 - - - - - - - - - - - - - - 1.000 -.247 .670 .677 .664 
6.2 - - - - - - - - - - - - - - - 1.000 -.323 -.337 -.373 
12.1 - - - - - - - - - - - - - - - - 1.000 .891 .864 
12.3 - - - - - - - - - - - - - - - - - 1.000 .839 
12.4 - - - - - - - - - - - - - - - - - - 1.000 








Rotated component loadings 
Pattern matrix Structure matrix 
1 2 3 4 1 2 3 4 
9.11 draft stiffness item 11 1.078 -.133 -.163 .030 .868 .603 .594 .517 
9.10 draft stiffness item 10 .944 -.040 -.164 .148 .876 .667 .616 .611 
9.21 draft stiffness item 21 .796 .143 .024 -.138 .841 .686 .670 .451 
9.12 draft stiffness item 12 .744 .135 .055 -.039 .867 .723 .707 .530 
10.25 draft stiffness item 25 .837 -.190 .118 -.015 .773 .530 .625 .435 
9.13 draft stiffness item 13 .712 .244 -.029 .002 .878 .774 .696 .577 
9.20 draft stiffness item 20 .774 .129 -.019 -.093 .802 .653 .623 .451 
9.16 draft stiffness item 16 .788 -.198 -.066 .362 .805 .596 .594 .681 
10.33 draft stiffness item 33 .618 -.104 .366 -.029 .803 .613 .755 .472 
10.24 draft stiffness item 24 .553 .102 .287 .000 .854 .732 .788 .552 
10.23 draft stiffness item 23 .579 .112 .304 -.137 .817 .686 .760 .446 
10.26 draft stiffness item 26 .591 -.125 .314 .058 .773 .590 .714 .502 
10.22 draft stiffness item 22 .653 .401 -.039 -.362 .711 .644 .561 .272 
9.18 draft stiffness item 18 .440 .237 .265 .038 .851 .789 .794 .597 
9.15 draft stiffness item 15 .477 .022 .328 .121 .822 .699 .776 .597 
9.19 draft stiffness item 19 .403 .308 .316 -.082 .836 .790 .804 .526 
9.17 draft stiffness item 17 .535 -.057 .061 .382 .772 .644 .635 .704 
11.35 draft stiffness item 35 .009 .737 .184 .092 .775 .932 .760 .665 
8.5 draft stiffness item 5 -.159 1.010 -.223 -.100 .386 .665 .316 .334 
12.3 traditional severity item G .045 .716 .163 .082 .774 .919 .748 .654 
12.4  traditional severity item C .144 .735 -.039 .100 .741 .882 .645 .639 
11.34 draft stiffness item 34 .046 .604 .307 .086 .803 .912 .815 .662 
6.2 traditional duration item D -.100 .744 .149 .002 .591 .774 .600 .497 













Rotated component loadings 
Pattern matrix  Structure matrix 
1 2 3 4 1 2 3 4 
11.36 draft stiffness item 36 -.042 .563 .419 .087 .771 .884 .831 .642 
7.2 draft stiffness item 2 .025 .552 -.202 .410 .544 .691 .422 .673 
7.3 draft stiffness item 3 .214 .513 -.293 .373 .609 .709 .430 .678 
11.37  draft stiffness item 37 -.084 -.434 -.111 .222 -.370 -.435 -.367 -.165 
10.28 draft stiffness item 28 -.209 -.007 .981 .082 .596 .579 .857 .463 
10.29 draft stiffness item 29 -.003 -.178 .916 .127 .647 .549 .854 .489 
10.27 draft stiffness item 27 .107 .049 .722 .089 .759 .700 .886 .563 
10.31 draft stiffness item 31 .284 -.087 .730 -.057 .747 .611 .858 .441 
10.32 draft stiffness item 32 .477 -.091 .557 -.035 .817 .649 .844 .489 
10.30 draft stiffness item 30 .422 .120 .475 -.044 .857 .754 .865 .539 
7.4 draft stiffness item 4 -.176 -.217 .154 .925 .339 .349 .347 .759 
8.8 draft stiffness item 8 -.087 .063 .128 .711 .494 .543 .477 .766 
8.7 draft stiffness item 7 .134 .155 .033 .558 .618 .639 .537 .756 
9.9 draft stiffness item 9 .348 .150 .047 .330 .701 .663 .595 .663 







Rotated component loadings 
Pattern matrix Structure matrix 
1 2 3 4 1 2 3 4 
9.11 draft stiffness item 11 1.062 -.062 -.184 -.007 .875 .548 .587 .410 
9.10 draft stiffness item 10 .981 .028 -.220 .103 .881 .603 .592 .504 
9.21 draft stiffness item 21 .711 .178 .086 -.160 .824 .665 .695 .291 
9.12 draft stiffness item 12 .779 .045 .100 -.027 .874 .645 .719 .405 
10.25 draft stiffness item 25 .881 -.123 .007 -.041 .780 .478 .583 .334 
9.13 draft stiffness item 13 .770 .131 .022 .006 .882 .685 .707 .441 
9.20 draft stiffness item 20 .807 .054 -.003 -.085 .801 .578 .622 .326 
9.16 draft stiffness item 16 .780 .000 -.141 .278 .806 .563 .563 .601 
10.33 draft stiffness item 33 .650 -.136 .359 -.058 .803 .539 .742 .333 
10.24 draft stiffness item 24 .599 .068 .278 -.006 .857 .675 .783 .416 
10.23 draft stiffness item 23 .522 .101 .360 -.132 .805 .657 .781 .298 
10.26 draft stiffness item 26 .653 -.074 .205 .050 .782 .542 .674 .410 
10.22 draft stiffness item 22 .609 .241 .067 -.235 .716 .613 .613 .185 
9.18 draft stiffness item 18 .505 .156 .295 .029 .855 .723 .802 .449 
9.15 draft stiffness item 15 .550 .005 .301 .100 .833 .638 .765 .481 
9.19 draft stiffness item 19 .469 .173 .379 -.089 .838 .724 .825 .353 
9.17 draft stiffness item 17 .522 .141 .027 .268 .770 .636 .627 .589 
11.35 draft stiffness item 35 -.008 .790 .219 .000 .710 .936 .758 .411 
8.5 draft stiffness item 5 .154 .791 -.487 .010 .337 .568 .182 .235 
12.3 traditional severity item G .016 .845 .143 -.017 .706 .948 .732 .400 
12.4  traditional severity item C .032 .837 .073 -.007 .667 .906 .672 .388 
11.34 draft stiffness item 34 .082 .621 .317 .017 .765 .903 .814 .437 
6.2 traditional duration item D .056 .658 .125 .035 .628 .799 .636 .387 





Rotated component loadings 
Pattern matrix  Structure matrix 
1 2 3 4 1 2 3 4 
11.36 draft stiffness item 36 .002 .494 .497 .034 .744 .852 .852 .430 
7.2 draft stiffness item 2 -.158 .961 -.070 .093 .502 .842 .507 .395 
7.3 draft stiffness item 3 -.019 1.053 -.276 -.042 .483 .832 .420 .288 
11.37  draft stiffness item 37 .098 -.529 -.365 .130 -.488 -.658 -.605 -.183 
10.28 draft stiffness item 28 -.063 -.127 .929 .144 .631 .530 .847 .410 
10.29 draft stiffness item 29 .090 -.200 .847 .120 .660 .498 .824 .399 
10.27 draft stiffness item 27 .135 .060 .714 .068 .759 .676 .885 .428 
10.31 draft stiffness item 31 .393 -.222 .685 .000 .765 .524 .834 .354 
10.32 draft stiffness item 32 .500 -.115 .544 -.033 .822 .595 .837 .365 
10.30 draft stiffness item 30 .499 .023 .481 -.040 .866 .686 .866 .392 
7.4 draft stiffness item 4 -.114 -.069 .138 .858 .358 .308 .326 .826 
8.8 draft stiffness item 8 .003 .056 .144 .725 .503 .463 .459 .805 
8.7 draft stiffness item 7 .151 .374 .027 .401 .625 .666 .552 .641 
9.9 draft stiffness item 9 .417 .200 .043 .250 .710 .625 .596 .551 
NB bold loadings = highest loading for that item; underlined loadings = other loadings ≥.4; *Specifying a 4 component ordinal solution 
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Appendix Z: Scoring the RAST 
Scoring instructions 
The RAST can be scored as individual components or as a total scale. To score, convert each item score to a % score using the tables below. 
To generate a % score for individual components, add the % scores together and divide by the number of items within the component. To 
generate a % score for the total scale add together each % score for each individual component and divide by three.  
 
Missing data 
One missing item per component is acceptable. In this case, individual component scores can be generated by adding together the item % scores 
from the available data and dividing that by the number of item % scores provided (one less than the component total). A score for each individual 


























































Severity % score  
(item 1 % score + item 2 % 
score + item 3 % score + 
item 4 % score + item 5 % 
score + item 6 % score + 
item 7 % score + item 8 % 


























Physical % score  
(item 9 % score + 10 % 
score + item 11 + item 12 
% score + item 13 % 
score + item 14 % score + 
item 15 % score + item 16 



















Psychosocial % score 
(item 17 % score + item 
18 % score + item 19 % 
score + item 20 % score + 










RAST total % score  
(Severity % score + Physical % 






Appendix AA: Final layout of the RA stiffness PROM 
 
Please tell us about your RA stiffness 
This questionnaire is about RA stiffness that comes and goes. It is not about joints 
that are permanently stuck (for example, due to an operation). However, we do 
appreciate that sometimes even permanently stuck joints do get stiffer (for example, 
when your disease is bad). Please just try think about the stiffness that comes and 




This section asks about the severity of your RA stiffness. 
 
 
1. Over the past 7 days when have you experienced RA stiffness? Please tick all that 
apply to you 
In the night 
 
 
In the morning 
 
In the afternoon 
 
In the evening 
 
None of these 
 
 
For each of the following questions, please tick the one answer that best applies to 
you 
 
2. Have you experienced RA stiffness in your joints over the past 7 days? 
No, not in any of my joints  
Yes, in a few of my joints  
Yes, in many of my joints  
Yes, in all of my joints  
 
3. Over the past 7 days have you experienced RA stiffness after a period of immobility 
(for example, after sitting for a while)? 
No, not at all 
 
Yes, a little 
 
Yes, quite a lot 
 






4. Please circle the number that best describes the severity of your RA stiffness over 
the past 7 days 
No stiffness 0 1 2 3 4 5 6 7 8 9 10 Extreme stiffness 
 
5. Please circle the number that best describes the impact that RA stiffness has had on 
your life over the past 7 days 
No impact at all 0 1 2 3 4 5 6 7 8 9 10 A great deal of impact 
 
6. Please circle the number that best describes how important RA stiffness has been in 
your life over the past 7 days 
Not important at 
all 
0 1 2 3 4 5 6 7 8 9 10 Very important 
 
The following questions are often used to assess stiffness. You may be familiar with 
them from clinic or other questionnaires.  
 
Question 7 asks about your stiffness today.  
 
7. Were your joints stiff when you woke up today?   No              Yes    
 If yes, how long did this extra stiffness last? 
 
 
Less than 30 minutes 
 
30 minutes to an hour 
 
1 - 2 hours 
 
2 - 4 hours 
 




Please answer question 8 in the most appropriate way for you. 
 
8. How would you describe the overall level of morning stiffness you have had from the 
time you wake up? 

















This section asks about the physical and daily life impact of your RA stiffness. 
 
 Not at 
all 




9. Has RA stiffness made it difficult 
to dress or undress yourself? 
    
10. Has RA stiffness made it difficult 
to wash yourself (for example, 
have a shower)? 
    
11. Has RA stiffness made it difficult 
to carry out your responsibilities or 
commitments? 
    
12. Has RA stiffness made it difficult 
to do your daily tasks or activities? 
    
13. Has RA stiffness made it difficult 
to get out of bed? 
    
14. Has RA stiffness made it difficult 
to do fine movements (for 
example, write with a pen)? 
    
15. Has RA stiffness made it difficult 
to grip or hold things? 
    
16. Has RA stiffness made it difficult 
to balance without physically 
supporting yourself? 
    
 
Psychosocial component 
This section asks about the psychosocial impact of your RA stiffness. 
 
 




17. Have you felt frustrated because 
of RA stiffness? 
    
18. Have you felt worried or 
concerned because of RA 
stiffness? 
    
19. Have you felt self-conscious 
because of RA stiffness? 
    
20. Have you had to change your 
plans or behaviour because of 
RA stiffness? 
    
21. Have you had to work around 
your RA stiffness (or do things 
in a different way)? 




Appendix BB: Abstract (Study 1) 
Patients’ experience of stiffness in RA are more than just duration and severity 
Halls, S., Dures, E., Kirwan, J., Pollock, J., Baker, G., Edmunds, A., Hewlett, S. (2014) 
 
Background: Stiffness is commonly experienced by patients with rheumatoid arthritis 
(RA). It has considerable impact on their daily lives and influences decisions to seek 
medication review. Traditionally, stiffness is evaluated by severity and duration, yet 
research into how patients experience the symptom is limited. 
 
Methods: Patients were purposefully sampled from out-patient rheumatology clinics to 
reflect a range of age, gender and disease duration. Semi-structured interviews were 
conducted according to a piloted interview guide. Interviews were analysed using 
thematic analysis, with a subset analysed by the research team including patient partners. 
 
Results: 16 patients (5 male, 11 female) aged 33 - 78 years (mean 57.3) with disease 
durations 1 - 27 years (mean 11.5) participated. Analysis identified six themes, each of 
which fitted around the central concept of ‘I experience stiffness as...’ 
 
‘Part of my disease’: Stiffness was considered a normal consequence of RA (“it’s really 
one of the most obvious symptoms of the condition”) and was influenced by disease 
related aspects such as flare and damaged joints (“once you’ve got damage, you’re 
always stiff”). Relationships to other symptoms such as pain were apparent, but patients 
could discuss stiffness independently. For some stiffness was a significant symptom in 
early disease (“stiffness was absolutely integral to the definition of the disease at that 
time”). 
 
‘Part of my behaviour and environment’: Movement was a key influence, and related to 
immobility (“you are stiff after being laid in bed”) and over-activity (“if I have had like a 
busy day, and I haven’t been able to rest then I might find that it is creeping back in the 
evening”). Patients also highlighted medications, weather and diet. 
 
‘Located within my body’: Stiffness was a bodily experience that affected the joints (“there 
is actual joint stiffness”). Location varied and was reported by some as more widespread 
during the morning or during a flare (“it affects more joints than it does when I’m not so 
bad”). 
 
‘Having consequences’: Patients defined stiffness by impact on a range of domains 
including physical function (“I could not get my fingers to pick up this blooming stupid 
screw”), quality of life and wellbeing. 
 
‘Needing to be managed’: Patients managed stiffness using movement, heat and cold, 
medications, gadgets, and behavioural strategies. 
 
‘Variable’: Stiffness varied within and between patients and was compounded by the 
fluctuating nature of RA e.g. stiffness during a flare was “an exaggeration of itself”. 
Additionally, there was temporal variability (“on a good day it is really just morning and 
evening”). 
 
Conclusions: Patients’ experiences of stiffness were varied, complex and not fully 
captured by severity and duration. Future research directions include using these findings 
to develop a more patient oriented measure of stiffness which might evaluate different 
dimensions of the symptom. 
 





Appendix CC: Abstract (Systematic literature review) 
A systematic literature review (SLR) of the measurement of stiffness in patients 
with rheumatoid arthritis (RA) 
Serena Halls, John Kirwan, Sarah Hewlett 
 
Background: Morning stiffness was omitted from the RA core set because of poor 
measurement properties of available patient reported outcome measures (PROMs)1, yet 
it remains a frequently used clinical and research outcome2 and is an important  symptom 
to RA patients3,4,5. In recent qualitative work, patients highlighted stiffness reduction as 
crucial to consider themselves in remission6. Additionally, an international patient and 
healthcare professional Delphi, prioritized stiffness (79% consensus)7 and included it as 
a core domain for flare assessment (91% consensus)8. In both remission and flare, the 
assessment of stiffness has been identified as an important area of investigation8,9. An 
SLR investigating stiffness PROMs for use in the assessment of RA patients in low 
disease activity or remission states concluded that there was insufficient evidence 
regarding stiffness assessment in that context9. 
 
Objectives: This SLR aimed to expand and update the previous SLR9 of stiffness in RA 
remission, to identify the current stiffness PROMs available for RA in general and 
summarise the evidence of their measurement properties. 
 
Methods: To update the previous SLR9 an extensive PubMed database search was 
performed for dates 20/11/12 to 22/09/15, but not limited to remission. Article screening 
and data extraction were performed using an approach that was consistent with the 
original SLR9 by multiple researchers. To expand the previous SLR9, data extraction was 
also performed by one author on the 16 articles identified in the original review (14 of 
which were previously excluded as they did not provide data on stiffness assessment in 
remission).  
 
Results: In the updated search 147 articles were identified, from which 23 full text articles 
were screened and 9 included. The 16 articles identified in the original SLR9 were also 
included, totalling 25 articles. The fifty identified PROMs predominantly assessed 
stiffness from the two concepts of severity/intensity or duration, and focused on morning 
or early morning stiffness alone. Despite covering so few concepts, there was great 
variation in these PROMs in relation to wording, response options, format and timeframe, 
and many items were poorly described. Reports of face, content, criterion and construct 
validity, and stability and sensitivity were minimal. 
 
Conclusions: Current RA stiffness assessment is varied, poorly defined and does not 
appear to have been developed according to PROM development guidelines10. 
Importantly it is also inconsistent with the patient perspective4,5 of this symptom. Further 
work is required to investigate the most appropriate way to assess stiffness in an RA 
population. 
 
References: 1Felson et al, 1993; 2Kalyoncu et al, 2009; 3Hewlett et al, 2005; 4Halls et al, 
2014; 5Orbai et al, 2014; 6van Tuyl et al, 2015; 7Bartlett et al, 2012; 8Bykerk et al, 2014; 





Appendix DD: Abstract (Study 4 development) 
Developing a new rheumatoid arthritis (RA) stiffness patient reported outcome 
measure (PROM) 
S. Halls, E. Dures, J. Kirwan, J. Pollock, G. Baker, A. Edmunds, S. Hewlett 
 
Background: Morning stiffness is a frequently used clinical and research outcome 
measure and is important to patients1, but was omitted from the RA core set because of 
poor measurement properties2. Current stiffness assessment is inconsistent with patient’s 
perspectives of the symptom3,4 and has not been developed according to PROM 
development guidelines5. The appropriate content of a new RA stiffness PROM was 
previously explored and developed through qualitative interview3 and focus group studies. 
Draft items were subsequently tested and refined with patients during cognitive 
interviews, resulting in 39 draft items for inclusion in a PROM. Here we report a 
quantitative assessment to create the smallest and most internally consistent set of items 
for a developmentally valid stiffness PROM. 
 
Objectives: To develop the content and structure of a new RA stiffness PROM. 
 
Methods: A postal questionnaire pack was sent to patients with RA based in the South-
West of England. It contained 45 items assessing stiffness (39 draft items and 6 items 
currently used in stiffness assessment), individual items capturing pain (VAS), fatigue 
(NRS), patient global assessment (VAS), questionnaires capturing disability (MHAQ), and 
patient-reported disease activity (PDAS26), and basic demographic information. Initial 
investigation identified items with poor response rates, distributions or correlations for 
removal. A series of principal component analyses were undertaken with the remaining 
items, balancing Cronbach’s alpha for internal consistency, stability of the component 
structure (assessed by multiple analyses using random 50% samples of the respondents 
(bootstrapping)) and parsimony. Based on the statistical results and aided by expert 
judgement, the smallest number of informative items were retained. 
 
Results: 277 patients (91 male) aged 23-97 years with disease durations 1-45 years 
participated in the study (42.9% response rate). Seven of the 45 items were removed 
during initial item investigation. The remaining 38 items demonstrated high Cronbach’s 
alpha (>0.9). During successive rounds of analytical refinement, 17 items were removed. 
 
After round 5, a 3-component structure emerged which remained consistent for a further 
13 rounds of testing item removal, demonstrating stability. These components captured 
‘stiffness severity’, ‘physical impact’ and ‘psychosocial impact’. The overall Cronbach’s 
alpha of the final 21 items was 0.95 indicating a homogenous set of items and 
bootstrapping further demonstrated the stability of the structure. 
 
Conclusions: A new 21 item, 3-component RA stiffness PROM has been developed 
based on qualitative work3 with RA patients to enhance content validity. Further testing is 
now required to assess the validity, reliability and sensitivity to change of the new RA 
stiffness PROM. 
 
References: 1Hewlett et al, 2005; 2Felson et al, 1993; 3Halls et al, 2014; 4Orbai et al, 






Appendix EE: Abstract (Study 4 testing) 
Construct validity testing of RAST, a new RA stiffness patient reported outcome 
measure (PROM)  
S. Halls, E. Dures, J. Kirwan, J. Pollock, G. Baker, A. Edmunds, S. Hewlett 
 
Background: Morning stiffness is a frequently used clinical and research outcome 
measure and is important to patients1, but was omitted from the RA core set because of 
poor measurement properties2. Current stiffness assessment is inconsistent with patient’s 
perspectives of the symptom3,4 and has not been developed according to PROM 
development guidelines5. A new 21 item, 3-component Rheumatoid Arthritis Stiffness 
questionnaire (RAST) has been developed based on qualitative work3 with RA patients 
and statistical assessment to enhance content validity and now requires testing for 
appropriate relationships with other measures of disease (construct validity). 
 
Objectives: To perform construct validity testing of RAST. 
 
Methods: The 21 item RAST was developed from 45 items assessing stiffness included 
in a questionnaire pack which was posted to patients with RA based in the South-West of 
England. The questionnaire pack also contained individual items capturing pain (VAS), 
fatigue (NRS), patient global assessment (PtG VAS), questionnaires capturing disability 
(MHAQ), and patient-reported disease activity (PDAS2)6, scores generated from an 
algorithm including PtG, swollen joint count (SJC), and MHAQ), and basic demographic 
information. The RAST was subjected to construct validity testing using a correlation 
matrix of Spearman’s correlation coefficients (reported as explained variance (R2)). 
 
Results: 277 patients (91 male) aged 23-97 years with disease durations 1-45 years 
participated in the study (42.9% response rate). The individual components and sum 
score of RAST demonstrated appropriate relationships with other measures of disease 
(pain R2=45-72%; fatigue R2=43-55%; PtG R2=48-68%; MHAQ R2=55-78%; PDAS26 
R2=56-78%). The shared variance indicated that while RAST (individual components and 
sum score) is related to other measures of disease, it is not measuring the same thing. 
Importantly, as identified by patients in earlier qualitative work3, the variance explained by 
the RAST (individual components and sum score) and the (patient-reported) SJC included 
within the PDAS26 was between 31-41% indicating that RAST may capture something 
not currently included within disease activity assessment. The pattern of relationships 
between individual components and measures of disease also provided support for the 3-
component structure. As expected, the ‘physical component’ shared the most variance 
with disability (R2=78%), the ‘severity component’ shared the most variance with pain 
(R2=72%) and PtG (R2=68%), and the ‘psychosocial component’ shared less variance 
with the above disease related measures. 
 
Conclusions: During preliminary validity testing RAST, the new RA stiffness PROM, 
demonstrated promising construct validity. Further testing of RAST is now required in a 
fresh population to generate measurement property evidence of reliability and sensitivity 
to change to support its use. 
 
References: 1Hewlett et al, 2005; 2Felson et al, 1993; 3Halls et al, 2014; 4Orbai et al, 
2014; 5FDA, 2009; 6Choy et al, 2008; 2015 
 
 
 
